
<html lang="en"     class="pb-page"  data-request-id="761a97c5-0e4e-4107-b772-b6392675ccac"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2014.57.issue-16;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/jm500766w;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer" /></meta><meta name="dc.Creator" content="John M.  Lambert" /></meta><meta name="dc.Creator" content="Ravi V. J.  Chari" /></meta><meta name="dc.Description" content="Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that combines the antitumor properties of the humanized anti-human epidermal growth factor receptor 2 (HER2) antibody, trastuzumab, w..." /></meta><meta name="Description" content="Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that combines the antitumor properties of the humanized anti-human epidermal growth factor receptor 2 (HER2) antibody, trastuzumab, w..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 10, 2014" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm500766w" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm500766w" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm500766w" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm500766w" /></link>
        
    
    

<title>Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm500766w" /></meta><meta property="og:title" content="Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0011.jpeg" /></meta><meta property="og:description" content="Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that combines the antitumor properties of the humanized anti-human epidermal growth factor receptor 2 (HER2) antibody, trastuzumab, with the maytansinoid, DM1, a potent microtubule-disrupting agent, joined by a stable linker. Upon binding to HER2, the conjugate is internalized via receptor-mediated endocytosis, and an active derivative of DM1 is subsequently released by proteolytic degradation of the antibody moiety within the lysosome. Initial clinical evaluation led to a phase III trial in advanced HER2-positive breast cancer patients who had relapsed after prior treatment with trastuzumab and a taxane, which showed that T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine. In 2013, T-DM1 received FDA approval for the treatment of patients with HER2-positive metastatic breast cancer who had previously received trastuzumab and a taxane, separately or in combination, the first ADC to receive full approval based on a randomized study." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm500766w"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm500766w">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm500766w&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm500766w&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm500766w&amp;href=/doi/10.1021/jm500766w" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 16</span><span class="cit-fg-pageRange">, 6949-6964</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/16" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm5004733" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/jm500262m" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+M.++Lambert">John M. Lambert</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ravi+V.+J.++Chari">Ravi V. J. Chari</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States</span></div><div class="corresp-info"><strong>*</strong>J.M.L.: e-mail, <a href="/cdn-cgi/l/email-protection#d9b3b6b1b7f7b5b8b4bbbcabad99b0b4b4acb7b6bebcb7f7bab6b4"><span class="__cf_email__" data-cfemail="cca6a3a4a2e2a0ada1aea9beb88ca5a1a1b9a2a3aba9a2e2afa3a1">[email protected]</span></a>; phone, 781-895-0600.</div><div class="corresp-info"><strong>*</strong>R.V.J.C.: e-mail, <a href="/cdn-cgi/l/email-protection#9ae8fbecf3b4f9f2fbe8f3daf3f7f7eff4f5fdfff4b4f9f5f7"><span class="__cf_email__" data-cfemail="097b687f60276a61687b60496064647c67666e6c67276a6664">[email protected]</span></a>; phone, 781-895-0600.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm500766w&amp;href=/doi/10.1021%2Fjm500766w" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 16</span><span class="cit-pageRange">, 6949–6964</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 26, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 May 2014</li><li><span class="item_label"><b>Published</b> online</span>10 July 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 August 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm500766w" title="DOI URL">https://doi.org/10.1021/jm500766w</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6949%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJohn%2BM.%2BLambert%252C%2BRavi%2BV.%2BJ.%2BChari%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D16%26contentID%3Djm500766w%26title%3DAdo-trastuzumab%2BEmtansine%2B%2528T-DM1%2529%253A%2BAn%2BAntibody%25E2%2580%2593Drug%2BConjugate%2B%2528ADC%2529%2Bfor%2BHER2-Positive%2BBreast%2BCancer%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6964%26publicationDate%3DAugust%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm500766w"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">18143</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">263</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm500766w" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;M. Lambert&quot;},{&quot;first_name&quot;:&quot;Ravi&quot;,&quot;last_name&quot;:&quot;V. J. Chari&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;16&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;6949-6964&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm500766w&quot;},&quot;abstract&quot;:&quot;Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that combines the antitumor properties of the humanized anti-human epidermal growth factor receptor 2 (HER2) antibody, trastuzumab, with the maytansinoid, DM1, a potent microtubule-disrupting agent, joined by a stable linker. Upon binding to HER2, the conjugate is internalized via receptor-mediated endocytosis, and an active derivative of DM1 is subsequently released by proteolytic degradation of the antibody moiety within the lysosome. Initial clinical evaluation led to a phase III trial in advanced HER2-positive breast cancer patients who had relapsed after prior treatment with trastuzumab and a taxane, which showed that T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine. In 2013, T-DM1 received FDA approval for the treatment of patients with HER2-positive metastatic breast cancer who had previously received trastuzumab and a taxane, separately or in combination, the first ADC&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500766w&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500766w" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500766w&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500766w" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500766w&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500766w" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm500766w&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500766w&amp;href=/doi/10.1021/jm500766w" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm500766w" /></input><a href="/doi/pdf/10.1021/jm500766w" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm500766w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm500766w%26sid%3Dliteratum%253Aachs%26pmid%3D24967516%26genre%3Darticle%26aulast%3DLambert%26date%3D2014%26atitle%3DAdo-trastuzumab%2BEmtansine%2B%2528T-DM1%2529%253A%2BAn%2BAntibody%25E2%2580%2593Drug%2BConjugate%2B%2528ADC%2529%2Bfor%2BHER2-Positive%2BBreast%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D16%26spage%3D6949%26epage%3D6964%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290975" title="Biopolymers">Biopolymers</a>,</li><li><a href="/action/doSearch?ConceptID=291290" title="Conjugate acid-base pairs">Conjugate acid-base pairs</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/16" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jmcmar.2014.57.issue-16/production/jmcmar.2014.57.issue-16.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that combines the antitumor properties of the humanized anti-human epidermal growth factor receptor 2 (HER2) antibody, trastuzumab, with the maytansinoid, DM1, a potent microtubule-disrupting agent, joined by a stable linker. Upon binding to HER2, the conjugate is internalized via receptor-mediated endocytosis, and an active derivative of DM1 is subsequently released by proteolytic degradation of the antibody moiety within the lysosome. Initial clinical evaluation led to a phase III trial in advanced HER2-positive breast cancer patients who had relapsed after prior treatment with trastuzumab and a taxane, which showed that T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine. In 2013, T-DM1 received FDA approval for the treatment of patients with HER2-positive metastatic breast cancer who had previously received trastuzumab and a taxane, separately or in combination, the first ADC to receive full approval based on a randomized study.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28518" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28518" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The HER2/<i>neu</i> proto-oncogene (also called c-<i>erb</i>B-2), shares extensive sequence homology with the epidermal growth factor receptor gene and other members of the epidermal growth factor receptor family. The gene was first identified in 1981 and was subsequently found to encode a 185 kDa transmembrane glycoprotein with tyrosine kinase activity. Amplification of the gene occurs in about 20–25% of human breast cancers and is associated with aggressive tumor growth and poor clinical outcome.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> A panel of murine monoclonal antibodies against the extracellular domain of HER2 was derived from immunization of mice with a cell line that had been transfected with the <i>erbB</i>-2 gene. From more than 100 antibodies that were obtained, 4D5 was chosen as the lead. This antibody was shown to specifically bind to HER2 and induced cytostatic growth inhibition of a number of HER2 overexpressing cell lines in vitro. This antibody also inhibited growth of HER2-expressing human breast tumor xenografts in athymic mice. In addition, treatment of tumor-bearing mice with a combination of 4D5 and the chemotherapeutic drug cis-platin resulted in synergistic anti-tumor activity.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Since the 4D5 antibody was of murine origin and had the potential to be immunogenic in humans, a series of humanized versions were produced by grafting the complementarity determining regions, involved in antigen binding, from the murine antibody into the human antibody framework. A humanized monoclonal antibody of the IgG1 isotype, trastuzumab, was selected as the lead based on its high binding affinity to the extracellular domain of HER2 and on the retention in the humanized antibody of the ability to inhibit growth of HER2-overexpressing cell lines and xenografts.</div><div class="NLM_p">There are multiple mechanisms through which trastuzumab is believed to effect cell kill. These include inhibition of constitutive HER2 signaling and disruption of HER2/HER3 interactions in HER2-overexpressing cells resulting in inhibition of cellular proliferation, together with activation of immune effector systems via binding of tumor cell-bound trastuzumab to the FcγRIII receptor on immune effector cells, leading to antibody-dependent cell mediated cytotoxicity (ADCC).<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Trastuzumab was also shown to enhance the cytotoxic effect of paclitaxel, in a dose-dependent manner, toward HER2 overexpressing breast cancer cells in vitro and also increase the antitumor activity of paclitaxel in breast carcinoma xenografts in vivo. On the basis of these preclinical data, trastuzumab, was advanced into clinical evaluation and ultimately received marketing approval by the U.S. Food and Drug Administration (FDA) in 1998 for use as a single agent for the treatment of patients with metastatic breast cancer (MBC) whose tumors overexpress the HER2 protein and who had received one or more prior chemotherapy regimens. When added to chemotherapy, trastuzumab (Herceptin) was shown to improve time to disease progression and overall survival in patients with HER2-positive MBC compared to chemotherapy alone.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Thus, trastuzumab was also approved in combination with paclitaxel in a first-line setting for the treatment of patients with MBC whose tumors overexpress the HER2 protein and who had not received prior chemotherapy.</div><div class="NLM_p">Although trastuzumab has had a major impact in the treatment of patients with HER2-positive MBC, a subset of patients do not respond to treatment, and most patients who are initially responsive to treatment ultimately experience disease progression.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The finding that tumors in these patients continued to express HER2 set off a wave of further research to develop additional approaches to target HER2. These included the development of small molecule kinase inhibitors of HER2, such as lapatinib, and antibodies such as pertuzumab that bind to different sites on HER2 than trastuzumab. Pertuzumab acts by binding to the extracellular dimerization domain II of HER2, thus inhibiting the binding of HER2 to other HER family members, especially HER3, preventing HER2–HER3 dimerization which is a robust activator of the PI3 kinase signaling pathway.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Despite these noteworthy advances in HER2-targeted therapy, breast cancer in these patients will eventually progress, underscoring the need for alternative therapies. These new HER2-targeted agents are generally given together with chemotherapeutic agents, thus retaining the toxic effects of chemotherapy in the therapeutic regimen.</div><div class="NLM_p">The concept of antibody–drug conjugates (ADCs) evolved as a means either to improve the tumor selectivity of cytotoxic drugs or to confer higher potency to monoclonal antibodies that display preferential binding to tumor cells but lack sufficient cytotoxicity. The FDA approvals of two ADCs, brentuximab vedotin and ado-trastuzumab emtansine, have provided proof of concept to this approach and have generated tremendous excitement. There are over 30 ADCs currently in clinical evaluation, and almost every major pharmaceutical company has embraced this technology.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The majority of ADCs in clinical evaluation utilize the highly potent tubulin-interacting agents, maytansinoids or auristatins. A few ADCs in the clinic have incorporated other potent effector molecules, such as the topoisomerase 1 inhibitor SN-38, and the DNA interacting agents, calicheamicin and pyrrolobenzodiazepines.</div><div class="NLM_p last">Targeted delivery of a cytotoxic agent to HER2-positive tumors in the form of an ADC, using trastuzumab as the targeting antibody, affords the potential of improved therapeutic activity with lower systemic toxicity. This annotation will review the rationale and preclinical data that drove the linker design and cytotoxic agent selection leading to the development of ado-trastuzumab emtansine (T-DM1).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Clinical data that led to the approval of T-DM1 by the U.S. FDA, for the treatment of patients with HER2-positive metastatic breast who have received prior treatment with trastuzumab and a taxane, will be briefly discussed.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Design of T-DM1</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60580" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60580" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> (a) Selection of the Cytotoxic Agent</h3><div class="NLM_p">Since taxanes were already used with trastuzumab in the clinic, an obvious ADC design would have consisted of linking taxanes directly to trastuzumab. However, at the time of the selection of the appropriate cytotoxic agent for use in an ADC with trastuzumab, clinical results with ADCs prepared utilizing conventional anticancer drugs such as methotrexate, doxorubicin, and vinblastine had failed to demonstrate therapeutic benefit. A careful retrospective analysis of the preclinical data that were used to support clinical development of these early ADCs revealed several shortcomings. (A) Poor in vitro potency is one shortcoming. Conjugation often led to decreased potency compared to the parent free drug. For example, an ADC with des-acetylvinblastine was reported to be 8-fold less potent than the unconjugated desacetylvinblastine drug. Similarly, a doxorubicin conjugate with the BR96 antibody was about 8-fold less potent than doxorubicin. Unlike the unconjugated dug that can freely diffuse into cells, delivery of the cytotoxic molecule by an antibody is limited by the relatively moderate number of antigen molecules on the cell surface to which the antibody can bind (typically ∼10<sup>5</sup> receptors/cell). In addition, internalization of cell-surface bound antigen–antibody complex, or intracellular processing to release the active drug moiety, may be inefficient. (B) Modest in vivo activity is another shortcoming. Although these early ADCs were shown to be more active than the corresponding unconjugated drugs in tumor xenograft models, long-term tumor regressions in such xenograft models were only achieved when large doses of ADC were used. For example, the doxorubicin conjugate BR96-Dox was used at a dose of 1 g/kg in vivo, while the clinically achievable dose was only ∼19 mg/kg. (C) Localization in human tumors is also a shortcoming. Dosimetry studies with radiolabeled antibodies in cancer patients have revealed that uptake by the tumor was quite low, ranging from 0.003% to 0.01% injected dose/g tumor.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> On the basis of these findings, a cytotoxic compound with considerably higher potency (IC<sub>50</sub> ≈ 10<sup>–11</sup> M) than the drugs used in the early ADCs was set as a key requirement. In addition to high potency, an important requirement that is often overlooked is that cytotoxic molecules for use in ADCs have to be stable and adequately soluble in the aqueous milieu of the antibody.<a onclick="showRef(event, 'ref8 ref11'); return false;" href="javascript:void(0);" class="ref ref8 ref11">(8, 11)</a></div><div class="NLM_p">Maytansine (<b>1</b>), a benzoansamacrolide natural product originally derived from the bark of the African shrub <i>Maytenus ovatus</i>, fits these requirements.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Maytansine was found to be a potent inhibitor of tubulin polymerization. Although maytansine bound to the same site on tubulin as the <i>Vinca</i> alkaloids, with similar in vitro inhibition constants, it was considerably more potent as a cell-killing agent. In a direct comparison of in vitro cytotoxicity toward the Burkitt’s lymphoma cell line Namalwa, maytansine was several orders of magnitude more potent than clinically used anticancer drugs such as vinblastine, methotrexate, mitomycin C, and daunorubicin (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Further testing of the cytotoxicity of maytansine on a panel of solid tumor cell lines typically showed IC<sub>50</sub> values between 30 and 100 pM, with the two tested breast cancer cell lines being among the most sensitive (IC<sub>50</sub> values of 30 and 44 pM for SK-Br-3 and MCF-7, respectively).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Since breast cancer in humans is known to be sensitive to tubulin agents, with paclitaxel and docetaxel often used in first-line treatment regimens, and given that maytansine is a tubulin agent with high potency toward breast tumor cell lines, it was deemed to be ideally suited for use in an ADC of trastuzumab. Maytansine had been extensively evaluated in phase I and II clinical trials in humans and was discontinued because of an insufficient therapeutic index.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> However, the wealth of safety data from these trials provided some level of comfort in the selection of maytansine as an effector molecule for ADCs. In addition, maytansine had excellent stability and acceptable solubility in aqueous solutions for use in ADCs.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Comparison of the in vitro potency of cytotoxic drugs toward the Burkitt lymphoma cell line Namalwa: maytansine (blue circle), vinblastine (red triangle), daunorubicin (green diamond), methotrexate (brown square), mitomycin C (purple triangle).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> (b) Design and Synthesis of Maytansinoids for Linkage to Antibodies</h3><div class="NLM_p">Although maytansine met all the biochemical and biological criteria for use as an effector molecule in ADCs, it lacked a suitable functional group that could facilitate conjugation to an antibody. Introduction of a thiol functionality into maytansine would provide the opportunity to exploit the two most efficient coupling chemistries available at, or near, neutral pH in the dilute aqueous solution necessitated by the antibody, namely, (a) thiol–disulfide exchange and (b) thioether formation with a reactive Michael acceptor, such as a maleimide. In order to introduce a thiol substituent, without affecting potency, a careful analysis of the SAR studies of maytansine was conducted to determine the best site for such incorporation. The aminoacyl side chain at C3 appeared to be ideal, as it was reported to be quite tolerant to different acyl chain lengths and was synthetically amenable to alterations.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Thus, synthetic methods were developed for the incorporation of new ester side chains bearing a terminal thiol group to enable linkage to antibodies (see Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Aminoacyl side chains at the C3 position of the maytansinoid molecule are typically installed by first hydrolyzing the C3 ester of maytansine to provide maytansinol and then re-esterification with different side chains to produce maytansinoids of interest. The first challenge was to find a source of maytansine, a plant product in short supply. Fortunately, the ansamitocins, which are a mixture of C3 esters (∼80% isobutanoyl and smaller amounts of <i>n</i>-propanoyl, isopropanoyl, and <i>n</i>-butanoyl) of maytansinol, could be obtained readily by fermentation of the microorganism <i>Actinosynnema pretiosum</i>. Since the maytansinoid molecule was known to be susceptible to β-elimination of the ester under mild alkaline conditions, controlled reduction with LiAl(OMe)<sub>3</sub>H at −40 °C was employed to convert ansamitocins into maytansinol. Esterification with a carboxylic acid that contained a disulfide in the presence of a coupling agent <i>N</i>-ethyl-<i>N</i>′-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and a Lewis acid (zinc chloride) provided maytansinoid disulfides. A panel of disulfide-containing maytansinoids were prepared to examine the effect of length of the acyl side chain on potency.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In addition, one or two methyl groups were introduced on the carbon atom geminal to the disulfide to evaluate the effect of steric hindrance on potency.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The in vitro cytotoxicity data of a representative set of these new maytansinoids on human cancer cell lines are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. All these maytansine analogues had similar or higher potency than maytansine, indicating that the disulfide substituent did not adversely affect potency. Reduction of the disulfide bond with dithiothreitol gave the desired thiol-bearing maytansinoids for linkage to antibodies.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Thiol-Containing Maytansinoids<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reaction conditions: (a) LiAlH(OMe)<sub>3</sub>/THF, −40 °C, (b) EDC/ZnCl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub>, rt, (c) dithiothreitol, rt.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Potency of Maytansinoids toward KB (Human Epidermal Carcinoma) and SK-Br-3 (Human Breast Tumor) Cell Lines, Using a Clonogenic Assay and a 72 h Exposure to the Drugs</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub>, nM</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">maytansinoid</th><th class="colsep0 rowsep0" align="center" char=".">KB cells</th><th class="colsep0 rowsep0" align="center" char=".">SK-Br-3 cells</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b> (maytansine)</td><td class="colsep0 rowsep0" align="char" char=".">0.034</td><td class="colsep0 rowsep0" align="char" char=".">0.030</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4a</b> (DM0-SMe)</td><td class="colsep0 rowsep0" align="char" char=".">0.190</td><td class="colsep0 rowsep0" align="char" char=".">0.180</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4b</b> (DM1-SMe)</td><td class="colsep0 rowsep0" align="char" char=".">0.029</td><td class="colsep0 rowsep0" align="char" char=".">0.014</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4c</b> (DM2′-SMe)</td><td class="colsep0 rowsep0" align="char" char=".">0.009</td><td class="colsep0 rowsep0" align="char" char=".">0.038</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4d</b> (DM3-SMe)</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4e</b> (DM4-SMe)</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td></tr></tbody></table></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> (c) Selection of the Linker</h3><div class="NLM_p">The availability of a reactive moiety in the form a sulfhydryl group on the maytansinoid molecule afforded the opportunity to link it to trastuzumab via a disulfide linker or a thioether linker. The disulfide bond strength of the conjugate could be modulated by using a maytansinoid with a sterically hindered thiol and reacting it with an antibody that had been modified with a linker bearing a sterically hindered disulfide bond.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The bifunctional cross-linking agent, succinimidyl-4-(<i>N</i>-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) was used to introduce maleimido group on the antibody to enable linkage of the maytansinoid via a nonreducible thioether bond. Linker structures used in these conjugations are shown (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of cross-linkers used in conjugate preparation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> (d) Conjugation Methods</h3><div class="NLM_p">Lysine residues on the antibody were selected as the conjugation sites, since a portion of their surface-accessible amino groups can be modified without disturbing the structural integrity and native function of the antibody, along with preserving its favorable pharmacokinetic properties. Briefly, treatment of the antibody with the disulfide-containing linkers resulted in aminolysis of the <i>N</i>-hydroxysuccinimide esters of the linker by lysine residues on the antibody, leading to amide formation and the incorporation of reactive disulfide groups (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>a). Disulfide exchange between the modified antibody and the thiol-containing maytansinoids resulted in the incorporation of an average of 3.5 maytansinoid molecules linked per antibody molecule. In order to test the role of linker, a trastuzumab conjugate bearing a nonreducible thioether link was prepared by reaction of the antibody with SMCC to introduce maleimido groups. Reaction with the thiol-containing maytansinoid DM1 proceeded smoothly to give a trastuzumab conjugate with an average of 3.5 DM1 molecules linked via thioether bonds (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>b). Mass spectrometric analysis of T-DM1 shows molecular masses corresponding to a distribution of different number of maytansinoid molecules linked per antibody. The maytansinoid to antibody ratio for T-DM1 was selected based on the desire to (a) minimize the amount of unconjugated antibody, which would diminish the cytotoxic potency of the conjugate, and (b) avoid species with higher maytansinoid load, which might pose manufacturing challenges because of lower solubility. Thus, an average maytansinoid load of ∼3.5 was found to be optimal, as the conjugate maintained good biochemical characteristics with a minimal amount of unconjugated antibody.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a></div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Representative Conjugation Processes for Trastuzumab-Maytansinoid Conjugates</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Preclinical Evaluation Leading to the Selection of Maytansinoid and Linker Component of T-DM1</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22064" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22064" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> (a) In Vitro Studies</h3><div class="NLM_p">The five trastuzumab–maytansinoid conjugates (four with a disulfide linker and one with a thioether linker) shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> were evaluated for their in vitro potency toward the HER2-amplified cell lines BT-474 and SK-BR-3.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The nature of the linker did not affect potency, as all five conjugates displayed similar high cytotoxicity, with IC<sub>50</sub> values ranging from 0.085 to 0.148 μg/mL toward BT-474 cells and from 0.007 to 0.018 μg/mL (4.7 × 10<sup>–11</sup> to 1.2 × 10<sup>–10</sup> M) toward SK-BR-3 cells, after 3 days of exposure to the ADCs. In contrast, unconjugated trastuzumab displayed only a modest cytotoxic effect (IC<sub>50</sub> > 10 μg/mL), indicating that conversion of trastuzumab into an ADC greatly enhanced its cell killing power. Breast tumor cell lines that had little (MCF-7) or no (MDA-MB-468) HER2 expression were much less susceptible to killing by any of the trastuzumab maytansinoid conjugates, with IC<sub>50</sub> values of >10 μg/mL for MCF-7 cells and about 3–5 μg/mL for MDA-MB-468 cells, demonstrating good antigen specificity of the cytotoxic effect, regardless of linker choice.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structural representation of trastuzumab-maytansinoid conjugates with a disulfide linker (<b>8a</b>–<b>d</b>) or a thioether linker (<b>8e</b>). Adapted by permission from the American Association for Cancer Research (<contrib-group>Lewis Phillips. G. D.; Li, G.; Dugger, D. L.; Crocker, L. M.; Parsons, K. L.; Mai, E.; Lambert, J. M.; Chari, R. V.; Lutz, R. J.; Wong, W. L.; Jacobson, F. S.; Koeppen, H.; Schwall, R. H.; Kenkare-Mitra, S. R.; Spencer, S. D.; Sliwkowski, M. X.</contrib-group>Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.  <cite>Cancer Res.</cite> <span class="NLM_year">2008</span>, <em>68</em>, 9280–9290).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> (b) In Vivo Pharmacokinetic Studies</h3><div class="NLM_p last">Since the in vitro potency assay did not distinguish between the ADCs bearing different linkers, all were submitted for in vivo evaluation. A pharmacokinetic study was conducted in CD1 mice to determine the serum concentration of the ADCs at various time points and thus gauge the relative stabilities of the linkers in vivo. In contrast to the in vitro cytotoxicity data, there were clear differences between the conjugates, with a clear correlation between the rate of reduction of the disulfide bond of the ADC as measured in vitro, and the in vivo half-life and exposure. As expected, the trastuzumab ADC with the least hindered disulfide (T-SPDP-DM1) showed the fastest clearance, with no detectable conjugate after 3 days in circulation.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> For the remaining ADCs, the clearance rate was also determined by the degree of steric hindrance of the disulfide bond. Thus, the ADC with one methyl group on each side of the disulfide bond (T-SSNPP-DM1) gave a higher serum concentration than the ADC with a methyl group just on one side of the disulfide bond. The clearance rate of the ADC with a high degree of steric hindrance (T-SSNPP-DM4) bearing three methyl groups adjacent to the disulfide bond mirrored that of the conjugate bearing the nonreducible thioether link (T-MCC-DM1). Overall, the stability ranking of the trastuzumab–maytansinoid conjugates determined in vivo matched well with the disulfide cleavage rate of a set of non-trastuzumab–maytansinoid ADCs, upon treatment with the reducing agent dithiothreitol.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> (c) In Vivo Antitumor Activity</h3><div class="NLM_p">The in vivo efficacy of the trastuzumab ADCs with different linkers was evaluated in the trastuzumab-resistant MMTV-HER2 Fo5 mammary tumor model, a syngeneic tumor-transplant model where murine tumors cells express the human <i>erbB-2</i> gene. Although the tumors express high levels of human HER2 (3+ expression by immunohistochemistry), they do not respond to trastuzumab alone, making it a suitable model to assess the value of arming the antibody with a maytansinoid. Four of the five linker-maytansinoid ADC formats evaluated in the pharmacokinetic study were tested (the ADC with the most labile linker (SPDP) was not included in the study). From this in vivo efficacy study, it was concluded that higher linker stability correlated with increased antitumor activity, since the nonreducible conjugate with the SMCC linker displayed a statistically significant improvement in activity over the ADC with the disulfide linker, SPP, at the single tested dose (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">04</a>).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Subsequently, however, a more thorough comparison, at three different doses, of trastuzumab conjugated to DM1 via an SMCC linker or an SPP linker failed to show a measurable difference in antitumor activity in a BT474-EEI tumor model.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Comparison of the in vivo efficacy of trastuzumab–maytansinoid conjugates with a disulfide linker (<b>8b</b> (green triangle), <b>8c</b> (purple cross), <b>8d</b> (red boxed cross)) or a thioether linker (<b>8e</b> (blue square)) at a single iv dose of 10 mg/kg conjugate and a vehicle control (×). Adapted by permission from the American Association for Cancer Research (<contrib-group>Lewis Phillips. G. D.; Li, G.; Dugger, D. L.; Crocker, L. M.; Parsons, K. L.; Mai, E.; Lambert, J. M.; Chari, R. V.; Lutz, R. J.; Wong, W. L.; Jacobson, F. S.; Koeppen, H.; Schwall, R. H.; Kenkare-Mitra, S. R.; Spencer, S. D.; Sliwkowski, M. X.</contrib-group>Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.  <cite>Cancer Res.</cite> <span class="NLM_year">2008</span>, <em>68</em>, 9280–9290).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Metabolism Studies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38088" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38088" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> (a) In Vitro Studies</h3><div class="NLM_p">In order to study the intracellular fate of T-DM1 and the role of linker on the amount and nature of catabolites formed, trastuzumab conjugates with the noncleavable SMCC linker (T-DM1) and a disulfide linker (T-SPP-DM1) were prepared using [<sup>3</sup>H]DM1, with the radiolabel incorporated at the C20 methoxy group of DM1. The HER2-overexpressing cell line BT474-EEI was exposed to the radiolabeled conjugates, and the cells were harvested at various time points, followed by extraction of protein-free maytansinoid catabolites using acetone. The extracts were subjected to HPLC analysis. Exposure to T-DM1 resulted in the formation of a sole metabolite that was identified as lysine-<i>N</i><sup>ε</sup>-MCC-DM1, presumably arising from lysosomal degradation of the antibody component leaving the lysine residue of the antibody attached to DM1 via the linker. The peak size increased significantly from the first time point (3 h) to the last one (24 h). Representative chromatograms at the 6 and 24 h time points are shown (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">05</a>A). Treatment of cells with the disulfide-linked conjugate, T-SPP-DM1, gave the expected lysine- <i>N</i><sup>ε</sup>-SPP-DM1 catabolite resulting from lysosomal degradation of the antibody. However, in this case, subsequent cleavage of the disulfide bond gave rise to the maytansinoid thiol, DM1, which was isolated as a stabilized <i>N</i>-ethylmaleimide (NEM) adduct. At the 6 h time point, the peak area for lysine-SPP-DM1 is somewhat greater than that of DM1, but at the 24 h time point further reduction has taken place to give DM1 as the major peak (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">05</a>B). The rate and extent of processing of T-SPP-DM1 by BT474-EEI cells in vitro were compared to those of T-DM1. The protein-free maytansinoid catabolites produced at various time points after exposure to the conjugates were quantified. Processing of both conjugates was found to be equally efficient and approached ∼70% at 24 h (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">05</a>C).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0006.jpeg" id="GRAPHIC-d3487e841-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) In vitro catabolism by BT474-EEI cells of the trastuzumab-MCC-DM1 conjugate <b>8e</b> (thioether linker): top panel, 6 h time point; bottom panel, 24 h time point. (B) In vitro catabolism by BT474-EEI cells of the trastuzumab-SPP-DM1 conjugate <b>8b</b> (disulfide linker): top panel, 6 h time point; bottom panel, 24 h time point. (C) Comparison of the rate and extent of in vitro processing of trastuzumab-SPP-DM1 conjugate <b>8b</b> (disulfide linker: blue squares) and trastuzumab-MCC-DM1 conjugate <b>8e</b> (thioether linker, red squares) by BT474-EEI cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> (b) In Vivo Studies</h3><div class="NLM_p">In order to determine how the results from the in vitro metabolism studies related to the in vivo situation, tumor xenografts were established in mice with the same cell line used for the in vitro studies (BT474-EEI). Mice bearing these tumor xenografts were treated with either radiolabeled T-DM1 or T-SPP-DM1 prepared with [<sup>3</sup>H]DM1. Tumors were excised at various time points and analyzed for both total radioactivity (antibody-bound plus small molecular weight catabolites) and protein-free maytansinoid catabolites by HPLC analysis. Although the T-SPP-DM1 conjugate displayed a faster plasma clearance than T-DM1, the amount of maytansinoid catabolites in the tumor xenograft at the various time points was quite similar, with maximum accumulation occurring between 2 and 4 days (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A). It was thus unsurprising that the antitumor activity of the two compounds was also similar in this study. The nature of the catabolites mirrored the pattern observed with the same cell line in vitro, with T-DM1 giving just one catabolite (lysine-<i>N</i><sup>ε</sup>-MCC-DM1) and with T-SPP-DM1 yielding the same two catabolites observed in vitro (lysine- <i>N</i><sup>ε</sup>-SPP-DM1 and DM1, stabilized as <i>N</i>-ethylmaleimide adduct). The catabolite profiles for the 2-day time-point are shown (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B), with T-SPP-DM1 giving predominantly DM1 (isolated as an <i>N</i>-ethylmaleimide adduct) after reduction of the SPP linker within tumor cells and T-DM1 showing a single peak of its sole catabolite.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0007.jpeg" id="GRAPHIC-d3487e890-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Time dependent formation of catabolite: comparison of in vivo catabolism of trastuzumab–maytansinoid conjugates in BT474-EEI tumor xenografts in mice: trastuzumab-SPP-DM1 conjugate <b>8b</b> (disulfide linker, blue square) and trastuzumab-MCC-DM1 conjugate <b>8e</b> (thioether linker, red square). (B) In vivo catabolism of trastuzumab–maytansinoid conjugates in BT474-EEI tumor xenografts in mice at 2-day time-point: top panel, <b>8b</b>, disulfide linker (SPP); bottom panel, <b>8e</b>, thioether linker (SMCC).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">In Vivo Tolerability Studies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63253" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63253" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In order to select the final linker format for the maytansinoid conjugated trastuzumab for ADC development, the tolerability of the two conjugates (SMCC linker versus SPP linker) was evaluated in Sprague–Dawley rats. In this single dose acute toxicity study, the ADC with the nonreducible SMCC linker was found to be at least about 2-fold better tolerated than the conjugate with the disulfide (SPP) linker. Thus, treatment at a dose of 22 mg/kg with the SPP conjugate resulted in significant (∼10%) body weight loss, while the SMCC conjugate could be dosed at 50 mg/kg without any weight loss. On the basis of these preliminary acute toxicity results, the SMCC linker afforded at least about a 2-fold greater therapeutic index in mice to a trastuzumab-DM1 conjugate compared with that provided by the disulfide linker, and so SMCC was the linker of choice for T-DM1, the development candidate ADC.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Biological Activity of T-DM1</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45720" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45720" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (a) In Vitro Cytotoxicity</h3><div class="NLM_p">Testing of the in vitro cytotoxicity of T-DM1 (<b>8e</b>) in comparison to unconjugated trastuzumab was expanded to a panel of cell lines with different levels of expression of HER2 and varying sensitivity to trastuzumab.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> This panel also included HER2-positive cell lines from tumor types other than breast, such as the lung carcinoma cell line Calu-3, the ovarian cancer cell line SK-OV-3, and the gastric carcinoma cell line MKN7. In all cases, T-DM1 was considerably more potent than free trastuzumab (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) toward the cancer cell lines. In contrast, the normal human mammary epithelial cells (HMEC) and normal human epidermal keratinocytes (NHEK) were much less sensitive to trastuzumab and T-DM1.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Since the small molecule kinase inhibitor lapatinib is used in the treatment of trastuzumab refractory breast cancer, it was important to test the potency of T-DM1 for HER2-amplified cells that were resistant to lapatinib. As a first test, SK-Br-3 cells, which are highly sensitive to T-DM1 and lapatinib, were exposed to increasing concentrations of lapitinib over a 9-month period. The resulting lapitinib-resistant clone was ∼200-fold less sensitive to lapatinib but remained as sensitive to T-DM1 as the parent clone. Another mechanism of resistance to lapatinib involves activation of the PI3 kinase pathway, either through the acquisition of a <i>PIKC</i>A mutation or loss of PTEN. The MCF7-neo/HER2 cell line cell line, which has an activated PI3 kinase pathway, was found to be resistant to lapatinb (IC<sub>50</sub> ≈ 20 μM) and to trastuzumab (IC<sub>50</sub> > 66 nM) but was quite sensitive to T-DM1 (IC<sub>50</sub> ≈ 0.16 nM). These results demonstrate that T-DM1 is a highly potent agent even against cells that are resistant to the approved therapy options (trastuzumab and lapatinib) for HER2-positive breast cancer.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Comparison of the in Vitro Potency of Trastuzumab and Trastuzumab-MCC-DM1 Conjugate toward Human Tumor and Normal Cell Lines after a 3-Day Exposure to the Antibody or Conjugate</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub>, μg/mL</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">origin</th><th class="colsep0 rowsep0" align="center" char=".">trastuzumab-MCC-DM1</th><th class="colsep0 rowsep0" align="center" char=".">trastuzumab</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SK-Br-3</td><td class="colsep0 rowsep0" align="left">human breast tumor</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BT-474-EEI</td><td class="colsep0 rowsep0" align="left">human breast tumor</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCC1954</td><td class="colsep0 rowsep0" align="left">human breast tumor</td><td class="colsep0 rowsep0" align="char" char=".">0.015</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KPL-4</td><td class="colsep0 rowsep0" align="left">human breast tumor</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Calu-3</td><td class="colsep0 rowsep0" align="left">human lung carcinoma</td><td class="colsep0 rowsep0" align="char" char=".">0.062</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MKN-7</td><td class="colsep0 rowsep0" align="left">human gastric carcinoma</td><td class="colsep0 rowsep0" align="char" char=".">0.266</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SK-OV-3</td><td class="colsep0 rowsep0" align="left">human ovarian cancer</td><td class="colsep0 rowsep0" align="char" char=".">0.009</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HMEC</td><td class="colsep0 rowsep0" align="left">human mammary epithelial cells</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NHEK</td><td class="colsep0 rowsep0" align="left">normal human epidermal keratinocytes</td><td class="colsep0 rowsep0" align="char" char=".">10.0</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr></tbody></table></div></div><div class="NLM_p last">Maytansinoids are reported to be substrates for the MDR1/PgP transporter leading to poorer killing of multidrug resistant (MDR) cells. MDR1/PgP is believed to confer resistance to maytansinoids via two mechanisms: (a) mediating efflux of the drug that diffuses into the plasma membrane from the extracellular space, thereby preventing the compound from reaching the cytoplasm and (b) effluxing any drug that does enter the cytoplasm back to the outside of the cell.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> ADCs, such as T-DM1, deliver the maytansinoids into cells via antigen-mediated endocytosis, thus bypassing the first MDR1 mechanism. Upon intracellular processing, T-DM1 is processed into a charged cytotoxic metabolite, lysine-<i>N</i><sup>ε</sup>-MCC-DM1, which is less susceptible to MDR1/PgP-mediated efflux. Only high levels of MDR1/PgP expression appear to confer resistance to DM1 and T-DM1, and the free maytansinoid and ADC were not substrates for BCRP/ABCG2. Breast cancer lines expressing a range of levels of MRP3/ABCC3 were not resistant to DM1 or T-DM1.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> (b) In Vivo Evaluation</h3><div class="NLM_p">The in vivo antitumor activity of T-DM1 was more thoroughly evaluated in multiple HER2-positive models in mice. For example, in a breast tumor xenograft model established with KPL-4 cells, a single iv administration of T-DM1 at 15 mg/kg gave complete tumor regression lasting for the duration of the experiment (125 days), while treatment with four weekly doses of trastuzumab at 15 mg/kg only achieved a modest delay in tumor growth (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>A).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In another example using the BT474-EEI breast tumor xenograft model, T-DM1 displayed dose-dependent antitumor activity, with tumor growth delay at the lower doses (0.3–3 mg/kg, q3w × 3), tumor regression at the 10 mg/kg dose, and complete regression at the 15 mg/kg dose (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>B).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Unconjugated trastuzumab showed little activity in this model. Similar results were obtained in the MMTV-HER2 Fo5 trastuzumab-resistant transgenic transplant model. Treatment with a control, nonbinding conjugate gave no tumor growth inhibition, demonstrating the antigen specificity of the activity of T-DM1.<a onclick="showRef(event, 'ref20 ref26'); return false;" href="javascript:void(0);" class="ref ref20 ref26">(20, 26)</a></div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0008.jpeg" id="GRAPHIC-d3487e1262-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Comparison of the in vivo antitumor activity of trastuzumab (red circle, 15 mg/kg × 4) and T-DM1 (blue square, 15 mg/kg, single dose), vehicle control (×), in the KPL-4 model. (Excerpted from Lewis-Phillips et al.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a>). (B) Dose-dependent antitumor activity of T-DM1 in the BT474-EEI model (dosing q3w × 3). Doses of T-DM1, are the following: 0.3 mg/kg (purple-outline triangle), 1 mg/kg (green triangle), 3 mg/kg (blue-outline triangle), 10 mg/kg (red triangle), 15 mg/kg (blue square), vehicle control (×); unconjugated trastuzumab (red circle, 15 mg/kg). Parts A and B are adapted by permission from the American Association for Cancer Research (<contrib-group>Lewis Phillips. G. D.; Li, G.; Dugger, D. L.; Crocker, L. M.; Parsons, K. L.; Mai, E.; Lambert, J. M.; Chari, R. V.; Lutz, R. J.; Wong, W. L.; Jacobson, F. S.; Koeppen, H.; Schwall, R. H.; Kenkare-Mitra, S. R.; Spencer, S. D.; Sliwkowski, M. X.</contrib-group>Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.  <cite>Cancer Res.</cite> <span class="NLM_year">2008</span>, <em>68</em>, 9280–9290).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Following up on the in vitro study described above, wherein T-DM1 was found to be active against lapatinib-resistant cell lines, an in vivo study was conducted to compare the activity of T-DM1 and lapatinib. Mice bearing established Fo5 tumors were found to insensitive to lapatinib, and regressions could not be attained even after daily treatment for 3 weeks. Treatment with T-DM1, however, was quite effective, resulting in complete regression in 3/10 animals and partial regression in 6/10 mice.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p last">A pharmacokinetic study was conducted in rats to compare the levels of T-DM1 and total trastuzumab. Serum concentration of total antibody was determine using a specific ELISA for trastuzumab, while intact T-DM1 conjugate was assayed by ELISA using an antibody against DM1. Circulating serum concentrations of T-DM1 measured for 1 week were similar to the measurement of total serum trastuzumab concentrations, demonstrating that there was negligible release of maytansinoid from the conjugate over 7 days in circulation in rats.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The anti-DM1 antibody used in the ELISA was found to bind appropriately with antibodies with different maytansinoid load, including one maytansinoid per antibody. Plasma samples spiked with T-DM1 were also analyzed by capillary LC–MS, using anti-DM1 antibody as the capture probe, and the results matched those obtained through ELISA measurements.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (c) Functional Activity</h3><div class="NLM_p last">Since trastuzumab is by itself an active antibody with biological function, it was important to show that conjugation to DM1 did not affect its functional properties. In a head to head comparison, T-DM1 was shown to retain the binding affinity of trastuzumab to the HER2 antigen. Thus, in a competition binding assay, T-DM1 competed as well as trastuzumab with the binding of radioiodinated trastuzumab to the antigen (HER2 extracellular domain) coated on a plate. Some of the functional activity of trastuzumab is attributed to its ability to cause ADCC. Both T-DM1 and trastuzumab were shown to mediate ADCC equally well in vitro. In control experiments, a nonbinding antibody–DM1 conjugate and a trastuzumab mutant that been engineered to abolish binding to FcγR on immune cells did not mediate ADCC. The cytotoxic effect of trastuzumab has been attributed, in part, to its ability to inhibit the phosphorylation of the HER family member HER3 resulting in inhibition of the PI3 kinase pathway. T-DM1 and trastuzumab were found to show similar levels of inhibition of AKT phosphorylation, demonstrating that conjugation to DM1 did not affect trastuzumab’s ability to inhibit AKT phosphorylation.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Preclinical Toxicology and Toxicokinetics of T-DM1</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33756" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33756" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Single- and repeat-dose safety toxicology studies were performed with T-DM1 in both rats and cynomolgus monkeys.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Trastuzumab recognized HER2 in cynomolgus monkeys but does not bind to the rat antigen. Thus, rats allowed assessment of antigen-independent toxicity of T-DM1, while cynomolgus monkeys allowed evaluation of the potential for any antigen-mediated effects in addition to antigen-independent toxicity. The toxicity of the free maytansinoid, DM1, was assessed in rats only.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> T-DM1 was well-tolerated at single intravenous doses up to 46 mg/kg (protein dose, equivalent to ∼4400 μg DM1/m<sup>2</sup>) in rats and 30 mg/kg (∼6000 μg DM1/m<sup>2</sup>) in monkeys. Rats given 60 mg/kg T-DM1 (∼6800–7800 μg DM1/m<sup>2</sup>) showed clinical signs of morbidity and/or mortality. DM1 was only tolerated up to 0.2 mg/kg (∼1600 μg DM1/m<sup>2</sup>) in rats, suggesting that 2–3 times higher doses of maytansinoid are tolerated in rats given T-DM1 versus free DM1. As noted above, the major low molecular weight maytansinoid metabolite of T-DM1 is the lysine adduct, lysine-<i>N</i><sup>ε</sup>-MCC-DM1.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The hydrophilic nature of the charged amino and carboxyl groups of the lysine greatly reduces the cytotoxicity of the adduct relative to DM1 and other noncharged maytansinoids and likely alters its distribution in vivo relative to noncharged maytansinoids, with a favorable effect on the tolerable dose.<a onclick="showRef(event, 'ref13 ref21'); return false;" href="javascript:void(0);" class="ref ref13 ref21">(13, 21)</a> Thus, the hydrophilic metabolite lysine-<i>N</i><sup>ε</sup>-MCC-DM1 is >200-fold less potent (IC<sub>50</sub> ≈ 7.5–17 nM) when applied to cancer cells in vitro, compared to noncharged maytansinoids such as maytansine (IC<sub>50</sub> ≈ 0.03–0.09 nM).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><div class="NLM_p">The principal acute toxicities in rats were comparable between T-DM1 and DM1 and were associated with dose-dependent effects in bone marrow/hematologic systems, lymphoid organs, and liver. Both agents induced minimal to moderate reductions in lymphocyte counts and reticulocyte counts and minimal to mild reductions in platelets, as well as an increase in absolute neutrophil counts.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> These clinical laboratory observations were consistent with histologic findings of bone marrow and lymphoid organ toxicities, although such findings were more severe for DM1 than for T-DM1 at their respective maximum tolerated doses (MTD), 1600 and 4400 μg DM1/m<sup>2</sup>, respectively. Elevations of serum transaminase levels were in the range of 2- to 4-fold at the MTD of both T-DM1 and DM1, consistent with histologic findings of liver toxicity.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> At the tolerated doses, all findings were partially or completely reversed during the recovery period. Histopathology revealed an increase in mitotic figures in a variety of tissues in rats dosed with T-DM1, notably in adrenals, liver, kidney, eye (corneal epithelium), and skin (epidermis), findings consistent with the expected pharmacologic action of maytansinoids in disrupting microtubule dynamicity resulting in cell cycle arrest.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Mitotic figures were found only in liver and kidney in rats dosed with free DM1.</div><div class="NLM_p">While the toxicity profiles of T-DM1 and DM1 were similar, the differences in severity in some findings (e.g., reduction in reticulocytes was more severe for DM1 versus T-DM1; different distribution of mitotic figures) are likely related to differences of pharmacokinetics, distribution, and metabolism between T-DM1 and DM1. Separate ELISA methods were used to measure T-DM1 and total trastuzumab in serum of rats dosed with T-DM1. The terminal <i>t</i><sub>1/2</sub> of T-DM1 in rats was about 3–5 days, with a slow clearance (CL) of 13–15 mL day<sup>–1</sup> kg<sup>–1</sup> and a volume of distribution approximating the plasma volume, characteristics of an antibody-based biologic agent.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> On the other hand, in rats dosed with DM1, pharmacokinetics showed a large volume of distribution (>5000 mL/kg) and rapid CL (20–55 mL min<sup>–1</sup> kg<sup>–1</sup>), as expected for the small molecule “payload”. The clearance of total trastuzumab (all conjugated species and any unconjugated antibody) in rats dosed with T-DM1 was about 2-fold slower than that of T-DM1, a finding that could be accounted for by one (or both) of two mechanisms: a certain rate of deconjugation in vivo to form species with a lower DM1-to-antibody ratio (DAR) or a somewhat faster clearance of species with higher-than-average DAR versus species with lower-than-average DAR. Free serum DM1 concentrations in rats treated with T-DM1 were low, approximately 50-fold lower than that of conjugated DM1 at any time-point.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Even this low level of free DM1 may be an overestimate of in vivo plasma concentrations, given that sample preparation utilized treatment with a reducing agent, which may result in ex vivo cleavage of any oxidized derivatives of the thioether.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><div class="NLM_p">T-DM1 was well tolerated in cynomolgus monkeys upon repeat dosing at 3-week intervals with 4 doses of up to 30 mg/kg (∼6000 μg DM1/m<sup>2</sup>) or with 8 doses at 10 mg/kg (∼2000 μg DM1/m<sup>2</sup>). Most adverse findings were similar to those described for rats, with liver and bone marrow/hematologic systems being the primary target organs for toxicity. A minimal to mild decrease in platelets was noted on day 3 after each dose, as was a reversible 2- to 4-fold increase in serum hepatic transaminase levels. Microscopic findings showed an increase in the number of cells in mitotic arrest in a variety of tissues in addition to liver findings. However, despite the fact that epithelial cells of many tissues express HER2, the incidence of cellular mitotic arrest in the rat studies was noted to be more widespread than in monkey, indicating that antigen-independent mechanisms predominate in the uptake and intracellular catabolism of T-DM1 and that antigen-dependent binding and uptake by normal tissue may not be a major safety concern.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> That antigen-mediated uptake does occur in cynomolgus monkeys was clearly demonstrated by the nonlinear pharmacokinetics, with the CL in animals treated at 3 mg/kg being 50% faster than those in the higher dose groups. At doses of ≥10 mg/kg, the <i>t</i><sub>1/2</sub> of T-DM1 in cynomolgus monkeys was approximately 3–5 days (as in rat), with CL in the range of 9.4–11.5 mL day<sup>–1</sup> kg<sup>–1</sup>. There was no accumulation of T-DM1 upon repeat dosing at 3-week intervals. As in the rat, free DM1 concentrations were always at least 50-fold lower than conjugated DM1 at any time-point. Also as observed in rats, the CL of the intact T-DM1 conjugate was faster than that of total trastuzumab. In 4 of 36 monkeys (11%) given repeated doses of T-DM1, antiproduct antibodies were detected, although there were no apparent effects on the toxicokinetic profiles in these animals.</div><div class="NLM_p last">Dose-dependent axonal degeneration was observed in the repeat-dose cynomolgus monkey studies, although these histopathologic findings were without any clinical observations of neurologic deficit.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> These finding were not reversible within the 6-week recovery period. Neuropathy is a common toxicity finding with microtubule-acting agents such as taxanes and the <i>Vinca</i> alkaloids, especially with the longer exposures of repeat-dose schedules of administration. There were no cardiovascular safety signals in the monkey studies.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The overall conclusions of the toxicity evaluation of T-DM1 were that the mechanism of toxicity is consistent with the pharmacology of DM1 as a microtubule-acting compound and that the observed toxicities were primarily through antigen-independent mechanisms of T-DM1 catabolism. The starting dose level of T-DM1 for the first-in-human phase I clinical trial was 0.3 mg/kg based on <sup>1</sup>/<sub>12</sub> of the highest nonseverely toxic dose in cynomolgus monkeys.<a onclick="showRef(event, 'ref28 ref31'); return false;" href="javascript:void(0);" class="ref ref28 ref31">(28, 31)</a></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Clinical Evaluation of T-DM1</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62318" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62318" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (a) Phase I Studies</h3><div class="NLM_p">The safety, tolerability, and pharmacokinetics of T-DM1 was evaluated in a phase I dose-escalation trial in patients with HER2-positive metastatic breast cancer (HER2-positive MBC) who had previously received a trastuzumab-containing regimen. Twenty-four patients were given T-DM1 at doses ranging from 0.3 to 4.8 mg/kg as an intravenous infusion once every 21 days.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> At the 4.8 mg/kg dose, two of three subjects had dose-limiting thrombocytopenia (grade 4). A total of 15 patients were treated at the maximum tolerated dose (MTD) of 3.6 mg/kg, where nearly all patients exhibited thrombocytopenia, generally grade 1 or 2 and rapidly reversible, with a nadir by about day 8 and recovery typically by day 15 of each cycle. Other commonly reported adverse events (AEs) included elevated hepatic transaminases (41.5% of patients), fatigue (37.5%), anemia (29.2%), and nausea (25.0%), generally grade 1 or 2, and reversible. There were no reports of greater than grade 1 nausea, vomiting, alopecia, or neuropathy or any cardiac observations that required dose modification.</div><div class="NLM_p">Pharmacokinetics were nonlinear in the dose range 0.3–4.8 mg/kg, consistent with the anticipated antigen-mediated clearance at these doses.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> The <i>t</i><sub>1/2</sub> of T-DM1 at the 3.6 mg/kg dose (<i>n</i> = 15) was about 3.5 days.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Six of the 24 patients had an objective partial response (five confirmed). All the responding patients had previously received at least one tubulin-acting agent among their prior chemotherapy treatments. In the 15 patients treated at the MTD, the confirmed response rate in patients with measurable disease (<i>n</i> = 9) was 44%, while the clinical benefit rate (CBR), including patients with stable disease of ≥6 months, was 73%, a substantial level of clinical activity in a heavily pretreated patient population.</div><div class="NLM_p">Once MTD had been established, a second arm of the study was opened to evaluate weekly administration. Twenty-eight patients received weekly T-DM1, from 1.2 to 2.9 mg/kg (5 dose levels). Two of three patients dosed at 2.9 mg/kg experienced dose-limiting toxicities (DLTs) preventing dosing on day 8, one case of grade 3 thrombocytopenia, and one case of grade 3 hepatic transaminase (AST) levels.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The MTD for T-DM1 administered weekly was established at 2.4 mg/kg, for a cumulative dose of 7.2 mg/kg over 3 weeks which was double that given as a single dose q3 weeks. The most common drug-related grade ≥3 adverse events seen in >10% of patients were increased AST (11%) and thrombocytopenia (11%). There was only a low incidence of any gastrointestinal toxicity, very few reports of infusion reactions, and no significant cardiac abnormalities in the study. Thirteen patients experienced eye disorders, two of which were grade 3.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In general, the tolerability of T-DM1 on the weekly schedule was similar to that of the q3 week schedule, with patients receiving a somewhat longer median duration of treatment (18.9 weeks versus 16.7 weeks). The DLT, reversible thrombocytopenia, was the same for both regimens, together with reversible minimal to moderate increases in hepatic transaminases consistently observed on both schedules. The incidence of adverse events associated with administration of maytansine, severe diarrhea, vomiting, and sensory neuropathy were low and of low grade when reported, consistent with minimal systemic exposure to free maytansinoid and demonstrating the benefit of the concept of an antibody–drug conjugate.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p last">Confirmed partial responses were reported in 46% (13 of 28) of patients enrolled in the weekly dosing arm of the phase I study, and the six-month CBR was 57% (16 of 28 patients).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Both the weekly and the q3 week schedules demonstrate that T-DM1 has substantial clinical activity in patients with previously treated HER2-positive MBC. The q3 week schedule was chosen for the subsequent phase II clinical evaluation of T-DM1.</div></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (b) Phase II Clinical Trials of T-DM1 as a Single Agent</h3><div class="NLM_p">A single arm phase II study (TDM4258g) was conducted in 112 patients with HER2-positive MBC utilizing the 3.6 mg/kg q3 week dosing schedule.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Patients had received a median of eight prior anticancer agents including trastuzumab (100%), a taxane (84%), an anthracycline (71%), capecitabine (66%), and lapatanib (60%). In this heavily pretreated patient population, 29 patients (25.9%) had objective partial responses by independent assessment. The median progression-free survival (PFS) was 4.6 months, while the medial duration of response was 9.4 months (investigator assessment). The overall response rate (ORR) was higher (33.8%) in patients whose HER2-overexpression status on archival primary tumor specimens was confirmed by a central laboratory (74 confirmed positive of 95 patients reassessed). The ORR in the 21 patients reassessed as HER2-normal was only 4.8%. T-DM1 was well-tolerated in this study, with safety findings similar to those observed in the phase I study. The median dose intensity (dose delivered/expected dose) was 99.7%, and dose modifications or discontinuations due to AEs were infrequent.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Twenty-one patients (18.8%) completed at least 1 year on treatment, suggesting that long-term administration was tolerated.</div><div class="NLM_p">A subsequent confirmatory single arm phase II study was conducted in 110 patients with HER2-positive MBC who had previously received a taxane, an anthracycline, capecitabine, as well as two HER2-targeted agents, trastuzumab and lapatinib, for a median of seven prior anticancer agents for their metastatic disease.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The ORR was 34.5% (38 of 110 patients). The median PFS was 6.9 months, and the median duration of response was 7.2 months. With inclusion of patients in stable disease for at least 6 months, the overall CBR was 48.2%. The HER2-positive (HER2-overexpression) status was confirmed upon reassessment by a central laboratory in 84% of patients, and in this subgroup of 80 patients, the ORR was 41% with a median PFS of 7.3 months. There were no new safety signals in this confirmatory phase II study, most adverse events being grade 1 or 2. Reversible thrombocytopenia was observed in 38.2% of patients (only 9.1% of grade ≥3); as with the prior studies, platelet transfusions were infrequent, hemorrhagic adverse events were generally mild, and no patient discontinued T-DM1 due to a bleeding event.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> This trial also confirmed the observation of generally mild transaminase elevations indicative of hepatic toxicities that appeared in temporal relationship with T-DM1 dosing (AST increases were seen in 26.4% of patients), although a few patients (8.2%) experienced a grade ≥3 adverse event.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p last">Given the encouraging efficacy signals and tolerable safety profile of T-DM1 in these single arm, single agent studies, a phase II randomized study was performed to directly compare T-DM1 as a single agent with an active regimen for first-line treatment of HER2-positive MBC, trastuzumab plus docetaxel.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> After a median follow-up of about 14 months, there was a significant improvement in PFS in patients treated with T-DM1 (14.2 months) compared with those treated with the standard-of-care (9.2 months). The overall response rates were similar, 64.2% in those patients treated with T-DM1 (<i>n</i> = 67), including seven complete responses (CRs), versus 58% in those patients treated with trastuzumab/docetaxel (<i>n</i> = 70) including three CRs.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Regarding safety in the first-line setting, the T-DM1 arm had about half the number of grade ≥3 adverse events than the trastuzumab/docetaxel arm (46.4% versus 90.9%, respectively). Only 7.2% of AEs led to discontinuation of treatment in patients treated with T-DM1, compared with 40.9% for patients treated with standard-of-care. There were no cases of clinically significant cardiac events, a concern due to the known association of trastuzumab with cardiac toxicity, although three patients on each arm had decreased left ventricular ejection fraction.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> Not only was the incidence of grade ≥3 AEs lower in the T-DM1 arm in comparison to the trastuzumab/docetaxel arm, but their nature was also different. The most common grade ≥3 AEs in the latter arm were neutropenia (62.1%), leukopenia (24.2%), and febrile neutropenia (13.6%), together with a high incidence of alopecia (66.7%), while grade ≥3 AEs in patients treated with T-DM1 were increases in hepatic transaminases (AST 8.7%; ALT 10.1%), thrombocytopenia (7.2%), and neutropenia (5.8%) with only a low incidence of alopecia (4.3%). This randomized study demonstrates the potential for an antibody–drug conjugate to deliver improved clinical benefit and decreased toxicity risk in these patients that should be validated in phase III trials.</div></div><div id="sec8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (c) Phase III Clinical Trials of T-DM1</h3><div class="NLM_p">The phase I and phase II studies led to a pivotal phase III trial (“EMILIA”) in which 991 patients with advanced HER2-positive MBC whose disease had progressed following treatment with trastuzumab and a taxane were randomized to receive either T-DM1 (single agent at 3.6 mg/kg, q3 weeks) or lapatinib plus capecitabine.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Preliminary results were first reported at the 2012 Annual Meeting of the American Society of Clinical Oncology. The median ORR, PFS, and overall survival all significantly favored the T-DM1 arm of the study, as summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">03</a>. The number of AEs of grade ≥3 was less in the T-DM1 arm (40.8%) than in the lapatinib/capecitabine arm (57.0%). As anticipated from the phase I and phase II experience, the incidence of thrombocytopenia, and of increased serum hepatic transaminase levels, were higher in patients treated with T-DM1, while the incidence of diarrhea, nausea, vomiting, and hand–foot syndrome were higher in patients treated with lapatinib/capecitabine (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">03</a>). The rates of cardiac adverse events were low, about 1.6–1.7% in both arms.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Efficacy and Safety Results Reported for the Phase III Clinical Trial, “EMILIA”, Which Randomized HER2-Positive Breast Cancer Patients Who Had Previously Received Trastuzumab and a Taxane for Treatment of Their Metastatic Disease To Receive Either T-DM1 (single agent) or Lapatinib + Capecitabine<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Efficacy</th><th class="colsep0 rowsep0" align="center">T-DM1</th><th class="colsep0 rowsep0" align="center">lapatinib + capecitabine</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of patients evaluable</td><td class="colsep0 rowsep0" align="left"><i>n</i> = 397</td><td class="colsep0 rowsep0" align="left"><i>n</i> = 389</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">objective response rate</td><td class="colsep0 rowsep0" align="left">43.6%</td><td class="colsep0 rowsep0" align="left">30.8%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">complete response</td><td class="colsep0 rowsep0" align="left">1% (<i>n</i> = 4)</td><td class="colsep0 rowsep0" align="left">0.5% (<i>n</i> = 2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">partial response</td><td class="colsep0 rowsep0" align="left">42.6% (<i>n</i> = 169)</td><td class="colsep0 rowsep0" align="left">30.3% (<i>n</i> = 118)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">median duration of response</td><td class="colsep0 rowsep0" align="left">12.6 months</td><td class="colsep0 rowsep0" align="left">6.5 months</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">estimated 1-year survival</td><td class="colsep0 rowsep0" align="left">85.2%</td><td class="colsep0 rowsep0" align="left">78.4%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">estimated 2-year survival</td><td class="colsep0 rowsep0" align="left">64.7%</td><td class="colsep0 rowsep0" align="left">51.8%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">median progression-free survival</td><td class="colsep0 rowsep0" align="left">9.6 months</td><td class="colsep0 rowsep0" align="left">6.4 months</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">median overall survival</td><td class="colsep0 rowsep0" align="left">30.9 months</td><td class="colsep0 rowsep0" align="left">25.1 months</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Safety</th><th class="colsep0 rowsep0" colspan="2" align="center">T-DM1</th><th class="colsep0 rowsep0" colspan="2" align="center">lapatinib + capecitabine</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of subjects evaluable</td><td class="colsep0 rowsep0" colspan="2" align="center"><i>n</i> = 490</td><td class="colsep0 rowsep0" colspan="2" align="center"><i>n</i> = 488</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">adverse events (≥15% of patients)</td><td class="colsep0 rowsep0" align="left">any grade</td><td class="colsep0 rowsep0" align="left">grade ≥3</td><td class="colsep0 rowsep0" align="left">any grade</td><td class="colsep0 rowsep0" align="left">grade ≥3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">any adverse event</td><td class="colsep0 rowsep0" align="left">95.9%</td><td class="colsep0 rowsep0" align="left">40.8%</td><td class="colsep0 rowsep0" align="left">97.7%</td><td class="colsep0 rowsep0" align="left">57.0%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">diarrhea</td><td class="colsep0 rowsep0" align="left">23.3%</td><td class="colsep0 rowsep0" align="left">1.6%</td><td class="colsep0 rowsep0" align="left">79.7%</td><td class="colsep0 rowsep0" align="left">20.7%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hand–foot syndrome</td><td class="colsep0 rowsep0" align="left">1.2%</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">58.0%</td><td class="colsep0 rowsep0" align="left">16.4%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vomiting</td><td class="colsep0 rowsep0" align="left">19.0%</td><td class="colsep0 rowsep0" align="left">0.8%</td><td class="colsep0 rowsep0" align="left">29.3%</td><td class="colsep0 rowsep0" align="left">4.5%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fatigue</td><td class="colsep0 rowsep0" align="left">35.1%</td><td class="colsep0 rowsep0" align="left">2.4%</td><td class="colsep0 rowsep0" align="left">27.9%</td><td class="colsep0 rowsep0" align="left">3.5%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nausea</td><td class="colsep0 rowsep0" align="left">39.2%</td><td class="colsep0 rowsep0" align="left">0.8%</td><td class="colsep0 rowsep0" align="left">44.7%</td><td class="colsep0 rowsep0" align="left">2.5%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mucosal inflammation</td><td class="colsep0 rowsep0" align="left">6.7%</td><td class="colsep0 rowsep0" align="left">0.2%</td><td class="colsep0 rowsep0" align="left">19.1%</td><td class="colsep0 rowsep0" align="left">2.3%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">thrombocytopenia</td><td class="colsep0 rowsep0" align="left">28.0%</td><td class="colsep0 rowsep0" align="left">12.9%</td><td class="colsep0 rowsep0" align="left">2.5%</td><td class="colsep0 rowsep0" align="left">0.2%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">elevated serum ALT</td><td class="colsep0 rowsep0" align="left">16.9%</td><td class="colsep0 rowsep0" align="left">2.9%</td><td class="colsep0 rowsep0" align="left">8.8%</td><td class="colsep0 rowsep0" align="left">1.4%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">elevated serum AST</td><td class="colsep0 rowsep0" align="left">22.4%</td><td class="colsep0 rowsep0" align="left">4.3%</td><td class="colsep0 rowsep0" align="left">9.4%</td><td class="colsep0 rowsep0" align="left">0.8%</td></tr></tbody></table></div></div><div class="NLM_p">The “EMILIA” trial established the safety and effectiveness of T-DM1, and it was approved as a new therapy for patients with HER2-positive late stage (metastatic) breast cancer, previously treated with trastuzumab and taxane chemotherapy, by the U.S. FDA on February 22, 2013. T-DM1 (ado-trastuzumab emtansine, Kadcyla) is the first antibody–drug conjugate to receive full approval from FDA on the basis of a randomized study for any indication.</div><div class="NLM_p">First results of another phase III trial (“TH3RESA”), in which 602 patients with advanced HER2-positive MBC previously treated with at least two HER2-directed therapies were randomized 2:1 to receive either T-DM1 or physician’s choice of treatment, were reported at the European Cancer Congress in September 2013.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The median PFS increased from 3.3 months in the reference arm to 6.2 months in patients receiving T-DM1. The ORR was 31.3% in the T-DM1 arm compared with only 8.6% in these very heavily pretreated patients receiving physician’s choice of treatment. Overall survival showed a trend in favor of T-DM1 (although it did not reach statistical significance at the reported interim analysis), and as with “EMILIA”, there were fewer grade ≥3 AEs in the T-DM1 arm.</div><div class="NLM_p">A phase III trial comparing single agent T-DM1 to trastuzumab plus docetaxel in first-line treatment of HER2-positive MBC is ongoing. This trial, called “MARIANNE”, builds upon the experience of the earlier phase II trial in patients previously untreated for metastatic disease and also includes a comparison of single agent T-DM1 to T-DM1 plus pertuzumab, another HER2-targeting antibody that binds to a distinct site on the HER2 extracellular domain.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Pertuzumab is approved for use in combination with trastuzumab and docetaxel to treat patients with HER2-positive breast cancer.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Including a T-DM1 plus pertuzumab arm in the MARIANNE trial was based on preclinical studies suggesting increased activity of the combination and an earlier phase Ib trial of the safety and preliminary efficacy of the combination in HER2-positive MBC patients.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41, 42)</a> The results of the “MARIANNE” trial are expected in 2014 and are eagerly awaited.</div><div class="NLM_p">Brain metastases are common in patients with HER2-positive MBC and are associated with poor prognosis.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Up to now, patients with symptomatic brain metastases were excluded from enrollment in clinical trials of T-DM1.<a onclick="showRef(event, 'ref31 ref34 ref38'); return false;" href="javascript:void(0);" class="ref ref31 ref34 ref38">(31, 34, 38)</a> However, a preliminary report documents a finding that brain metastases of a HER2-postive breast cancer patient can respond to systemic therapy with single-agent T-DM1, suggesting that the blood–brain barrier is impaired in the vicinity of the tumor and can allow passage of antibodies into the metastatic tumor tissue.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Further investigation of the potential of T-DM1 for treating HER2-positive MBC patients with brain metastases is warranted.</div><div class="NLM_p last">Besides development of T-DM1 in MBC, there is an ongoing phase II/III clinical trial to evaluate T-DM1 versus taxane therapy in patients with previously treated, advanced HER2-positive gastric cancer (<a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a>). Preclinical studies have demonstrated that T-DM1 is active in HER2-positive gastric cancer models.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Clinical Pharmacokinetics and Metabolism of T-DM1</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57704" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57704" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The pharmacokinetic properties of T-DM1 were assessed utilizing two analytical methodologies, those typically used for large proteinaceous molecules (e.g., antibodies), as well as those used for quantifying small molecules. The analytes included total trastuzumab concentrations (unconjugated antibody as well as conjugated antibody irrespective of the number of linked DM1 molecules) and DM1-conjugated trastuzumab concentrations (T-DM1), both measured by specific ELISA methods, as well as free DM1 and DM1 catabolites which were measured using LC–MS/MS methodology.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><div class="NLM_p">T-DM1 showed linear pharmacokinetics across doses ranging from 2.4 to 4.8 mg/kg. Lower doses (<1.2 mg/kg) administered to patients in the phase I trial showed evidence of nonlinearity, consistent with a contribution of concentration-dependent target-mediated clearance to the overall clearance.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> In an analysis of 272 patients dosed at 3.6 mg/kg across four clinical studies, the <i>C</i><sub>max</sub> for T-DM1 was 75.6–80.9 μg/mL, the <i>t</i><sub>1/2</sub> was about 4.0 days, and the CL was 7.0–13 mL day<sup>–1</sup> kg<sup>–1</sup>.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> There was no significant accumulation of T-DM1 on the q3 week schedule. The total trastuzumab measurements showed a longer <i>t</i><sub>1/2</sub> (about 9–11 days) and a slower CL (about 4–5 mL day<sup>–1</sup> kg<sup>–1</sup>) than T-DM1, which can be explained by a slow rate of deconjugation.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44, 45)</a> Furthermore, given that T-DM1 is a mixture of molecules from one to eight linked DM1 molecules per antibody, a slightly faster clearance of T-DM1 species bearing higher amounts of linked DM1 (e.g., species with ≥5 DM1/antibody) versus species with lower amounts of linked DM1 (e.g., ≤3 DM1/antibody) could also contribute to the observed slow decrease in the average ratio of DM1/antibody in circulation over time.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45, 46)</a> Population pharmacokinetic analysis suggests that T-DM1 exposure was relatively constant among patients, although body weight did have the greatest impact on the interindividual variability in some of the pharmacokinetic parameters.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Markers of liver function of renal function had no clinically meaningful effect on the pharmacokinetics of T-DM1.</div><div class="NLM_p">Plasma DM1 concentrations were consistently low, with an average level of about 5 ng/mL in patients dosed with T-DM1 at 3.6 mg/kg, levels of free DM1 that correspond to only about 0.3% of the total conjugated DM1 in circulation, demonstrating the good stability of the linker chemistry in vivo.<a onclick="showRef(event, 'ref44 ref47'); return false;" href="javascript:void(0);" class="ref ref44 ref47">(44, 47)</a> Exploratory analysis of maytansinoid catabolites from T-DM1 showed low concentrations of the linker–DM1 adduct (MCC-DM1) and lysine–linker–DM1 (lysine-<i>N</i><sup>ε</sup>-MCC-DM1) in plasma (<1.9–122 ng/mL and <1.08–6.38 ng/mL, respectively). The MCC-DM1 levels were highest immediately after dosing, while the lysine-<i>N</i><sup>ε</sup>-MCC-DM1 levels peaked at later time-points as might be expected for a catabolite generated via intracellular proteolytic degradation of T-DM1 within lysosomes of cells.<a onclick="showRef(event, 'ref21 ref48'); return false;" href="javascript:void(0);" class="ref ref21 ref48">(21, 48)</a> The maytansinoid metabolites detected in clinical samples were as expected from metabolic studies in rats of T-DM1 made with tritium-labeled DM1. The fecal/biliary route appears to be the major pathway of elimination of the DM1-containing catabolites.<a onclick="showRef(event, 'ref29 ref48'); return false;" href="javascript:void(0);" class="ref ref29 ref48">(29, 48)</a></div><div class="NLM_p last">The incidence of a human anti-T-DM1 antibody response has been low (<5%) in patients exposed to repeated doses of T-DM1. Where they were observed in clinical trials (in 13 of 286 patients), there were no obvious changes in pharmacokinetics, safety profiles, or efficacy outcomes.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Safety and Tolerability Profile of T-DM1</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41522" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41522" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Nearly all patients receiving T-DM1 at 3.6 mg/kg, q3 weeks, experience transient declines in platelets, often beginning 1 day after each dose and reaching a nadir on about day 8 with recovery by about day 15.<a onclick="showRef(event, 'ref31 ref34 ref35 ref38 ref47 ref49'); return false;" href="javascript:void(0);" class="ref ref31 ref34 ref35 ref38 ref47 ref49">(31, 34, 35, 38, 47, 49)</a> Most such AEs were grade 1 or 2, while grade ≥3 events were infrequent, seen in about 10% of patients across most studies, and were generally rapidly reversible and noncumulative.<a onclick="showRef(event, 'ref31 ref34 ref35 ref47'); return false;" href="javascript:void(0);" class="ref ref31 ref34 ref35 ref47">(31, 34, 35, 47)</a> Reports of any clinically significant bleeding events were uncommon, and only rarely were there any reports of the need for platelet transfusions. Nonclinical studies suggest that T-DM1 can be taken up by megakaryocytes via nontarget mediated uptake mechanisms (perhaps pinocytosis), whereupon intracellular generation of the active catabolite, lysine-<i>N</i><sup>ε</sup>-MCC-DM1, can result in disruption of microtubules and proplatelet production, pointing to a possible mechanism for thrombocytopenia in patients.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> It is interesting to note that while thrombocytopenia defined the DLT of T-DM1 in human, the severity of thrombocytopenia in the non-human primate toxicology studies was minimal at much higher doses and did not define MTD in the preclinical safety studies (see <a class="ref internalNav" href="#sec7" aria-label="Preclinical Toxicology and Toxicokinetics of T-DM1">Preclinical Toxicology and Toxicokinetics of T-DM1</a>, above).</div><div class="NLM_p last">Similar to thrombocytopenia, reversible elevations in serum levels of hepatic transaminases were seen in many patients upon dosing with T-DM1, the majority of such events being grade 1 or 2 with grade 3 or 4 AEs seen in less than 10% of patients and one grade 5 event reported to date in a patient with underlying fatty liver disease.<a onclick="showRef(event, 'ref35 ref38'); return false;" href="javascript:void(0);" class="ref ref35 ref38">(35, 38)</a> Other potential toxicities common to microtubule-disrupting agents were notable by their infrequency: alopecia was almost never seen, while neutropenia, leukopenia, and nervous system toxicities were not reported at clinically significant grades or frequencies.<a onclick="showRef(event, 'ref31 ref34 ref36'); return false;" href="javascript:void(0);" class="ref ref31 ref34 ref36">(31, 34, 36)</a> While a serious adverse event of trastuzumab treatment is cardiotoxicity seen in <5% of patients,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> the clinical studies thus far suggest that the risk of cardiotoxicity of T-DM1 is low,<a onclick="showRef(event, 'ref31 ref32 ref34 ref38'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref34 ref38">(31, 32, 34, 38)</a> although most evidence reported to date is for patients who previously received trastuzumab, so susceptible patients may have been excluded from most of the reported clinical studies.<a onclick="showRef(event, 'ref34 ref38'); return false;" href="javascript:void(0);" class="ref ref34 ref38">(34, 38)</a></div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83580" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83580" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">T-DM1, ado-trastuzumab emtansine, is the first antibody–drug conjugate (ADC) to receive full approval from FDA (February 22, 2013). It was approved as a new therapy for patients with HER2-positive late stage (metastatic) breast cancer, previously treated with trastuzumab and taxane chemotherapy. It fulfils the long-sought objective of ADC development, that of better tolerated, more active anticancer agents, and its early promise encourages the development of other agents based on similar ADC platform technologies for a wide array of cancers.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm500766w" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05145" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05145" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John M. Lambert</span> - <span class="hlFld-Affiliation affiliation">ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#cba1a4a3a5e5a7aaa6a9aeb9bf8ba2a6a6bea5a4acaea5e5a8a4a6"><span class="__cf_email__" data-cfemail="81ebeee9efafede0ece3e4f3f5c1e8ececf4efeee6e4efafe2eeec">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ravi V. J. Chari</span> - <span class="hlFld-Affiliation affiliation">ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#334152455a1d505b52415a735a5e5e465d5c54565d1d505c5e"><span class="__cf_email__" data-cfemail="88fae9fee1a6ebe0e9fae1c8e1e5e5fde6e7efede6a6ebe7e5">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): The authors are employees of ImmunoGen, Inc., the developer of the maytansinoid ADC platform utilized in T-DM1.<br /></br></div></li></ul></div><div class="ack" id="ACK-d3487e2114-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65244" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65244" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Gail Lewis Phillips from Genentech, a member of the Roche group, for kindly providing us some figures for inclusion in this paper.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i33" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i33"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i34" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i34"> Abbreviations Used</h2><tr><td class="NLM_term">T-DM1</td><td class="NLM_def"><p class="first last">ado-trastuzumab emtansine</p></td></tr><tr><td class="NLM_term">DM1</td><td class="NLM_def"><p class="first last"><i>N</i><sup>2′</sup>-deacetyl-<i>N</i><sup>2′</sup>-(3-mercapto-1-oxopropyl)maytansine</p></td></tr><tr><td class="NLM_term">SPDP</td><td class="NLM_def"><p class="first last"><i>N</i>-succinimidyl 3-(2-pyridyldithio)propionate</p></td></tr><tr><td class="NLM_term">SPP</td><td class="NLM_def"><p class="first last"><i>N</i>-succinimidyl 4-(2-pyridyldithio)pentanoate</p></td></tr><tr><td class="NLM_term">SSNPP</td><td class="NLM_def"><p class="first last"><i>N</i>-sulfosuccinimidyl 4-(5-nitro-2-pyridyldithio)pentanoate</p></td></tr><tr><td class="NLM_term">SMCC</td><td class="NLM_def"><p class="first last"><i>N</i>-succinimidyl-4-(<i>N</i>-maleimidomethyl)cyclohexane-1-carboxylate</p></td></tr><tr><td class="NLM_term">MCC</td><td class="NLM_def"><p class="first last">4-(<i>N</i>-maleimidomethyl)cyclohexane-1-carboxylate</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last"><i>N</i>-ethyl-<i>N</i>′-(3-dimethylaminopropyl) carbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody–drug conjugate</p></td></tr><tr><td class="NLM_term">ADCC</td><td class="NLM_def"><p class="first last">antibody-dependent cell-mediated cytotoxicity</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">MBC</td><td class="NLM_def"><p class="first last">metastatic breast cancer</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistance</p></td></tr><tr><td class="NLM_term">DAR</td><td class="NLM_def"><p class="first last">DM1-to-antibody ratio</p></td></tr><tr><td class="NLM_term">MTD</td><td class="NLM_def"><p class="first last">maximum tolerated dose</p></td></tr><tr><td class="NLM_term">DLT</td><td class="NLM_def"><p class="first last">dose-limiting toxicity</p></td></tr><tr><td class="NLM_term">AE</td><td class="NLM_def"><p class="first last">adverse event</p></td></tr><tr><td class="NLM_term">CBR</td><td class="NLM_def"><p class="first last">clinical benefit rate</p></td></tr><tr><td class="NLM_term">ORR</td><td class="NLM_def"><p class="first last">overall response rate</p></td></tr><tr><td class="NLM_term">CR</td><td class="NLM_def"><p class="first last">complete response</p></td></tr><tr><td class="NLM_term">PFS</td><td class="NLM_def"><p class="first last">progression-free survival</p></td></tr><tr><td class="NLM_term">AST</td><td class="NLM_def"><p class="first last">aspartate aminotransferase</p></td></tr><tr><td class="NLM_term">ALT</td><td class="NLM_def"><p class="first last">alanine aminotransferase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74701" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74701" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 50 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Colomer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shamon, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupu, R.</span><span> </span><span class="NLM_article-title">Herceptin: from the bench to the clinic</span> <span class="citation_source-journal">Cancer Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=49-56&author=R.+Colomerauthor=L.+A.+Shamonauthor=M.+S.+Tsaiauthor=R.+Lupu&title=Herceptin%3A+from+the+bench+to+the+clinic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColomer%26aufirst%3DR.%26aulast%3DShamon%26aufirst%3DL.%2BA.%26aulast%3DTsai%26aufirst%3DM.%2BS.%26aulast%3DLupu%26aufirst%3DR.%26atitle%3DHerceptin%253A%2520from%2520the%2520bench%2520to%2520the%2520clinic%26jtitle%3DCancer%2520Invest.%26date%3D2001%26volume%3D19%26spage%3D49%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Pegram, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konecny, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Callaghan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beryt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietras, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span> </span><span class="NLM_article-title">Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">749</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1093%2Fjnci%2Fdjh131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=15150302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Sqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2004&pages=739-749&author=M.+D.+Pegramauthor=G.+E.+Konecnyauthor=C.+O%E2%80%99Callaghanauthor=M.+Berytauthor=R.+Pietrasauthor=D.+J.+Slamon&title=Rational+combinations+of+trastuzumab+with+chemotherapeutic+drugs+used+in+the+treatment+of+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer</span></div><div class="casAuthors">Pegram, Mark D.; Konecny, Gottfried E.; O'Callaghan, Carminda; Beryt, Malgorzata; Pietras, Richard; Slamon, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">739-749</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Trastuzumab, a humanized anti-HER2 antibody, increases the clin. benefit of first-line chemotherapy in patients with metastatic breast cancers that overexpress HER2.  We characterized interactions between trastuzumab and chemotherapeutic agents commonly used in the treatment of breast cancer.  Multiple drug effect/combination index isobologram anal. was used to study the efficacy of chemotherapeutic drug plus trastuzumab combinations tested against four HER2-overexpressing breast cancer cell lines (SK-BR-3, BT-474, MDA-MB-361, and MDA-MB-453).  Combination index values were derived from parameters of the median effect plots, and statistical tests were used to det. whether the mean combination index values at multiple effect levels were statistically significantly different from a combination index value of 1.0.  Values less than 1.0 indicate synergistic interactions, values greater than 1.0 indicate antagonistic interactions, and values equal to 1.0 indicate additive interactions.  At a wide range of clin. achievable drug concns., synergistic interactions were obsd. in all four breast cancer cell lines for trastuzumab plus carboplatin (mean combination index values ranged from 0.32 [P<.001] to 0.53 [P<.001]), 4-hydroxycyclophosphamide (mean combination index values ranged from 0.38 [P<.001] to 0.73 [P = .010]), docetaxel (mean combination index values ranged from 0.30 [P<.001] to 0.62 [P<.001]), and vinorelbine (mean combination index values ranged from 0.24 [P<.001] to 0.78 [P<.034]).  Additive interactions were obsd. in all four cell lines with trastuzumab plus doxorubicin, epirubicin, and paclitaxel.  Interactions between trastuzumab and gemcitabine were synergistic at low concns. of gemcitabine and antagonistic at high concns.  A synergistic interaction was obsd. with a three-drug combination of docetaxel plus carboplatin plus trastuzumab in SK-BR-3 cells (mean combination index value = 0.09; P<.001).  Consistent synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine across a wide range of clin. relevant concns. in HER2-overexpressing breast cancer cells indicate that these are rational combinations to test in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ5NdDhTJwpLVg90H21EOLACvtfcHk0lgW1N2OtjmjMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Sqsbo%253D&md5=1fb831bd3fbb62277de025c4a99f383d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjh131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjh131%26sid%3Dliteratum%253Aachs%26aulast%3DPegram%26aufirst%3DM.%2BD.%26aulast%3DKonecny%26aufirst%3DG.%2BE.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DC.%26aulast%3DBeryt%26aufirst%3DM.%26aulast%3DPietras%26aufirst%3DR.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DRational%2520combinations%2520of%2520trastuzumab%2520with%2520chemotherapeutic%2520drugs%2520used%2520in%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2004%26volume%3D96%26spage%3D739%26epage%3D749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Shepard, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarup, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendly, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maneval, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mordenti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figari, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotts, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palladino, M. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic</span> <span class="citation_source-journal">J. Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1007%2FBF00918679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=1679763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADyaK3MXmsFent7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1991&pages=117-127&author=H.+M.+Shepardauthor=G.+D.+Lewisauthor=J.+C.+Sarupauthor=B.+M.+Fendlyauthor=D.+Manevalauthor=J.+Mordentiauthor=I.+Figariauthor=C.+E.+Kottsauthor=M.+A.+Palladinoauthor=A.+Ullrich&title=Monoclonal+antibody+therapy+of+human+cancer%3A+taking+the+HER2+protooncogene+to+the+clinic"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Monoclonal antibody therapy of human cancer:  taking the HER2 protooncogene to the clinic</span></div><div class="casAuthors">Shepard, H. Michael; Lewis, Gail D.; Sarup, Jay C.; Fendly, Brian M.; Maneval, Daniel; Mordenti, Joyce; Figari, Irene; Kotts, Claire E.; Palladino, Michael A., Jr.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Immunology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">117-27</span>CODEN:
                <span class="NLM_cas:coden">JCIMDO</span>;
        ISSN:<span class="NLM_cas:issn">0271-9142</span>.
    </div><div class="casAbstract">A review, with 35 refs., on: the HER2 protoncogene and human cancer; derivation of muMAb 4D5; in vivo preclin. efficacy; and mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE9uMsOqiof7Vg90H21EOLACvtfcHk0ljkdtT7cV0hJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmsFent7w%253D&md5=8c323a0c6d081fc00a2b3328a8711f75</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2FBF00918679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00918679%26sid%3Dliteratum%253Aachs%26aulast%3DShepard%26aufirst%3DH.%2BM.%26aulast%3DLewis%26aufirst%3DG.%2BD.%26aulast%3DSarup%26aufirst%3DJ.%2BC.%26aulast%3DFendly%26aufirst%3DB.%2BM.%26aulast%3DManeval%26aufirst%3DD.%26aulast%3DMordenti%26aufirst%3DJ.%26aulast%3DFigari%26aufirst%3DI.%26aulast%3DKotts%26aufirst%3DC.%2BE.%26aulast%3DPalladino%26aufirst%3DM.%2BA.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DMonoclonal%2520antibody%2520therapy%2520of%2520human%2520cancer%253A%2520taking%2520the%2520HER2%2520protooncogene%2520to%2520the%2520clinic%26jtitle%3DJ.%2520Clin.%2520Immunol.%26date%3D1991%26volume%3D11%26spage%3D117%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Spector, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwell, K. L.</span><span> </span><span class="NLM_article-title">Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">5838</span><span class="NLM_x">–</span> <span class="NLM_lpage">5847</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1200%2FJCO.2009.22.1507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=19884552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVWitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=5838-5847&author=N.+L.+Spectorauthor=K.+L.+Blackwell&title=Understanding+the+mechanisms+behind+trastuzumab+therapy+for+human+epidermal+growth+factor+receptor+2-positive+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer</span></div><div class="casAuthors">Spector, Neil L.; Blackwell, Kimberly L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">5838-5847</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Purpose: Targeted therapy with the humanized monoclonal antibody trastuzumab has become a mainstay for human epidermal growth factor receptor 2 (HER2) -pos. breast cancer (BC).  The mechanisms of action of trastuzumab have not been fully elucidated, and data available to date are reviewed here.  The impact of the mechanisms of action on clin. benefit also is discussed.  Methods: An extensive literature review of trastuzumab and proposed mechanisms of action was performed.  Results: At least five potential extracellular and intracellular antitumor mechanisms of trastuzumab have been identified in the preclin. setting.  These include activation of antibody-dependent cellular cytotoxicity, inhibition of extracellular domain cleavage, abrogation of intracellular signaling, redn. of angiogenesis, and decreased DNA repair.  These effects lead to tumor cell stasis and/or death.  Clin. benefit from trastuzumab-based therapy in both early and advanced BC has been demonstrated.  The benefit of trastuzumab use beyond progression has also been shown, which indicates the need for continuous suppression of the HER2 pathway.  Targeting both HER2, with various approaches, and other pathways may enhance the clin. benefit obsd. with trastuzumab and overcome potential resistance.  Novel combinations include pertuzumab (a HER2 dimerization inhibitor), lapatinib (a HER1/HER2 tyrosine kinase inhibitor), bevacizumab (an antiangiogenic agent), tanespimycin (a heat shock protein inhibitor), antiestrogen therapies, and an antibody-drug conjugate (trastuzumab-DM1).  Conclusion: Trastuzumab is the foundation of care for patients with HER2-pos. BC.  Emerging data from studies of other targeted agents may provide alternative treatment combinations to maximize the clin. benefit from trastuzumab and prevent or delay resistance.  The continued development of trastuzumab highlights promising treatment approaches for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUKW7T01USzrVg90H21EOLACvtfcHk0ljkdtT7cV0hJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVWitro%253D&md5=d54f228c3b69c973238fb1279ee8572d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.22.1507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.22.1507%26sid%3Dliteratum%253Aachs%26aulast%3DSpector%26aufirst%3DN.%2BL.%26aulast%3DBlackwell%26aufirst%3DK.%2BL.%26atitle%3DUnderstanding%2520the%2520mechanisms%2520behind%2520trastuzumab%2520therapy%2520for%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202-positive%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D5838%26epage%3D5847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leyland-Jones, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paton, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajamonde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span> </span><span class="NLM_article-title">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">783</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1056%2FNEJM200103153441101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=11248153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVGktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=783-792&author=D.+J.+Slamonauthor=B.+Leyland-Jonesauthor=S.+Shakauthor=H.+Fuchsauthor=V.+Patonauthor=A.+Bajamondeauthor=T.+Flemingauthor=W.+Eiermannauthor=J.+Wolterauthor=M.+Pegramauthor=J.+Baselgaauthor=L.+Norton&title=Use+of+chemotherapy+plus+a+monoclonal+antibody+against+HER2+for+metastatic+breast+cancer+that+overexpresses+HER2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span></div><div class="casAuthors">Slamon, Dennis J.; Leyland-Jones, Brian; Shak, Steven; Fuchs, Hank; Paton, Virginia; Bajamonde, Alex; Fleming, Thomas; Eiermann, Wolfgang; Wolter, Janet; Pegram, Mark; Baselga, Jose; Norton, Larry</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">783-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 % of breast cancers, increasing the aggressiveness of the tumor.  We evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody against HER2, in women with metastatic breast cancer that overexpressed HER2.  We randomly assigned 234 patients to receive std. chemotherapy plus trastuzumab.  Patients who had not previously received adjuvant (postoperative) therapy with an anthracycline were treated with doxorubicin (or epirubicin in the case of 36 women) and cyclophosphamide with (143 women) or without trastuzumab (138 women).  Patients who had previously received adjuvant anthracycline were treated with paclitaxel alone (96 women) or paclitaxel with trastuzumab (92 women).  The addn. of trastuzumab to chemotherapy was assocd. with a longer time to disease progression (median, 7.4 vs. 4.6 mo; P<0.001), a higher rate of objective response (50 % vs. 32 %, P<0.001), a longer duration of response (median, 9.1 vs. 6.1 mo; P<0.001), a lower rate of death at 1 yr (22 % vs. 33 %, P=0.008), longer survival (median survival, 25.1 vs. 20.3 mo; P=0.046), and a 20 % redn. in the risk of death.  The most important adverse event was cardiac dysfunction, which occurred in 27 % of the group given an anthracycline, cyclophosphamide, and trastuzumab; 8 % of the group given an anthracycline and cyclophosphamide alone; 13 % of the group given paclitaxel and trastuzumab; and 1 % of the group given paclitaxel alone.  Although the cardiotoxicity was potentially severe and, in some cases, life-threatening, the symptoms generally improved with std. medical management.  Trastuzumab increases the clin. benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGK_4WWRZLKLVg90H21EOLACvtfcHk0lhD2N71Re15xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVGktrc%253D&md5=81112f11ffc66fc3a898b61e104322b6</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJM200103153441101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200103153441101%26sid%3Dliteratum%253Aachs%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DLeyland-Jones%26aufirst%3DB.%26aulast%3DShak%26aufirst%3DS.%26aulast%3DFuchs%26aufirst%3DH.%26aulast%3DPaton%26aufirst%3DV.%26aulast%3DBajamonde%26aufirst%3DA.%26aulast%3DFleming%26aufirst%3DT.%26aulast%3DEiermann%26aufirst%3DW.%26aulast%3DWolter%26aufirst%3DJ.%26aulast%3DPegram%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DNorton%26aufirst%3DL.%26atitle%3DUse%2520of%2520chemotherapy%2520plus%2520a%2520monoclonal%2520antibody%2520against%2520HER2%2520for%2520metastatic%2520breast%2520cancer%2520that%2520overexpresses%2520HER2%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D783%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Nahta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteva, F. J.</span><span> </span><span class="NLM_article-title">HER-2-targeted therapy: lessons learned and future directions</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">5078</span><span class="NLM_x">–</span> <span class="NLM_lpage">5084</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=14613984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVOgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=5078-5084&author=R.+Nahtaauthor=F.+J.+Esteva&title=HER-2-targeted+therapy%3A+lessons+learned+and+future+directions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">HER-2-Targeted Therapy: Lessons Learned and Future Directions</span></div><div class="casAuthors">Nahta, Rita; Esteva, Francisco J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5078-5084</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  HER-2 is overexpressed in 20-25% of invasive breast cancers and is assocd. with an aggressive tumor phenotype and reduced survival rates.  The HER-2 status of a tumor is the crit. determinant of response to the HER-2-targeted antibody trastuzumab.  Thus, accurate assessment of HER-2 expression levels is essential for identifying breast cancer patients who will benefit from HER-2-targeted therapy.  Trastuzumab combined with chemotherapy increases response rates, time to progression, and survival.  However, the majority of cancers that initially respond to trastuzumab begin to progress again within 1 yr.  This minireview describes HER-2 targeting strategies currently in use or in stages of development for the treatment of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaJ78rVpE6ybVg90H21EOLACvtfcHk0lhD2N71Re15xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVOgtb4%253D&md5=0c48944fbc257ee35c8197d04b31595f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNahta%26aufirst%3DR.%26aulast%3DEsteva%26aufirst%3DF.%2BJ.%26atitle%3DHER-2-targeted%2520therapy%253A%2520lessons%2520learned%2520and%2520future%2520directions%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D5078%26epage%3D5084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Metzger-Filho, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I.</span><span> </span><span class="NLM_article-title">Pertuzumab: optimizing HER2 blockade</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5552</span><span class="NLM_x">–</span> <span class="NLM_lpage">5556</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1158%2F1078-0432.CCR-13-0518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=23942091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ahurzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=5552-5556&author=O.+Metzger-Filhoauthor=E.+P.+Winerauthor=I.+Krop&title=Pertuzumab%3A+optimizing+HER2+blockade"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Pertuzumab: Optimizing HER2 Blockade</span></div><div class="casAuthors">Metzger-Filho, Otto; Winer, Eric P.; Krop, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5552-5556</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Pertuzumab has been approved by the U.S. Food and Drug Administration for use in combination with trastuzumab and docetaxel for the first-line treatment of patients with advanced HER2-pos. (HER2+) breast cancer.  Pertuzumab is a recombinant humanized monoclonal antibody that binds to the extracellular dimerization domain II of HER2 and inhibits heterodimerization of HER2 with other HER family members, including EGF receptor (EGFR), HER3, and HER4.  The HER2-HER3 heterodimer is a robust activator of phosphoinositide 3-kinase (PI3K) pathway signaling and functions as the most transforming and mitogenic of the receptor complexes formed by the HER family of proteins; thus, blockade of HER2-HER3 likely represents the most relevant action of pertuzumab.  In the seminal phase III study, patients with HER2+ metastatic breast cancer were randomized to receive trastuzumab and docetaxel, with or without pertuzumab: Addn. of pertuzumab significantly prolonged progression-free survival with an increase of 6.1 mo (12.4 vs. 18.5 mo, resp.).  In a subsequent anal. with 30 mo of median follow-up, pertuzumab conferred a 34% redn. in the risk of mortality.  Here, we review the mechanism of action of pertuzumab, the rationale for combining it with trastuzumab/pertuzumab, clin. data, and future directions for this work.  Clin Cancer Res; 19(20); 5552-6. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo90EvFOonkWrVg90H21EOLACvtfcHk0lhD2N71Re15xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ahurzK&md5=a72443fe22216b25ad4b438bd604f44e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0518%26sid%3Dliteratum%253Aachs%26aulast%3DMetzger-Filho%26aufirst%3DO.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DKrop%26aufirst%3DI.%26atitle%3DPertuzumab%253A%2520optimizing%2520HER2%2520blockade%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D5552%26epage%3D5556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W. C.</span><span> </span><span class="NLM_article-title">Antibody–drug conjugates: an emerging concept in cancer therapy</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3796</span><span class="NLM_x">–</span> <span class="NLM_lpage">3827</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=3796-3827&author=R.+V.+Chariauthor=M.+L.+Millerauthor=W.+C.+Widdison&title=Antibody%E2%80%93drug+conjugates%3A+an+emerging+concept+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26atitle%3DAntibody%25E2%2580%2593drug%2520conjugates%253A%2520an%2520emerging%2520concept%2520in%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D3796%26epage%3D3827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Blattler, W. A.; Chari, R. V. J.</span><span> </span><span class="NLM_article-title">Methods of treatment using anti-ERBB antibody–maytansinoid conjugates</span>. U.S. Patent 8,337,856,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=W.+A.+Blattler&author=R.+V.+J.+Chari&title=Methods+of+treatment+using+anti-ERBB+antibody%E2%80%93maytansinoid+conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26atitle%3DMethods%2520of%2520treatment%2520using%2520anti-ERBB%2520antibody%25E2%2580%2593maytansinoid%2520conjugates%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Sedlacek, H. H.</span> <span class="citation_source-book">Antibodies as Carriers of Cytotoxicity</span>; <span class="NLM_publisher-name">Karger</span>: <span class="NLM_publisher-loc">Basel, Switzerland</span>,<span class="NLM_x"> </span><span class="NLM_year">1992</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&pages=1-145&author=H.+H.+Sedlacek&title=Antibodies+as+Carriers+of+Cytotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSedlacek%26aufirst%3DH.%2BH.%26btitle%3DAntibodies%2520as%2520Carriers%2520of%2520Cytotoxicity%26pub%3DKarger%26date%3D1992%26spage%3D1%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Chari Ravi, V. J.</span><span> </span><span class="NLM_article-title">Targeted cancer therapy: conferring specificity to cytotoxic drugs</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=98-107&author=V.+J.+Chari+Ravi&title=Targeted+cancer+therapy%3A+conferring+specificity+to+cytotoxic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChari%2BRavi%26aufirst%3DV.%2BJ.%26atitle%3DTargeted%2520cancer%2520therapy%253A%2520conferring%2520specificity%2520to%2520cytotoxic%2520drugs%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D98%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Kupchan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komoda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branfman, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sneden, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Court, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hintz, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howie, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dailey, R. G.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerly, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumner, W. C.,  Jr.</span><span> </span><span class="NLM_article-title">The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">2349</span><span class="NLM_x">–</span> <span class="NLM_lpage">2357</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00434a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1977&pages=2349-2357&author=S.+M.+Kupchanauthor=Y.+Komodaauthor=A.+R.+Branfmanauthor=A.+T.+Snedenauthor=W.+A.+Courtauthor=G.+J.+Thomasauthor=H.+P.+Hintzauthor=R.+M.+Smithauthor=A.+Karimauthor=G.+A.+Howieauthor=A.+K.+Vermaauthor=Y.+Nagaoauthor=R.+G.+Daileyauthor=V.+A.+Zimmerlyauthor=W.+C.+Sumner&title=The+maytansinoids.+Isolation%2C+structural+elucidation%2C+and+chemical+interrelation+of+novel+ansa+macrolides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjo00434a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00434a001%26sid%3Dliteratum%253Aachs%26aulast%3DKupchan%26aufirst%3DS.%2BM.%26aulast%3DKomoda%26aufirst%3DY.%26aulast%3DBranfman%26aufirst%3DA.%2BR.%26aulast%3DSneden%26aufirst%3DA.%2BT.%26aulast%3DCourt%26aufirst%3DW.%2BA.%26aulast%3DThomas%26aufirst%3DG.%2BJ.%26aulast%3DHintz%26aufirst%3DH.%2BP.%26aulast%3DSmith%26aufirst%3DR.%2BM.%26aulast%3DKarim%26aufirst%3DA.%26aulast%3DHowie%26aufirst%3DG.%2BA.%26aulast%3DVerma%26aufirst%3DA.%2BK.%26aulast%3DNagao%26aufirst%3DY.%26aulast%3DDailey%26aufirst%3DR.%2BG.%26aulast%3DZimmerly%26aufirst%3DV.%2BA.%26aulast%3DSumner%26aufirst%3DW.%2BC.%26atitle%3DThe%2520maytansinoids.%2520Isolation%252C%2520structural%2520elucidation%252C%2520and%2520chemical%2520interrelation%2520of%2520novel%2520ansa%2520macrolides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1977%26volume%3D42%26spage%3D2349%26epage%3D2357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Widdison, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavanagh, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leece, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovtun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeves, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span> </span><span class="NLM_article-title">Semisynthetic maytansine analogues for the targeted treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4392</span><span class="NLM_x">–</span> <span class="NLM_lpage">4408</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060319f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFent7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4392-4408&author=W.+C.+Widdisonauthor=S.+D.+Wilhelmauthor=E.+E.+Cavanaghauthor=K.+R.+Whitemanauthor=B.+A.+Leeceauthor=Y.+Kovtunauthor=V.+S.+Goldmacherauthor=H.+Xieauthor=R.+M.+Steevesauthor=R.+J.+Lutzauthor=R.+Zhaoauthor=L.+Wangauthor=W.+A.+Blattlerauthor=R.+V.+Chari&title=Semisynthetic+maytansine+analogues+for+the+targeted+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Semisynthetic Maytansine Analogs for the Targeted Treatment of Cancer</span></div><div class="casAuthors">Widdison, Wayne C.; Wilhelm, Sharon D.; Cavanagh, Emily E.; Whiteman, Kathleen R.; Leece, Barbara A.; Kovtun, Yelena; Goldmacher, Victor S.; Xie, Hongsheng; Steeves, Rita M.; Lutz, Robert J.; Zhao, Robert; Wang, Lintao; Blaettler, Walter A.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4392-4408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clin. trials because of unacceptable systemic toxicity.  The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells.  A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized.  The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied.  Several of these maytansinoids were found to be even more potent in vitro than maytansine.  The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozfQO-pe0iJLVg90H21EOLACvtfcHk0ljc35nqXy18fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFent7o%253D&md5=a06c19d2d5166b0ca806babf9624c48b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm060319f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060319f%26sid%3Dliteratum%253Aachs%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DWilhelm%26aufirst%3DS.%2BD.%26aulast%3DCavanagh%26aufirst%3DE.%2BE.%26aulast%3DWhiteman%26aufirst%3DK.%2BR.%26aulast%3DLeece%26aufirst%3DB.%2BA.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DSteeves%26aufirst%3DR.%2BM.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DSemisynthetic%2520maytansine%2520analogues%2520for%2520the%2520targeted%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4392%26epage%3D4408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Issell, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crooke, S. T.</span><span> </span><span class="NLM_article-title">Maytansine</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1016%2FS0305-7372%2878%2980014-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=367597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A280%3ADyaE1M7gsFektw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1978&pages=199-207&author=B.+F.+Issellauthor=S.+T.+Crooke&title=Maytansine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Maytansine</span></div><div class="casAuthors">Issell B F; Crooke S T</div><div class="citationInfo"><span class="NLM_cas:title">Cancer treatment reviews</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">199-207</span>
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQuFvddg8VPVMve_zCu79I8fW6udTcc2eawOjBZaR7IELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE1M7gsFektw%253D%253D&md5=73ec733c0581edc2085d87aa26291f26</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS0305-7372%2878%2980014-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0305-7372%252878%252980014-0%26sid%3Dliteratum%253Aachs%26aulast%3DIssell%26aufirst%3DB.%2BF.%26aulast%3DCrooke%26aufirst%3DS.%2BT.%26atitle%3DMaytansine%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D1978%26volume%3D5%26spage%3D199%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Kupchan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sneden, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branfman, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howie, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebhun, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIvor, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnaitman, T. C.</span><span> </span><span class="NLM_article-title">Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00199a006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1978&pages=31-37&author=S.+M.+Kupchanauthor=A.+T.+Snedenauthor=A.+R.+Branfmanauthor=G.+A.+Howieauthor=L.+I.+Rebhunauthor=W.+E.+McIvorauthor=R.+W.+Wangauthor=T.+C.+Schnaitman&title=Structural+requirements+for+antileukemic+activity+among+the+naturally+occurring+and+semisynthetic+maytansinoids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm00199a006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00199a006%26sid%3Dliteratum%253Aachs%26aulast%3DKupchan%26aufirst%3DS.%2BM.%26aulast%3DSneden%26aufirst%3DA.%2BT.%26aulast%3DBranfman%26aufirst%3DA.%2BR.%26aulast%3DHowie%26aufirst%3DG.%2BA.%26aulast%3DRebhun%26aufirst%3DL.%2BI.%26aulast%3DMcIvor%26aufirst%3DW.%2BE.%26aulast%3DWang%26aufirst%3DR.%2BW.%26aulast%3DSchnaitman%26aufirst%3DT.%2BC.%26atitle%3DStructural%2520requirements%2520for%2520antileukemic%2520activity%2520among%2520the%2520naturally%2520occurring%2520and%2520semisynthetic%2520maytansinoids%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1978%26volume%3D21%26spage%3D31%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martell, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenzie, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span> </span><span class="NLM_article-title">Immunoconjugates containing novel maytansinoids: promising anticancer drugs</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">131</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=1727373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADyaK38Xht1Snu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1992&pages=127-131&author=R.+V.+Chariauthor=B.+A.+Martellauthor=J.+L.+Grossauthor=S.+B.+Cookauthor=S.+A.+Shahauthor=W.+A.+Blattlerauthor=S.+J.+McKenzieauthor=V.+S.+Goldmacher&title=Immunoconjugates+containing+novel+maytansinoids%3A+promising+anticancer+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoconjugates containing novel maytansinoids:  promising anticancer drugs</span></div><div class="casAuthors">Chari, Ravi V. J.; Martell, Bridget A.; Gross, Jonathan L.; Cook, Sherrilyn B.; Shah, Sudhir A.; Blattler, Walter A.; McKenzie, Sara J.; Goldmacher, Victor S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-31</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">The potential of immunoconjugates of cytotoxic drugs for the treatment of cancer has not yet been realized owing to the difficulty of delivering therapeutic concns. of these drugs to the target cells.  In an effort to overcome this problem the authors have synthesized maytansinoids that have 100- to 1000-fold higher cytotoxic potency than clin. used anticancer drugs.  These maytansinoids are linked to antibodies via disulfide bonds, which ensures the release of fully active drug inside the cells.  The conjugates show high antigen-specific cytotoxicity for cultured human cancer cells (50% inhibiting concn., 10 to 40 pM), low systemic toxicity in mice, and good pharmacokinetic behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9PfQvlOYozLVg90H21EOLACvtfcHk0ljCECDhGR74WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xht1Snu7s%253D&md5=33e7613da2a71800fc13e0b2bc6e21f1</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DMartell%26aufirst%3DB.%2BA.%26aulast%3DGross%26aufirst%3DJ.%2BL.%26aulast%3DCook%26aufirst%3DS.%2BB.%26aulast%3DShah%26aufirst%3DS.%2BA.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DMcKenzie%26aufirst%3DS.%2BJ.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26atitle%3DImmunoconjugates%2520containing%2520novel%2520maytansinoids%253A%2520promising%2520anticancer%2520drugs%26jtitle%3DCancer%2520Res.%26date%3D1992%26volume%3D52%26spage%3D127%26epage%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Kellogg, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovtun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leece, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeves, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span> </span><span class="NLM_article-title">Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">717</span><span class="NLM_x">–</span> <span class="NLM_lpage">727</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc100480a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFKnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=717-727&author=B.+A.+Kelloggauthor=L.+Garrettauthor=Y.+Kovtunauthor=K.+C.+Laiauthor=B.+Leeceauthor=M.+Millerauthor=G.+Payneauthor=R.+Steevesauthor=K.+R.+Whitemanauthor=W.+Widdisonauthor=H.+Xieauthor=R.+Singhauthor=R.+V.+Chariauthor=J.+M.+Lambertauthor=R.+J.+Lutz&title=Disulfide-linked+antibody-maytansinoid+conjugates%3A+optimization+of+in+vivo+activity+by+varying+the+steric+hindrance+at+carbon+atoms+adjacent+to+the+disulfide+linkage"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage</span></div><div class="casAuthors">Kellogg, Brenda A.; Garrett, Lisa; Kovtun, Yelena; Lai, Katharine C.; Leece, Barbara; Miller, Michael; Payne, Gillian; Steeves, Rita; Whiteman, Kathleen R.; Widdison, Wayne; Xie, Hongsheng; Singh, Rajeeva; Chari, Ravi V. J.; Lambert, John M.; Lutz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">717-727</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this report, we describe the synthesis of a panel of disulfide-linked huC242 (anti-CanAg) antibody maytansinoid conjugates (AMCs), which have varying levels of steric hindrance around the disulfide bond, in order to investigate the relationship between stability to redn. of the disulfide linker and antitumor activity of the conjugate in vivo.  The conjugates were first tested for stability to redn. by dithiothreitol in vitro and for plasma stability in CD1 mice.  It was found that the conjugates having the more sterically hindered disulfide linkages were more stable to reductive cleavage of the maytansinoid in both settings.  When the panel of conjugates was tested for in vivo efficacy in two human colon cancer xenograft models in SCID mice, it was found that the conjugate with intermediate disulfide bond stability having two Me groups on the maytansinoid side of the disulfide bond and no Me groups on the linker side of the disulfide bond (huC242-SPDB-DM4) displayed the best efficacy.  The ranking of in vivo efficacies of the conjugates was not predicted by their in vitro potencies, since all conjugates were highly active in vitro, including a huC242-SMCC-DM1 conjugate with a noncleavable linkage which showed only marginal activity in vivo.  These data suggest that factors in addn. to intrinsic conjugate potency and conjugate half-life in plasma influence the magnitude of antitumor activity obsd. for an AMC in vivo.  We provide evidence that bystander killing of neighboring nontargeted tumor cells by diffusible cytotoxic metabolites produced from target cell processing of disulfide-linked antibody-maytansinoid conjugates may be one addnl. factor contributing to the activity of these conjugates in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGmGw-cH238bVg90H21EOLACvtfcHk0ljCECDhGR74WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFKnsro%253D&md5=ef2969ceaaea23e81da2edf06f62ea7e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fbc100480a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc100480a%26sid%3Dliteratum%253Aachs%26aulast%3DKellogg%26aufirst%3DB.%2BA.%26aulast%3DGarrett%26aufirst%3DL.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DK.%2BC.%26aulast%3DLeece%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DPayne%26aufirst%3DG.%26aulast%3DSteeves%26aufirst%3DR.%26aulast%3DWhiteman%26aufirst%3DK.%2BR.%26aulast%3DWiddison%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26atitle%3DDisulfide-linked%2520antibody-maytansinoid%2520conjugates%253A%2520optimization%2520of%2520in%2520vivo%2520activity%2520by%2520varying%2520the%2520steric%2520hindrance%2520at%2520carbon%2520atoms%2520adjacent%2520to%2520the%2520disulfide%2520linkage%26jtitle%3DBioconjugate%2520Chem.%26date%3D2011%26volume%3D22%26spage%3D717%26epage%3D727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Wakankar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gokarn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, F. S.</span><span> </span><span class="NLM_article-title">Analytical methods for physicochemical characterization of antibody drug conjugates</span> <span class="citation_source-journal">mAbs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=161-172&author=A.+Wakankarauthor=Y.+Chenauthor=Y.+Gokarnauthor=F.+S.+Jacobson&title=Analytical+methods+for+physicochemical+characterization+of+antibody+drug+conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakankar%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGokarn%26aufirst%3DY.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26atitle%3DAnalytical%2520methods%2520for%2520physicochemical%2520characterization%2520of%2520antibody%2520drug%2520conjugates%26jtitle%3DmAbs%26date%3D2011%26volume%3D3%26spage%3D161%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Wakankar, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. J.</span><span> </span><span class="NLM_article-title">Physicochemical stability of the antibody–drug conjugate trastuzumab-DM1: changes due to modification and conjugation processes</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1588</span><span class="NLM_x">–</span> <span class="NLM_lpage">1595</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc900434c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=1588-1595&author=A.+A.+Wakankarauthor=M.+B.+Feeneyauthor=J.+Riveraauthor=Y.+Chenauthor=M.+Kimauthor=V.+K.+Sharmaauthor=Y.+J.+Wang&title=Physicochemical+stability+of+the+antibody%E2%80%93drug+conjugate+trastuzumab-DM1%3A+changes+due+to+modification+and+conjugation+processes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical Stability of the Antibody-Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation Processes</span></div><div class="casAuthors">Wakankar, Aditya A.; Feeney, Maria B.; Rivera, Javier; Chen, Yan; Kim, Michael; Sharma, Vikas K.; Wang, Y. John</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1588-1595</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the manuf. of the antibody-drug conjugate Trastuzumab-DM1 (T-DM1), the lysine residues on the antibody trastuzumab (Tmab) are modified to form the intermediate Tmab-MCC (T-MCC) and then conjugated with the drug DM1.  Our goal is to understand the effects of modification and conjugation steps on the physicochem. stability of the antibody.  The structural stability of Tmab relative to its modified and conjugated forms was assessed, employing thermally induced stress conditions to formulations contg. Tmab, T-MCC, and T-DM1.  DSC, SEC, CE-SDS, and LC-MS were used to study the stability of Tmab, T-MCC, and T-DM1 to thermal stress.  The DSC thermograms show a decrease in melting temp. for the CH2 transition, in the order Tmab > T-MCC > T-DM1.  As per SEC anal., a significant increase in level of aggregation was detected in T-MCC (∼32%) and T-DM1 (∼5%) after 14 days at 40°.  Tmab did not show significant aggregate formation.  CE-SDS and LC-MS data demonstrate that the aggregation in the case of T-MCC is largely covalent and involves mechanisms other than formation of intermol. disulfide crosslinks.  The aggregation obsd. for T-MCC was significantly inhibited upon addn. of amino acids with nucleophilic side chains contg. thiol (Cys) and hydroxyl moieties (Ser, Tyr).  The covalent aggregation obsd. for T-MCC and the ability of nucleophilic amino acids, particularly Cys, to inhibit it indicate that the maleimide moiety in the MCC linker may react to form intermol. covalent crosslinks between T-MCC mols., possibly through a Michael addn. mechanism.  In addn., DSC results demonstrate that the conjugation of the drug moiety DM1 to Tmab results in destabilization of the CH2 domain of the antibody.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoTooyTYRrPLVg90H21EOLACvtfcHk0lg0XmAYGiuP5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyltbk%253D&md5=6c67fb904a35f97adfeb62ec69b7d4be</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fbc900434c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc900434c%26sid%3Dliteratum%253Aachs%26aulast%3DWakankar%26aufirst%3DA.%2BA.%26aulast%3DFeeney%26aufirst%3DM.%2BB.%26aulast%3DRivera%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DSharma%26aufirst%3DV.%2BK.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26atitle%3DPhysicochemical%2520stability%2520of%2520the%2520antibody%25E2%2580%2593drug%2520conjugate%2520trastuzumab-DM1%253A%2520changes%2520due%2520to%2520modification%2520and%2520conjugation%2520processes%26jtitle%3DBioconjugate%2520Chem.%26date%3D2010%26volume%3D21%26spage%3D1588%26epage%3D1595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwall, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenkare-Mitra, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9280</span><span class="NLM_x">–</span> <span class="NLM_lpage">9290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1158%2F0008-5472.CAN-08-1776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=19010901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9280-9290&author=G.+D.+Lewis+Phillipsauthor=G.+Liauthor=D.+L.+Duggerauthor=L.+M.+Crockerauthor=K.+L.+Parsonsauthor=E.+Maiauthor=W.+A.+Blattlerauthor=J.+M.+Lambertauthor=R.+V.+Chariauthor=R.+J.+Lutzauthor=W.+L.+Wongauthor=F.+S.+Jacobsonauthor=H.+Koeppenauthor=R.+H.+Schwallauthor=S.+R.+Kenkare-Mitraauthor=S.+D.+Spencerauthor=M.+X.+Sliwkowski&title=Targeting+HER2-positive+breast+cancer+with+trastuzumab-DM1%2C+an+antibody-cytotoxic+drug+conjugate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate</span></div><div class="casAuthors">Lewis Phillips, Gail D.; Li, Guangmin; Dugger, Debra L.; Crocker, Lisa M.; Parsons, Kathryn L.; Mai, Elaine; Blaettler, Walter A.; Lambert, John M.; Chari, Ravi V. J.; Lutz, Robert J.; Wong, Wai Lee T.; Jacobson, Frederic S.; Koeppen, Hartmut; Schwall, Ralph H.; Kenkare-Mitra, Sara R.; Spencer, Susan D.; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9280-9290</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER2 is a validated target in breast cancer therapy.  Two drugs are currently approved for HER2-pos. breast cancer: trastuzumab (Herceptin), introduced in 1998, and lapatinib (Tykerb), in 2007.  Despite these advances, some patients progress through therapy and succumb to their disease.  A variation on antibody-targeted therapy is utilization of antibodies to deliver cytotoxic agents specifically to antigen-expressing tumors.  We detd. in vitro and in vivo efficacy, pharmacokinetics, and toxicity of trastuzumab-maytansinoid (microtubule-depolymg. agents) conjugates using disulfide and thioether linkers.  Antiproliferative effects of trastuzumab-maytansinoid conjugates were evaluated on cultured normal and tumor cells.  In vivo activity was detd. in mouse breast cancer models, and toxicity was assessed in rats as measured by body wt. loss.  Surprisingly, trastuzumab linked to DM1 through a nonreducible thioether linkage (SMCC), displayed superior activity compared with unconjugated trastuzumab or trastuzumab linked to other maytansinoids through disulfide linkers.  Serum concns. of trastuzumab-MCC-DM1 remained elevated compared with other conjugates, and toxicity in rats was negligible compared with free DM1 or trastuzumab linked to DM1 through a reducible linker.  Potent activity was obsd. on all HER2-overexpressing tumor cells, whereas nontransformed cells and tumor cell lines with normal HER2 expression were unaffected.  In addn., trastuzumab-DM1 was active on HER2-overexpressing, trastuzumab-refractory tumors.  In summary, trastuzumab-DM1 shows greater activity compared with nonconjugated trastuzumab while maintaining selectivity for HER2-overexpressing tumor cells.  Because trastuzumab linked to DM1 through a nonreducible linker offers improved efficacy and pharmacokinetics and reduced toxicity over the reducible disulfide linkers evaluated, trastuzumab-MCC-DM1 was selected for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpP5fkJnRorrVg90H21EOLACvtfcHk0lg0XmAYGiuP5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK&md5=e86e8687d5f8884f8e28514299dcbbf1</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1776%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DSchwall%26aufirst%3DR.%2BH.%26aulast%3DKenkare-Mitra%26aufirst%3DS.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTargeting%2520HER2-positive%2520breast%2520cancer%2520with%2520trastuzumab-DM1%252C%2520an%2520antibody-cytotoxic%2520drug%2520conjugate%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9280%26epage%3D9290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Erickson, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leipold, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Provenzano, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audette, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span> </span><span class="NLM_article-title">The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1133</span><span class="NLM_x">–</span> <span class="NLM_lpage">1142</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1158%2F1535-7163.MCT-11-0727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=22408268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1yrtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1133-1142&author=H.+K.+Ericksonauthor=G.+D.+Lewis+Phillipsauthor=D.+D.+Leipoldauthor=C.+A.+Provenzanoauthor=E.+Maiauthor=H.+A.+Johnsonauthor=B.+Gunterauthor=C.+A.+Audetteauthor=M.+Guptaauthor=J.+Pinkasauthor=J.+Tibbitts&title=The+effect+of+different+linkers+on+target+cell+catabolism+and+pharmacokinetics%2Fpharmacodynamics+of+trastuzumab+maytansinoid+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates</span></div><div class="casAuthors">Erickson, Hans K.; Lewis Phillips, Gail D.; Leipold, Douglas D.; Provenzano, Carmela A.; Mai, Elaine; Johnson, Holly A.; Gunter, Bert; Audette, Charlene A.; Gupta, Manish; Pinkas, Jan; Tibbitts, Jay</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1133-1142</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate consisting of the anti-HER2 antibody trastuzumab linked via a nonreducible thioether linker to the maytansinoid antitubulin agent DM1.  T-DM1 has shown favorable safety and efficacy in patients with HER2-pos. metastatic breast cancer.  In previous animal studies, T-DM1 exhibited better pharmacokinetics (PK) and slightly more efficacy than several disulfide-linked versions.  The efficacy findings are unique, as other disulfide-linked antibody-drug conjugates (ADC) have shown greater efficacy than thioether-linked designs.  To explore this further, the in vitro and in vivo activity, PK, and target cell activation of T-DM1 and the disulfide-linked T-SPP-DM1 were examd.  Both ADCs showed high in vitro potency, with T-DM1 displaying greater potency in two of four breast cancer cell lines.  In vitro target cell processing of T-DM1 and T-SPP-DM1 produced lysine-N.vepsiln.-MCC-DM1, and lysine-N.vepsiln.-SPP-DM1 and DM1, resp.; in vivo studies confirmed these results.  The in vitro processing rates for the two conjugate to their resp. catabolites were similar.  In vivo, the potencies of the conjugates were similar, and T-SPP-DM1 had a faster plasma clearance than T-DM1.  Slower T-DM1 clearance translated to higher overall tumor concns. (conjugate plus catabolites), but unexpectedly, similar levels of tumor catabolite.  These results indicate that, although the ADC linker can have clear impact on the PK and the chem. nature of the catabolites formed, both linkers seem to offer the same payload delivery to the tumor.  Mol Cancer Ther; 11(5); 1133-42.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoynXKVoEvq_7Vg90H21EOLACvtfcHk0lhZscAuTyNQqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1yrtLs%253D&md5=e7485e8164a5bf3210f6c68f174df112</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0727%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DH.%2BK.%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DProvenzano%26aufirst%3DC.%2BA.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DJohnson%26aufirst%3DH.%2BA.%26aulast%3DGunter%26aufirst%3DB.%26aulast%3DAudette%26aufirst%3DC.%2BA.%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DPinkas%26aufirst%3DJ.%26aulast%3DTibbitts%26aufirst%3DJ.%26atitle%3DThe%2520effect%2520of%2520different%2520linkers%2520on%2520target%2520cell%2520catabolism%2520and%2520pharmacokinetics%252Fpharmacodynamics%2520of%2520trastuzumab%2520maytansinoid%2520conjugates%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1133%26epage%3D1142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Junttila, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1007%2Fs10549-010-1090-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=20730488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnslehsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2011&pages=347-356&author=T.+T.+Junttilaauthor=G.+Liauthor=K.+Parsonsauthor=G.+L.+Phillipsauthor=M.+X.+Sliwkowski&title=Trastuzumab-DM1+%28T-DM1%29+retains+all+the+mechanisms+of+action+of+trastuzumab+and+efficiently+inhibits+growth+of+lapatinib+insensitive+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer</span></div><div class="casAuthors">Junttila, Teemu T.; Li, Guangmin; Parsons, Kathryn; Phillips, Gail Lewis; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">347-356</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Trastuzumab (Herceptin) is currently used as a treatment for patients whose breast tumors overexpress HER2/ErbB2.  Trastuzumab-DM1 (T-DM1, trastuzumab emtansine) is designed to combine the clin. benefits of trastuzumab with a potent microtubule-disrupting drug, DM1 (a maytansine deriv.).  Currently T-DM1 is being tested in multiple clin. trials.  The mechanisms of action for trastuzumab include inhibition of PI3K/AKT signaling pathway, inhibition of HER-2 shedding and Fcγ receptor mediated engagement of immune cells, which may result in antibody-dependent cellular cytotoxicity (ADCC).  Here we report that T-DM1 retains the mechanisms of action of unconjugated trastuzumab and is active against lapatinib resistant cell lines and tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_OYfy685E27Vg90H21EOLACvtfcHk0lhZscAuTyNQqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnslehsbo%253D&md5=f3b04d9b9bb099007f338c619dd65f00</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs10549-010-1090-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-010-1090-x%26sid%3Dliteratum%253Aachs%26aulast%3DJunttila%26aufirst%3DT.%2BT.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DParsons%26aufirst%3DK.%26aulast%3DPhillips%26aufirst%3DG.%2BL.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTrastuzumab-DM1%2520%2528T-DM1%2529%2520retains%2520all%2520the%2520mechanisms%2520of%2520action%2520of%2520trastuzumab%2520and%2520efficiently%2520inhibits%2520growth%2520of%2520lapatinib%2520insensitive%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2011%26volume%3D128%26spage%3D347%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Barok, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koninki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isola, J.</span><span> </span><span class="NLM_article-title">Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">306</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1016%2Fj.canlet.2011.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=21458915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsV2nt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2011&pages=171-179&author=M.+Barokauthor=M.+Tannerauthor=K.+Koninkiauthor=J.+Isola&title=Trastuzumab-DM1+is+highly+effective+in+preclinical+models+of+HER2-positive+gastric+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer</span></div><div class="casAuthors">Barok, Mark; Tanner, Minna; Koeninki, Katri; Isola, Jorma</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-179</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: A novel antibody-drug conjugate (trastuzumab-DM1, T-DM1) is currently in clin. trials for patients with trastuzumab resistant HER2-pos. breast cancer.  Since no clin. data is available from gastric cancer, we studied T-DM1 on HER2-pos. human gastric cancer cells and xenograft tumors.  Methods: Effects of T-DM1 were studied in four HER2-pos. gastric cancer cell lines (N-87, OE-19, SNU-216 and MKN-7) in vitro.  Xenograft tumors from N-87 and OE-19 were studied to det. the effect of T-DM1 in vivo.  Results: T-DM1 was found more effective than trastuzumab in N-87 and OE-19, and moderately effective in MKN-7 cells.  On SNU-216 cells both trastuzumab and T-DM1 showed limited efficacy.  In xenograft tumor expts., complete pathol. response was obsd. in all OE-19 xenografted mice and in half of the N-87 xenografted mice.  The results were equally good irresp. of the tumor burden at therapy initiation, or preceding trastuzumab treatment.  T-DM1 treatment showed direct effects (apoptotic cell death and aberrant mitosis) as well as it mediated antibody-dependent cellular cytotoxcity (ADCC).  Conclusions: T-DM1 showed a promising anti-tumor effect in HER2-pos. gastric cancer cell lines in vitro and in vivo, even in tumors which had developed resistance to trastuzumab.  T-DM1 therapy may warrant clin. trials for HER2-pos. gastric cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi4stzIURpSrVg90H21EOLACvtfcHk0lhZscAuTyNQqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsV2nt7k%253D&md5=b3c549e901da81d69ccdf85af4808310</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2011.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2011.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DBarok%26aufirst%3DM.%26aulast%3DTanner%26aufirst%3DM.%26aulast%3DKoninki%26aufirst%3DK.%26aulast%3DIsola%26aufirst%3DJ.%26atitle%3DTrastuzumab-DM1%2520is%2520highly%2520effective%2520in%2520preclinical%2520models%2520of%2520HER2-positive%2520gastric%2520cancer%26jtitle%3DCancer%2520Lett.%26date%3D2011%26volume%3D306%26spage%3D171%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Kovtun, Y. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audette, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ab, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellogg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span> </span><span class="NLM_article-title">Antibody–maytansinoid conjugates designed to bypass multidrug resistance</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">2528</span><span class="NLM_x">–</span> <span class="NLM_lpage">2537</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=2528-2537&author=Y.+V.+Kovtunauthor=C.+A.+Audetteauthor=M.+F.+Mayoauthor=G.+E.+Jonesauthor=H.+Dohertyauthor=E.+K.+Maloneyauthor=H.+K.+Ericksonauthor=X.+Sunauthor=S.+Wilhelmauthor=O.+Abauthor=K.+C.+Laiauthor=W.+C.+Widdisonauthor=B.+Kelloggauthor=H.+Johnsonauthor=J.+Pinkasauthor=R.+J.+Lutzauthor=R.+Singhauthor=V.+S.+Goldmacherauthor=R.+V.+Chari&title=Antibody%E2%80%93maytansinoid+conjugates+designed+to+bypass+multidrug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKovtun%26aufirst%3DY.%2BV.%26aulast%3DAudette%26aufirst%3DC.%2BA.%26aulast%3DMayo%26aufirst%3DM.%2BF.%26aulast%3DJones%26aufirst%3DG.%2BE.%26aulast%3DDoherty%26aufirst%3DH.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DErickson%26aufirst%3DH.%2BK.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DAb%26aufirst%3DO.%26aulast%3DLai%26aufirst%3DK.%2BC.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DKellogg%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DH.%26aulast%3DPinkas%26aufirst%3DJ.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DAntibody%25E2%2580%2593maytansinoid%2520conjugates%2520designed%2520to%2520bypass%2520multidrug%2520resistance%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D2528%26epage%3D2537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span> </span><span class="NLM_article-title">Role of multidrug resistance transporters in the biological response to trastuzumab–cytotoxic drug conjugates</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">Abstract 618</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=Abstract+618&issue=Suppl.+1&author=J.+Guoauthor=G.+Liauthor=G.+D.+Lewis+Phillips&title=Role+of+multidrug+resistance+transporters+in+the+biological+response+to+trastuzumab%E2%80%93cytotoxic+drug+conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26atitle%3DRole%2520of%2520multidrug%2520resistance%2520transporters%2520in%2520the%2520biological%2520response%2520to%2520trastuzumab%25E2%2580%2593cytotoxic%2520drug%2520conjugates%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26issue%3DSuppl.%25201%26spage%3DAbstract%2520618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Jumbe, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leipold, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielder, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span> </span><span class="NLM_article-title">Modeling the efficacy of trastuzumab–DM1, an antibody drug conjugate, in mice</span> <span class="citation_source-journal">J. Pharmacokinet. Pharmacodyn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1007%2Fs10928-010-9156-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=20424896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnslyktLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=221-242&author=N.+L.+Jumbeauthor=Y.+Xinauthor=D.+D.+Leipoldauthor=L.+Crockerauthor=D.+Duggerauthor=E.+Maiauthor=M.+X.+Sliwkowskiauthor=P.+J.+Fielderauthor=J.+Tibbitts&title=Modeling+the+efficacy+of+trastuzumab%E2%80%93DM1%2C+an+antibody+drug+conjugate%2C+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice</span></div><div class="casAuthors">Jumbe, Nelson L.; Xin, Yan; Leipold, Douglas D.; Crocker, Lisa; Dugger, Debra; Mai, Elaine; Sliwkowski, Mark X.; Fielder, Paul J.; Tibbitts, Jay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacokinetics and Pharmacodynamics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-242</span>CODEN:
                <span class="NLM_cas:coden">JPPOAH</span>;
        ISSN:<span class="NLM_cas:issn">1567-567X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Trastuzumab-DM1 (T-DM1) is a novel antibody-drug conjugate under investigation for the treatment of human epidermal growth factor receptor 2 (HER2)-pos. metastatic breast cancer.  One challenge in oncol. drug development is detg. the optimal dose and treatment schedule.  A novel dose regimen-finding strategy was developed for T-DM1 using exptl. data and pharmacokinetic/pharmacodynamic modeling.  To characterize the disposition of T-DM1, pharmacokinetic studies were conducted in athymic nude and beige nude mice.  The pharmacokinetics of T-DM1 were described well by a two-compartment model.  Tumor response data were obtained from single-dose, multiple-dose and time-dose-fractionation studies of T-DM1 in animal models of HER2-pos. breast cancer, specifically engineered to be insensitive to trastuzumab.  A sequential population-based pharmacokinetic/pharmacodynamic modeling approach was developed to describe the anti-tumor activity of T-DM1.  A cell-cycle-phase nonspecific tumor cell kill model incorporating transit compartments captured well the features of tumor growth and the activity of T-DM1.  Key findings of the model were that tumor cell growth rate played a significant role in the sensitivity of tumors to T-DM1; anti-tumor activity was schedule independent; and tumor response was linked to the ratio of exposure to a concn. required for tumor stasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbvgyQzzXl_7Vg90H21EOLACvtfcHk0li7lYGFpFX7KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnslyktLw%253D&md5=28bac6e680530a3aeba7b44607669c8c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs10928-010-9156-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10928-010-9156-2%26sid%3Dliteratum%253Aachs%26aulast%3DJumbe%26aufirst%3DN.%2BL.%26aulast%3DXin%26aufirst%3DY.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DCrocker%26aufirst%3DL.%26aulast%3DDugger%26aufirst%3DD.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DFielder%26aufirst%3DP.%2BJ.%26aulast%3DTibbitts%26aufirst%3DJ.%26atitle%3DModeling%2520the%2520efficacy%2520of%2520trastuzumab%25E2%2580%2593DM1%252C%2520an%2520antibody%2520drug%2520conjugate%252C%2520in%2520mice%26jtitle%3DJ.%2520Pharmacokinet.%2520Pharmacodyn.%26date%3D2010%26volume%3D37%26spage%3D221%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dere, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrasco-Triguero, M.</span><span> </span><span class="NLM_article-title">Bioanalytical assay strategies for the development of antibody–drug conjugate biotherapeutics</span> <span class="citation_source-journal">Bioanalysis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">226</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=201-226&author=S.+Kaurauthor=K.+Xuauthor=O.+M.+Saadauthor=R.+C.+Dereauthor=M.+Carrasco-Triguero&title=Bioanalytical+assay+strategies+for+the+development+of+antibody%E2%80%93drug+conjugate+biotherapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DSaad%26aufirst%3DO.%2BM.%26aulast%3DDere%26aufirst%3DR.%2BC.%26aulast%3DCarrasco-Triguero%26aufirst%3DM.%26atitle%3DBioanalytical%2520assay%2520strategies%2520for%2520the%2520development%2520of%2520antibody%25E2%2580%2593drug%2520conjugate%2520biotherapeutics%26jtitle%3DBioanalysis%26date%3D2013%26volume%3D5%26spage%3D201%26epage%3D226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Poon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dybdal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, T.</span><span> </span><span class="NLM_article-title">Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability</span> <span class="citation_source-journal">Toxicol. Appl. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1016%2Fj.taap.2013.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=24035823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslGlsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=2013&pages=298-313&author=K.+A.+Poonauthor=K.+Flagellaauthor=J.+Beyerauthor=J.+Tibbittsauthor=S.+Kaurauthor=O.+Saadauthor=J.+H.+Yiauthor=S.+Girishauthor=N.+Dybdalauthor=T.+Reynolds&title=Preclinical+safety+profile+of+trastuzumab+emtansine+%28T-DM1%29%3A+mechanism+of+action+of+its+cytotoxic+component+retained+with+improved+tolerability"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability</span></div><div class="casAuthors">Poon, Kirsten Achilles; Flagella, Kelly; Beyer, Joseph; Tibbitts, Jay; Kaur, Surinder; Saad, Ola; Yi, Joo-Hee; Girish, Sandhya; Dybdal, Noel; Reynolds, Theresa</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">298-313</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is the first antibody-drug conjugate (ADC) approved for patients with human epidermal growth factor receptor 2 (HER2)-pos. metastatic breast cancer.  The therapeutic premise of ADCs is based on the hypothesis that targeted delivery of potent cytotoxic drugs to tumors will provide better tolerability and efficacy compared with non-targeted delivery, where poor tolerability can limit efficacious doses.  Here, we present results from preclin. studies characterizing the toxicity profile of T-DM1, including limited assessment of unconjugated DM1.  T-DM1 binds primate ErbB2 and human HER2 but not the rodent homolog c-neu.  Therefore, antigen-dependent and non-antigen-dependent toxicity was evaluated in monkeys and rats, resp., in both single- and repeat-dose studies; toxicity of DM1 was assessed in rats only.  T-DM1 was well tolerated at doses up to 40 mg/kg (~ 4400 μg DM1/m2) and 30 mg/kg (~ 6000 μg DM1/m2) in rats and monkeys, resp.  In contrast, DM1 was only tolerated up to 0.2 mg/kg (1600 μg DM1/m2).  This suggests that at least two-fold higher doses of the cytotoxic agent are tolerated in T-DM1, supporting the premise of ADCs to improve the therapeutic index.  In addn., T-DM1 and DM1 safety profiles were similar and consistent with the mechanism of action of DM1 (i.e., microtubule disruption).  Findings included hepatic, bone marrow/hematol. (primarily platelet), lymphoid organ, and neuronal toxicities, and increased nos. of cells of epithelial and phagocytic origin in metaphase arrest.  These adverse effects did not worsen with chronic dosing in monkeys and are consistent with those reported in T-DM1-treated patients to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp36u8JDO92mbVg90H21EOLACvtfcHk0li7lYGFpFX7KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslGlsbbO&md5=f2ae6f6fc865d8ad027752e1301be3cc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2013.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2013.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DPoon%26aufirst%3DK.%2BA.%26aulast%3DFlagella%26aufirst%3DK.%26aulast%3DBeyer%26aufirst%3DJ.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DSaad%26aufirst%3DO.%26aulast%3DYi%26aufirst%3DJ.%2BH.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DDybdal%26aufirst%3DN.%26aulast%3DReynolds%26aufirst%3DT.%26atitle%3DPreclinical%2520safety%2520profile%2520of%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529%253A%2520mechanism%2520of%2520action%2520of%2520its%2520cytotoxic%2520component%2520retained%2520with%2520improved%2520tolerability%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2013%26volume%3D273%26spage%3D298%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leece, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, H.</span><span> </span><span class="NLM_article-title">Design of antibody–maytansinoid conjugates allows for efficient detoxification via liver metabolism</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">728</span><span class="NLM_x">–</span> <span class="NLM_lpage">735</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc100498q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivFyitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=728-735&author=X.+Sunauthor=W.+Widdisonauthor=M.+Mayoauthor=S.+Wilhelmauthor=B.+Leeceauthor=R.+Chariauthor=R.+Singhauthor=H.+Erickson&title=Design+of+antibody%E2%80%93maytansinoid+conjugates+allows+for+efficient+detoxification+via+liver+metabolism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Antibody-Maytansinoid Conjugates Allows for Efficient Detoxification via Liver Metabolism</span></div><div class="casAuthors">Sun, Xiuxia; Widdison, Wayne; Mayo, Michele; Wilhelm, Sharon; Leece, Barbara; Chari, Ravi; Singh, Rajeeva; Erickson, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">728-735</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody-maytansinoid conjugates (AMCs) are targeted chemotherapeutic agents consisting of a potent microtubule-depolymg. maytansinoid (DM1 or DM4) attached to lysine residues of a monoclonal antibody (mAb) using an uncleavable thioether linker or a stable disulfide linker.  Most of the administered dose of an antibody-based therapeutic is slowly catabolized by the liver and other tissues of the reticuloendothelial system.  Maytansinoids released from an AMC during this catabolic process could potentially be a source of toxicity.  To investigate this, we isolated and identified liver metabolites in mice for three different [3H]AMCs with structures similar to those currently undergoing evaluation in the clinic.  We then synthesized each metabolite to confirm the identification and assessed their cytotoxic potencies when added extracellularly.  We found that the uncleavable mAb-SMCC-[3H]DM1 conjugate was degraded to a single major maytansinoid metabolite, lysine-SMCC-[3H]DM1, that was nearly 50-fold less cytotoxic than maytansine.  The two disulfide-linked conjugates, mAb-SPP-[3H]DM1 and mAb-SPDB-[3H]DM4, were also catabolized to the analogous lysine-linked maytansinoid metabolites.  However, subsequent redn., S-methylation, and NADPH-dependent oxidn. steps in the liver yielded the corresponding S-Me sulfoxide and S-Me sulfone derivs.  The cytotoxic potencies of the oxidized maytansinoids toward several human carcinoma cell lines were 5- to 50-fold less potent than maytansine.  Our results suggest that liver plays an important role in the detoxification of both cleavable and uncleavable AMCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT3zBTd4ysBbVg90H21EOLACvtfcHk0ligRDI_hx5fqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivFyitL4%253D&md5=042dafa46e287f5a8a76af8714c124ce</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fbc100498q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc100498q%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DWiddison%26aufirst%3DW.%26aulast%3DMayo%26aufirst%3DM.%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DLeece%26aufirst%3DB.%26aulast%3DChari%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DErickson%26aufirst%3DH.%26atitle%3DDesign%2520of%2520antibody%25E2%2580%2593maytansinoid%2520conjugates%2520allows%2520for%2520efficient%2520detoxification%2520via%2520liver%2520metabolism%26jtitle%3DBioconjugate%2520Chem.%26date%3D2011%26volume%3D22%26spage%3D728%26epage%3D735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Fishkin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span> </span><span class="NLM_article-title">A novel pathway for maytansinoid release from thioether linked antibody–drug conjugates (ADCs) under oxidative conditions</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">10752</span><span class="NLM_x">–</span> <span class="NLM_lpage">10754</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=10752-10754&author=N.+Fishkinauthor=E.+K.+Maloneyauthor=R.+V.+Chariauthor=R.+Singh&title=A+novel+pathway+for+maytansinoid+release+from+thioether+linked+antibody%E2%80%93drug+conjugates+%28ADCs%29+under+oxidative+conditions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFishkin%26aufirst%3DN.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DSingh%26aufirst%3DR.%26atitle%3DA%2520novel%2520pathway%2520for%2520maytansinoid%2520release%2520from%2520thioether%2520linked%2520antibody%25E2%2580%2593drug%2520conjugates%2520%2528ADCs%2529%2520under%2520oxidative%2520conditions%26jtitle%3DChem.%2520Commun.%26date%3D2011%26volume%3D47%26spage%3D10752%26epage%3D10754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holden, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutzker, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.</span><span> </span><span class="NLM_article-title">Phase I study of trastuzumab–DM1, an HER2 antibody–drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">2698</span><span class="NLM_x">–</span> <span class="NLM_lpage">2704</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1200%2FJCO.2009.26.2071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=20421541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXoslykt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=2698-2704&author=I.+E.+Kropauthor=M.+Beeramauthor=S.+Modiauthor=S.+F.+Jonesauthor=S.+N.+Holdenauthor=W.+Yuauthor=S.+Girishauthor=J.+Tibbittsauthor=J.+H.+Yiauthor=M.+X.+Sliwkowskiauthor=F.+Jacobsonauthor=S.+G.+Lutzkerauthor=H.+A.+Burris&title=Phase+I+study+of+trastuzumab%E2%80%93DM1%2C+an+HER2+antibody%E2%80%93drug+conjugate%2C+given+every+3+weeks+to+patients+with+HER2-positive+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer</span></div><div class="casAuthors">Krop, Ian E.; Beeram, Muralidhar; Modi, Shanu; Jones, Suzanne F.; Holden, Scott N.; Yu, Wei; Girish, Sandhy; Tibbitts, Jay; Yi, Joo-Hee; Sliwkowski, Mark X.; Jacobson, Fred; Lutzker, Stuart G.; Burris, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2698-2704</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate that uses trastuzumab to specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-pos. cells.  This first-in-human study of T-DM1 evaluated safety, pharmacokinetics, and preliminary activity of T-DM1 in patients with advanced HER2-pos. breast cancer.  Patients and Methods: Successive cohorts of patients who had progressed on trastuzumab-based therapy received escalating doses of T-DM1.  Outcomes were assessed by std. solid-tumor phase I methods.  Results: Twenty-four patients who had received a median of four prior chemotherapeutic agents for metastatic disease received T-DM1 at 0.3 mg/kg to 4.8 mg/kg on an every-3-wk schedule.  Transient thrombocytopenia was dose-limiting at 4.8 mg/kg; the max.-tolerated dose (MTD) was 3.6 mg/kg.  The half-life of T-DM1 at the MTD was 3.5 days, with peak DM1 levels < 10 ng/mL.  Clearance at doses < 1.2 mg/kg was faster than at higher doses.  Common drug-related adverse events (AEs) included grade ≤ 2 thrombocytopenia, elevated transaminases, fatigue, nausea, and anemia.  No grade > 1 nausea, vomiting, alopecia, or neuropathy events and no cardiac effects requiring dose modification were reported.  The clin. benefit rate (objective response plus stable disease at 6 mo) among 15 patients treated at the MTD was 73%, including five objective responses.  The confirmed response rate in patients with measurable disease at the MTD (n = 9) was 44%.  Conclusion: At the MTD of 3.6 mg/kg every 3 wk, T-DM1 was assocd. with mild, reversible toxicity and substantial clin. activity in a heavily pretreated population.  Phase II and III trials in patients with advanced HER2-pos. breast cancer are under way.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo65WWeQ3_JV7Vg90H21EOLACvtfcHk0ligRDI_hx5fqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXoslykt7c%253D&md5=98ba29a289f4ac0ea38c37a9b6bd0c5d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.26.2071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.26.2071%26sid%3Dliteratum%253Aachs%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DS.%2BF.%26aulast%3DHolden%26aufirst%3DS.%2BN.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DYi%26aufirst%3DJ.%2BH.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DJacobson%26aufirst%3DF.%26aulast%3DLutzker%26aufirst%3DS.%2BG.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26atitle%3DPhase%2520I%2520study%2520of%2520trastuzumab%25E2%2580%2593DM1%252C%2520an%2520HER2%2520antibody%25E2%2580%2593drug%2520conjugate%252C%2520given%2520every%25203%2520weeks%2520to%2520patients%2520with%2520HER2-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D2698%26epage%3D2704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Phase I and II clinical trials of trastuzumab</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S49</span><span class="NLM_x">–</span> <span class="NLM_lpage">S55</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=S49-S55&issue=Suppl.+1&author=J.+Baselga&title=Phase+I+and+II+clinical+trials+of+trastuzumab"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DPhase%2520I%2520and%2520II%2520clinical%2520trials%2520of%2520trastuzumab%26jtitle%3DAnn.%2520Oncol.%26date%3D2001%26volume%3D12%26issue%3DSuppl.%25201%26spage%3DS49%26epage%3DS55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holden, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span> </span><span class="NLM_article-title">A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">5733</span><span class="NLM_x">–</span> <span class="NLM_lpage">5740</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2012&pages=5733-5740&author=M.+Beeramauthor=I.+E.+Kropauthor=H.+A.+Burrisauthor=S.+R.+Girishauthor=W.+Yuauthor=M.+W.+Luauthor=S.+N.+Holdenauthor=S.+Modi&title=A+phase+1+study+of+weekly+dosing+of+trastuzumab+emtansine+%28T-DM1%29+in+patients+with+advanced+human+epidermal+growth+factor+2-positive+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DGirish%26aufirst%3DS.%2BR.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DHolden%26aufirst%3DS.%2BN.%26aulast%3DModi%26aufirst%3DS.%26atitle%3DA%2520phase%25201%2520study%2520of%2520weekly%2520dosing%2520of%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529%2520in%2520patients%2520with%2520advanced%2520human%2520epidermal%2520growth%2520factor%25202-positive%2520breast%2520cancer%26jtitle%3DCancer%26date%3D2012%26volume%3D118%26spage%3D5733%26epage%3D5740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Burris, H. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugo, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vukelja, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limentani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan-Chiu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klencke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shaughnessy, J. A.</span><span> </span><span class="NLM_article-title">Phase II study of the antibody drug conjugate trastuzumab–DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">398</span><span class="NLM_x">–</span> <span class="NLM_lpage">405</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1200%2FJCO.2010.29.5865" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=21172893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivFWmsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=398-405&author=H.+A.+Burrisauthor=H.+S.+Rugoauthor=S.+J.+Vukeljaauthor=C.+L.+Vogelauthor=R.+A.+Borsonauthor=S.+Limentaniauthor=E.+Tan-Chiuauthor=I.+E.+Kropauthor=R.+A.+Michaelsonauthor=S.+Girishauthor=L.+Amlerauthor=M.+Zhengauthor=Y.+W.+Chuauthor=B.+Klenckeauthor=J.+A.+O%E2%80%99Shaughnessy&title=Phase+II+study+of+the+antibody+drug+conjugate+trastuzumab%E2%80%93DM1+for+the+treatment+of+human+epidermal+growth+factor+receptor+2+%28HER2%29-positive+breast+cancer+after+prior+HER2-directed+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy</span></div><div class="casAuthors">Burris, Howard A., III; Rugo, Hope S.; Vukelja, Svetislava J.; Vogel, Charles L.; Borson, Rachel A.; Limentani, Steven; Tan-Chiu, Elizabeth; Krop, Ian E.; Michaelson, Richard A.; Girish, Sandhya; Amler, Lukas; Zheng, Maoxia; Chu, Yu-Waye; Klencke, Barbara; O'Shaughnessy, Joyce A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">398-405</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The antibody-drug conjugate trastuzumab-DM1 (T-DM1) combines the biol. activity of trastuzumab with targeted delivery of a potent antimicrotubule agent, DM1, to human epidermal growth factor receptor 2 (HER2) -overexpressing cancer cells.  Based on results from a phase I study that showed T-DM1 was well tolerated at the max.-tolerated dose of 3.6 mg/kg every 3 wk, with evidence of efficacy, in patients with HER2-pos. metastatic breast cancer (MBC) who were previously treated with trastuzumab, we conducted a phase II study to further define the safety and efficacy of T-DM1 in this patient population.  This report describes a single-arm phase II study (TDM4258g) that assessed efficacy and safety of i.v. T-DM1 (3.6 mg/kg every 3 wk) in patients with HER2-pos. MBC who had tumor progression after prior treatment with HER2-directed therapy and who had received prior chemotherapy.  With a follow-up of ≥ 12 mo among 112 treated patients, the objective response rate by independent assessment was 25.9% (95% CI, 18.4% to 34.4%).  Median duration of response was not reached as a result of insufficient events (lower limit of 95% CI, 6.2 mo), and median progression-free survival time was 4.6 mo (95% CI, 3.9 to 8.6 mo).  The response rates were higher among patients with confirmed HER2-pos. tumors (immunohistochem. 3+ or fluorescent in situ hybridization pos.) by retrospective central testing (n = 74).  Higher response rates were also obsd. in patients whose tumors expressed ≥ median HER2 levels by quant. reverse transcriptase polymerase chain reaction for HER2 expression, compared with patients who had less than median HER2 levels.  T-DM1 was well tolerated with no dose-limiting cardiotoxicity.  Most adverse events (AEs) were grade 1 or 2; the most frequent grade ≥ 3 AEs were hypokalemia (8.9%), thrombocytopenia (8.0%), and fatigue (4.5%).  T-DM1 has robust single-agent activity in patients with heavily pretreated, HER2-pos. MBC and is well tolerated at the recommended phase II dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhJbpnx142HbVg90H21EOLACvtfcHk0ljTJmwSrFF4cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivFWmsrc%253D&md5=94f0c939a12a7875590fc02f3f056d65</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.29.5865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.29.5865%26sid%3Dliteratum%253Aachs%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DVukelja%26aufirst%3DS.%2BJ.%26aulast%3DVogel%26aufirst%3DC.%2BL.%26aulast%3DBorson%26aufirst%3DR.%2BA.%26aulast%3DLimentani%26aufirst%3DS.%26aulast%3DTan-Chiu%26aufirst%3DE.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DMichaelson%26aufirst%3DR.%2BA.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DAmler%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DKlencke%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%2BA.%26atitle%3DPhase%2520II%2520study%2520of%2520the%2520antibody%2520drug%2520conjugate%2520trastuzumab%25E2%2580%2593DM1%2520for%2520the%2520treatment%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520%2528HER2%2529-positive%2520breast%2520cancer%2520after%2520prior%2520HER2-directed%2520therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D398%26epage%3D405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yardley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guardino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugo, H. S.</span><span> </span><span class="NLM_article-title">A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3234</span><span class="NLM_x">–</span> <span class="NLM_lpage">3241</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1200%2FJCO.2011.40.5902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=22649126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKrsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3234-3241&author=I.+E.+Kropauthor=P.+LoRussoauthor=K.+D.+Millerauthor=S.+Modiauthor=D.+Yardleyauthor=G.+Rodriguezauthor=E.+Guardinoauthor=M.+Luauthor=M.+Zhengauthor=S.+Girishauthor=L.+Amlerauthor=E.+P.+Winerauthor=H.+S.+Rugo&title=A+phase+II+study+of+trastuzumab+emtansine+in+patients+with+human+epidermal+growth+factor+receptor+2-positive+metastatic+breast+cancer+who+were+previously+treated+with+trastuzumab%2C+lapatinib%2C+an+anthracycline%2C+a+taxane%2C+and+capecitabine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine</span></div><div class="casAuthors">Krop, Ian E.; LoRusso, Patricia; Miller, Kathy D.; Modi, Shanu; Yardley, Denise; Rodriguez, Gladys; Guardino, Ellie; Lu, Michael; Zheng, Maoxia; Girish, Sandhya; Amler, Lukas; Winer, Eric P.; Rugo, Hope S.; Krop, Ian E.; Winer, Eric P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3234-3241</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose. To det. whether the antibody-drug conjugate trastuzumab emtansine (T-DM1), which combines human epidermal growth factor receptor 2 (HER2) -targeted delivery of the potent antimicrotubule agent DM1 with the antitumor activity of trastuzumab, is effective in patients with HER2-pos. metastatic breast cancer (MBC) who have previously received all std. HER2-directed therapies.  Patients and Methods. In this single-arm phase II study, T-DM1 3.6 mg/kg was administered i.v. every 3 wk to patients with HER2-pos. MBC who had prior treatment with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.  The primary objectives were overall response rate (ORR) by independent review and safety.  Results. Among 110 pretreated patients (median, seven prior agents for MBC; median follow-up, 17.4 mo), the ORR was 34.5% (95% CI, 26.1% to 43.9%), clin. benefit rate was 48.2% (95% CI, 38.8% to 57.9%), median progression-free survival (PFS) was 6.9 mo (95% CI, 4.2 to 8.4 mo), and median duration of response was 7.2 mo (95% CI, 4.6 mo to not estimable).  In patients with confirmed HER2-pos. tumors (n = 80 by retrospective central testing), the response rate was 41.3% (95% CI, 30.4% to 52.8%), and median PFS was 7.3 mo (95% CI, 4.6 to 12.3 mo).  Most adverse events were grades 1 to 2; the most frequent grade ≥ 3 events were thrombocytopenia (9.1%), fatigue (4.5%), and cellulitis (3.6%).  Conclusion. T-DM1 is well tolerated and has single-agent activity in patients with HER2-pos. MBC who have previously received both approved HER2-directed therapies and multiple chemotherapy agents.  T-DM1 may be an effective new treatment for this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQImjifp0YS7Vg90H21EOLACvtfcHk0ljTJmwSrFF4cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKrsL%252FJ&md5=e3c54c63b8a2c6a585818e35c0e4aab9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.40.5902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.40.5902%26sid%3Dliteratum%253Aachs%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DYardley%26aufirst%3DD.%26aulast%3DRodriguez%26aufirst%3DG.%26aulast%3DGuardino%26aufirst%3DE.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DAmler%26aufirst%3DL.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520trastuzumab%2520emtansine%2520in%2520patients%2520with%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202-positive%2520metastatic%2520breast%2520cancer%2520who%2520were%2520previously%2520treated%2520with%2520trastuzumab%252C%2520lapatinib%252C%2520an%2520anthracycline%252C%2520a%2520taxane%252C%2520and%2520capecitabine%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3234%26epage%3D3241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Hurvitz, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dirix, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocsis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinholes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guardino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, E. A.</span><span> </span><span class="NLM_article-title">Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1157</span><span class="NLM_x">–</span> <span class="NLM_lpage">1163</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1200%2FJCO.2012.44.9694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=23382472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVyhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1157-1163&author=S.+A.+Hurvitzauthor=L.+Dirixauthor=J.+Kocsisauthor=G.+V.+Bianchiauthor=J.+Luauthor=J.+Vinholesauthor=E.+Guardinoauthor=C.+Songauthor=B.+Tongauthor=V.+Ngauthor=Y.+W.+Chuauthor=E.+A.+Perez&title=Phase+II+randomized+study+of+trastuzumab+emtansine+versus+trastuzumab+plus+docetaxel+in+patients+with+human+epidermal+growth+factor+receptor+2-positive+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer</span></div><div class="casAuthors">Hurvitz, Sara A.; Dirix, Luc; Kocsis, Judit; Bianchi, Giulia V.; Lu, Janice; Vinholes, Jeferson; Guardino, Ellie; Song, Chunyan; Tong, Barbara; Ng, Vivian; Chu, Yu-Waye; Perez, Edith A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1157-1163</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Trastuzumab emtansine (T-DM1), an antibody-drug conjugate composed of the cytotoxic agent DM1 conjugated to trastuzumab via a stable thioether linker, has shown clin. activity in single-arm studies enrolling patients with human epidermal growth factor receptor 2 (HER2)-pos. metastatic breast cancer (MBC) whose disease had progressed on HER2-targeted therapy in the metastatic setting.  Patients and Methods: Patients (N = 137) with HER2-pos. MBC or recurrent locally advanced breast cancer were randomly assigned to trastuzumab plus docetaxel (HT; n = 70) or T-DM1 (n = 67) as first-line treatment until disease progression or unacceptable toxicity.  Primary end points were investigator-assessed progression-free survival (PFS) and safety.  Key secondary end points included overall survival (OS), objective response rate (ORR), duration of objective response, clin. benefit rate, and quality of life.  Results: Median PFS was 9.2 mo with HT and 14.2 mo with T-DM1 (hazard ratio, 0.59; 95% CI, 0.36 to 0.97); median follow-up was approx. 14 mo in both arms.  ORR was 58.0% (95% CI, 45.5% to 69.2%) with HT and 64.2% (95% CI, 51.8% to 74.8%) with T-DM1.  T-DM1 had a favorable safety profile vs. HT, with fewer grade ≥ 3 adverse events (AEs; 46.4% v 90.9%), AEs leading to treatment discontinuations (7.2% v 34.8%), and serious AEs (20.3% v 25.8%).  Preliminary OS results were similar between treatment arms; median follow-up was approx. 23 mo in both arms.  Conclusion: In this randomized phase II study, first-line treatment with T-DM1 for patients with HER2-pos. MBC provided a significant improvement in PFS, with a favorable safety profile, vs. HT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv8fMDYaxdIrVg90H21EOLACvtfcHk0lhER9r166NJMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVyhtbs%253D&md5=95cd6eb05ce016e971b2af745d1b587f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.44.9694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.44.9694%26sid%3Dliteratum%253Aachs%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DDirix%26aufirst%3DL.%26aulast%3DKocsis%26aufirst%3DJ.%26aulast%3DBianchi%26aufirst%3DG.%2BV.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DVinholes%26aufirst%3DJ.%26aulast%3DGuardino%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DB.%26aulast%3DNg%26aufirst%3DV.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DPerez%26aufirst%3DE.%2BA.%26atitle%3DPhase%2520II%2520randomized%2520study%2520of%2520trastuzumab%2520emtansine%2520versus%2520trastuzumab%2520plus%2520docetaxel%2520in%2520patients%2520with%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D1157%26epage%3D1163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Suter, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Procter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Veldhuisen, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muscholl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlomagno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perren, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passalacqua, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bighin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klijn, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ageev, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groetz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knap, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gnant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muehlbauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelber, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piccart-Gebhart, M. J.</span><span> </span><span class="NLM_article-title">Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3859</span><span class="NLM_x">–</span> <span class="NLM_lpage">3865</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1200%2FJCO.2006.09.1611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=17646669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFanu7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=3859-3865&author=T.+M.+Suterauthor=M.+Procterauthor=D.+J.+van+Veldhuisenauthor=M.+Muschollauthor=J.+Berghauthor=C.+Carlomagnoauthor=T.+Perrenauthor=R.+Passalacquaauthor=C.+Bighinauthor=J.+G.+Klijnauthor=F.+T.+Ageevauthor=E.+Hitreauthor=J.+Groetzauthor=H.+Iwataauthor=M.+Knapauthor=M.+Gnantauthor=S.+Muehlbauerauthor=A.+Spenceauthor=R.+D.+Gelberauthor=M.+J.+Piccart-Gebhart&title=Trastuzumab-associated+cardiac+adverse+effects+in+the+herceptin+adjuvant+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial</span></div><div class="casAuthors">Suter, Thomas M.; Procter, Marion; van Veldhuisen, Dirk J.; Muscholl, Michael; Bergh, Jonas; Carlomagno, Chiara; Perren, Timothy; Passalacqua, Rodolfo; Bighin, Claudia; Klijn, Jan G. M.; Ageev, Fail T.; Hitre, Erika; Greetz, Juergen; Iwata, Hiroji; Knap, Malgorzata; Gnant, Michael; Muehlbauer, Susanne; Spence, Alison; Gelber, Richard D.; Piccart-Gebhart, Martine J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">3859-3865</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: The purpose of this anal. was to investigate trastuzumab-assocd. cardiac adverse effects in breast cancer patients after completion of (neo)adjuvant chemotherapy with or without radiotherapy.  Patients and Methods: The Herceptin Adjuvant (HERA) trial is a three-group, multicenter, open-label randomized trial that compared 1 or 2 years of trastuzumab given once every 3 wk with observation in patients with HER-2-pos. breast cancer.  Only patients who after completion of (neo)adjuvant chemotherapy with or without radiotherapy had normal left ventricular ejection fraction (LVEF ≥ 55%) were eligible.  A repeat LVEF assessment was performed in case of cardiac dysfunction.  Results: Data were available for 1,693 patients randomly assigned to 1 yr trastuzumab and 1,693 patients randomly assigned to observation.  The incidence of trastuzumab discontinuation due to cardiac disorders was low (4.3%).  The incidence of cardiac end points was higher in the trastuzumab group compared with observation (severe congestive heart failure [CHF], 0.60% v 0.00%; symptomatic CHF, 2.15% v 0.12%; confirmed significant LVEF drops, 3.04% v 0.53%).  Most patients with cardiac dysfunction recovered in fewer than 6 mo.  Patients with trastuzumab-assocd. cardiac dysfunction were treated with higher cumulative doses of doxorubicin (287 mg/m2 v 257 mg/m2) or epirubicin (480 mg/m2 v 422 mg/m2) and had a lower screening LVEF and a higher body mass index.  Conclusion: Given the clear benefit in disease-free survival, the low incidence of cardiac adverse events, and the suggestion that cardiac dysfunction might be reversible, adjuvant trastuzumab should be considered for treatment of breast cancer patients who fulfill the HERA trial eligibility criteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUJztSuVkZCbVg90H21EOLACvtfcHk0lhER9r166NJMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFanu7zE&md5=9aa4ecb50b0566677b2552e7c645b2f2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.09.1611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.09.1611%26sid%3Dliteratum%253Aachs%26aulast%3DSuter%26aufirst%3DT.%2BM.%26aulast%3DProcter%26aufirst%3DM.%26aulast%3Dvan%2BVeldhuisen%26aufirst%3DD.%2BJ.%26aulast%3DMuscholl%26aufirst%3DM.%26aulast%3DBergh%26aufirst%3DJ.%26aulast%3DCarlomagno%26aufirst%3DC.%26aulast%3DPerren%26aufirst%3DT.%26aulast%3DPassalacqua%26aufirst%3DR.%26aulast%3DBighin%26aufirst%3DC.%26aulast%3DKlijn%26aufirst%3DJ.%2BG.%26aulast%3DAgeev%26aufirst%3DF.%2BT.%26aulast%3DHitre%26aufirst%3DE.%26aulast%3DGroetz%26aufirst%3DJ.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DKnap%26aufirst%3DM.%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DMuehlbauer%26aufirst%3DS.%26aulast%3DSpence%26aufirst%3DA.%26aulast%3DGelber%26aufirst%3DR.%2BD.%26aulast%3DPiccart-Gebhart%26aufirst%3DM.%2BJ.%26atitle%3DTrastuzumab-associated%2520cardiac%2520adverse%2520effects%2520in%2520the%2520herceptin%2520adjuvant%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26spage%3D3859%26epage%3D3865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Verma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welslau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dieras, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guardino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwell, K.</span><span> </span><span class="NLM_article-title">Trastuzumab emtansine for HER2-positive advanced breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">1783</span><span class="NLM_x">–</span> <span class="NLM_lpage">1791</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1056%2FNEJMoa1209124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=23020162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1783-1791&author=S.+Vermaauthor=D.+Milesauthor=L.+Gianniauthor=I.+E.+Kropauthor=M.+Welslauauthor=J.+Baselgaauthor=M.+Pegramauthor=D.+Y.+Ohauthor=V.+Dierasauthor=E.+Guardinoauthor=L.+Fangauthor=M.+W.+Luauthor=S.+Olsenauthor=K.+Blackwell&title=Trastuzumab+emtansine+for+HER2-positive+advanced+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab emtansine for HER2-positive advanced breast cancer</span></div><div class="casAuthors">Verma, Sunil; Miles, David; Gianni, Luca; Krop, Ian E.; Welslau, Manfred; Baselga, Jose; Pegram, Mark; Oh, Do-Youn; Dieras, Veronique; Guardino, Ellie; Fang, Liang; Lu, Michael W.; Olsen, Steven; Blackwell, Kim</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1783-1791</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.  The antibody and the cytotoxic agent are conjugated by means of a stable linker.  METHODS: We randomly assigned patients with HER2-pos. advanced breast cancer, who had previously been treated with trastuzumab and a taxane, to T-DM1 or lapatinib plus capecitabine.  The primary end points were progression-free survival (as assessed by independent review), overall survival, and safety.  Secondary end points included progression-free survival (investigator-assessed), the objective response rate, and the time to symptom progression.  Two interim analyses of overall survival were conducted.  RESULTS: Among 991 randomly assigned patients, median progression-free survival as assessed by independent review was 9.6 mo with T-DM1 vs. 6.4 mo with lapatinib plus capecitabine (hazard ratio for progression or death from any cause, 0.65; 95% confidence interval [CI], 0.55 to 0.77; P<0.001), and median overall survival at the second interim anal. crossed the stopping boundary for efficacy (30.9 mo vs. 25.1 mo; hazard ratio for death from any cause, 0.68; 95% CI, 0.55 to 0.85; P<0.001).  The objective response rate was higher with T-DM1 (43.6%, vs. 30.8% with lapatinib plus capecitabine; P<0.001); results for all addnl. secondary end points favored T-DM1.  Rates of grade 3 or above were higher with lapatinib plus capecitabine than with T-DM1 (57% vs. 41%).  The incidences of thrombocytopenia and increased serum aminotransferase levels were higher with T-DM1, whereas the incidences of diarrhea, nausea, vomiting, and palmar-plantar erythrodysesthesia were higher with lapatinib plus capecitabine.  CONCLUSIONS: T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-pos. advanced breast cancer previously treated with trastuzumab and a taxane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGRhxRQ7JSJrVg90H21EOLACvtfcHk0lhZ2N-x3y9LAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73M&md5=3be5bac27a81b530442dc8a6b4a1f82e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1209124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1209124%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DS.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DGianni%26aufirst%3DL.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DWelslau%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DPegram%26aufirst%3DM.%26aulast%3DOh%26aufirst%3DD.%2BY.%26aulast%3DDieras%26aufirst%3DV.%26aulast%3DGuardino%26aufirst%3DE.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DS.%26aulast%3DBlackwell%26aufirst%3DK.%26atitle%3DTrastuzumab%2520emtansine%2520for%2520HER2-positive%2520advanced%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1783%26epage%3D1791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Martin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrero, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wildiers, H.</span><span> </span><span class="NLM_article-title">Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomized open-label phase 3 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">689</span><span class="NLM_x">–</span> <span class="NLM_lpage">699</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1016%2FS1470-2045%2814%2970178-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=24793816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntl2gs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=689-699&author=I.+E.+Kropauthor=S.+B.+Kimauthor=A.+Gonzalez-Martinauthor=P.+M.+LoRussoauthor=J.+M.+Ferreroauthor=M.+Smittauthor=R.+Yuauthor=A.+Leungauthor=H.+Wildiers&title=Trastuzumab+emtansine+versus+treatment+of+physician%E2%80%99s+choice+for+pretreated+HER2-positive+advanced+breast+cancer+%28TH3RESA%29%3A+a+randomized+open-label+phase+3+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial</span></div><div class="casAuthors">Krop, Ian E.; Kim, Sung-Bae; Gonzalez-Martin, Antonio; LoRusso, Patricia M.; Ferrero, Jean-Marc; Smitt, Melanie; Yu, Ron; Leung, Abraham C. F.; Wildiers, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">689-699</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic breast cancer have few effective therapeutic options.  We aimed to compare trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent DM1 linked to trastuzumab, with treatment of physician's choice in this population of patients.This randomised, open-label, phase 3 trial took place in medical centers in 22 countries across Europe, North America, South America, and Asia-Pacific.  Eligible patients (≥18 years, left ventricular ejection fraction ≥50%, Eastern Cooperative Oncol. Group performance status 0-2) with progressive HER2-pos. advanced breast cancer who had received two or more HER2-directed regimens in the advanced setting, including trastuzumab and lapatinib, and previous taxane therapy in any setting, were randomly assigned (in a 2:1 ratio) to trastuzumab emtansine (3·6 mg/kg i.v. every 21 days) or physician's choice using a permuted block randomization scheme by an interactive voice and web response system.  Patients were stratified according to world region (USA vs western Europe vs other), no. of previous regimens (excluding single-agent hormonal therapy) for the treatment of advanced disease (two to three vs more than three), and presence of visceral disease (any vs none).  Coprimary endpoints were investigator-assessed progression-free survival (PFS) and overall survival in the intention-to-treat population.  We report the final PFS anal. and the first interim overall survival anal.  This study is registered with ClinicalTrials.gov, no. NCT01419197.From Sept 14, 2011, to Nov 19, 2012, 602 patients were randomly assigned (404 to trastuzumab emtansine and 198 to physician's choice).  At data cutoff (Feb 11, 2013), 44 patients assigned to physician's choice had crossed over to trastuzumab emtansine.  After a median follow-up of 7·2 mo (IQR 5·0-10·1 mo) in the trastuzumab emtansine group and 6·5 mo (IQR 4·1-9·7) in the physician's choice group, 219 (54%) patients in the trastuzumab emtansine group and 129 (65%) of patients in the physician's choice group had PFS events.  PFS was significantly improved with trastuzumab emtansine compared with physician's choice (median 6·2 mo [95% CI 5·59-6·87] vs 3·3 mo [2·89-4·14]; stratified hazard ratio [HR] 0·528 [0·422-0·661]; p<0·0001).  Interim overall survival anal. showed a trend favoring trastuzumab emtansine (stratified HR 0·552 [95% CI 0·369-0·826]; p=0·0034), but the stopping boundary was not crossed.  A lower incidence of grade 3 or worse adverse events was reported with trastuzumab emtansine than with physician's choice (130 events [32%] in 403 patients vs 80 events [43%] in 184 patients).  Neutropenia (ten [2%] vs 29 [16%]), diarrhoea (three [<1%] vs eight [4%]), and febrile neutropenia (one [<1%] vs seven [4%]) were grade 3 or worse adverse events that were more common in the physician's choice group than in the trastuzumab emtansine group.  Thrombocytopenia (19 [5%] vs three [2%]) was the grade 3 or worse adverse event that was more common in the trastuzumab emtansine group. 74 (18%) patients in the trastuzumab emtansine group and 38 (21%) in the physician's choice group reported a serious adverse event.  Trastuzumab emtansine should be considered as a new std. for patients with HER2-pos. advanced breast cancer who have previously received trastuzumab and lapatinib.Genentech.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNXUpmCIdTY7Vg90H21EOLACvtfcHk0lhZ2N-x3y9LAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntl2gs7o%253D&md5=975dd9e786d96360b163c2583aefc4b8</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970178-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970178-0%26sid%3Dliteratum%253Aachs%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DKim%26aufirst%3DS.%2BB.%26aulast%3DGonzalez-Martin%26aufirst%3DA.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DFerrero%26aufirst%3DJ.%2BM.%26aulast%3DSmitt%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DR.%26aulast%3DLeung%26aufirst%3DA.%26aulast%3DWildiers%26aufirst%3DH.%26atitle%3DTrastuzumab%2520emtansine%2520versus%2520treatment%2520of%2520physician%25E2%2580%2599s%2520choice%2520for%2520pretreated%2520HER2-positive%2520advanced%2520breast%2520cancer%2520%2528TH3RESA%2529%253A%2520a%2520randomized%2520open-label%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D689%26epage%3D699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedrini, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pienkowski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knott, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benyunes, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swain, S. M.</span><span> </span><span class="NLM_article-title">Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1056%2FNEJMoa1113216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=22149875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFSlt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=109-119&author=J.+Baselgaauthor=J.+Cortesauthor=S.+B.+Kimauthor=S.+A.+Imauthor=R.+Heggauthor=Y.+H.+Imauthor=L.+Romanauthor=J.+L.+Pedriniauthor=T.+Pienkowskiauthor=A.+Knottauthor=E.+Clarkauthor=M.+C.+Benyunesauthor=G.+Rossauthor=S.+M.+Swain&title=Pertuzumab+plus+trastuzumab+plus+docetaxel+for+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer</span></div><div class="casAuthors">Baselga, Jose; Cortes, Javier; Kim, Sung-Bae; Im, Seock-Ah; Hegg, Roberto; Im, Young-Hyuck; Roman, Laslo; Pedrini, Jose Luiz; Pienkowski, Tadeusz; Knott, Adam; Clark, Emma; Benyunes, Mark C.; Ross, Graham; Swain, Sandra M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-119</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The anti-human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-pos. metastatic breast cancer.  However, most cases of advanced disease eventually progress.  Pertuzumab, an anti-HER2 humanized monoclonal antibody that inhibits receptor dimerization, has a mechanism of action that is complementary to that of trastuzumab, and combination therapy with the two antibodies has shown promising activity and an acceptable safety profile in phase 2 studies involving patients with HER2-pos. breast cancer.  METHODS We randomly assigned 808 patients with HER2-pos. metastatic breast cancer to receive placebo plus trastuzumab plus docetaxel (control group) or pertuzumab plus trastuzumab plus docetaxel (pertuzumab group) as first-line treatment until the time of disease progression or the development of toxic effects that could not be effectively managed.  The primary end point was independently assessed progression-free survival.  Secondary end points included overall survival, progression-free survival as assessed by the investigator, the objective response rate, and safety.  RESULTS The median progression-free survival was 12.4 mo in the control group, as com pared with 18.5 mo in the pertuzumab group (hazard ratio for progression or death, 0.62; 95% confidence interval, 0.51 to 0.75; P < 0.001).  The interim anal. of overall survival showed a strong trend in favor of pertuzumab plus trastuzumab plus docetaxel.  The safety profile was generally similar in the two groups, with no increase in left ventricular systolic dysfunction; the rates of febrile neutropenia and diarrhea of grade 3 or above were higher in the pertuzumab group than in the control group.  CONCLUSIONS The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-pos. metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmwMDP53z_VLVg90H21EOLACvtfcHk0lhZ2N-x3y9LAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFSlt7Y%253D&md5=8f8a05c82e4722049923dd069f1863b4</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1113216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1113216%26sid%3Dliteratum%253Aachs%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BB.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DHegg%26aufirst%3DR.%26aulast%3DIm%26aufirst%3DY.%2BH.%26aulast%3DRoman%26aufirst%3DL.%26aulast%3DPedrini%26aufirst%3DJ.%2BL.%26aulast%3DPienkowski%26aufirst%3DT.%26aulast%3DKnott%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DE.%26aulast%3DBenyunes%26aufirst%3DM.%2BC.%26aulast%3DRoss%26aufirst%3DG.%26aulast%3DSwain%26aufirst%3DS.%2BM.%26atitle%3DPertuzumab%2520plus%2520trastuzumab%2520plus%2520docetaxel%2520for%2520metastatic%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D109%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fields, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowbenko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albain, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbeck, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dieras, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crivellari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guardino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">456</span><span class="NLM_x">–</span> <span class="NLM_lpage">468</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1158%2F1078-0432.CCR-13-0358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=24097864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKrs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=456-468&author=G.+D.+Phillipsauthor=C.+T.+Fieldsauthor=G.+Liauthor=D.+Dowbenkoauthor=G.+Schaeferauthor=K.+Millerauthor=F.+Andreauthor=H.+A.+Burrisauthor=K.+S.+Albainauthor=N.+Harbeckauthor=V.+Dierasauthor=D.+Crivellariauthor=L.+Fangauthor=E.+Guardinoauthor=S.+R.+Olsenauthor=L.+M.+Crockerauthor=M.+X.+Sliwkowski&title=Dual+targeting+of+HER2-positive+cancer+with+trastuzumab+emtansine+and+pertuzumab%3A+critical+role+for+neuregulin+blockade+in+antitumor+response+to+combination+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy</span></div><div class="casAuthors">Phillips, Gail D. Lewis; Fields, Carter T.; Li, Guangmin; Dowbenko, Donald; Schaefer, Gabriele; Miller, Kathy; Andre, Fabrice; Burris, Howard A.; Albain, Kathy S.; Harbeck, Nadia; Dieras, Veronique; Crivellari, Diana; Fang, Liang; Guardino, Ellie; Olsen, Steven R.; Crocker, Lisa M.; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">456-468</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Targeting HER2 with multiple HER2-directed therapies represents a promising area of treatment for HER2-pos. cancers.  We investigated combining the HER2-directed antibody-drug conjugate trastuzumab emtansine (T-DM1) with the HER2 dimerization inhibitor pertuzumab (Perjeta).  Exptl. Design: Drug combination studies with T-DM1 and pertuzumab were performed on cultured tumor cells and in mouse xenograft models of HER2-amplified cancer.  In patients with HER2-pos. locally advanced or metastatic breast cancer (mBC), T-DM1 was dose-escalated with a fixed std. pertuzumab dose in a 3+3 phase Ib/II study design.  Results: Treatment of HER2-overexpressing tumor cells in vitro with T-DM1 plus pertuzumab resulted in synergistic inhibition of cell proliferation and induction of apoptotic cell death.  The presence of the HER3 ligand, heregulin (NRG-1β), reduced the cytotoxic activity of T-DM1 in a subset of breast cancer lines; this effect was reversed by the addn. of pertuzumab.  Results from mouse xenograft models showed enhanced antitumor efficacy with T-DM1 and pertuzumab resulting from the unique antitumor activities of each agent.  In patients with mBC previously treated with trastuzumab, lapatinib, and chemotherapy, T-DM1 could be dosed at the max. tolerated dose (MTD; 3.6 mg/kg every 3 wk) with std. dose pertuzumab.  Adverse events were mostly grade 1 and 2, with indications of clin. activity.  Conclusions: Dual targeting of HER2 with the combination of T-DM1 and pertuzumab in cell culture and mouse xenograft models resulted in enhanced antitumor activity.  In patients, this combination showed an encouraging safety and tolerability profile with preliminary evidence of efficacy.  Clin Cancer Res; 20(2); 456-68. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXtv33Olw_qrVg90H21EOLACvtfcHk0lhmh8fO99nxuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKrs7c%253D&md5=71f2be1c5fccaee1d613d09c0eaf48b5</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0358%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DG.%2BD.%26aulast%3DFields%26aufirst%3DC.%2BT.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDowbenko%26aufirst%3DD.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DAlbain%26aufirst%3DK.%2BS.%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DDieras%26aufirst%3DV.%26aulast%3DCrivellari%26aufirst%3DD.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DGuardino%26aufirst%3DE.%26aulast%3DOlsen%26aufirst%3DS.%2BR.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DDual%2520targeting%2520of%2520HER2-positive%2520cancer%2520with%2520trastuzumab%2520emtansine%2520and%2520pertuzumab%253A%2520critical%2520role%2520for%2520neuregulin%2520blockade%2520in%2520antitumor%2520response%2520to%2520combination%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D456%26epage%3D468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dees, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span> </span><span class="NLM_article-title">Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">911</span><span class="NLM_x">–</span> <span class="NLM_lpage">922</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.2174%2F138920012802138688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=22475266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1OlurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=911-922&author=D.+Luauthor=H.+A.+Burrisauthor=B.+Wangauthor=E.+C.+Deesauthor=J.+Cortesauthor=A.+Joshiauthor=M.+Guptaauthor=J.+H.+Yiauthor=Y.+W.+Chuauthor=T.+Shihauthor=L.+Fangauthor=S.+Girish&title=Drug+interaction+potential+of+trastuzumab+emtansine+%28T-DM1%29+combined+with+pertuzumab+in+patients+with+HER2-positive+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer</span></div><div class="casAuthors">Lu, Dan; Burris, Howard A., III; Wang, Bei; Dees, E. Claire; Cortes, Javier; Joshi, Amita; Gupta, Manish; Yi, Joo-Hee; Chu, Yu-Waye; Shih, Ted; Fang, Liang; Girish, Sandhya</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">911-922</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate comprised of trastuzumab and the cytotoxic agent DM1 (deriv. of maytansine) linked by a stable linker N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC).  T-DM1 targets an epitope located at subdomain IV of human epidermal growth factor receptor 2 (HER2).  Pertuzumab is a monoclonal antibody that targets an epitope located at subdomain II of HER2, distinct from the epitope recognized by T-DM1.  The pharmacokinetics (PK), safety, and efficacy of T-DM1 combined with pertuzumab were studied in a phase 1b/2 trial in 67 patients with HER2-pos., locally advanced or metastatic breast cancer (MBC).  The therapeutic protein-drug interaction (TP-DI) potential of T-DM1 plus pertuzumab was evaluated.  The PK of T-DM1-related analytes and pertuzumab were compared with historical PK data.  The results show that the exposure of T-DM1 and DM1, as estd. by noncompartmental analyses, was comparable with that reported by historical single-agent studies in patients with HER2-pos. MBC.  T-DM1 clearance and vol. of distribution in the central compartment, as estd. by population PK anal., were also comparable between this study and historical single-agent studies in patients with HER2-pos. MBC.  Summary statistics of pertuzumab trough and maximal exposure (concns. at predose and 15-30 min after the end of infusion at cycle 1 and at steady state) were similar with those obsd. in a representative historical single-agent study with the same dosing regimen.  The visual predictive check plot by population simulation further confirmed that T-DM1 did not alter pertuzumab PK.  Based on these data and the PK and pharmacodynamic properties of T-DM1 and pertuzumab, the risk of TP-DI appears to be low when T-DM1 and pertuzumab are given together.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeUAf0n581h7Vg90H21EOLACvtfcHk0lhmh8fO99nxuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1OlurrO&md5=ee2756eb89baee7a08a95ff9d43eb736</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.2174%2F138920012802138688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012802138688%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DDees%26aufirst%3DE.%2BC.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DYi%26aufirst%3DJ.%2BH.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DShih%26aufirst%3DT.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DGirish%26aufirst%3DS.%26atitle%3DDrug%2520interaction%2520potential%2520of%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529%2520combined%2520with%2520pertuzumab%2520in%2520patients%2520with%2520HER2-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D911%26epage%3D922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Bartsch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berghoff, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preusser, M.</span><span> </span><span class="NLM_article-title">Breast cancer brain metastases responding to primary systemic therapy with T-DM1</span> <span class="citation_source-journal">J. Neuro-Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1007%2Fs11060-013-1257-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=24065570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252Fht1SlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2014&pages=205-206&author=R.+Bartschauthor=A.+S.+Berghoffauthor=M.+Preusser&title=Breast+cancer+brain+metastases+responding+to+primary+systemic+therapy+with+T-DM1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer brain metastases responding to primary systemic therapy with T-DM1</span></div><div class="casAuthors">Bartsch Rupert; Berghoff Anna S; Preusser Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">205-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRM0sDqGuOnpXtlzo9xastyfW6udTcc2eY0trvNjI95srntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252Fht1SlsA%253D%253D&md5=cb5391468373267301aadd8c16fc8e06</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs11060-013-1257-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-013-1257-5%26sid%3Dliteratum%253Aachs%26aulast%3DBartsch%26aufirst%3DR.%26aulast%3DBerghoff%26aufirst%3DA.%2BS.%26aulast%3DPreusser%26aufirst%3DM.%26atitle%3DBreast%2520cancer%2520brain%2520metastases%2520responding%2520to%2520primary%2520systemic%2520therapy%2520with%2520T-DM1%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2014%26volume%3D116%26spage%3D205%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holden, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, A.</span><span> </span><span class="NLM_article-title">Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1229</span><span class="NLM_x">–</span> <span class="NLM_lpage">1240</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1007%2Fs00280-011-1817-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=22271209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1Kru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=1229-1240&author=S.+Girishauthor=M.+Guptaauthor=B.+Wangauthor=D.+Luauthor=I.+E.+Kropauthor=C.+L.+Vogelauthor=H.+A.+Burrisauthor=P.+M.+LoRussoauthor=J.+H.+Yiauthor=O.+Saadauthor=B.+Tongauthor=Y.+W.+Chuauthor=S.+Holdenauthor=A.+Joshi&title=Clinical+pharmacology+of+trastuzumab+emtansine+%28T-DM1%29%3A+an+antibody%E2%80%93drug+conjugate+in+development+for+the+treatment+of+HER2-positive+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer</span></div><div class="casAuthors">Girish, Sandhya; Gupta, Manish; Wang, Bei; Lu, Dan; Krop, Ian E.; Vogel, Charles L.; Burris, Howard A., III; LoRusso, Patricia M.; Yi, Joo-Hee; Saad, Ola; Tong, Barbara; Chu, Yu-Waye; Holden, Scott; Joshi, Amita</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1229-1240</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate comprising trastuzumab and DM1, a microtubule polymn. inhibitor, covalently bound via a stable thioether linker.  To characterize the pharmacokinetics (PK) of T-DM1 in patients with human epidermal growth factor receptor 2 (HER2)-pos. metastatic breast cancer, data from four studies (TDM3569g, TDM4258g, TDM4374g, and TDM4688g) of single-agent T-DM1 administered at 3.6 mg/kg every 3 wk (q3w) were assessed in aggregate.  Methods: Multiple analytes-T-DM1, total trastuzumab (TT), DM1, and key metabolites-were quantified using enzyme-linked immunosorbent assays or liq. chromatog. tandem mass spectrometry.  PK parameters of T-DM1, TT, and DM1 exposure were calcd. using std. noncompartmental approaches and correlated to efficacy (objective response rate) and safety (platelet counts, hepatic transaminase concns.).  Immunogenicity was evaluated by measuring anti-therapeutic antibodies (ATA) to T-DM1 after repeated dosing using validated bridging antibody electrochemiluminescence or enzyme-linked immunosorbent assays.  Results: PK parameters for T-DM1, TT, and DM1 were consistent across studies at cycle 1 and steady state.  T-DM1 PK was not affected by residual trastuzumab from prior therapy or circulating extracellular domain of HER2.  No significant correlations were obsd. between T-DM1 exposure and efficacy, thrombocytopenia, or increased concns. of transaminases.  Across the studies, ATA formation was detected in 4.5% (13/286) of evaluable patients receiving T-DM1 q3w.  Conclusions The PK profile of single-agent T-DM1 (3.6 mg/kg q3w) is predictable, well characterized, and unaffected by circulating levels of HER2 extracellular domain or residual trastuzumab.  T-DM1 exposure does not correlate with clin. responses or key adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjA6MaBSuH37Vg90H21EOLACvtfcHk0ljMVwexWtG6Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1Kru70%253D&md5=f4b2a4ef4aaa79a96adbb1810a0c44d9</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1817-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1817-3%26sid%3Dliteratum%253Aachs%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DVogel%26aufirst%3DC.%2BL.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DYi%26aufirst%3DJ.%2BH.%26aulast%3DSaad%26aufirst%3DO.%26aulast%3DTong%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DHolden%26aufirst%3DS.%26aulast%3DJoshi%26aufirst%3DA.%26atitle%3DClinical%2520pharmacology%2520of%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529%253A%2520an%2520antibody%25E2%2580%2593drug%2520conjugate%2520in%2520development%2520for%2520the%2520treatment%2520of%2520HER2-positive%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D1229%26epage%3D1240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span> </span><span class="NLM_article-title">An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">672</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1007%2Fs40262-013-0060-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=23553425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVSnu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=657-672&author=D.+Luauthor=A.+Joshiauthor=B.+Wangauthor=S.+Olsenauthor=J.+H.+Yiauthor=I.+E.+Kropauthor=H.+A.+Burrisauthor=S.+Girish&title=An+integrated+multiple-analyte+pharmacokinetic+model+to+characterize+trastuzumab+emtansine+%28T-DM1%29+clearance+pathways+and+to+evaluate+reduced+pharmacokinetic+sampling+in+patients+with+HER2-positive+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer</span></div><div class="casAuthors">Lu, Dan; Joshi, Amita; Wang, Bei; Olsen, Steve; Yi, Joo-Hee; Krop, Ian E.; Burris, Howard A.; Girish, Sandhya</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">657-672</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background and Objective: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate recently approved by the US Food and Drug Administration for the treatment of human epidermal growth factor receptor 2 (HER2)-pos. metastatic breast cancer previously treated with trastuzumab and taxane chemotherapy.  It comprises the microtubule inhibitory cytotoxic agent DM1 conjugated to the HER2-targeted humanized monoclonal antibody trastuzumab via a stable linker.  To characterize the pharmacokinetics of T-DM1 in patients with metastatic breast cancer, concns. of multiple analytes were quantified, including serum concns. of T-DM1 conjugate and total trastuzumab (the sum of conjugated and unconjugated trastuzumab), as well as plasma concns. of DM1.  The clearance of T-DM1 conjugate is approx. 2 to 3 times faster than its parent antibody, trastuzumab.  However, the clearance pathways accounting for this faster clearance rate are unclear.  An integrated population pharmacokinetic model that simultaneously fits the pharmacokinetics of T-DM1 conjugate and total trastuzumab can help to elucidate the clearance pathways of T-DM1.  The model can also be used to predict total trastuzumab pharmacokinetic profiles based on T-DM1 conjugate pharmacokinetic data and sparse total trastuzumab pharmacokinetic data, thereby reducing the frequency of pharmacokinetic sampling.  Methods: T-DM1 conjugate and total trastuzumab serum concn. data, including baseline trastuzumab concns. prior to T-DM1 treatment, from phase I and II studies were used to develop this integrated population pharmacokinetic model.  Based on a hypothetical T-DM1 catabolism scheme, two-compartment models for T-DM1 conjugate and trastuzumab were integrated by assuming a one-step deconjugation clearance from T-DM1 conjugate to trastuzumab.  The ability of the model to predict the total trastuzumab pharmacokinetic profile based on T-DM1 conjugate pharmacokinetics and various sampling schemes of total trastuzumab pharmacokinetics was assessed to evaluate total trastuzumab sampling schemes.  Results: The final model reflects a simplified catabolism scheme of T-DM1, suggesting that T-DM1 clearance pathways include both deconjugation and proteolytic degrdn.  The model fits T-DM1 conjugate and total trastuzumab pharmacokinetic data simultaneously.  The deconjugation clearance of T-DM1 was estd. to be ∼0.4 L/day.  Proteolytic degrdn. clearances for T-DM1 and trastuzumab were similar (∼0.3 L/day).  This model accurately predicts total trastuzumab pharmacokinetic profiles based on T-DM1 conjugate pharmacokinetic data and sparse total trastuzumab pharmacokinetic data sampled at preinfusion and end of infusion in cycle 1, and in one addnl. steady state cycle.  Conclusions: This semi-mechanistic integrated model links T-DM1 conjugate and total trastuzumab pharmacokinetic data, and supports the inclusion of both proteolytic degrdn. and deconjugation as clearance pathways in the hypothetical T-DM1 catabolism scheme.  The model attributes a faster T-DM1 conjugate clearance vs. that of trastuzumab to the presence of a deconjugation process and suggests a similar proteolytic clearance of T-DM1 and trastuzumab.  Based on the model and T-DM1 conjugate pharmacokinetic data, a sparse pharmacokinetic sampling scheme for total trastuzumab provides an entire pharmacokinetic profile with similar predictive accuracy to that of a dense pharmacokinetic sampling scheme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeRfgJg8C3KrVg90H21EOLACvtfcHk0ljMVwexWtG6Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVSnu7jI&md5=b5b591684a66774da1b9161926217f32</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs40262-013-0060-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-013-0060-y%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DOlsen%26aufirst%3DS.%26aulast%3DYi%26aufirst%3DJ.%2BH.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DGirish%26aufirst%3DS.%26atitle%3DAn%2520integrated%2520multiple-analyte%2520pharmacokinetic%2520model%2520to%2520characterize%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529%2520clearance%2520pathways%2520and%2520to%2520evaluate%2520reduced%2520pharmacokinetic%2520sampling%2520in%2520patients%2520with%2520HER2-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2013%26volume%3D52%26spage%3D657%26epage%3D672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Chudasama, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaedeli Stark, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrold, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mager, D. E.</span><span> </span><span class="NLM_article-title">Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">520</span><span class="NLM_x">–</span> <span class="NLM_lpage">527</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1038%2Fclpt.2012.153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=22968044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2iurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=520-527&author=V.+L.+Chudasamaauthor=F.+Schaedeli+Starkauthor=J.+M.+Harroldauthor=J.+Tibbittsauthor=S.+R.+Girishauthor=M.+Guptaauthor=N.+Freyauthor=D.+E.+Mager&title=Semi-mechanistic+population+pharmacokinetic+model+of+multivalent+trastuzumab+emtansine+in+patients+with+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Semi-mechanistic Population Pharmacokinetic Model of Multivalent Trastuzumab Emtansine in Patients with Metastatic Breast Cancer</span></div><div class="casAuthors">Chudasama, V. L.; Schaedeli Stark, F.; Harrold, J. M.; Tibbitts, J.; Girish, S. R.; Gupta, M.; Frey, N.; Mager, D. E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">520-527</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) composed of multiple mols. of the antimicrotubule agent DM1 linked to trastuzumab, a humanized anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody.  Pharmacokinetics data from phase I (n = 52) and phase II (n = 111) studies in HER2-pos. metastatic breast cancer patients show a shorter terminal half-life for T-DM1 than for total trastuzumab (TTmAb).  In this work, we translated prior preclin. modeling in monkeys to develop a semi-mechanistic population pharmacokinetics model to characterize T-DM1 and TTmAb concn. profiles.  A series of transit compartments with the same disposition parameters was used to describe the deconjugation process from higher to lower drug-to-antibody ratios (DARs).  The structure could explain the shorter terminal half-life of T-DM1 relative to TTmab.  The final model integrates prior knowledge of T-DM1 DARs from preclin. studies and could provide a platform for understanding and characterizing the pharmacokinetics of other ADC systems.  Clin. Pharmacol. & Therapeutics (2012); 92 4, 520-527. doi:10.1038/clpt.2012.153.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsh_7mNP3TbrVg90H21EOLACvtfcHk0ljMVwexWtG6Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2iurfP&md5=1d04057bdead10453770c704e5ed28f4</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2012.153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2012.153%26sid%3Dliteratum%253Aachs%26aulast%3DChudasama%26aufirst%3DV.%2BL.%26aulast%3DSchaedeli%2BStark%26aufirst%3DF.%26aulast%3DHarrold%26aufirst%3DJ.%2BM.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DGirish%26aufirst%3DS.%2BR.%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DFrey%26aufirst%3DN.%26aulast%3DMager%26aufirst%3DD.%2BE.%26atitle%3DSemi-mechanistic%2520population%2520pharmacokinetic%2520model%2520of%2520multivalent%2520trastuzumab%2520emtansine%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D92%26spage%3D520%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Bender, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaedeli-Stark, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friberg, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, M.</span><span> </span><span class="NLM_article-title">A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">601</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1007%2Fs00280-012-1934-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=22886072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVentbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2012&pages=591-601&author=B.+C.+Benderauthor=F.+Schaedeli-Starkauthor=R.+Kochauthor=A.+Joshiauthor=Y.+W.+Chuauthor=H.+Rugoauthor=I.+E.+Kropauthor=S.+Girishauthor=L.+E.+Fribergauthor=M.+Gupta&title=A+population+pharmacokinetic%2Fpharmacodynamic+model+of+thrombocytopenia+characterizing+the+effect+of+trastuzumab+emtansine+%28T-DM1%29+on+platelet+counts+in+patients+with+HER2-positive+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer</span></div><div class="casAuthors">Bender, Brendan C.; Schaedeli-Stark, Franziska; Koch, Reinhold; Joshi, Amita; Chu, Yu-Waye; Rugo, Hope; Krop, Ian E.; Girish, Sandhya; Friberg, Lena E.; Gupta, Manish</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">591-601</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate in the development for the treatment of human epidermal growth factor receptor 2-pos. cancers.  Thrombocytopenia (TCP) is the dose-limiting toxicity of T-DM1.  A semimechanistic population pharmacokinetic/pharmacodynamic (PK/PD) model was developed to characterize the effect of T-DM1 on patient platelet counts.  Methods: A PK/PD model with transit compartments that mimic platelet development and circulation was fit to concn.-platelet-time course data from two T-DM1 single-agent studies (TDM3569g; N = 52 and TDM4258g; N = 112).  NONMEM 7 software was used for model development.  Data from a sep. phase II study (TDM4374g; N = 110) were used for model evaluation.  Patient baseline characteristics were evaluated as covariates of model PD parameters.  Results: The model described the platelet data well and predicted the incidence of grade ≥3 TCP.  The model predicted that with T-DM1 3.6 mg/kg given every 3 wk (q3w), the lowest platelet nadir would occur after the first dose.  Also predicted was a patient subgroup (46 %) having variable degrees of downward drifting platelet-time profiles, which were predicted to stabilize by the eighth treatment cycle to platelet counts above grade 3 TCP.  Baseline characteristics were not significant covariates of PD parameters in the model.  Conclusions: This semimechanistic PK/PD model accurately captures the cycle 1 platelet nadir, the downward drift noted in some patient platelet-time profiles, and the ∼8 % incidence of grade ≥3 TCP with T-DM1 3.6 mg/kg q3w.  This model supports T-DM1 3.6 mg/kg q3w as a well-tolerated dose with minimal dose delays or redns. for TCP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIqlu3H3iJv7Vg90H21EOLACvtfcHk0liGFb5dZT3zNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVentbjN&md5=52d01f2d24af314edf8c54d87304af23</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2Fs00280-012-1934-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-012-1934-7%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DB.%2BC.%26aulast%3DSchaedeli-Stark%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DR.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DRugo%26aufirst%3DH.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DFriberg%26aufirst%3DL.%2BE.%26aulast%3DGupta%26aufirst%3DM.%26atitle%3DA%2520population%2520pharmacokinetic%252Fpharmacodynamic%2520model%2520of%2520thrombocytopenia%2520characterizing%2520the%2520effect%2520of%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529%2520on%2520platelet%2520counts%2520in%2520patients%2520with%2520HER2-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D70%26spage%3D591%26epage%3D601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Shen, B. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bumbaca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastuskovas, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span> </span><span class="NLM_article-title">Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">901</span><span class="NLM_x">–</span> <span class="NLM_lpage">910</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.2174%2F138920012802138598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=22475269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1OlurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=901-910&author=B.+Q.+Shenauthor=D.+Bumbacaauthor=O.+Saadauthor=Q.+Yueauthor=C.+V.+Pastuskovasauthor=S.+C.+Khojastehauthor=J.+Tibbittsauthor=S.+Kaurauthor=B.+Wangauthor=Y.+W.+Chuauthor=P.+M.+LoRussoauthor=S.+Girish&title=Catabolic+fate+and+pharmacokinetic+characterization+of+trastuzumab+emtansine+%28T-DM1%29%3A+an+emphasis+on+preclinical+and+clinical+catabolism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism</span></div><div class="casAuthors">Shen, Ben-Quan; Bumbaca, Daniela; Saad, Ola; Yue, Qin; Pastuskovas, Cinthia V.; Khojasteh, S. Cyrus; Tibbitts, Jay; Kaur, Surinder; Wang, Bei; Chu, Yu-Waye; LoRusso, Patricia M.; Girish, Sandhya</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">901-910</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate in clin. development for the treatment of human epidermal growth factor receptor 2 (HER2)-pos. cancers.  Herein, we describe a series of studies to assess T-DM1 absorption, distribution, metab., and excretion (ADME) in rats as well as to assess human exposure to T-DM1 catabolites.  Following administration of unlabeled and radiolabeled T-DM1 in female Sprague Dawley rats as a single dose, plasma, urine, bile and feces were assessed for mass balance, profiling and identification of catabolites.  In rats, the major circulating species in plasma was T-DM1, while DM1 concns. were low (1.08 to 15.6 ng/mL).  The major catabolites found circulating in rat plasma were DM1, [N-maleimidomethyl] cyclohexane-1-carboxylate-DM1 (MCC-DM1), and Lysine-MCC-DM1.  These catabolites identified in rats were also detected in plasma samples from patients with HER2-pos. metastatic breast cancer who received single-agent T-DM1 (3.6 mg/kg every 3 wk) in a phase 2 clin. study.  There was no evidence of tissue accumulation in rats or catabolite accumulation in human plasma following multiple dosing.  In rats, T-DM1 was distributed nonspecifically to the organs without accumulation.  The major pathway of DM1-contg. catabolite elimination in rats was the fecal/biliary route, with up to 80% of radioactivity recovered in the feces and 50% in the bile.  The rat T-DM1 ADME profile is likely similar to the human profile, although there may be differences since trastuzumab does not bind the rat HER2- like receptor.  Further research is necessary to more fully understand the T-DM1 ADME profile in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDuHn1EbzEhLVg90H21EOLACvtfcHk0liGFb5dZT3zNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1OlurrN&md5=faf70e5692e4d6a5a7789a0510705837</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.2174%2F138920012802138598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012802138598%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DB.%2BQ.%26aulast%3DBumbaca%26aufirst%3DD.%26aulast%3DSaad%26aufirst%3DO.%26aulast%3DYue%26aufirst%3DQ.%26aulast%3DPastuskovas%26aufirst%3DC.%2BV.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DGirish%26aufirst%3DS.%26atitle%3DCatabolic%2520fate%2520and%2520pharmacokinetic%2520characterization%2520of%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529%253A%2520an%2520emphasis%2520on%2520preclinical%2520and%2520clinical%2520catabolism%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D901%26epage%3D910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Thon, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begonja, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Italiano, J. E.,  Jr.</span><span> </span><span class="NLM_article-title">High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">1975</span><span class="NLM_x">–</span> <span class="NLM_lpage">1984</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=1975-1984&author=J.+N.+Thonauthor=M.+T.+Devineauthor=A.+J.+Begonjaauthor=J.+Tibbittsauthor=J.+E.+Italiano&title=High-content+live-cell+imaging+assay+used+to+establish+mechanism+of+trastuzumab+emtansine+%28T-DM1%29-mediated+inhibition+of+platelet+production"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThon%26aufirst%3DJ.%2BN.%26aulast%3DDevine%26aufirst%3DM.%2BT.%26aulast%3DBegonja%26aufirst%3DA.%2BJ.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DItaliano%26aufirst%3DJ.%2BE.%26atitle%3DHigh-content%2520live-cell%2520imaging%2520assay%2520used%2520to%2520establish%2520mechanism%2520of%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529-mediated%2520inhibition%2520of%2520platelet%2520production%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26spage%3D1975%26epage%3D1984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Sendur, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aksoy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altundag, K.</span><span> </span><span class="NLM_article-title">Cardiotoxicity of novel HER2-targeted therapies</span> <span class="citation_source-journal">Curr. Med. Res. Opin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1015</span><span class="NLM_x">–</span> <span class="NLM_lpage">1024</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1185%2F03007995.2013.807232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=23692263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeqsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2013&pages=1015-1024&author=M.+A.+Sendurauthor=S.+Aksoyauthor=K.+Altundag&title=Cardiotoxicity+of+novel+HER2-targeted+therapies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiotoxicity of novel HER2-targeted therapies</span></div><div class="casAuthors">Sendur, Mehmet A. N.; Aksoy, Sercan; Altundag, Kadri</div><div class="citationInfo"><span class="NLM_cas:title">Current Medical Research and Opinion</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1015-1024</span>CODEN:
                <span class="NLM_cas:coden">CMROCX</span>;
        ISSN:<span class="NLM_cas:issn">0300-7995</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Trastuzumab, an anti-HER2 humanized monoclonal antibody, is the std. treatment for both early and metastatic HER2-pos. breast cancer.  In addn. to other chemotherapeutic agents, trastuzumab significantly improves response rate and survival in HER2-pos. early and metastatic breast cancer.  Although it is well known that trastuzumab therapy is closely assocd. with both symptomatic and asymptomatic cardiotoxicity, less is known about novel HER2-targeted therapies.  The aim of this review is to discuss the cardiac safety data from recent studies of novel anti-HER2 drugs other than trastuzumab.  Scope: Novel HER2-targeted therapies showed favorable results in HER2 pos. metastatic breast cancer patients.  Pubmed database, ASCO and San Antonio Breast Cancer Symposium Meeting abstrs. were searched until Jan. 2013 using the following search keywords; trastuzumab, trastuzumab cardiotoxicity, HER-2 targeted therapies, lapatinib, pertuzumab, trastuzumab emtansine, afatinib and neratinib; papers which were considered relevant for the aim of this review were selected by the authors.  Lapatinib, pertuzumab, T-DM1, neratinib and afatinib mols. are evaluated in the study.  Findings: In a comprehensive anal., 3689 lapatinib treated patients enrolled in 49 trials; asymptomatic cardiac events were reported in 53 patients (1.4%) and symptomatic grade III and IV systolic dysfunction was obsd. only in 7 patients (0.2%) treated with lapatinib.  In phase I-III trials of pertuzumab, cardiac dysfunction was seen in 4.5-14.5% of patients with pertuzumab treatment and cardiac dysfunction was usually grade I and II.  Cardiotoxicity of pertuzumab was usually reported with the trastuzumab combination and no additive cardiotoxicity was reported with addn. of pertuzumab to trastuzumab.  T-DM1 had a better safety profile compared to trastuzumab, no significant cardiotoxicity was obsd. with T-DM1 in heavily pre-treated patients.  In the EMILIA study, only in 1.7% of patients in the T-DM1 group experienced redn. of left ventricular ejection fraction (LVEF) and grade III LVEF redn. developed only in one patient (0.2%) in the T-DM1 group compared to the lapatinib plus capecitabine group.  In phase I-II trials with neratinib no cardiotoxicity was reported whereas cardiotoxicity was seen between 0-5.3% with afatinib treatment.  Conclusion: Although cardiac toxicity has been reported as an adverse event for novel HER2-targeted therapies, cardiac dysfunction rate of the novel HER2-targeted therapies is significantly lower than the trastuzumab and combination of these agents with trastuzumab did not significantly increase the cardiac adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3-0lVbOFDsbVg90H21EOLACvtfcHk0liGFb5dZT3zNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeqsL%252FN&md5=a5a593ec4ce6bbbb95584eb1e1d38d05</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1185%2F03007995.2013.807232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1185%252F03007995.2013.807232%26sid%3Dliteratum%253Aachs%26aulast%3DSendur%26aufirst%3DM.%2BA.%26aulast%3DAksoy%26aufirst%3DS.%26aulast%3DAltundag%26aufirst%3DK.%26atitle%3DCardiotoxicity%2520of%2520novel%2520HER2-targeted%2520therapies%26jtitle%3DCurr.%2520Med.%2520Res.%2520Opin.%26date%3D2013%26volume%3D29%26spage%3D1015%26epage%3D1024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 263 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Lin Zhang, Zewei Wang, Zhiyuan Wang, Fang Luo, Mingfeng Guan, Meimei Xu, Yundong Li, Yaoyang Zhang, Zhaoyin Wang, <span class="NLM_string-name hlFld-ContribAuthor">Wenyuan Wang</span>. </span><span class="cited-content_cbyCitation_article-title">A Simple and Efficient Method to Generate Dual Site-Specific Conjugation ADCs with Cysteine Residue and an Unnatural Amino Acid. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2021,</strong> <em>32 </em>
                                    (6)
                                     , 1094-1104. <a href="https://doi.org/10.1021/acs.bioconjchem.1c00134" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.1c00134</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.1c00134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.1c00134%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DA%252BSimple%252Band%252BEfficient%252BMethod%252Bto%252BGenerate%252BDual%252BSite-Specific%252BConjugation%252BADCs%252Bwith%252BCysteine%252BResidue%252Band%252Ban%252BUnnatural%252BAmino%252BAcid%26aulast%3DZhang%26aufirst%3DLin%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D17032021%26date%3D28042021%26date%3D20052021%26volume%3D32%26issue%3D6%26spage%3D1094%26epage%3D1104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ryo Okajima, Shuichi Hiraoka, <span class="NLM_string-name hlFld-ContribAuthor">Takefumi Yamashita</span>. </span><span class="cited-content_cbyCitation_article-title">Environmental Effects on Salt Bridge Stability in the Protein–Protein Interface: The Case of Hen Egg-White Lysozyme and Its Antibody, HyHEL-10. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Physical Chemistry B</span><span> <strong>2021,</strong> <em>125 </em>
                                    (6)
                                     , 1542-1549. <a href="https://doi.org/10.1021/acs.jpcb.0c09248" title="DOI URL">https://doi.org/10.1021/acs.jpcb.0c09248</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jpcb.0c09248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jpcb.0c09248%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Physical%2520Chemistry%2520B%26atitle%3DEnvironmental%252BEffects%252Bon%252BSalt%252BBridge%252BStability%252Bin%252Bthe%252BProtein%2525E2%252580%252593Protein%252BInterface%25253A%252BThe%252BCase%252Bof%252BHen%252BEgg-White%252BLysozyme%252Band%252BIts%252BAntibody%25252C%252BHyHEL-10%26aulast%3DOkajima%26aufirst%3DRyo%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D2021%26date%3D12102020%26date%3D21012021%26date%3D05022021%26volume%3D125%26issue%3D6%26spage%3D1542%26epage%3D1549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Heinz Fabian Raber, Thomas Heerde, Suzanne Nour El Din, Carolin Flaig, Fabienne Hilgers, Nora Bitzenhofer, Karl-Erich Jäger, Thomas Drepper, Kay-Eberhard Gottschalk, Nicholas Emil Bodenberger, Tanja Weil, Dennis Horst Kubiczek, <span class="NLM_string-name hlFld-ContribAuthor">Frank Rosenau</span>. </span><span class="cited-content_cbyCitation_article-title">Azulitox—A Pseudomonas aeruginosa P28-Derived Cancer-Cell-Specific Protein Photosensitizer. </span><span class="cited-content_cbyCitation_journal-name">Biomacromolecules</span><span> <strong>2020,</strong> <em>21 </em>
                                    (12)
                                     , 5067-5076. <a href="https://doi.org/10.1021/acs.biomac.0c01216" title="DOI URL">https://doi.org/10.1021/acs.biomac.0c01216</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biomac.0c01216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biomac.0c01216%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomacromolecules%26atitle%3DAzulitox%2525E2%252580%252594A%252BPseudomonas%252Baeruginosa%252BP28-Derived%252BCancer-Cell-Specific%252BProtein%252BPhotosensitizer%26aulast%3DRaber%26aufirst%3DHeinz%2BFabian%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D18082020%26date%3D20102020%26date%3D03112020%26volume%3D21%26issue%3D12%26spage%3D5067%26epage%3D5076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yam B. Poudel, Naidu S. Chowdari, Heng Cheng, Christiana I. Iwuagwu, H. Dalton King, Srikanth Kotapati, David Passmore, Richard Rampulla, Arvind Mathur, Gregory Vite, <span class="NLM_string-name hlFld-ContribAuthor">Sanjeev Gangwar</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical Modification of Linkers Provides Stable Linker–Payloads for the Generation of Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 2190-2194. <a href="https://doi.org/10.1021/acsmedchemlett.0c00325" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00325</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00325%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DChemical%252BModification%252Bof%252BLinkers%252BProvides%252BStable%252BLinker%2525E2%252580%252593Payloads%252Bfor%252Bthe%252BGeneration%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DPoudel%26aufirst%3DYam%2BB.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D12062020%26date%3D22092020%26date%3D25092020%26date%3D22092020%26volume%3D11%26issue%3D11%26spage%3D2190%26epage%3D2194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hans-Georg Lerchen, Beatrix Stelte-Ludwig, Anette Sommer, Sandra Berndt, Anne-Sophie Rebstock, Sarah Johannes, Christoph Mahlert, Simone Greven, Lisa Dietz, <span class="NLM_string-name hlFld-ContribAuthor">Hannah Jörißen</span>. </span><span class="cited-content_cbyCitation_article-title">Tailored Linker Chemistries for the Efficient and Selective Activation of ADCs with KSPi Payloads. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2020,</strong> <em>31 </em>
                                    (8)
                                     , 1893-1898. <a href="https://doi.org/10.1021/acs.bioconjchem.0c00357" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.0c00357</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.0c00357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.0c00357%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DTailored%252BLinker%252BChemistries%252Bfor%252Bthe%252BEfficient%252Band%252BSelective%252BActivation%252Bof%252BADCs%252Bwith%252BKSPi%252BPayloads%26aulast%3DLerchen%26aufirst%3DHans-Georg%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D16062020%26date%3D09072020%26date%3D22072020%26date%3D15072020%26volume%3D31%26issue%3D8%26spage%3D1893%26epage%3D1898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">María A. Oliva, Andrea E. Prota, Javier Rodríguez-Salarichs, Youssef L. Bennani, Jesús Jiménez-Barbero, Katja Bargsten, Ángeles Canales, Michel O. Steinmetz, <span class="NLM_string-name hlFld-ContribAuthor">J. Fernando Díaz</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Basis of Noscapine Activation for Tubulin Binding. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8495-8501. <a href="https://doi.org/10.1021/acs.jmedchem.0c00855" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00855</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00855%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BBasis%252Bof%252BNoscapine%252BActivation%252Bfor%252BTubulin%252BBinding%26aulast%3DOliva%26aufirst%3DMar%25C3%25ADa%2BA.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20052020%26date%3D29072020%26date%3D13072020%26volume%3D63%26issue%3D15%26spage%3D8495%26epage%3D8501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marı́a Maneiro, Nafsika Forte, Maria M. Shchepinova, Cyrille S. Kounde, Vijay Chudasama, James Richard Baker, <span class="NLM_string-name hlFld-ContribAuthor">Edward W. Tate</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2020,</strong> <em>15 </em>
                                    (6)
                                     , 1306-1312. <a href="https://doi.org/10.1021/acschembio.0c00285" title="DOI URL">https://doi.org/10.1021/acschembio.0c00285</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.0c00285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.0c00285%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DAntibody%2525E2%252580%252593PROTAC%252BConjugates%252BEnable%252BHER2-Dependent%252BTargeted%252BProtein%252BDegradation%252Bof%252BBRD4%26aulast%3DManeiro%26aufirst%3DMar%25C4%25B1%25CC%2581a%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15042020%26date%3D27042020%26date%3D30042020%26date%3D27042020%26volume%3D15%26issue%3D6%26spage%3D1306%26epage%3D1312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jiaxun Wan, Yongjing Li, Ke Jin, Jia Guo, Jiangtao Xu, <span class="NLM_string-name hlFld-ContribAuthor">Changchun Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Robust Strategy for Antibody–Polymer–Drug Conjugation: Significance of Conjugating Orientation and Linker Charge on Targeting Ability. </span><span class="cited-content_cbyCitation_journal-name">ACS Applied Materials & Interfaces</span><span> <strong>2020,</strong> <em>12 </em>
                                    (21)
                                     , 23717-23725. <a href="https://doi.org/10.1021/acsami.0c04471" title="DOI URL">https://doi.org/10.1021/acsami.0c04471</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsami.0c04471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsami.0c04471%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Applied%2520Materials%2520%2526%2520Interfaces%26atitle%3DRobust%252BStrategy%252Bfor%252BAntibody%2525E2%252580%252593Polymer%2525E2%252580%252593Drug%252BConjugation%25253A%252BSignificance%252Bof%252BConjugating%252BOrientation%252Band%252BLinker%252BCharge%252Bon%252BTargeting%252BAbility%26aulast%3DWan%26aufirst%3DJiaxun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09032020%26date%3D05052020%26date%3D15052020%26date%3D05052020%26volume%3D12%26issue%3D21%26spage%3D23717%26epage%3D23725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Fang Dong, Jian-Quan Liu, <span class="NLM_string-name hlFld-ContribAuthor">Xiang-Shan Wang</span>. </span><span class="cited-content_cbyCitation_article-title">CuBr-Catalyzed α-Arylation and Aerobic Oxidative Dehydrogenative C–N Coupling for the Synthesis of Spiro[cyclohexane-1,12′-isoindolo[1,2-b]quinazolin]-10′-one Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (8)
                                     , 2887-2891. <a href="https://doi.org/10.1021/acs.orglett.0c00497" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c00497</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c00497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c00497%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCuBr-Catalyzed%252B%2525CE%2525B1-Arylation%252Band%252BAerobic%252BOxidative%252BDehydrogenative%252BC%2525E2%252580%252593N%252BCoupling%252Bfor%252Bthe%252BSynthesis%252Bof%252BSpiro%25255Bcyclohexane-1%25252C12%2525E2%252580%2525B2-isoindolo%25255B1%25252C2-b%25255Dquinazolin%25255D-10%2525E2%252580%2525B2-one%252BDerivatives%26aulast%3DDong%26aufirst%3DFang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07022020%26date%3D31032020%26volume%3D22%26issue%3D8%26spage%3D2887%26epage%3D2891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Eiko Seki, Tatsuo Yanagisawa, Mitsuo Kuratani, Kensaku Sakamoto, <span class="NLM_string-name hlFld-ContribAuthor">Shigeyuki Yokoyama</span>. </span><span class="cited-content_cbyCitation_article-title">Fully Productive Cell-Free Genetic Code Expansion by Structure-Based Engineering of Methanomethylophilus alvus Pyrrolysyl-tRNA Synthetase. </span><span class="cited-content_cbyCitation_journal-name">ACS Synthetic Biology</span><span> <strong>2020,</strong> <em>9 </em>
                                    (4)
                                     , 718-732. <a href="https://doi.org/10.1021/acssynbio.9b00288" title="DOI URL">https://doi.org/10.1021/acssynbio.9b00288</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acssynbio.9b00288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facssynbio.9b00288%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Synthetic%2520Biology%26atitle%3DFully%252BProductive%252BCell-Free%252BGenetic%252BCode%252BExpansion%252Bby%252BStructure-Based%252BEngineering%252Bof%252BMethanomethylophilus%252Balvus%252BPyrrolysyl-tRNA%252BSynthetase%26aulast%3DSeki%26aufirst%3DEiko%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D11072019%26date%3D17032020%26volume%3D9%26issue%3D4%26spage%3D718%26epage%3D732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Iván Ramos-Tomillero, Gema Pérez-Chacon, Beatriz Somovilla-Crespo, Francisco Sánchez-Madrid, Carmen Cuevas, Juan Manuel Zapata, Juan Manuel Domínguez, Hortensia Rodríguez, <span class="NLM_string-name hlFld-ContribAuthor">Fernando Albericio</span>. </span><span class="cited-content_cbyCitation_article-title">From Ugi Multicomponent Reaction to Linkers for Bioconjugation. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (13)
                                     , 7424-7431. <a href="https://doi.org/10.1021/acsomega.0c00099" title="DOI URL">https://doi.org/10.1021/acsomega.0c00099</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c00099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c00099%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DFrom%252BUgi%252BMulticomponent%252BReaction%252Bto%252BLinkers%252Bfor%252BBioconjugation%26aulast%3DRamos-Tomillero%26aufirst%3DIv%25C3%25A1n%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D08012020%26date%3D14022020%26date%3D23032020%26volume%3D5%26issue%3D13%26spage%3D7424%26epage%3D7431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Arnab Rudra, Junwei Li, Rameen Shakur, Sachin Bhagchandani, <span class="NLM_string-name hlFld-ContribAuthor">Robert Langer</span>. </span><span class="cited-content_cbyCitation_article-title">Trends in Therapeutic Conjugates: Bench to Clinic. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2020,</strong> <em>31 </em>
                                    (3)
                                     , 462-473. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00828" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00828</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00828%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DTrends%252Bin%252BTherapeutic%252BConjugates%25253A%252BBench%252Bto%252BClinic%26aulast%3DRudra%26aufirst%3DArnab%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D2020%26date%3D06122019%26date%3D23012020%26date%3D11022020%26date%3D28012020%26volume%3D31%26issue%3D3%26spage%3D462%26epage%3D473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chen Bai, Emily E. Reid, Alan Wilhelm, Manami Shizuka, Erin K. Maloney, Rassol Laleau, Lauren Harvey, Katie E. Archer, Dilrukshi Vitharana, Sharlene Adams, Yelena Kovtun, Michael L. Miller, Ravi Chari, Thomas A. Keating, <span class="NLM_string-name hlFld-ContribAuthor">Nicholas C. Yoder</span>. </span><span class="cited-content_cbyCitation_article-title">Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody–Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2020,</strong> <em>31 </em>
                                    (1)
                                     , 93-103. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00777" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00777</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00777%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DSite-Specific%252BConjugation%252Bof%252Bthe%252BIndolinobenzodiazepine%252BDGN549%252Bto%252BAntibodies%252BAffords%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252Bwith%252Ban%252BImproved%252BTherapeutic%252BIndex%252Bas%252BCompared%252Bwith%252BLysine%252BConjugation%26aulast%3DBai%26aufirst%3DChen%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D15112019%26date%3D10122019%26date%3D20112019%26volume%3D31%26issue%3D1%26spage%3D93%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Vasilii F. Otvagin, Natalia S. Kuzmina, Lubov V. Krylova, Arthur B. Volovetsky, Alexander V. Nyuchev, Andrei E. Gavryushin, Ivan N. Meshkov, Yulia G. Gorbunova, Yuliya V. Romanenko, Oscar I. Koifman, Irina V. Balalaeva, <span class="NLM_string-name hlFld-ContribAuthor">Alexey Yu Fedorov</span>. </span><span class="cited-content_cbyCitation_article-title">Water-Soluble Chlorin/Arylaminoquinazoline Conjugate for Photodynamic and Targeted Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 11182-11193. <a href="https://doi.org/10.1021/acs.jmedchem.9b01294" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01294</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01294%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWater-Soluble%252BChlorin%25252FArylaminoquinazoline%252BConjugate%252Bfor%252BPhotodynamic%252Band%252BTargeted%252BTherapy%26aulast%3DOtvagin%26aufirst%3DVasilii%2BF.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D08082019%26date%3D13122019%26date%3D29112019%26volume%3D62%26issue%3D24%26spage%3D11182%26epage%3D11193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alexei S. Karpov, Cristina M. Nieto-Oberhuber, Tinya Abrams, Edwige Beng-Louka, Enrique Blanco, Sylvie Chamoin, Patrick Chene, Isabelle Dacquignies, Dylan Daniel, Michael P. Dillon, Lionel Doumampouom-Metoul, Nikolaos Drosos, Pavel Fedoseev, Markus Furegati, Brian Granda, Robert M. Grotzfeld, Suzanna Hess Clark, Emilie Joly, Darryl Jones, Marion Lacaud-Baumlin, Stephanie Lagasse-Guerro, Edward G. Lorenzana, William Mallet, Piotr Martyniuk, Andreas L. Marzinzik, Yannick Mesrouze, Sandro Nocito, Yoko Oei, Francesca Perruccio, Grazia Piizzi, Etienne Richard, Patrick J. Rudewicz, Patrick Schindler, Mélanie Velay, Kristine Venstrom, Peiyin Wang, Mauro Zurini, <span class="NLM_string-name hlFld-ContribAuthor">Marc Lafrance</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Selective Antibody–Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (12)
                                     , 1674-1679. <a href="https://doi.org/10.1021/acsmedchemlett.9b00468" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00468</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00468%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BSelective%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252Bwith%252BEg5%252BInhibitors%252Bthrough%252BLinker%252Band%252BPayload%252BOptimization%26aulast%3DKarpov%26aufirst%3DAlexei%2BS.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D10102019%26date%3D03122019%26date%3D04122019%26date%3D03122019%26volume%3D10%26issue%3D12%26spage%3D1674%26epage%3D1679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Paulin L. Salomon, Emily E. Reid, Katie E. Archer, Luke Harris, Erin K. Maloney, Alan J. Wilhelm, Michael L. Miller, Ravi V. J. Chari, Thomas A. Keating, <span class="NLM_string-name hlFld-ContribAuthor">Rajeeva Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Optimizing Lysosomal Activation of Antibody–Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2019,</strong> <em>16 </em>
                                    (12)
                                     , 4817-4825. <a href="https://doi.org/10.1021/acs.molpharmaceut.9b00696" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.9b00696</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.9b00696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.9b00696%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DOptimizing%252BLysosomal%252BActivation%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252B%252528ADCs%252529%252Bby%252BIncorporation%252Bof%252BNovel%252BCleavable%252BDipeptide%252BLinkers%26aulast%3DSalomon%26aufirst%3DPaulin%2BL.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D25062019%26date%3D14102019%26date%3D07102019%26date%3D29102019%26date%3D14102019%26volume%3D16%26issue%3D12%26spage%3D4817%26epage%3D4825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joshua
A. Walker, John J. Bohn, Francis Ledesma, Michelle R. Sorkin, Sneha R. Kabaria, Dana N. Thornlow, <span class="NLM_string-name hlFld-ContribAuthor">Christopher A. Alabi</span>. </span><span class="cited-content_cbyCitation_article-title">Substrate Design Enables Heterobifunctional, Dual “Click” Antibody Modification via Microbial Transglutaminase. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2019,</strong> <em>30 </em>
                                    (9)
                                     , 2452-2457. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00522" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00522</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00522%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DSubstrate%252BDesign%252BEnables%252BHeterobifunctional%25252C%252BDual%252B%2525E2%252580%25259CClick%2525E2%252580%25259D%252BAntibody%252BModification%252Bvia%252BMicrobial%252BTransglutaminase%26aulast%3DWalker%26aufirst%3DJoshua%2BA.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D31072019%26date%3D13082019%26date%3D21082019%26date%3D13082019%26volume%3D30%26issue%3D9%26spage%3D2452%26epage%3D2457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nicholas C. Yoder, Chen Bai, Daniel Tavares, Wayne C. Widdison, Kathleen R. Whiteman, Alan Wilhelm, Sharon D. Wilhelm, Molly A. McShea, Erin K. Maloney, Olga Ab, Lintao Wang, Shan Jin, Hans K. Erickson, Thomas A. Keating, <span class="NLM_string-name hlFld-ContribAuthor">John M. Lambert</span>. </span><span class="cited-content_cbyCitation_article-title">A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2019,</strong> <em>16 </em>
                                    (9)
                                     , 3926-3937. <a href="https://doi.org/10.1021/acs.molpharmaceut.9b00529" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.9b00529</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.9b00529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.9b00529%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DA%252BCase%252BStudy%252BComparing%252BHeterogeneous%252BLysine-%252Band%252BSite-Specific%252BCysteine-Conjugated%252BMaytansinoid%252BAntibody-Drug%252BConjugates%252B%252528ADCs%252529%252BIllustrates%252Bthe%252BBenefits%252Bof%252BLysine%252BConjugation%26aulast%3DYoder%26aufirst%3DNicholas%2BC.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15052019%26date%3D09072019%26date%3D03072019%26date%3D31072019%26date%3D09072019%26volume%3D16%26issue%3D9%26spage%3D3926%26epage%3D3937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kelsey
E. Knewtson, Chamani Perera, David Hymel, Zhe Gao, Molly M. Lee, <span class="NLM_string-name hlFld-ContribAuthor">Blake R. Peterson</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–Drug Conjugate that Exhibits Synergistic Cytotoxicity with an Endosome–Disruptive Peptide. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (7)
                                     , 12955-12968. <a href="https://doi.org/10.1021/acsomega.9b01585" title="DOI URL">https://doi.org/10.1021/acsomega.9b01585</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b01585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b01585%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DAntibody%2525E2%252580%252593Drug%252BConjugate%252Bthat%252BExhibits%252BSynergistic%252BCytotoxicity%252Bwith%252Ban%252BEndosome%2525E2%252580%252593Disruptive%252BPeptide%26aulast%3DKnewtson%26aufirst%3DKelsey%2BE.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D17062019%26date%3D17072019%26volume%3D4%26issue%3D7%26spage%3D12955%26epage%3D12968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dian Su, Jinhua Chen, Ely Cosino, Josefa dela Cruz-Chuh, Helen Davis, Geoffrey Del Rosario, Isabel Figueroa, Leanne Goon, Jintang He, Amrita V. Kamath, Surinder Kaur, Katherine R. Kozak, Jeffrey Lau, Donna Lee, M. Violet Lee, Douglas Leipold, Luna Liu, Peter Liu, Guo-Liang Lu, Chris Nelson, Carl Ng, Thomas H. Pillow, Paul Polakis, Andrew G. Polson, Rebecca K. Rowntree, Ola Saad, Brian Safina, Nicola J. Stagg, Moana Tercel, Richard Vandlen, Breanna S. Vollmar, John Wai, Tao Wang, BinQing Wei, Keyang Xu, Juanjuan Xue, Zijin Xu, Gang Yan, Hui Yao, Shang-Fan Yu, Donglu Zhang, Fiona Zhong, <span class="NLM_string-name hlFld-ContribAuthor">Peter S. Dragovich</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2019,</strong> <em>30 </em>
                                    (5)
                                     , 1356-1370. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00133" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00133</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00133%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DAntibody%2525E2%252580%252593Drug%252BConjugates%252BDerived%252Bfrom%252BCytotoxic%252Bseco-CBI-Dimer%252BPayloads%252BAre%252BHighly%252BEfficacious%252Bin%252BXenograft%252BModels%252Band%252BForm%252BProtein%252BAdducts%252BIn%252BVivo%26aulast%3DSu%26aufirst%3DDian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D17022019%26date%3D22042019%26date%3D10042019%26volume%3D30%26issue%3D5%26spage%3D1356%26epage%3D1370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Arnaud
C. Tiberghien, Philip W. Howard, William R. F. Goundry, Marc McCormick, <span class="NLM_string-name hlFld-ContribAuthor">Jeremy S. Parker</span>. </span><span class="cited-content_cbyCitation_article-title">An Alternative Focus for Route Design for the Synthesis of Antibody–Drug Conjugate Payloads. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (8)
                                     , 4830-4836. <a href="https://doi.org/10.1021/acs.joc.8b02876" title="DOI URL">https://doi.org/10.1021/acs.joc.8b02876</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b02876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b02876%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAn%252BAlternative%252BFocus%252Bfor%252BRoute%252BDesign%252Bfor%252Bthe%252BSynthesis%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252BPayloads%26aulast%3DTiberghien%26aufirst%3DArnaud%2BC.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D10112018%26date%3D11012019%26date%3D02012019%26volume%3D84%26issue%3D8%26spage%3D4830%26epage%3D4836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Brian H. White, Kerry Whalen, Kristina Kriksciukaite, Rossitza Alargova, Tsun Au Yeung, Patrick Bazinet, Adam Brockman, Michelle DuPont, Haley Oller, Charles-Andre Lemelin, Patrick Lim Soo, Benoît Moreau, Samantha Perino, James M. Quinn, Gitanjali Sharma, Rajesh Shinde, Beata Sweryda-Krawiec, Richard Wooster, <span class="NLM_string-name hlFld-ContribAuthor">Mark T. Bilodeau</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (5)
                                     , 2708-2719. <a href="https://doi.org/10.1021/acs.jmedchem.8b02036" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b02036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b02036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b02036%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ban%252BSSTR2-Targeting%252BMaytansinoid%252BConjugate%252B%252528PEN-221%252529%252Bwith%252BPotent%252BActivity%252Bin%252BVitro%252Band%252Bin%252BVivo%26aulast%3DWhite%26aufirst%3DBrian%2BH.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D30122018%26date%3D28022019%26date%3D08022019%26volume%3D62%26issue%3D5%26spage%3D2708%26epage%3D2719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xun Liu, Fan Wu, Yong Ji, <span class="NLM_string-name hlFld-ContribAuthor">Lichen Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in Anti-cancer Protein/Peptide Delivery. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2019,</strong> <em>30 </em>
                                    (2)
                                     , 305-324. <a href="https://doi.org/10.1021/acs.bioconjchem.8b00750" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.8b00750</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.8b00750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.8b00750%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DRecent%252BAdvances%252Bin%252BAnti-cancer%252BProtein%25252FPeptide%252BDelivery%26aulast%3DLiu%26aufirst%3DXun%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D16102018%26date%3D12112018%26date%3D26112018%26date%3D14112018%26volume%3D30%26issue%3D2%26spage%3D305%26epage%3D324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anokha
S. Ratnayake, Li-ping Chang, L. Nathan Tumey, Frank Loganzo, Joseph A. Chemler, Melissa Wagenaar, Sylvia Musto, Fengping Li, Jeffrey E. Janso, T. Eric Ballard, Brian Rago, Greg L. Steele, WeiDong Ding, Xidong Feng, Christine Hosselet, Vlad Buklan, Judy Lucas, Frank E. Koehn, Christopher J. O’Donnell, <span class="NLM_string-name hlFld-ContribAuthor">Edmund I. Graziani</span>. </span><span class="cited-content_cbyCitation_article-title">Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2019,</strong> <em>30 </em>
                                    (1)
                                     , 200-209. <a href="https://doi.org/10.1021/acs.bioconjchem.8b00843" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.8b00843</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.8b00843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.8b00843%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DNatural%252BProduct%252BBis-Intercalator%252BDepsipeptides%252Bas%252Ba%252BNew%252BClass%252Bof%252BPayloads%252Bfor%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DRatnayake%26aufirst%3DAnokha%2BS.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D21112018%26date%3D13122018%26volume%3D30%26issue%3D1%26spage%3D200%26epage%3D209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hyungjun Kim, Dobeen Hwang, Minsuk Choi, Soyoung Lee, Sukmo Kang, Yonghyun Lee, Sunghyun Kim, Junho Chung, <span class="NLM_string-name hlFld-ContribAuthor">Sangyong Jon</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody-Assisted Delivery of a Peptide–Drug Conjugate for Targeted Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2019,</strong> <em>16 </em>
                                    (1)
                                     , 165-172. <a href="https://doi.org/10.1021/acs.molpharmaceut.8b00924" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.8b00924</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.8b00924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.8b00924%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DAntibody-Assisted%252BDelivery%252Bof%252Ba%252BPeptide%2525E2%252580%252593Drug%252BConjugate%252Bfor%252BTargeted%252BCancer%252BTherapy%26aulast%3DKim%26aufirst%3DHyungjun%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D02092018%26date%3D06122018%26date%3D08112018%26date%3D17122018%26date%3D06122018%26volume%3D16%26issue%3D1%26spage%3D165%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhengyang Jiang, Zhen Yang, Feng Li, Zheng Li, Nathan Fishkin, <span class="NLM_string-name hlFld-ContribAuthor">Kevin Burgess</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Maytansinoid Conjugate Improves Therapeutic Index for Metastatic Breast Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2018,</strong> <em>29 </em>
                                    (9)
                                     , 2920-2926. <a href="https://doi.org/10.1021/acs.bioconjchem.8b00340" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.8b00340</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.8b00340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.8b00340%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DTargeted%252BMaytansinoid%252BConjugate%252BImproves%252BTherapeutic%252BIndex%252Bfor%252BMetastatic%252BBreast%252BCancer%252BCells%26aulast%3DJiang%26aufirst%3DZhengyang%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D16052018%26date%3D16072018%26date%3D13082018%26volume%3D29%26issue%3D9%26spage%3D2920%26epage%3D2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alexei S. Karpov, Tinya Abrams, Suzanna Clark, Ankita Raikar, Joseph A. D’Alessio, Michael P. Dillon, Thomas G. Gesner, Darryl Jones, Marion Lacaud, William Mallet, Piotr Martyniuk, Erik Meredith, Morvarid Mohseni, Cristina M. Nieto-Oberhuber, Daniel Palacios, Francesca Perruccio, Grazia Piizzi, Mauro Zurini, <span class="NLM_string-name hlFld-ContribAuthor">Carl Uli Bialucha</span>. </span><span class="cited-content_cbyCitation_article-title">Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (8)
                                     , 838-842. <a href="https://doi.org/10.1021/acsmedchemlett.8b00254" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00254</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00254%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNicotinamide%252BPhosphoribosyltransferase%252BInhibitor%252Bas%252Ba%252BNovel%252BPayload%252Bfor%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DKarpov%26aufirst%3DAlexei%2BS.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D04062018%26date%3D28062018%26date%3D12072018%26date%3D28062018%26volume%3D9%26issue%3D8%26spage%3D838%26epage%3D842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hang-Ping Yao, Liang Feng, Tian-Hao Weng, Chen-Yu Hu, Sreedhar Reddy Suthe, A. G. M. Mostofa, Ling-Hui Chen, Zhi-Gang Wu, Wei-Lin Wang, <span class="NLM_string-name hlFld-ContribAuthor">Ming-Hai Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical Efficacy of Anti-RON Antibody–Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2018,</strong> <em>15 </em>
                                    (8)
                                     , 3260-3271. <a href="https://doi.org/10.1021/acs.molpharmaceut.8b00298" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.8b00298</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.8b00298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.8b00298%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DPreclinical%252BEfficacy%252Bof%252BAnti-RON%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252BZt%25252Fg4-MMAE%252Bfor%252BTargeted%252BTherapy%252Bof%252BPancreatic%252BCancer%252BOverexpressing%252BRON%252BReceptor%252BTyrosine%252BKinase%26aulast%3DYao%26aufirst%3DHang-Ping%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27032018%26date%3D15062018%26date%3D06062018%26date%3D26062018%26volume%3D15%26issue%3D8%26spage%3D3260%26epage%3D3271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dian Su, Katherine R. Kozak, Jack Sadowsky, Shang-Fan Yu, Aimee Fourie-O’Donohue, Christopher Nelson, Richard Vandlen, Rachana Ohri, Luna Liu, Carl Ng, Jintang He, Helen Davis, Jeff Lau, Geoffrey Del Rosario, Ely Cosino, Josefa dela Cruz-Chuh, Yong Ma, Donglu Zhang, Martine Darwish, Wenwen Cai, Chunjiao Chen, Hongxiang Zhou, Jiawei Lu, Yichin Liu, Surinder Kaur, Keyang Xu, <span class="NLM_string-name hlFld-ContribAuthor">Thomas H. Pillow</span>. </span><span class="cited-content_cbyCitation_article-title">Modulating Antibody–Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2018,</strong> <em>29 </em>
                                    (4)
                                     , 1155-1167. <a href="https://doi.org/10.1021/acs.bioconjchem.7b00785" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.7b00785</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.7b00785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.7b00785%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DModulating%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252BPayload%252BMetabolism%252Bby%252BConjugation%252BSite%252Band%252BLinker%252BModification%26aulast%3DSu%26aufirst%3DDian%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D2018%26date%3D12122017%26date%3D19022018%26date%3D13032018%26date%3D26022018%26volume%3D29%26issue%3D4%26spage%3D1155%26epage%3D1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeremy S.  Parker</span>, <span class="hlFld-ContribAuthor ">Marc  McCormick</span>, <span class="hlFld-ContribAuthor ">David W.  Anderson</span>, <span class="hlFld-ContribAuthor ">Beatrice A.  Maltman</span>, <span class="hlFld-ContribAuthor ">Lakshmaiah  Gingipalli</span>, and <span class="hlFld-ContribAuthor ">Dorin  Toader</span>  . </span><span class="cited-content_cbyCitation_article-title">The Development and Scale-Up of an Antibody Drug Conjugate Tubulysin Payload. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2017,</strong> <em>21 </em>
                                    (10)
                                     , 1602-1609. <a href="https://doi.org/10.1021/acs.oprd.7b00232" title="DOI URL">https://doi.org/10.1021/acs.oprd.7b00232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.7b00232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.7b00232%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DThe%252BDevelopment%252Band%252BScale-Up%252Bof%252Ban%252BAntibody%252BDrug%252BConjugate%252BTubulysin%252BPayload%26aulast%3DParker%26aufirst%3DJeremy%2BS.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D07072017%26date%3D29082017%26date%3D20102017%26date%3D01082017%26volume%3D21%26issue%3D10%26spage%3D1602%26epage%3D1609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dorian M.  Cheff</span> and <span class="hlFld-ContribAuthor ">Matthew D.  Hall</span>  . </span><span class="cited-content_cbyCitation_article-title">A Drug of Such Damned Nature.1 Challenges and Opportunities in Translational Platinum Drug Research. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (11)
                                     , 4517-4532. <a href="https://doi.org/10.1021/acs.jmedchem.6b01351" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01351</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01351%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BDrug%252Bof%252BSuch%252BDamned%252BNature.1%252BChallenges%252Band%252BOpportunities%252Bin%252BTranslational%252BPlatinum%252BDrug%252BResearch%26aulast%3DCheff%26aufirst%3DDorian%2BM.%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D09092016%26date%3D28022017%26date%3D08062017%26date%3D14022017%26volume%3D60%26issue%3D11%26spage%3D4517%26epage%3D4532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiuxia  Sun</span>, <span class="hlFld-ContribAuthor ">Jose F.  Ponte</span>, <span class="hlFld-ContribAuthor ">Nicholas C.  Yoder</span>, <span class="hlFld-ContribAuthor ">Rassol  Laleau</span>, <span class="hlFld-ContribAuthor ">Jennifer  Coccia</span>, <span class="hlFld-ContribAuthor ">Leanne  Lanieri</span>, <span class="hlFld-ContribAuthor ">Qifeng  Qiu</span>, <span class="hlFld-ContribAuthor ">Rui  Wu</span>, <span class="hlFld-ContribAuthor ">Erica  Hong</span>, <span class="hlFld-ContribAuthor ">Megan  Bogalhas</span>, <span class="hlFld-ContribAuthor ">Lintao  Wang</span>, <span class="hlFld-ContribAuthor ">Ling  Dong</span>, <span class="hlFld-ContribAuthor ">Yulius  Setiady</span>, <span class="hlFld-ContribAuthor ">Erin K.  Maloney</span>, <span class="hlFld-ContribAuthor ">Olga  Ab</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Zhang</span>, <span class="hlFld-ContribAuthor ">Jan  Pinkas</span>, <span class="hlFld-ContribAuthor ">Thomas A.  Keating</span>, <span class="hlFld-ContribAuthor ">Ravi  Chari</span>, <span class="hlFld-ContribAuthor ">Hans K.  Erickson</span>, and <span class="hlFld-ContribAuthor ">John M.  Lambert</span>  . </span><span class="cited-content_cbyCitation_article-title">Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2017,</strong> <em>28 </em>
                                    (5)
                                     , 1371-1381. <a href="https://doi.org/10.1021/acs.bioconjchem.7b00062" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.7b00062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.7b00062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.7b00062%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DEffects%252Bof%252BDrug%2525E2%252580%252593Antibody%252BRatio%252Bon%252BPharmacokinetics%25252C%252BBiodistribution%25252C%252BEfficacy%25252C%252Band%252BTolerability%252Bof%252BAntibody%2525E2%252580%252593Maytansinoid%252BConjugates%26aulast%3DSun%26aufirst%3DXiuxia%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D03022017%26date%3D31032017%26date%3D13042017%26date%3D17052017%26date%3D07042017%26volume%3D28%26issue%3D5%26spage%3D1371%26epage%3D1381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nazzareno  Dimasi</span>, <span class="hlFld-ContribAuthor ">Ryan  Fleming</span>, <span class="hlFld-ContribAuthor ">Haihong  Zhong</span>, <span class="hlFld-ContribAuthor ">Binyam  Bezabeh</span>, <span class="hlFld-ContribAuthor ">Krista  Kinneer</span>, <span class="hlFld-ContribAuthor ">Ronald J.  Christie</span>, <span class="hlFld-ContribAuthor ">Christine  Fazenbaker</span>, <span class="hlFld-ContribAuthor ">Herren  Wu</span>, and <span class="hlFld-ContribAuthor ">Changshou  Gao</span>  . </span><span class="cited-content_cbyCitation_article-title">Efficient Preparation of Site-Specific Antibody–Drug Conjugates Using Cysteine Insertion. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2017,</strong> <em>14 </em>
                                    (5)
                                     , 1501-1516. <a href="https://doi.org/10.1021/acs.molpharmaceut.6b00995" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.6b00995</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.6b00995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.6b00995%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DEfficient%252BPreparation%252Bof%252BSite-Specific%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252BUsing%252BCysteine%252BInsertion%26aulast%3DDimasi%26aufirst%3DNazzareno%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D2017%26date%3D03112016%26date%3D28022017%26date%3D23022017%26date%3D16032017%26date%3D01052017%26date%3D28022017%26volume%3D14%26issue%3D5%26spage%3D1501%26epage%3D1516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chethana  Kulkarni</span>, <span class="hlFld-ContribAuthor ">James E.  Finley</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Bessire</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Zhong</span>, <span class="hlFld-ContribAuthor ">Sylvia  Musto</span>, and <span class="hlFld-ContribAuthor ">Edmund I.  Graziani</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of Fluorophore-Labeled Thailanstatin Antibody-Drug Conjugates for Cellular Trafficking Studies. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2017,</strong> <em>28 </em>
                                    (4)
                                     , 1041-1047. <a href="https://doi.org/10.1021/acs.bioconjchem.6b00718" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.6b00718</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.6b00718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.6b00718%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DDevelopment%252Bof%252BFluorophore-Labeled%252BThailanstatin%252BAntibody-Drug%252BConjugates%252Bfor%252BCellular%252BTrafficking%252BStudies%26aulast%3DKulkarni%26aufirst%3DChethana%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D2017%26date%3D15122016%26date%3D06022017%26date%3D01032017%26date%3D19042017%26date%3D13022017%26volume%3D28%26issue%3D4%26spage%3D1041%26epage%3D1047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">April L.  Risinger</span>, <span class="hlFld-ContribAuthor ">Jing  Li</span>, <span class="hlFld-ContribAuthor ">Lin  Du</span>, <span class="hlFld-ContribAuthor ">Raymond  Benavides</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Robles</span>, <span class="hlFld-ContribAuthor ">Robert H.  Cichewicz</span>, <span class="hlFld-ContribAuthor ">John G.  Kuhn</span>, and <span class="hlFld-ContribAuthor ">Susan L.  Mooberry</span>  . </span><span class="cited-content_cbyCitation_article-title">Pharmacokinetic Analysis and in Vivo Antitumor Efficacy of Taccalonolides AF and AJ. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2017,</strong> <em>80 </em>
                                    (2)
                                     , 409-414. <a href="https://doi.org/10.1021/acs.jnatprod.6b00944" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.6b00944</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.6b00944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.6b00944%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DPharmacokinetic%252BAnalysis%252Band%252Bin%252BVivo%252BAntitumor%252BEfficacy%252Bof%252BTaccalonolides%252BAF%252Band%252BAJ%26aulast%3DRisinger%26aufirst%3DApril%2BL.%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D13102016%26date%3D23012017%26date%3D24022017%26volume%3D80%26issue%3D2%26spage%3D409%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jose F.  Ponte</span>, <span class="hlFld-ContribAuthor ">Xiuxia  Sun</span>, <span class="hlFld-ContribAuthor ">Nicholas C.  Yoder</span>, <span class="hlFld-ContribAuthor ">Nathan  Fishkin</span>, <span class="hlFld-ContribAuthor ">Rassol  Laleau</span>, <span class="hlFld-ContribAuthor ">Jennifer  Coccia</span>, <span class="hlFld-ContribAuthor ">Leanne  Lanieri</span>, <span class="hlFld-ContribAuthor ">Megan  Bogalhas</span>, <span class="hlFld-ContribAuthor ">Lintao  Wang</span>, <span class="hlFld-ContribAuthor ">Sharon  Wilhelm</span>, <span class="hlFld-ContribAuthor ">Wayne  Widdison</span>, <span class="hlFld-ContribAuthor ">Jan  Pinkas</span>, <span class="hlFld-ContribAuthor ">Thomas A.  Keating</span>, <span class="hlFld-ContribAuthor ">Ravi  Chari</span>, <span class="hlFld-ContribAuthor ">Hans K.  Erickson</span>, and <span class="hlFld-ContribAuthor ">John M.  Lambert</span>  . </span><span class="cited-content_cbyCitation_article-title">Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody–Maytansinoid Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2016,</strong> <em>27 </em>
                                    (7)
                                     , 1588-1598. <a href="https://doi.org/10.1021/acs.bioconjchem.6b00117" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.6b00117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.6b00117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.6b00117%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DUnderstanding%252BHow%252Bthe%252BStability%252Bof%252Bthe%252BThiol-Maleimide%252BLinkage%252BImpacts%252Bthe%252BPharmacokinetics%252Bof%252BLysine-Linked%252BAntibody%2525E2%252580%252593Maytansinoid%252BConjugates%26aulast%3DPonte%26aufirst%3DJose%2BF.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D29022016%26date%3D10052016%26date%3D20062016%26date%3D20072016%26date%3D13052016%26volume%3D27%26issue%3D7%26spage%3D1588%26epage%3D1598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David Y.  Jackson</span>  . </span><span class="cited-content_cbyCitation_article-title">Processes for Constructing Homogeneous Antibody Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2016,</strong> <em>20 </em>
                                    (5)
                                     , 852-866. <a href="https://doi.org/10.1021/acs.oprd.6b00067" title="DOI URL">https://doi.org/10.1021/acs.oprd.6b00067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.6b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.6b00067%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DProcesses%252Bfor%252BConstructing%252BHomogeneous%252BAntibody%252BDrug%252BConjugates%26aulast%3DJackson%26aufirst%3DDavid%2BY.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D04032016%26date%3D04052016%26date%3D20052016%26date%3D14042016%26volume%3D20%26issue%3D5%26spage%3D852%26epage%3D866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hannes  Merten</span>, <span class="hlFld-ContribAuthor ">Fabian  Brandl</span>, <span class="hlFld-ContribAuthor ">Andreas  Plückthun</span>, and <span class="hlFld-ContribAuthor ">Uwe  Zangemeister-Wittke</span>  . </span><span class="cited-content_cbyCitation_article-title">Antibody–Drug Conjugates for Tumor Targeting—Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2015,</strong> <em>26 </em>
                                    (11)
                                     , 2176-2185. <a href="https://doi.org/10.1021/acs.bioconjchem.5b00260" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.5b00260</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.5b00260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.5b00260%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DAntibody%2525E2%252580%252593Drug%252BConjugates%252Bfor%252BTumor%252BTargeting%2525E2%252580%252594Novel%252BConjugation%252BChemistries%252Band%252Bthe%252BPromise%252Bof%252Bnon-IgG%252BBinding%252BProteins%26aulast%3DMerten%26aufirst%3DHannes%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D06052015%26date%3D14062015%26date%3D08072015%26date%3D18112015%26date%3D18062015%26volume%3D26%26issue%3D11%26spage%3D2176%26epage%3D2185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kohta  Mohri</span>, <span class="hlFld-ContribAuthor ">Naoki  Morimoto</span>, <span class="hlFld-ContribAuthor ">Megumi  Maruyama</span>, <span class="hlFld-ContribAuthor ">Norimasa  Nakamoto</span>, <span class="hlFld-ContribAuthor ">Emi  Hayashi</span>, <span class="hlFld-ContribAuthor ">Kengo  Nagata</span>, <span class="hlFld-ContribAuthor ">Kohei  Miyata</span>, <span class="hlFld-ContribAuthor ">Kyohei  Ochiai</span>, <span class="hlFld-ContribAuthor ">Ken-ichiro  Hiwatari</span>, <span class="hlFld-ContribAuthor ">Kazufumi  Tsubaki</span>, <span class="hlFld-ContribAuthor ">Etsuo  Tobita</span>, <span class="hlFld-ContribAuthor ">Yuki  Ishimaru</span>, <span class="hlFld-ContribAuthor ">Sadaaki  Maeda</span>, and <span class="hlFld-ContribAuthor ">Shinji  Sakuma</span>  . </span><span class="cited-content_cbyCitation_article-title">Potential of d-Octaarginine-Linked Polymers as an in Vitro Transfection Tool for Biomolecules. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2015,</strong> <em>26 </em>
                                    (8)
                                     , 1782-1790. <a href="https://doi.org/10.1021/acs.bioconjchem.5b00323" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.5b00323</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.5b00323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.5b00323%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DPotential%252Bof%252Bd-Octaarginine-Linked%252BPolymers%252Bas%252Ban%252Bin%252BVitro%252BTransfection%252BTool%252Bfor%252BBiomolecules%26aulast%3DMohri%26aufirst%3DKohta%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D08062015%26date%3D30072015%26date%3D07082015%26date%3D19082015%26volume%3D26%26issue%3D8%26spage%3D1782%26epage%3D1790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paulin L.  Salomon</span> and <span class="hlFld-ContribAuthor ">Rajeeva  Singh</span>  . </span><span class="cited-content_cbyCitation_article-title">Sensitive ELISA Method for the Measurement of Catabolites of Antibody–Drug Conjugates (ADCs) in Target Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2015,</strong> <em>12 </em>
                                    (6)
                                     , 1752-1761. <a href="https://doi.org/10.1021/acs.molpharmaceut.5b00028" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.5b00028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.5b00028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.5b00028%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DSensitive%252BELISA%252BMethod%252Bfor%252Bthe%252BMeasurement%252Bof%252BCatabolites%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252B%252528ADCs%252529%252Bin%252BTarget%252BCancer%252BCells%26aulast%3DSalomon%26aufirst%3DPaulin%2BL.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D12012015%26date%3D04032015%26date%3D19022015%26date%3D17032015%26date%3D01062015%26date%3D04032015%26volume%3D12%26issue%3D6%26spage%3D1752%26epage%3D1761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Serengulam V.  Govindan</span>, <span class="hlFld-ContribAuthor ">Thomas M.  Cardillo</span>, <span class="hlFld-ContribAuthor ">Edmund A.  Rossi</span>, <span class="hlFld-ContribAuthor ">Preeti  Trisal</span>, <span class="hlFld-ContribAuthor ">William J.  McBride</span>, <span class="hlFld-ContribAuthor ">Robert M.  Sharkey</span>, and <span class="hlFld-ContribAuthor ">David M.  Goldenberg</span>  . </span><span class="cited-content_cbyCitation_article-title">Improving the Therapeutic Index in Cancer Therapy by Using Antibody–Drug Conjugates Designed with a Moderately Cytotoxic Drug. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2015,</strong> <em>12 </em>
                                    (6)
                                     , 1836-1847. <a href="https://doi.org/10.1021/mp5006195" title="DOI URL">https://doi.org/10.1021/mp5006195</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/mp5006195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fmp5006195%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DImproving%252Bthe%252BTherapeutic%252BIndex%252Bin%252BCancer%252BTherapy%252Bby%252BUsing%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252BDesigned%252Bwith%252Ba%252BModerately%252BCytotoxic%252BDrug%26aulast%3DGovindan%26aufirst%3DSerengulam%2BV.%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D15092014%26date%3D17112014%26date%3D31102014%26date%3D25112014%26date%3D01062015%26date%3D17112014%26volume%3D12%26issue%3D6%26spage%3D1836%26epage%3D1847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andreas  Maderna</span> and <span class="hlFld-ContribAuthor ">Carolyn A.  Leverett</span>  . </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Development of New Auristatins: Structural Modifications and Application in Antibody Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2015,</strong> <em>12 </em>
                                    (6)
                                     , 1798-1812. <a href="https://doi.org/10.1021/mp500762u" title="DOI URL">https://doi.org/10.1021/mp500762u</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/mp500762u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fmp500762u%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDevelopment%252Bof%252BNew%252BAuristatins%25253A%252BStructural%252BModifications%252Band%252BApplication%252Bin%252BAntibody%252BDrug%252BConjugates%26aulast%3DMaderna%26aufirst%3DAndreas%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D2015%26date%3D16112014%26date%3D16022015%26date%3D07022015%26date%3D05032015%26date%3D01062015%26date%3D19022015%26volume%3D12%26issue%3D6%26spage%3D1798%26epage%3D1812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ronald C.  Elgersma</span>, <span class="hlFld-ContribAuthor ">Ruud G. E.  Coumans</span>, <span class="hlFld-ContribAuthor ">Tijl  Huijbregts</span>, <span class="hlFld-ContribAuthor ">Wiro M. P. B.  Menge</span>, <span class="hlFld-ContribAuthor ">John A. F.  Joosten</span>, <span class="hlFld-ContribAuthor ">Henri J.  Spijker</span>, <span class="hlFld-ContribAuthor ">Franciscus M. H.  de Groot</span>, <span class="hlFld-ContribAuthor ">Miranda M. C.  van der Lee</span>, <span class="hlFld-ContribAuthor ">Ruud  Ubink</span>, <span class="hlFld-ContribAuthor ">Diels J.  van den Dobbelsteen</span>, <span class="hlFld-ContribAuthor ">David F.  Egging</span>, <span class="hlFld-ContribAuthor ">Wim H. A.  Dokter</span>, <span class="hlFld-ContribAuthor ">Gijs F. M.  Verheijden</span>, <span class="hlFld-ContribAuthor ">Jacques M.  Lemmens</span>, <span class="hlFld-ContribAuthor ">C. Marco  Timmers</span>, and <span class="hlFld-ContribAuthor ">Patrick H.  Beusker</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2015,</strong> <em>12 </em>
                                    (6)
                                     , 1813-1835. <a href="https://doi.org/10.1021/mp500781a" title="DOI URL">https://doi.org/10.1021/mp500781a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/mp500781a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fmp500781a%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BEvaluation%252Bof%252BLinker-Duocarmycin%252BPayloads%25253A%252BToward%252BSelection%252Bof%252BHER2-Targeting%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252BSYD985%26aulast%3DElgersma%26aufirst%3DRonald%2BC.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D2015%26date%3D24112014%26date%3D30012015%26date%3D21012015%26date%3D18022015%26date%3D01062015%26date%3D30012015%26volume%3D12%26issue%3D6%26spage%3D1813%26epage%3D1835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kelly E.  Burns</span>, <span class="hlFld-ContribAuthor ">Matthew K.  Robinson</span>, and <span class="hlFld-ContribAuthor ">Damien  Thévenin</span>  . </span><span class="cited-content_cbyCitation_article-title">Inhibition of Cancer Cell Proliferation and Breast Tumor Targeting of pHLIP–Monomethyl Auristatin E Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2015,</strong> <em>12 </em>
                                    (4)
                                     , 1250-1258. <a href="https://doi.org/10.1021/mp500779k" title="DOI URL">https://doi.org/10.1021/mp500779k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/mp500779k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fmp500779k%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DInhibition%252Bof%252BCancer%252BCell%252BProliferation%252Band%252BBreast%252BTumor%252BTargeting%252Bof%252BpHLIP%2525E2%252580%252593Monomethyl%252BAuristatin%252BE%252BConjugates%26aulast%3DBurns%26aufirst%3DKelly%2BE.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D2015%26date%3D21112014%26date%3D05032015%26date%3D28012015%26date%3D13032015%26date%3D06042015%26date%3D05032015%26volume%3D12%26issue%3D4%26spage%3D1250%26epage%3D1258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carlos  Garcia-Echeverria</span>  . </span><span class="cited-content_cbyCitation_article-title">Developing Second Generation Antibody–Drug Conjugates: The Quest for New Technologies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (19)
                                     , 7888-7889. <a href="https://doi.org/10.1021/jm501298k" title="DOI URL">https://doi.org/10.1021/jm501298k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501298k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501298k%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDeveloping%252BSecond%252BGeneration%252BAntibody%2525E2%252580%252593Drug%252BConjugates%25253A%252BThe%252BQuest%252Bfor%252BNew%252BTechnologies%26aulast%3DGarcia-Echeverria%26aufirst%3DCarlos%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D25082014%26date%3D15092014%26date%3D09102014%26volume%3D57%26issue%3D19%26spage%3D7888%26epage%3D7889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dengyang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yao  Guo</span>, <span class="hlFld-ContribAuthor ">Yuming  Zhao</span>, <span class="hlFld-ContribAuthor ">Liuting  Yu</span>, <span class="hlFld-ContribAuthor ">Zhiguang  Chang</span>, <span class="hlFld-ContribAuthor ">Hanzhong  Pei</span>, <span class="hlFld-ContribAuthor ">Junbin  Huang</span>, <span class="hlFld-ContribAuthor ">Chun  Chen</span>, <span class="hlFld-ContribAuthor ">Hongman  Xue</span>, <span class="hlFld-ContribAuthor ">Xiaojun  Xu</span>, <span class="hlFld-ContribAuthor ">Yihang  Pan</span>, <span class="hlFld-ContribAuthor ">Ningning  Li</span>, <span class="hlFld-ContribAuthor ">Chengming  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhizhuang Joe  Zhao</span>, <span class="hlFld-ContribAuthor ">Jian  Yu</span>, <span class="hlFld-ContribAuthor ">Yun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression. </span><span class="cited-content_cbyCitation_journal-name">Microbial Cell Factories</span><span> <strong>2021,</strong> <em>20 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12934-021-01559-6" title="DOI URL">https://doi.org/10.1186/s12934-021-01559-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12934-021-01559-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12934-021-01559-6%26sid%3Dliteratum%253Aachs%26jtitle%3DMicrobial%2520Cell%2520Factories%26atitle%3DExpression%252Bof%252Ba%252Brecombinant%252BFLT3%252Bligand%252Band%252Bits%252Bemtansine%252Bconjugate%252Bas%252Ba%252Btherapeutic%252Bcandidate%252Bagainst%252Bacute%252Bmyeloid%252Bleukemia%252Bcells%252Bwith%252BFLT3%252Bexpression%26aulast%3DZhang%26aufirst%3DDengyang%26date%3D2021%26date%3D2021%26volume%3D20%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">T.  Tedeschini</span>, <span class="hlFld-ContribAuthor ">B.  Campara</span>, <span class="hlFld-ContribAuthor ">A.  Grigoletto</span>, <span class="hlFld-ContribAuthor ">M.  Bellini</span>, <span class="hlFld-ContribAuthor ">M.  Salvalaio</span>, <span class="hlFld-ContribAuthor ">Y.  Matsuno</span>, <span class="hlFld-ContribAuthor ">A.  Suzuki</span>, <span class="hlFld-ContribAuthor ">H.  Yoshioka</span>, <span class="hlFld-ContribAuthor ">G.  Pasut</span>. </span><span class="cited-content_cbyCitation_article-title">Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2021,</strong> <em>337 </em>, 431-447. <a href="https://doi.org/10.1016/j.jconrel.2021.07.041" title="DOI URL">https://doi.org/10.1016/j.jconrel.2021.07.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2021.07.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2021.07.041%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DPolyethylene%252Bglycol-based%252Blinkers%252Bas%252Bhydrophilicity%252Breservoir%252Bfor%252Bantibody-drug%252Bconjugates%26aulast%3DTedeschini%26aufirst%3DT.%26date%3D2021%26volume%3D337%26spage%3D431%26epage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen‐Qian  Li</span>, <span class="hlFld-ContribAuthor ">Han‐Fei  Guo</span>, <span class="hlFld-ContribAuthor ">Ling‐Yu  Li</span>, <span class="hlFld-ContribAuthor ">Yong‐Fei  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiu‐Wei  Cui</span>. </span><span class="cited-content_cbyCitation_article-title">The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively. </span><span class="cited-content_cbyCitation_journal-name">Cancer Medicine</span><span> <strong>2021,</strong> <em>10 </em>
                                    (14)
                                     , 4677-4696. <a href="https://doi.org/10.1002/cam4.4052" title="DOI URL">https://doi.org/10.1002/cam4.4052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cam4.4052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcam4.4052%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Medicine%26atitle%3DThe%252Bpromising%252Brole%252Bof%252Bantibody%252Bdrug%252Bconjugate%252Bin%252Bcancer%252Btherapy%25253A%252BCombining%252Btargeting%252Bability%252Bwith%252Bcytotoxicity%252Beffectively%26aulast%3DLi%26aufirst%3DWen%25E2%2580%2590Qian%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D14%26spage%3D4677%26epage%3D4696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Florian  Füssl</span>, <span class="hlFld-ContribAuthor ">Conor S.  Barry</span>, <span class="hlFld-ContribAuthor ">Kathryn M.  Pugh</span>, <span class="hlFld-ContribAuthor ">K. Phin  Chooi</span>, <span class="hlFld-ContribAuthor ">Balakumar  Vijayakrishnan</span>, <span class="hlFld-ContribAuthor ">Gyoung-Dong  Kang</span>, <span class="hlFld-ContribAuthor ">Christina  von Bulow</span>, <span class="hlFld-ContribAuthor ">Philip W.  Howard</span>, <span class="hlFld-ContribAuthor ">Jonathan  Bones</span>. </span><span class="cited-content_cbyCitation_article-title">Simultaneous Monitoring of Multiple Attributes of Pyrrolobenzodiazepine Antibody-Drug Conjugates by Size Exclusion Chromatography – High Resolution Mass Spectrometry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical and Biomedical Analysis</span><span> <strong>2021,</strong> <em>30 </em>, 114287. <a href="https://doi.org/10.1016/j.jpba.2021.114287" title="DOI URL">https://doi.org/10.1016/j.jpba.2021.114287</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpba.2021.114287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpba.2021.114287%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520and%2520Biomedical%2520Analysis%26atitle%3DSimultaneous%252BMonitoring%252Bof%252BMultiple%252BAttributes%252Bof%252BPyrrolobenzodiazepine%252BAntibody-Drug%252BConjugates%252Bby%252BSize%252BExclusion%252BChromatography%252B%2525E2%252580%252593%252BHigh%252BResolution%252BMass%252BSpectrometry%26aulast%3DF%25C3%25BCssl%26aufirst%3DFlorian%26date%3D2021%26volume%3D30%26spage%3D114287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">K. C.  Nicolaou</span>, <span class="hlFld-ContribAuthor ">Stephan  Rigol</span>, <span class="hlFld-ContribAuthor ">Emmanuel N.  Pitsinos</span>, <span class="hlFld-ContribAuthor ">Dipendu  Das</span>, <span class="hlFld-ContribAuthor ">Yong  Lu</span>, <span class="hlFld-ContribAuthor ">Subhrajit  Rout</span>, <span class="hlFld-ContribAuthor ">Alexander W.  Schammel</span>, <span class="hlFld-ContribAuthor ">Dane  Holte</span>, <span class="hlFld-ContribAuthor ">Baiwei  Lin</span>, <span class="hlFld-ContribAuthor ">Christine  Gu</span>, <span class="hlFld-ContribAuthor ">Hetal  Sarvaiya</span>, <span class="hlFld-ContribAuthor ">Jose  Trinidad</span>, <span class="hlFld-ContribAuthor ">Nicole  Barbour</span>, <span class="hlFld-ContribAuthor ">Amanda M.  Valdiosera</span>, <span class="hlFld-ContribAuthor ">Joseph  Sandoval</span>, <span class="hlFld-ContribAuthor ">Christina  Lee</span>, <span class="hlFld-ContribAuthor ">Monette  Aujay</span>, <span class="hlFld-ContribAuthor ">Hanan  Fernando</span>, <span class="hlFld-ContribAuthor ">Anukriti  Dhar</span>, <span class="hlFld-ContribAuthor ">Holger  Karsunky</span>, <span class="hlFld-ContribAuthor ">Nicole  Taylor</span>, <span class="hlFld-ContribAuthor ">Marybeth  Pysz</span>, <span class="hlFld-ContribAuthor ">Julia  Gavrilyuk</span>. </span><span class="cited-content_cbyCitation_article-title">Uncialamycin-based antibody–drug conjugates: Unique enediyne ADCs exhibiting bystander killing effect. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2021,</strong> <em>118 </em>
                                    (25)
                                     , e2107042118. <a href="https://doi.org/10.1073/pnas.2107042118" title="DOI URL">https://doi.org/10.1073/pnas.2107042118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.2107042118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.2107042118%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DUncialamycin-based%252Bantibody%2525E2%252580%252593drug%252Bconjugates%25253A%252BUnique%252Benediyne%252BADCs%252Bexhibiting%252Bbystander%252Bkilling%252Beffect%26aulast%3DNicolaou%26aufirst%3DK.%2BC.%26date%3D2021%26date%3D2021%26volume%3D118%26issue%3D25%26spage%3De2107042118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ya‐Ping  Liu</span>, <span class="hlFld-ContribAuthor ">Can‐Can  Zheng</span>, <span class="hlFld-ContribAuthor ">Yun‐Na  Huang</span>, <span class="hlFld-ContribAuthor ">Ming‐Liang  He</span>, <span class="hlFld-ContribAuthor ">Wen Wen  Xu</span>, <span class="hlFld-ContribAuthor ">Bin  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular mechanisms of chemo‐ and radiotherapy resistance and the potential implications for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">MedComm</span><span> <strong>2021,</strong> <em>2 </em><a href="https://doi.org/10.1002/mco2.55" title="DOI URL">https://doi.org/10.1002/mco2.55</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/mco2.55&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmco2.55%26sid%3Dliteratum%253Aachs%26jtitle%3DMedComm%26atitle%3DMolecular%252Bmechanisms%252Bof%252Bchemo%2525E2%252580%252590%252Band%252Bradiotherapy%252Bresistance%252Band%252Bthe%252Bpotential%252Bimplications%252Bfor%252Bcancer%252Btreatment%26aulast%3DLiu%26aufirst%3DYa%25E2%2580%2590Ping%26date%3D2021%26date%3D2021%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan  Li</span>, <span class="hlFld-ContribAuthor ">Siyu  Guo</span>, <span class="hlFld-ContribAuthor ">Qiang  Hua</span>, <span class="hlFld-ContribAuthor ">Fengxian  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Improved AP-3 production through combined ARTP mutagenesis, fermentation optimization, and subsequent genome shuffling. </span><span class="cited-content_cbyCitation_journal-name">Biotechnology Letters</span><span> <strong>2021,</strong> <em>43 </em>
                                    (6)
                                     , 1143-1154. <a href="https://doi.org/10.1007/s10529-020-03034-5" title="DOI URL">https://doi.org/10.1007/s10529-020-03034-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10529-020-03034-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10529-020-03034-5%26sid%3Dliteratum%253Aachs%26jtitle%3DBiotechnology%2520Letters%26atitle%3DImproved%252BAP-3%252Bproduction%252Bthrough%252Bcombined%252BARTP%252Bmutagenesis%25252C%252Bfermentation%252Boptimization%25252C%252Band%252Bsubsequent%252Bgenome%252Bshuffling%26aulast%3DLi%26aufirst%3DJuan%26date%3D2021%26date%3D2021%26volume%3D43%26issue%3D6%26spage%3D1143%26epage%3D1154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aurora K.  Vikan</span>, <span class="hlFld-ContribAuthor ">Michal  Kostas</span>, <span class="hlFld-ContribAuthor ">Ellen Margrethe  Haugsten</span>, <span class="hlFld-ContribAuthor ">Pål K.  Selbo</span>, <span class="hlFld-ContribAuthor ">Jørgen  Wesche</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy and Selectivity of FGF2-Saporin Cytosolically Delivered by PCI in Cells Overexpressing FGFR1. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2021,</strong> <em>10 </em>
                                    (6)
                                     , 1476. <a href="https://doi.org/10.3390/cells10061476" title="DOI URL">https://doi.org/10.3390/cells10061476</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells10061476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells10061476%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DEfficacy%252Band%252BSelectivity%252Bof%252BFGF2-Saporin%252BCytosolically%252BDelivered%252Bby%252BPCI%252Bin%252BCells%252BOverexpressing%252BFGFR1%26aulast%3DVikan%26aufirst%3DAurora%2BK.%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D6%26spage%3D1476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angeliki  Andrikopoulou</span>, <span class="hlFld-ContribAuthor ">Eleni  Zografos</span>, <span class="hlFld-ContribAuthor ">Michalis  Liontos</span>, <span class="hlFld-ContribAuthor ">Konstantinos  Koutsoukos</span>, <span class="hlFld-ContribAuthor ">Meletios-Athanasios  Dimopoulos</span>, <span class="hlFld-ContribAuthor ">Flora  Zagouri</span>. </span><span class="cited-content_cbyCitation_article-title">Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Clinical Breast Cancer</span><span> <strong>2021,</strong> <em>21 </em>
                                    (3)
                                     , e212-e219. <a href="https://doi.org/10.1016/j.clbc.2020.08.006" title="DOI URL">https://doi.org/10.1016/j.clbc.2020.08.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.clbc.2020.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.clbc.2020.08.006%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Breast%2520Cancer%26atitle%3DTrastuzumab%252BDeruxtecan%252B%252528DS-8201a%252529%25253A%252BThe%252BLatest%252BResearch%252Band%252BAdvances%252Bin%252BBreast%252BCancer%26aulast%3DAndrikopoulou%26aufirst%3DAngeliki%26date%3D2021%26volume%3D21%26issue%3D3%26spage%3De212%26epage%3De219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yiming  Jin</span>, <span class="hlFld-ContribAuthor ">Megan A.  Schladetsch</span>, <span class="hlFld-ContribAuthor ">Xueting  Huang</span>, <span class="hlFld-ContribAuthor ">Marcy J.  Balunas</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Wiemer</span>. </span><span class="cited-content_cbyCitation_article-title">Stepping forward in antibody-drug conjugate development. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2021,</strong> <em>39 </em>, 107917. <a href="https://doi.org/10.1016/j.pharmthera.2021.107917" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2021.107917</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2021.107917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2021.107917%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DStepping%252Bforward%252Bin%252Bantibody-drug%252Bconjugate%252Bdevelopment%26aulast%3DJin%26aufirst%3DYiming%26date%3D2021%26volume%3D39%26spage%3D107917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ya-Nan  Li</span>, <span class="hlFld-ContribAuthor ">Jia-Nan  Li</span>, <span class="hlFld-ContribAuthor ">Qin  Ouyang</span>, <span class="hlFld-ContribAuthor ">Yu-Bo  Zhou</span>, <span class="hlFld-ContribAuthor ">Chun  Lei</span>, <span class="hlFld-ContribAuthor ">Ming-Jun  Cui</span>, <span class="hlFld-ContribAuthor ">Kai-Cong  Fu</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>, <span class="hlFld-ContribAuthor ">Jian-Ming  Huang</span>, <span class="hlFld-ContribAuthor ">Ai-Jun  Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Determination of maytansinoids in Trewia nudiflora using QuEChERS extraction combined with HPLC. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical and Biomedical Analysis</span><span> <strong>2021,</strong> <em>198 </em>, 113993. <a href="https://doi.org/10.1016/j.jpba.2021.113993" title="DOI URL">https://doi.org/10.1016/j.jpba.2021.113993</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpba.2021.113993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpba.2021.113993%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520and%2520Biomedical%2520Analysis%26atitle%3DDetermination%252Bof%252Bmaytansinoids%252Bin%252BTrewia%252Bnudiflora%252Busing%252BQuEChERS%252Bextraction%252Bcombined%252Bwith%252BHPLC%26aulast%3DLi%26aufirst%3DYa-Nan%26date%3D2021%26volume%3D198%26spage%3D113993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andreia  Gameiro</span>, <span class="hlFld-ContribAuthor ">Catarina  Nascimento</span>, <span class="hlFld-ContribAuthor ">Jorge  Correia</span>, <span class="hlFld-ContribAuthor ">Fernando  Ferreira</span>. </span><span class="cited-content_cbyCitation_article-title">HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (9)
                                     , 2007. <a href="https://doi.org/10.3390/cancers13092007" title="DOI URL">https://doi.org/10.3390/cancers13092007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13092007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13092007%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DHER2-Targeted%252BImmunotherapy%252Band%252BCombined%252BProtocols%252BShowed%252BPromising%252BAntiproliferative%252BEffects%252Bin%252BFeline%252BMammary%252BCarcinoma%252BCell-Based%252BModels%26aulast%3DGameiro%26aufirst%3DAndreia%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D9%26spage%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Milad  Abbasi</span>, <span class="hlFld-ContribAuthor ">Salar Hafez  Ghoran</span>, <span class="hlFld-ContribAuthor ">Mohammad Hadi  Niakan</span>, <span class="hlFld-ContribAuthor ">Kazem  Jamali</span>, <span class="hlFld-ContribAuthor ">Zohre  Moeini</span>, <span class="hlFld-ContribAuthor ">Ali  Jangjou</span>, <span class="hlFld-ContribAuthor ">Peyman  Izadpanah</span>, <span class="hlFld-ContribAuthor ">Ali Mohammad  Amani</span>. </span><span class="cited-content_cbyCitation_article-title">Mesoporous silica nanoparticle: Heralding a brighter future in cancer nanomedicine. </span><span class="cited-content_cbyCitation_journal-name">Microporous and Mesoporous Materials</span><span> <strong>2021,</strong> <em>319 </em>, 110967. <a href="https://doi.org/10.1016/j.micromeso.2021.110967" title="DOI URL">https://doi.org/10.1016/j.micromeso.2021.110967</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.micromeso.2021.110967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.micromeso.2021.110967%26sid%3Dliteratum%253Aachs%26jtitle%3DMicroporous%2520and%2520Mesoporous%2520Materials%26atitle%3DMesoporous%252Bsilica%252Bnanoparticle%25253A%252BHeralding%252Ba%252Bbrighter%252Bfuture%252Bin%252Bcancer%252Bnanomedicine%26aulast%3DAbbasi%26aufirst%3DMilad%26date%3D2021%26volume%3D319%26spage%3D110967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rakesh Kumar  Dhritlahre</span>, <span class="hlFld-ContribAuthor ">Ankit  Saneja</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in HER2-targeted delivery for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2021,</strong> <em>26 </em>
                                    (5)
                                     , 1319-1329. <a href="https://doi.org/10.1016/j.drudis.2020.12.014" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.12.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.12.014%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DRecent%252Badvances%252Bin%252BHER2-targeted%252Bdelivery%252Bfor%252Bcancer%252Btherapy%26aulast%3DDhritlahre%26aufirst%3DRakesh%2BKumar%26date%3D2021%26volume%3D26%26issue%3D5%26spage%3D1319%26epage%3D1329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>. </span><span class="cited-content_cbyCitation_article-title">The Design and Development of Antibody–Drug Conjugates (ADC
              s
              ) for the Treatment of Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-39. <a href="https://doi.org/10.1002/0471266949.bmc283" title="DOI URL">https://doi.org/10.1002/0471266949.bmc283</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc283%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BDesign%252Band%252BDevelopment%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252B%252528ADC%252Bs%252B%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BCancer%26aulast%3DTumey%26aufirst%3DL.%2BNathan%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D39%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joselina Magali  Mondaca</span>, <span class="hlFld-ContribAuthor ">Ana Carla Castro  Guijarro</span>, <span class="hlFld-ContribAuthor ">Marina Inés  Flamini</span>, <span class="hlFld-ContribAuthor ">Angel Matias  Sanchez</span>. </span><span class="cited-content_cbyCitation_article-title">Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+ breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Breast Cancer Research and Treatment</span><span> <strong>2021,</strong> <em>186 </em>
                                    (2)
                                     , 363-377. <a href="https://doi.org/10.1007/s10549-020-06089-0" title="DOI URL">https://doi.org/10.1007/s10549-020-06089-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10549-020-06089-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10549-020-06089-0%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Cancer%2520Research%2520and%2520Treatment%26atitle%3DHeregulin-induced%252Bcell%252Bmigration%252Bis%252Bprevented%252Bby%252Btrastuzumab%252Band%252Btrastuzumab-emtansine%252Bin%252BHER2%25252B%2525E2%252580%252589breast%252Bcancer%26aulast%3DMondaca%26aufirst%3DJoselina%2BMagali%26date%3D2021%26date%3D2021%26volume%3D186%26issue%3D2%26spage%3D363%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohamed  Alhamar</span>, <span class="hlFld-ContribAuthor ">Bassam  Alkamachi</span>, <span class="hlFld-ContribAuthor ">Harshita  Mehrotra</span>, <span class="hlFld-ContribAuthor ">Jessica  Sanchez</span>, <span class="hlFld-ContribAuthor ">Haythem  Ali</span>, <span class="hlFld-ContribAuthor ">Daniel  Schultz</span>, <span class="hlFld-ContribAuthor ">Dhananjay A.  Chitale</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical significance of quantitative categorization of HER2 fluorescent in situ hybridization results in invasive breast cancer patients treated with HER2-targeted agents. </span><span class="cited-content_cbyCitation_journal-name">Modern Pathology</span><span> <strong>2021,</strong> <em>34 </em>
                                    (4)
                                     , 720-734. <a href="https://doi.org/10.1038/s41379-020-00728-z" title="DOI URL">https://doi.org/10.1038/s41379-020-00728-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41379-020-00728-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41379-020-00728-z%26sid%3Dliteratum%253Aachs%26jtitle%3DModern%2520Pathology%26atitle%3DClinical%252Bsignificance%252Bof%252Bquantitative%252Bcategorization%252Bof%252BHER2%252Bfluorescent%252Bin%252Bsitu%252Bhybridization%252Bresults%252Bin%252Binvasive%252Bbreast%252Bcancer%252Bpatients%252Btreated%252Bwith%252BHER2-targeted%252Bagents%26aulast%3DAlhamar%26aufirst%3DMohamed%26date%3D2021%26date%3D2021%26volume%3D34%26issue%3D4%26spage%3D720%26epage%3D734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew Tae-Jun  Kwon</span>, <span class="hlFld-ContribAuthor ">Kohta  Mohri</span>, <span class="hlFld-ContribAuthor ">Satoshi  Takizawa</span>, <span class="hlFld-ContribAuthor ">Takahiro  Arakawa</span>, <span class="hlFld-ContribAuthor ">Maiko  Takahashi</span>, <span class="hlFld-ContribAuthor ">Bogumil  Kaczkowski</span>, <span class="hlFld-ContribAuthor ">Masaaki  Furuno</span>, <span class="hlFld-ContribAuthor ">Harukazu  Suzuki</span>, <span class="hlFld-ContribAuthor ">Shunsuke  Tagami</span>, <span class="hlFld-ContribAuthor ">Hidefumi  Mukai</span>, <span class="hlFld-ContribAuthor ">Erik  Arner</span>. </span><span class="cited-content_cbyCitation_article-title">Development of p53 Knockout U87MG Cell Line for Unbiased Drug Delivery Testing System Using CRISPR-Cas9 and Transcriptomic Analysis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biotechnology</span><span> <strong>2021,</strong> <em>507 </em><a href="https://doi.org/10.1016/j.jbiotec.2021.03.017" title="DOI URL">https://doi.org/10.1016/j.jbiotec.2021.03.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jbiotec.2021.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jbiotec.2021.03.017%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biotechnology%26atitle%3DDevelopment%252Bof%252Bp53%252BKnockout%252BU87MG%252BCell%252BLine%252Bfor%252BUnbiased%252BDrug%252BDelivery%252BTesting%252BSystem%252BUsing%252BCRISPR-Cas9%252Band%252BTranscriptomic%252BAnalysis%26aulast%3DKwon%26aufirst%3DAndrew%2BTae-Jun%26date%3D2021%26volume%3D507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Su</span>, <span class="hlFld-ContribAuthor ">Dian  Xiao</span>, <span class="hlFld-ContribAuthor ">Fei  Xie</span>, <span class="hlFld-ContribAuthor ">Lianqi  Liu</span>, <span class="hlFld-ContribAuthor ">Yanming  Wang</span>, <span class="hlFld-ContribAuthor ">Shiyong  Fan</span>, <span class="hlFld-ContribAuthor ">Xinbo  Zhou</span>, <span class="hlFld-ContribAuthor ">Song  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–drug conjugates: Recent advances in linker chemistry. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>8 </em><a href="https://doi.org/10.1016/j.apsb.2021.03.042" title="DOI URL">https://doi.org/10.1016/j.apsb.2021.03.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2021.03.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2021.03.042%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DAntibody%2525E2%252580%252593drug%252Bconjugates%25253A%252BRecent%252Badvances%252Bin%252Blinker%252Bchemistry%26aulast%3DSu%26aufirst%3DZheng%26date%3D2021%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Esposito</span>, <span class="hlFld-ContribAuthor ">Shridar  Ganesan</span>, <span class="hlFld-ContribAuthor ">Yibin  Kang</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging strategies for treating metastasis. </span><span class="cited-content_cbyCitation_journal-name">Nature Cancer</span><span> <strong>2021,</strong> <em>2 </em>
                                    (3)
                                     , 258-270. <a href="https://doi.org/10.1038/s43018-021-00181-0" title="DOI URL">https://doi.org/10.1038/s43018-021-00181-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s43018-021-00181-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs43018-021-00181-0%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Cancer%26atitle%3DEmerging%252Bstrategies%252Bfor%252Btreating%252Bmetastasis%26aulast%3DEsposito%26aufirst%3DMark%26date%3D2021%26date%3D2021%26volume%3D2%26issue%3D3%26spage%3D258%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Louise  Conilh</span>, <span class="hlFld-ContribAuthor ">Guy  Fournet</span>, <span class="hlFld-ContribAuthor ">Eric  Fourmaux</span>, <span class="hlFld-ContribAuthor ">Angélique  Murcia</span>, <span class="hlFld-ContribAuthor ">Eva-Laure  Matera</span>, <span class="hlFld-ContribAuthor ">Benoît  Joseph</span>, <span class="hlFld-ContribAuthor ">Charles  Dumontet</span>, <span class="hlFld-ContribAuthor ">Warren  Viricel</span>. </span><span class="cited-content_cbyCitation_article-title">Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2021,</strong> <em>14 </em>
                                    (3)
                                     , 247. <a href="https://doi.org/10.3390/ph14030247" title="DOI URL">https://doi.org/10.3390/ph14030247</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph14030247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph14030247%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DExatecan%252BAntibody%252BDrug%252BConjugates%252BBased%252Bon%252Ba%252BHydrophilic%252BPolysarcosine%252BDrug-Linker%252BPlatform%26aulast%3DConilh%26aufirst%3DLouise%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D3%26spage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pankaj  Goyal</span>, <span class="hlFld-ContribAuthor ">Dinesh Chandra  Doval</span>, <span class="hlFld-ContribAuthor ">Chaturbhuj  Agarwal</span>, <span class="hlFld-ContribAuthor ">Parveen  Jain</span>, <span class="hlFld-ContribAuthor ">Krushna  Chaudhari</span>, <span class="hlFld-ContribAuthor ">Kshitij  Domadia</span>, <span class="hlFld-ContribAuthor ">Pallavi  Redhu</span>, <span class="hlFld-ContribAuthor ">Venkata Pradeep Babu  Koyyala</span>, <span class="hlFld-ContribAuthor ">Varun  Goel</span>, <span class="hlFld-ContribAuthor ">Ullas  Batra</span>, <span class="hlFld-ContribAuthor ">Vineet  Talwar</span>, <span class="hlFld-ContribAuthor ">Sneha  Bothra</span>. </span><span class="cited-content_cbyCitation_article-title">Current Treatment Approaches for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Adjuvant and Neoadjuvant Settings. </span><span class="cited-content_cbyCitation_journal-name">Indian Journal of Medical and Paediatric Oncology</span><span> <strong>2021,</strong> <em>42 </em>
                                    (01)
                                     , 035-045. <a href="https://doi.org/10.1055/s-0041-1729726" title="DOI URL">https://doi.org/10.1055/s-0041-1729726</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0041-1729726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0041-1729726%26sid%3Dliteratum%253Aachs%26jtitle%3DIndian%2520Journal%2520of%2520Medical%2520and%2520Paediatric%2520Oncology%26atitle%3DCurrent%252BTreatment%252BApproaches%252Bfor%252BHuman%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B2-Positive%252BBreast%252BCancer%252Bin%252BAdjuvant%252Band%252BNeoadjuvant%252BSettings%26aulast%3DGoyal%26aufirst%3DPankaj%26date%3D2021%26date%3D2021%26volume%3D42%26issue%3D01%26spage%3D035%26epage%3D045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Biagio  Ricciuti</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Lamberti</span>, <span class="hlFld-ContribAuthor ">Elisa  Andrini</span>, <span class="hlFld-ContribAuthor ">Carlo  Genova</span>, <span class="hlFld-ContribAuthor ">Andrea  De Giglio</span>, <span class="hlFld-ContribAuthor ">Vanessa  Bianconi</span>, <span class="hlFld-ContribAuthor ">Amirhossein  Sahebkar</span>, <span class="hlFld-ContribAuthor ">Rita  Chiari</span>, <span class="hlFld-ContribAuthor ">Matteo  Pirro</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–drug conjugates for lung cancer in the era of personalized oncology. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2021,</strong> <em>69 </em>, 268-278. <a href="https://doi.org/10.1016/j.semcancer.2019.12.024" title="DOI URL">https://doi.org/10.1016/j.semcancer.2019.12.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2019.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2019.12.024%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DAntibody%2525E2%252580%252593drug%252Bconjugates%252Bfor%252Blung%252Bcancer%252Bin%252Bthe%252Bera%252Bof%252Bpersonalized%252Boncology%26aulast%3DRicciuti%26aufirst%3DBiagio%26date%3D2021%26volume%3D69%26spage%3D268%26epage%3D278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahfoozur  Rahman</span>, <span class="hlFld-ContribAuthor ">Kainat  Alam</span>, <span class="hlFld-ContribAuthor ">Abdul  Hafeez</span>, <span class="hlFld-ContribAuthor ">Rafida  Ilyas</span>, <span class="hlFld-ContribAuthor ">Sarwar  Beg</span>. </span><span class="cited-content_cbyCitation_article-title">Protein-based nanomedicines as anticancer drug delivery platforms. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 153-169. <a href="https://doi.org/10.1016/B978-0-12-821095-6.00005-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-821095-6.00005-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-821095-6.00005-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-821095-6.00005-7%26sid%3Dliteratum%253Aachs%26atitle%3DProtein-based%252Bnanomedicines%252Bas%252Banticancer%252Bdrug%252Bdelivery%252Bplatforms%26aulast%3DRahman%26aufirst%3DMahfoozur%26date%3D2021%26spage%3D153%26epage%3D169%26pub%3DElsevier%26atitle%3DNanoformulation%252BStrategies%252Bfor%252BCancer%252BTreatment%26date%3D2021%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yukinori  Endo</span>, <span class="hlFld-ContribAuthor ">Nishant  Mohan</span>, <span class="hlFld-ContribAuthor ">Milos  Dokmanovic</span>, <span class="hlFld-ContribAuthor ">Wen Jin  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicities. </span><span class="cited-content_cbyCitation_journal-name">Antibody Therapeutics</span><span> <strong>2021,</strong> <em>4 </em>
                                    (1)
                                     , 55-59. <a href="https://doi.org/10.1093/abt/tbab005" title="DOI URL">https://doi.org/10.1093/abt/tbab005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/abt/tbab005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fabt%2Ftbab005%26sid%3Dliteratum%253Aachs%26jtitle%3DAntibody%2520Therapeutics%26atitle%3DMechanisms%252Bcontributing%252Bto%252Bado-trastuzumab%252Bemtansine-induced%252Btoxicities%25253A%252Ba%252Bgateway%252Bto%252Bbetter%252Bunderstanding%252Bof%252BADC-associated%252Btoxicities%26aulast%3DEndo%26aufirst%3DYukinori%26date%3D2021%26date%3D2021%26volume%3D4%26issue%3D1%26spage%3D55%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David W.  Meyer</span>, <span class="hlFld-ContribAuthor ">Fu  Li</span>, <span class="hlFld-ContribAuthor ">Robert P.  Lyon</span>. </span><span class="cited-content_cbyCitation_article-title">Contribution of Nontarget Cells to the Disposition, Antitumor Activity, and Antigen-Independent Toxicity of Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 357-382. <a href="https://doi.org/10.1007/978-1-0716-1250-7_16" title="DOI URL">https://doi.org/10.1007/978-1-0716-1250-7_16</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-0716-1250-7_16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-0716-1250-7_16%26sid%3Dliteratum%253Aachs%26atitle%3DContribution%252Bof%252BNontarget%252BCells%252Bto%252Bthe%252BDisposition%25252C%252BAntitumor%252BActivity%25252C%252Band%252BAntigen-Independent%252BToxicity%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DMeyer%26aufirst%3DDavid%2BW.%26date%3D2021%26date%3D2021%26spage%3D357%26epage%3D382%26pub%3DSpringer%2520US%26atitle%3DQuantitative%252BAnalysis%252Bof%252BCellular%252BDrug%252BTransport%25252C%252BDisposition%25252C%252Band%252BDelivery%26aulast%3DRosania%26aufirst%3DGus%2BR.%26date%3D2021%26volume%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiraborrirak  Charoenpattarapreeda</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Walsh</span>, <span class="hlFld-ContribAuthor ">Jason S.  Carroll</span>, <span class="hlFld-ContribAuthor ">David R.  Spring</span>. </span><span class="cited-content_cbyCitation_article-title">Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (51)
                                     , 23245-23250. <a href="https://doi.org/10.1002/ange.202010090" title="DOI URL">https://doi.org/10.1002/ange.202010090</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202010090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202010090%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DExpeditious%252BTotal%252BSynthesis%252Bof%252BHemiasterlin%252Bthrough%252Ba%252BConvergent%252BMulticomponent%252BStrategy%252Band%252BIts%252BUse%252Bin%252BTargeted%252BCancer%252BTherapeutics%26aulast%3DCharoenpattarapreeda%26aufirst%3DJiraborrirak%26date%3D2020%26date%3D2020%26volume%3D132%26issue%3D51%26spage%3D23245%26epage%3D23250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiraborrirak  Charoenpattarapreeda</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Walsh</span>, <span class="hlFld-ContribAuthor ">Jason S.  Carroll</span>, <span class="hlFld-ContribAuthor ">David R.  Spring</span>. </span><span class="cited-content_cbyCitation_article-title">Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (51)
                                     , 23045-23050. <a href="https://doi.org/10.1002/anie.202010090" title="DOI URL">https://doi.org/10.1002/anie.202010090</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202010090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202010090%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DExpeditious%252BTotal%252BSynthesis%252Bof%252BHemiasterlin%252Bthrough%252Ba%252BConvergent%252BMulticomponent%252BStrategy%252Band%252BIts%252BUse%252Bin%252BTargeted%252BCancer%252BTherapeutics%26aulast%3DCharoenpattarapreeda%26aufirst%3DJiraborrirak%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D51%26spage%3D23045%26epage%3D23050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Florczak</span>, <span class="hlFld-ContribAuthor ">Tomasz  Deptuch</span>, <span class="hlFld-ContribAuthor ">Anna  Lewandowska</span>, <span class="hlFld-ContribAuthor ">Karolina  Penderecka</span>, <span class="hlFld-ContribAuthor ">Elzbieta  Kramer</span>, <span class="hlFld-ContribAuthor ">Andrzej  Marszalek</span>, <span class="hlFld-ContribAuthor ">Andrzej  Mackiewicz</span>, <span class="hlFld-ContribAuthor ">Hanna  Dams-Kozlowska</span>. </span><span class="cited-content_cbyCitation_article-title">Functionalized silk spheres selectively and effectively deliver a cytotoxic drug to targeted cancer cells in vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Nanobiotechnology</span><span> <strong>2020,</strong> <em>18 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12951-020-00734-y" title="DOI URL">https://doi.org/10.1186/s12951-020-00734-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12951-020-00734-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12951-020-00734-y%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Nanobiotechnology%26atitle%3DFunctionalized%252Bsilk%252Bspheres%252Bselectively%252Band%252Beffectively%252Bdeliver%252Ba%252Bcytotoxic%252Bdrug%252Bto%252Btargeted%252Bcancer%252Bcells%252Bin%252Bvivo%26aulast%3DFlorczak%26aufirst%3DAnna%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ji-Yoon  Noh</span>, <span class="hlFld-ContribAuthor ">Huiyun  Seo</span>, <span class="hlFld-ContribAuthor ">Jungwoon  Lee</span>, <span class="hlFld-ContribAuthor ">Haiyoung  Jung</span>. </span><span class="cited-content_cbyCitation_article-title">Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (21)
                                     , 8000. <a href="https://doi.org/10.3390/ijms21218000" title="DOI URL">https://doi.org/10.3390/ijms21218000</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21218000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21218000%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DImmunotherapy%252Bin%252BHematologic%252BMalignancies%25253A%252BEmerging%252BTherapies%252Band%252BNovel%252BApproaches%26aulast%3DNoh%26aufirst%3DJi-Yoon%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D21%26spage%3D8000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Setsuko  Tsuboi</span>, <span class="hlFld-ContribAuthor ">Takashi  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-colour (near-infrared/visible) emitting annexin V for fluorescence imaging of tumour cell apoptosis
              in vitro
              and
              in vivo. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (63)
                                     , 38244-38250. <a href="https://doi.org/10.1039/D0RA06495E" title="DOI URL">https://doi.org/10.1039/D0RA06495E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA06495E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA06495E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DDual-colour%252B%252528near-infrared%25252Fvisible%252529%252Bemitting%252Bannexin%252BV%252Bfor%252Bfluorescence%252Bimaging%252Bof%252Btumour%252Bcell%252Bapoptosis%252Bin%252Bvitro%252Band%252Bin%252Bvivo%26aulast%3DTsuboi%26aufirst%3DSetsuko%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D63%26spage%3D38244%26epage%3D38250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raj  Kumar</span>, <span class="hlFld-ContribAuthor ">Kunal  Mondal</span>, <span class="hlFld-ContribAuthor ">Pritam Kumar  Panda</span>, <span class="hlFld-ContribAuthor ">Ajeet  Kaushik</span>, <span class="hlFld-ContribAuthor ">Reza  Abolhassani</span>, <span class="hlFld-ContribAuthor ">Rajeev  Ahuja</span>, <span class="hlFld-ContribAuthor ">Horst-Günter  Rubahn</span>, <span class="hlFld-ContribAuthor ">Yogendra Kumar  Mishra</span>. </span><span class="cited-content_cbyCitation_article-title">Core–shell nanostructures: perspectives towards drug delivery applications. </span><span class="cited-content_cbyCitation_journal-name">Journal of Materials Chemistry B</span><span> <strong>2020,</strong> <em>8 </em>
                                    (39)
                                     , 8992-9027. <a href="https://doi.org/10.1039/D0TB01559H" title="DOI URL">https://doi.org/10.1039/D0TB01559H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0TB01559H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0TB01559H%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Materials%2520Chemistry%2520B%26atitle%3DCore%2525E2%252580%252593shell%252Bnanostructures%25253A%252Bperspectives%252Btowards%252Bdrug%252Bdelivery%252Bapplications%26aulast%3DKumar%26aufirst%3DRaj%26date%3D2020%26date%3D2020%26volume%3D8%26issue%3D39%26spage%3D8992%26epage%3D9027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Edmund I.  Graziani</span>, <span class="hlFld-ContribAuthor ">Matthew  Sung</span>, <span class="hlFld-ContribAuthor ">Dangshe  Ma</span>, <span class="hlFld-ContribAuthor ">Bitha  Narayanan</span>, <span class="hlFld-ContribAuthor ">Kimberly  Marquette</span>, <span class="hlFld-ContribAuthor ">Sujiet  Puthenveetil</span>, <span class="hlFld-ContribAuthor ">L. Nathan  Tumey</span>, <span class="hlFld-ContribAuthor ">Jack  Bikker</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Casavant</span>, <span class="hlFld-ContribAuthor ">Eric M.  Bennett</span>, <span class="hlFld-ContribAuthor ">Manoj B.  Charati</span>, <span class="hlFld-ContribAuthor ">Jonathon  Golas</span>, <span class="hlFld-ContribAuthor ">Christine  Hosselet</span>, <span class="hlFld-ContribAuthor ">Cynthia M.  Rohde</span>, <span class="hlFld-ContribAuthor ">George  Hu</span>, <span class="hlFld-ContribAuthor ">Magali  Guffroy</span>, <span class="hlFld-ContribAuthor ">Hadi  Falahatpisheh</span>, <span class="hlFld-ContribAuthor ">Martin  Finkelstein</span>, <span class="hlFld-ContribAuthor ">Tracey  Clark</span>, <span class="hlFld-ContribAuthor ">Frank  Barletta</span>, <span class="hlFld-ContribAuthor ">Lioudmila  Tchistiakova</span>, <span class="hlFld-ContribAuthor ">Judy  Lucas</span>, <span class="hlFld-ContribAuthor ">Edward  Rosfjord</span>, <span class="hlFld-ContribAuthor ">Frank  Loganzo</span>, <span class="hlFld-ContribAuthor ">Christopher J.  O'Donnell</span>, <span class="hlFld-ContribAuthor ">Hans-Peter  Gerber</span>, <span class="hlFld-ContribAuthor ">Puja  Sapra</span>. </span><span class="cited-content_cbyCitation_article-title">PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (10)
                                     , 2068-2078. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0237" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0237</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0237%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DPF-06804103%25252C%252BA%252BSite-specific%252BAnti-HER2%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252Bfor%252Bthe%252BTreatment%252Bof%252BHER2-expressing%252BBreast%25252C%252BGastric%25252C%252Band%252BLung%252BCancers%26aulast%3DGraziani%26aufirst%3DEdmund%2BI.%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D10%26spage%3D2068%26epage%3D2078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alison  Betts</span>, <span class="hlFld-ContribAuthor ">Tracey  Clark</span>, <span class="hlFld-ContribAuthor ">Paul  Jasper</span>, <span class="hlFld-ContribAuthor ">John  Tolsma</span>, <span class="hlFld-ContribAuthor ">Piet H.  van der Graaf</span>, <span class="hlFld-ContribAuthor ">Edmund I.  Graziani</span>, <span class="hlFld-ContribAuthor ">Edward  Rosfjord</span>, <span class="hlFld-ContribAuthor ">Matthew  Sung</span>, <span class="hlFld-ContribAuthor ">Dangshe  Ma</span>, <span class="hlFld-ContribAuthor ">Frank  Barletta</span>. </span><span class="cited-content_cbyCitation_article-title">Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacokinetics and Pharmacodynamics</span><span> <strong>2020,</strong> <em>47 </em>
                                    (5)
                                     , 513-526. <a href="https://doi.org/10.1007/s10928-020-09702-3" title="DOI URL">https://doi.org/10.1007/s10928-020-09702-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10928-020-09702-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10928-020-09702-3%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacokinetics%2520and%2520Pharmacodynamics%26atitle%3DUse%252Bof%252Btranslational%252Bmodeling%252Band%252Bsimulation%252Bfor%252Bquantitative%252Bcomparison%252Bof%252BPF-06804103%25252C%252Ba%252Bnew%252Bgeneration%252BHER2%252BADC%25252C%252Bwith%252BTrastuzumab-DM1%26aulast%3DBetts%26aufirst%3DAlison%26date%3D2020%26date%3D2020%26volume%3D47%26issue%3D5%26spage%3D513%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takuma  Yotsumoto</span>, <span class="hlFld-ContribAuthor ">Keita  Maemura</span>, <span class="hlFld-ContribAuthor ">Kousuke  Watanabe</span>, <span class="hlFld-ContribAuthor ">Yosuke  Amano</span>, <span class="hlFld-ContribAuthor ">Yoko  Matsumoto</span>, <span class="hlFld-ContribAuthor ">Koichi  Zokumasu</span>, <span class="hlFld-ContribAuthor ">Takahiro  Ando</span>, <span class="hlFld-ContribAuthor ">Masanori  Kawakami</span>, <span class="hlFld-ContribAuthor ">Hidenori  Kage</span>, <span class="hlFld-ContribAuthor ">Jun  Nakajima</span>, <span class="hlFld-ContribAuthor ">Yutaka  Yatomi</span>, <span class="hlFld-ContribAuthor ">Takahide  Nagase</span>, <span class="hlFld-ContribAuthor ">Daiya  Takai</span>. </span><span class="cited-content_cbyCitation_article-title">NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2020,</strong> <em>11 </em>
                                    (39)
                                     , 3590-3600. <a href="https://doi.org/10.18632/oncotarget.27718" title="DOI URL">https://doi.org/10.18632/oncotarget.27718</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.27718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.27718%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DNRXN1%252Bas%252Ba%252Bnovel%252Bpotential%252Btarget%252Bof%252Bantibody-drug%252Bconjugates%252Bfor%252Bsmall%252Bcell%252Blung%252Bcancer%26aulast%3DYotsumoto%26aufirst%3DTakuma%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D39%26spage%3D3590%26epage%3D3600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ran  Li</span>, <span class="hlFld-ContribAuthor ">Thomas S. C.  Ng</span>, <span class="hlFld-ContribAuthor ">Michelle A.  Garlin</span>, <span class="hlFld-ContribAuthor ">Ralph  Weissleder</span>, <span class="hlFld-ContribAuthor ">Miles A.  Miller</span>. </span><span class="cited-content_cbyCitation_article-title">Understanding the In Vivo Fate of Advanced Materials by Imaging. </span><span class="cited-content_cbyCitation_journal-name">Advanced Functional Materials</span><span> <strong>2020,</strong> <em>30 </em>
                                    (37)
                                     , 1910369. <a href="https://doi.org/10.1002/adfm.201910369" title="DOI URL">https://doi.org/10.1002/adfm.201910369</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adfm.201910369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadfm.201910369%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Functional%2520Materials%26atitle%3DUnderstanding%252Bthe%252BIn%252BVivo%252BFate%252Bof%252BAdvanced%252BMaterials%252Bby%252BImaging%26aulast%3DLi%26aufirst%3DRan%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D37%26spage%3D1910369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengxuan  Zhao</span>, <span class="hlFld-ContribAuthor ">Yuebao  Zhang</span>, <span class="hlFld-ContribAuthor ">Wenqing  Li</span>, <span class="hlFld-ContribAuthor ">Christopher  Jeanty</span>, <span class="hlFld-ContribAuthor ">Guangya  Xiang</span>, <span class="hlFld-ContribAuthor ">Yizhou  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances of antibody drug conjugates for clinical applications. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2020,</strong> <em>10 </em>
                                    (9)
                                     , 1589-1600. <a href="https://doi.org/10.1016/j.apsb.2020.04.012" title="DOI URL">https://doi.org/10.1016/j.apsb.2020.04.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2020.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2020.04.012%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DRecent%252Badvances%252Bof%252Bantibody%252Bdrug%252Bconjugates%252Bfor%252Bclinical%252Bapplications%26aulast%3DZhao%26aufirst%3DPengxuan%26date%3D2020%26volume%3D10%26issue%3D9%26spage%3D1589%26epage%3D1600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laurence  Gauzy-Lazo</span>, <span class="hlFld-ContribAuthor ">Ingrid  Sassoon</span>, <span class="hlFld-ContribAuthor ">Marie-Priscille  Brun</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2020,</strong> <em>25 </em>
                                    (8)
                                     , 843-868. <a href="https://doi.org/10.1177/2472555220912955" title="DOI URL">https://doi.org/10.1177/2472555220912955</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2472555220912955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2472555220912955%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DAdvances%252Bin%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252BDesign%25253A%252BCurrent%252BClinical%252BLandscape%252Band%252BFuture%252BInnovations%26aulast%3DGauzy-Lazo%26aufirst%3DLaurence%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D8%26spage%3D843%26epage%3D868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Celia  Nieto</span>, <span class="hlFld-ContribAuthor ">Milena A.  Vega</span>, <span class="hlFld-ContribAuthor ">Eva M.  Martín del Valle</span>. </span><span class="cited-content_cbyCitation_article-title">Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine. </span><span class="cited-content_cbyCitation_journal-name">Nanomaterials</span><span> <strong>2020,</strong> <em>10 </em>
                                    (9)
                                     , 1674. <a href="https://doi.org/10.3390/nano10091674" title="DOI URL">https://doi.org/10.3390/nano10091674</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/nano10091674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fnano10091674%26sid%3Dliteratum%253Aachs%26jtitle%3DNanomaterials%26atitle%3DTrastuzumab%25253A%252BMore%252Bthan%252Ba%252BGuide%252Bin%252BHER2-Positive%252BCancer%252BNanomedicine%26aulast%3DNieto%26aufirst%3DCelia%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D9%26spage%3D1674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Cao</span>, <span class="hlFld-ContribAuthor ">Yue-Hui  Dong</span>, <span class="hlFld-ContribAuthor ">De-Feng  Wang</span>, <span class="hlFld-ContribAuthor ">Zhao-Peng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>27 </em>
                                    (27)
                                     , 4567-4576. <a href="https://doi.org/10.2174/0929867327666200316144610" title="DOI URL">https://doi.org/10.2174/0929867327666200316144610</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867327666200316144610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867327666200316144610%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DTubulin%252BMaytansine%252BSite%252BBinding%252BLigands%252Band%252Btheir%252BApplications%252Bas%252BMTAs%252Band%252BADCs%252Bfor%252BCancer%252BTherapy%26aulast%3DCao%26aufirst%3DShuo%26date%3D2020%26volume%3D27%26issue%3D27%26spage%3D4567%26epage%3D4576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juliette  Sauveur</span>, <span class="hlFld-ContribAuthor ">Louise  Conilh</span>, <span class="hlFld-ContribAuthor ">Sabine  Beaumel</span>, <span class="hlFld-ContribAuthor ">Kamel  Chettab</span>, <span class="hlFld-ContribAuthor ">Lars‐Petter  Jordheim</span>, <span class="hlFld-ContribAuthor ">Eva‐Laure  Matera</span>, <span class="hlFld-ContribAuthor ">Charles  Dumontet</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of T‐DM1‐resistant breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology Research & Perspectives</span><span> <strong>2020,</strong> <em>8 </em>
                                    (4)
                                     <a href="https://doi.org/10.1002/prp2.617" title="DOI URL">https://doi.org/10.1002/prp2.617</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/prp2.617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fprp2.617%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520Research%2520%2526%2520Perspectives%26atitle%3DCharacterization%252Bof%252BT%2525E2%252580%252590DM1%2525E2%252580%252590resistant%252Bbreast%252Bcancer%252Bcells%26aulast%3DSauveur%26aufirst%3DJuliette%26date%3D2020%26date%3D2020%26volume%3D8%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yukinari  Kato</span>, <span class="hlFld-ContribAuthor ">Tomokazu  Ohishi</span>, <span class="hlFld-ContribAuthor ">Junko  Takei</span>, <span class="hlFld-ContribAuthor ">Takuro  Nakamura</span>, <span class="hlFld-ContribAuthor ">Masato  Sano</span>, <span class="hlFld-ContribAuthor ">Teizo  Asano</span>, <span class="hlFld-ContribAuthor ">Yusuke  Sayama</span>, <span class="hlFld-ContribAuthor ">Hideki  Hosono</span>, <span class="hlFld-ContribAuthor ">Manabu  Kawada</span>, <span class="hlFld-ContribAuthor ">Mika K.  Kaneko</span>. </span><span class="cited-content_cbyCitation_article-title">An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H
              2
              Mab-19 Exerts Antitumor Activity in Mouse Colon Cancer Xenografts. </span><span class="cited-content_cbyCitation_journal-name">Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</span><span> <strong>2020,</strong> <em>39 </em>
                                    (4)
                                     , 123-128. <a href="https://doi.org/10.1089/mab.2020.0009" title="DOI URL">https://doi.org/10.1089/mab.2020.0009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1089/mab.2020.0009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1089%2Fmab.2020.0009%26sid%3Dliteratum%253Aachs%26jtitle%3DMonoclonal%2520Antibodies%2520in%2520Immunodiagnosis%2520and%2520Immunotherapy%26atitle%3DAn%252BAnti-Human%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B2%252BMonoclonal%252BAntibody%252BH%252B2%252BMab-19%252BExerts%252BAntitumor%252BActivity%252Bin%252BMouse%252BColon%252BCancer%252BXenografts%26aulast%3DKato%26aufirst%3DYukinari%26date%3D2020%26volume%3D39%26issue%3D4%26spage%3D123%26epage%3D128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yukinari  Kato</span>, <span class="hlFld-ContribAuthor ">Tomokazu  Ohishi</span>, <span class="hlFld-ContribAuthor ">Junko  Takei</span>, <span class="hlFld-ContribAuthor ">Takuro  Nakamura</span>, <span class="hlFld-ContribAuthor ">Manabu  Kawada</span>, <span class="hlFld-ContribAuthor ">Mika K.  Kaneko</span>. </span><span class="cited-content_cbyCitation_article-title">An Antihuman Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H
              2
              Mab-19) Exerts Antitumor Activity in Glioblastoma Xenograft Models. </span><span class="cited-content_cbyCitation_journal-name">Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</span><span> <strong>2020,</strong> <em>39 </em>
                                    (4)
                                     , 135-139. <a href="https://doi.org/10.1089/mab.2020.0013" title="DOI URL">https://doi.org/10.1089/mab.2020.0013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1089/mab.2020.0013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1089%2Fmab.2020.0013%26sid%3Dliteratum%253Aachs%26jtitle%3DMonoclonal%2520Antibodies%2520in%2520Immunodiagnosis%2520and%2520Immunotherapy%26atitle%3DAn%252BAntihuman%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B2%252BMonoclonal%252BAntibody%252B%252528H%252B2%252BMab-19%252529%252BExerts%252BAntitumor%252BActivity%252Bin%252BGlioblastoma%252BXenograft%252BModels%26aulast%3DKato%26aufirst%3DYukinari%26date%3D2020%26volume%3D39%26issue%3D4%26spage%3D135%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sara  Ponziani</span>, <span class="hlFld-ContribAuthor ">Giulia  Di Vittorio</span>, <span class="hlFld-ContribAuthor ">Giuseppina  Pitari</span>, <span class="hlFld-ContribAuthor ">Anna Maria  Cimini</span>, <span class="hlFld-ContribAuthor ">Matteo  Ardini</span>, <span class="hlFld-ContribAuthor ">Roberta  Gentile</span>, <span class="hlFld-ContribAuthor ">Stefano  Iacobelli</span>, <span class="hlFld-ContribAuthor ">Gianluca  Sala</span>, <span class="hlFld-ContribAuthor ">Emily  Capone</span>, <span class="hlFld-ContribAuthor ">David J.  Flavell</span>, <span class="hlFld-ContribAuthor ">Rodolfo  Ippoliti</span>, <span class="hlFld-ContribAuthor ">Francesco  Giansanti</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody-Drug Conjugates: The New Frontier of Chemotherapy. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (15)
                                     , 5510. <a href="https://doi.org/10.3390/ijms21155510" title="DOI URL">https://doi.org/10.3390/ijms21155510</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21155510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21155510%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DAntibody-Drug%252BConjugates%25253A%252BThe%252BNew%252BFrontier%252Bof%252BChemotherapy%26aulast%3DPonziani%26aufirst%3DSara%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D15%26spage%3D5510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Congcong  Zhang</span>, <span class="hlFld-ContribAuthor ">Rina M.  Ötjengerdes</span>, <span class="hlFld-ContribAuthor ">Julian  Roewe</span>, <span class="hlFld-ContribAuthor ">Rebeca  Mejias</span>, <span class="hlFld-ContribAuthor ">Andrea L. J.  Marschall</span>. </span><span class="cited-content_cbyCitation_article-title">Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology. </span><span class="cited-content_cbyCitation_journal-name">BioDrugs</span><span> <strong>2020,</strong> <em>34 </em>
                                    (4)
                                     , 435-462. <a href="https://doi.org/10.1007/s40259-020-00419-w" title="DOI URL">https://doi.org/10.1007/s40259-020-00419-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40259-020-00419-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40259-020-00419-w%26sid%3Dliteratum%253Aachs%26jtitle%3DBioDrugs%26atitle%3DApplying%252BAntibodies%252BInside%252BCells%25253A%252BPrinciples%252Band%252BRecent%252BAdvances%252Bin%252BNeurobiology%25252C%252BVirology%252Band%252BOncology%26aulast%3DZhang%26aufirst%3DCongcong%26date%3D2020%26date%3D2020%26volume%3D34%26issue%3D4%26spage%3D435%26epage%3D462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua T.  Burgess</span>, <span class="hlFld-ContribAuthor ">Maddison  Rose</span>, <span class="hlFld-ContribAuthor ">Didier  Boucher</span>, <span class="hlFld-ContribAuthor ">Jennifer  Plowman</span>, <span class="hlFld-ContribAuthor ">Christopher  Molloy</span>, <span class="hlFld-ContribAuthor ">Mark  Fisher</span>, <span class="hlFld-ContribAuthor ">Connor  O'Leary</span>, <span class="hlFld-ContribAuthor ">Derek J.  Richard</span>, <span class="hlFld-ContribAuthor ">Kenneth J.  O'Byrne</span>, <span class="hlFld-ContribAuthor ">Emma  Bolderson</span>. </span><span class="cited-content_cbyCitation_article-title">The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.3389/fonc.2020.01256" title="DOI URL">https://doi.org/10.3389/fonc.2020.01256</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2020.01256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2020.01256%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DThe%252BTherapeutic%252BPotential%252Bof%252BDNA%252BDamage%252BRepair%252BPathways%252Band%252BGenomic%252BStability%252Bin%252BLung%252BCancer%26aulast%3DBurgess%26aufirst%3DJoshua%2BT.%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gaia  Griguolo</span>, <span class="hlFld-ContribAuthor ">Fara  Brasó-Maristany</span>, <span class="hlFld-ContribAuthor ">Blanca  González-Farré</span>, <span class="hlFld-ContribAuthor ">Tomás  Pascual</span>, <span class="hlFld-ContribAuthor ">Núria  Chic</span>, <span class="hlFld-ContribAuthor ">Tamara  Saurí</span>, <span class="hlFld-ContribAuthor ">Ronald  Kates</span>, <span class="hlFld-ContribAuthor ">Oleg  Gluz</span>, <span class="hlFld-ContribAuthor ">Débora  Martínez</span>, <span class="hlFld-ContribAuthor ">Laia  Paré</span>, <span class="hlFld-ContribAuthor ">Vassilena  Tsvetkova</span>, <span class="hlFld-ContribAuthor ">David  Pesantez</span>, <span class="hlFld-ContribAuthor ">Maria  Vidal</span>, <span class="hlFld-ContribAuthor ">Barbara  Adamo</span>, <span class="hlFld-ContribAuthor ">Montserrat  Muñoz</span>, <span class="hlFld-ContribAuthor ">Patricia  Galván</span>, <span class="hlFld-ContribAuthor ">Laura  Barberá</span>, <span class="hlFld-ContribAuthor ">Miriam  Cuatrecasas</span>, <span class="hlFld-ContribAuthor ">Mathias  Christgen</span>, <span class="hlFld-ContribAuthor ">Hans  Kreipe</span>, <span class="hlFld-ContribAuthor ">Inés  Monge-Escartín</span>, <span class="hlFld-ContribAuthor ">Patricia  Villagrasa</span>, <span class="hlFld-ContribAuthor ">Dolors  Soy</span>, <span class="hlFld-ContribAuthor ">Tommaso  Giarratano</span>, <span class="hlFld-ContribAuthor ">Maria Vittoria  Dieci</span>, <span class="hlFld-ContribAuthor ">Pierfranco  Conte</span>, <span class="hlFld-ContribAuthor ">Nadia  Harbeck</span>, <span class="hlFld-ContribAuthor ">Valentina  Guarneri</span>, <span class="hlFld-ContribAuthor ">Aleix  Prat</span>. </span><span class="cited-content_cbyCitation_article-title">ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (7)
                                     , 1902. <a href="https://doi.org/10.3390/cancers12071902" title="DOI URL">https://doi.org/10.3390/cancers12071902</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12071902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12071902%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DERBB2%252BmRNA%252BExpression%252Band%252BResponse%252Bto%252BAdo-Trastuzumab%252BEmtansine%252B%252528T-DM1%252529%252Bin%252BHER2-Positive%252BBreast%252BCancer%26aulast%3DGriguolo%26aufirst%3DGaia%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D7%26spage%3D1902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kohsuke  Gonda</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Negishi</span>, <span class="hlFld-ContribAuthor ">Mayumi  Takano-Kasuya</span>, <span class="hlFld-ContribAuthor ">Narufumi  Kitamura</span>, <span class="hlFld-ContribAuthor ">Naoko  Furusawa</span>, <span class="hlFld-ContribAuthor ">Yasushi  Nakano</span>, <span class="hlFld-ContribAuthor ">Yoh  Hamada</span>, <span class="hlFld-ContribAuthor ">Masayuki  Tokunaga</span>, <span class="hlFld-ContribAuthor ">Hideo  Higuchi</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Tada</span>, <span class="hlFld-ContribAuthor ">Takanori  Ishida</span>. </span><span class="cited-content_cbyCitation_article-title">Heterogeneous Drug Efficacy of an Antibody-Drug Conjugate Visualized Using Simultaneous Imaging of Its Delivery and Intracellular Damage in Living Tumor Tissues. </span><span class="cited-content_cbyCitation_journal-name">Translational Oncology</span><span> <strong>2020,</strong> <em>13 </em>
                                    (6)
                                     , 100764. <a href="https://doi.org/10.1016/j.tranon.2020.100764" title="DOI URL">https://doi.org/10.1016/j.tranon.2020.100764</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tranon.2020.100764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tranon.2020.100764%26sid%3Dliteratum%253Aachs%26jtitle%3DTranslational%2520Oncology%26atitle%3DHeterogeneous%252BDrug%252BEfficacy%252Bof%252Ban%252BAntibody-Drug%252BConjugate%252BVisualized%252BUsing%252BSimultaneous%252BImaging%252Bof%252BIts%252BDelivery%252Band%252BIntracellular%252BDamage%252Bin%252BLiving%252BTumor%252BTissues%26aulast%3DGonda%26aufirst%3DKohsuke%26date%3D2020%26volume%3D13%26issue%3D6%26spage%3D100764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yukinari  Kato</span>, <span class="hlFld-ContribAuthor ">Tomokazu  Ohishi</span>, <span class="hlFld-ContribAuthor ">Masato  Sano</span>, <span class="hlFld-ContribAuthor ">Teizo  Asano</span>, <span class="hlFld-ContribAuthor ">Yusuke  Sayama</span>, <span class="hlFld-ContribAuthor ">Junko  Takei</span>, <span class="hlFld-ContribAuthor ">Manabu  Kawada</span>, <span class="hlFld-ContribAuthor ">Mika K.  Kaneko</span>. </span><span class="cited-content_cbyCitation_article-title">H
              2
              Mab-19 Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody Therapy Exerts Antitumor Activity in Pancreatic Cancer Xenograft Models. </span><span class="cited-content_cbyCitation_journal-name">Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</span><span> <strong>2020,</strong> <em>39 </em>
                                    (3)
                                     , 61-65. <a href="https://doi.org/10.1089/mab.2020.0011" title="DOI URL">https://doi.org/10.1089/mab.2020.0011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1089/mab.2020.0011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1089%2Fmab.2020.0011%26sid%3Dliteratum%253Aachs%26jtitle%3DMonoclonal%2520Antibodies%2520in%2520Immunodiagnosis%2520and%2520Immunotherapy%26atitle%3DH%252B2%252BMab-19%252BAnti-Human%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B2%252BMonoclonal%252BAntibody%252BTherapy%252BExerts%252BAntitumor%252BActivity%252Bin%252BPancreatic%252BCancer%252BXenograft%252BModels%26aulast%3DKato%26aufirst%3DYukinari%26date%3D2020%26volume%3D39%26issue%3D3%26spage%3D61%26epage%3D65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanting  Wu</span>, <span class="hlFld-ContribAuthor ">Qianjin  Kang</span>, <span class="hlFld-ContribAuthor ">Li-Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Linquan  Bai</span>. </span><span class="cited-content_cbyCitation_article-title">Subtilisin-Involved Morphology Engineering for Improved Antibiotic Production in Actinomycetes. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2020,</strong> <em>10 </em>
                                    (6)
                                     , 851. <a href="https://doi.org/10.3390/biom10060851" title="DOI URL">https://doi.org/10.3390/biom10060851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom10060851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom10060851%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DSubtilisin-Involved%252BMorphology%252BEngineering%252Bfor%252BImproved%252BAntibiotic%252BProduction%252Bin%252BActinomycetes%26aulast%3DWu%26aufirst%3DYuanting%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D6%26spage%3D851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hyun Jung  Kim</span>, <span class="hlFld-ContribAuthor ">Ho Jin  Sung</span>, <span class="hlFld-ContribAuthor ">Yul Min  Lee</span>, <span class="hlFld-ContribAuthor ">Sun Il  Choi</span>, <span class="hlFld-ContribAuthor ">Yun-Hee  Kim</span>, <span class="hlFld-ContribAuthor ">Kyun  Heo</span>, <span class="hlFld-ContribAuthor ">In-Hoo  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody). </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (9)
                                     , 3286. <a href="https://doi.org/10.3390/ijms21093286" title="DOI URL">https://doi.org/10.3390/ijms21093286</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21093286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21093286%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DTherapeutic%252BApplication%252Bof%252BDrug-Conjugated%252BHER2%252BOligobody%252B%252528HER2-DOligobody%252529%26aulast%3DKim%26aufirst%3DHyun%2BJung%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D9%26spage%3D3286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eugen  Merkul</span>, <span class="hlFld-ContribAuthor ">Niels J.  Sijbrandi</span>, <span class="hlFld-ContribAuthor ">Ibrahim  Aydin</span>, <span class="hlFld-ContribAuthor ">Joey A.  Muns</span>, <span class="hlFld-ContribAuthor ">Ruud J. R. W.  Peters</span>, <span class="hlFld-ContribAuthor ">Paul  Laarhoven</span>, <span class="hlFld-ContribAuthor ">Hendrik-Jan  Houthoff</span>, <span class="hlFld-ContribAuthor ">Guus A. M. S.  van Dongen</span>. </span><span class="cited-content_cbyCitation_article-title">A successful search for new, efficient, and silver-free manufacturing processes for key platinum(
              ii
              ) intermediates applied in antibody–drug conjugate (ADC) production. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2020,</strong> <em>22 </em>
                                    (7)
                                     , 2203-2212. <a href="https://doi.org/10.1039/C9GC03130H" title="DOI URL">https://doi.org/10.1039/C9GC03130H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9GC03130H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9GC03130H%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DA%252Bsuccessful%252Bsearch%252Bfor%252Bnew%25252C%252Befficient%25252C%252Band%252Bsilver-free%252Bmanufacturing%252Bprocesses%252Bfor%252Bkey%252Bplatinum%252528%252Bii%252B%252529%252Bintermediates%252Bapplied%252Bin%252Bantibody%2525E2%252580%252593drug%252Bconjugate%252B%252528ADC%252529%252Bproduction%26aulast%3DMerkul%26aufirst%3DEugen%26date%3D2020%26date%3D2020%26volume%3D22%26issue%3D7%26spage%3D2203%26epage%3D2212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jessica K.  Simmons</span>, <span class="hlFld-ContribAuthor ">Patrick J.  Burke</span>, <span class="hlFld-ContribAuthor ">Julia H.  Cochran</span>, <span class="hlFld-ContribAuthor ">Paul G  Pittman</span>, <span class="hlFld-ContribAuthor ">Robert P.  Lyon</span>. </span><span class="cited-content_cbyCitation_article-title">Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation. </span><span class="cited-content_cbyCitation_journal-name">Toxicology and Applied Pharmacology</span><span> <strong>2020,</strong> <em>392 </em>, 114932. <a href="https://doi.org/10.1016/j.taap.2020.114932" title="DOI URL">https://doi.org/10.1016/j.taap.2020.114932</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.taap.2020.114932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.taap.2020.114932%26sid%3Dliteratum%253Aachs%26jtitle%3DToxicology%2520and%2520Applied%2520Pharmacology%26atitle%3DReducing%252Bthe%252Bantigen-independent%252Btoxicity%252Bof%252Bantibody-drug%252Bconjugates%252Bby%252Bminimizing%252Btheir%252Bnon-specific%252Bclearance%252Bthrough%252BPEGylation%26aulast%3DSimmons%26aufirst%3DJessica%2BK.%26date%3D2020%26volume%3D392%26spage%3D114932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena  Vagia</span>, <span class="hlFld-ContribAuthor ">Devalingam  Mahalingam</span>, <span class="hlFld-ContribAuthor ">Massimo  Cristofanilli</span>. </span><span class="cited-content_cbyCitation_article-title">The Landscape of Targeted Therapies in TNBC. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (4)
                                     , 916. <a href="https://doi.org/10.3390/cancers12040916" title="DOI URL">https://doi.org/10.3390/cancers12040916</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12040916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12040916%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DThe%252BLandscape%252Bof%252BTargeted%252BTherapies%252Bin%252BTNBC%26aulast%3DVagia%26aufirst%3DElena%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D4%26spage%3D916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ian  Nessler</span>, <span class="hlFld-ContribAuthor ">Eshita  Khera</span>, <span class="hlFld-ContribAuthor ">Steven  Vance</span>, <span class="hlFld-ContribAuthor ">Anna  Kopp</span>, <span class="hlFld-ContribAuthor ">Qifeng  Qiu</span>, <span class="hlFld-ContribAuthor ">Thomas A.  Keating</span>, <span class="hlFld-ContribAuthor ">Adnan O.  Abu-Yousif</span>, <span class="hlFld-ContribAuthor ">Thomas  Sandal</span>, <span class="hlFld-ContribAuthor ">James  Legg</span>, <span class="hlFld-ContribAuthor ">Lorraine  Thompson</span>, <span class="hlFld-ContribAuthor ">Normann  Goodwin</span>, <span class="hlFld-ContribAuthor ">Greg M.  Thurber</span>. </span><span class="cited-content_cbyCitation_article-title">Increased Tumor Penetration of Single-Domain Antibody–Drug Conjugates Improves
              In Vivo
              Efficacy in Prostate Cancer Models. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2020,</strong> <em>80 </em>
                                    (6)
                                     , 1268-1278. <a href="https://doi.org/10.1158/0008-5472.CAN-19-2295" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-19-2295</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-19-2295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-19-2295%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DIncreased%252BTumor%252BPenetration%252Bof%252BSingle-Domain%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252BImproves%252BIn%252BVivo%252BEfficacy%252Bin%252BProstate%252BCancer%252BModels%26aulast%3DNessler%26aufirst%3DIan%26date%3D2020%26date%3D2020%26volume%3D80%26issue%3D6%26spage%3D1268%26epage%3D1278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm500766w&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-16%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm500766w%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=263&amp;pagesCount=3&amp;pageNumber=2" title="Load more citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load more citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Comparison of the in vitro potency of cytotoxic drugs toward the Burkitt lymphoma cell line Namalwa: maytansine (blue circle), vinblastine (red triangle), daunorubicin (green diamond), methotrexate (brown square), mitomycin C (purple triangle).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Thiol-Containing Maytansinoids<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reaction conditions: (a) LiAlH(OMe)<sub>3</sub>/THF, −40 °C, (b) EDC/ZnCl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub>, rt, (c) dithiothreitol, rt.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of cross-linkers used in conjugate preparation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Representative Conjugation Processes for Trastuzumab-Maytansinoid Conjugates</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structural representation of trastuzumab-maytansinoid conjugates with a disulfide linker (<b>8a</b>–<b>d</b>) or a thioether linker (<b>8e</b>). Adapted by permission from the American Association for Cancer Research (<contrib-group>Lewis Phillips. G. D.; Li, G.; Dugger, D. L.; Crocker, L. M.; Parsons, K. L.; Mai, E.; Lambert, J. M.; Chari, R. V.; Lutz, R. J.; Wong, W. L.; Jacobson, F. S.; Koeppen, H.; Schwall, R. H.; Kenkare-Mitra, S. R.; Spencer, S. D.; Sliwkowski, M. X.</contrib-group>Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.  <cite>Cancer Res.</cite> <span class="NLM_year">2008</span>, <em>68</em>, 9280–9290).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Comparison of the in vivo efficacy of trastuzumab–maytansinoid conjugates with a disulfide linker (<b>8b</b> (green triangle), <b>8c</b> (purple cross), <b>8d</b> (red boxed cross)) or a thioether linker (<b>8e</b> (blue square)) at a single iv dose of 10 mg/kg conjugate and a vehicle control (×). Adapted by permission from the American Association for Cancer Research (<contrib-group>Lewis Phillips. G. D.; Li, G.; Dugger, D. L.; Crocker, L. M.; Parsons, K. L.; Mai, E.; Lambert, J. M.; Chari, R. V.; Lutz, R. J.; Wong, W. L.; Jacobson, F. S.; Koeppen, H.; Schwall, R. H.; Kenkare-Mitra, S. R.; Spencer, S. D.; Sliwkowski, M. X.</contrib-group>Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.  <cite>Cancer Res.</cite> <span class="NLM_year">2008</span>, <em>68</em>, 9280–9290).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0006.jpeg" id="rightTab-GRAPHIC-d3487e841-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) In vitro catabolism by BT474-EEI cells of the trastuzumab-MCC-DM1 conjugate <b>8e</b> (thioether linker): top panel, 6 h time point; bottom panel, 24 h time point. (B) In vitro catabolism by BT474-EEI cells of the trastuzumab-SPP-DM1 conjugate <b>8b</b> (disulfide linker): top panel, 6 h time point; bottom panel, 24 h time point. (C) Comparison of the rate and extent of in vitro processing of trastuzumab-SPP-DM1 conjugate <b>8b</b> (disulfide linker: blue squares) and trastuzumab-MCC-DM1 conjugate <b>8e</b> (thioether linker, red squares) by BT474-EEI cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0007.jpeg" id="rightTab-GRAPHIC-d3487e890-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Time dependent formation of catabolite: comparison of in vivo catabolism of trastuzumab–maytansinoid conjugates in BT474-EEI tumor xenografts in mice: trastuzumab-SPP-DM1 conjugate <b>8b</b> (disulfide linker, blue square) and trastuzumab-MCC-DM1 conjugate <b>8e</b> (thioether linker, red square). (B) In vivo catabolism of trastuzumab–maytansinoid conjugates in BT474-EEI tumor xenografts in mice at 2-day time-point: top panel, <b>8b</b>, disulfide linker (SPP); bottom panel, <b>8e</b>, thioether linker (SMCC).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/medium/jm-2014-00766w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0008.jpeg" id="rightTab-GRAPHIC-d3487e1262-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Comparison of the in vivo antitumor activity of trastuzumab (red circle, 15 mg/kg × 4) and T-DM1 (blue square, 15 mg/kg, single dose), vehicle control (×), in the KPL-4 model. (Excerpted from Lewis-Phillips et al.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a>). (B) Dose-dependent antitumor activity of T-DM1 in the BT474-EEI model (dosing q3w × 3). Doses of T-DM1, are the following: 0.3 mg/kg (purple-outline triangle), 1 mg/kg (green triangle), 3 mg/kg (blue-outline triangle), 10 mg/kg (red triangle), 15 mg/kg (blue square), vehicle control (×); unconjugated trastuzumab (red circle, 15 mg/kg). Parts A and B are adapted by permission from the American Association for Cancer Research (<contrib-group>Lewis Phillips. G. D.; Li, G.; Dugger, D. L.; Crocker, L. M.; Parsons, K. L.; Mai, E.; Lambert, J. M.; Chari, R. V.; Lutz, R. J.; Wong, W. L.; Jacobson, F. S.; Koeppen, H.; Schwall, R. H.; Kenkare-Mitra, S. R.; Spencer, S. D.; Sliwkowski, M. X.</contrib-group>Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.  <cite>Cancer Res.</cite> <span class="NLM_year">2008</span>, <em>68</em>, 9280–9290).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-16/jm500766w/production/images/large/jm-2014-00766w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500766w&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66134" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66134" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 50 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Colomer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shamon, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupu, R.</span><span> </span><span class="NLM_article-title">Herceptin: from the bench to the clinic</span> <span class="citation_source-journal">Cancer Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=49-56&author=R.+Colomerauthor=L.+A.+Shamonauthor=M.+S.+Tsaiauthor=R.+Lupu&title=Herceptin%3A+from+the+bench+to+the+clinic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColomer%26aufirst%3DR.%26aulast%3DShamon%26aufirst%3DL.%2BA.%26aulast%3DTsai%26aufirst%3DM.%2BS.%26aulast%3DLupu%26aufirst%3DR.%26atitle%3DHerceptin%253A%2520from%2520the%2520bench%2520to%2520the%2520clinic%26jtitle%3DCancer%2520Invest.%26date%3D2001%26volume%3D19%26spage%3D49%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Pegram, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konecny, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Callaghan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beryt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietras, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span> </span><span class="NLM_article-title">Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">749</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1093%2Fjnci%2Fdjh131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=15150302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Sqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2004&pages=739-749&author=M.+D.+Pegramauthor=G.+E.+Konecnyauthor=C.+O%E2%80%99Callaghanauthor=M.+Berytauthor=R.+Pietrasauthor=D.+J.+Slamon&title=Rational+combinations+of+trastuzumab+with+chemotherapeutic+drugs+used+in+the+treatment+of+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer</span></div><div class="casAuthors">Pegram, Mark D.; Konecny, Gottfried E.; O'Callaghan, Carminda; Beryt, Malgorzata; Pietras, Richard; Slamon, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">739-749</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Trastuzumab, a humanized anti-HER2 antibody, increases the clin. benefit of first-line chemotherapy in patients with metastatic breast cancers that overexpress HER2.  We characterized interactions between trastuzumab and chemotherapeutic agents commonly used in the treatment of breast cancer.  Multiple drug effect/combination index isobologram anal. was used to study the efficacy of chemotherapeutic drug plus trastuzumab combinations tested against four HER2-overexpressing breast cancer cell lines (SK-BR-3, BT-474, MDA-MB-361, and MDA-MB-453).  Combination index values were derived from parameters of the median effect plots, and statistical tests were used to det. whether the mean combination index values at multiple effect levels were statistically significantly different from a combination index value of 1.0.  Values less than 1.0 indicate synergistic interactions, values greater than 1.0 indicate antagonistic interactions, and values equal to 1.0 indicate additive interactions.  At a wide range of clin. achievable drug concns., synergistic interactions were obsd. in all four breast cancer cell lines for trastuzumab plus carboplatin (mean combination index values ranged from 0.32 [P<.001] to 0.53 [P<.001]), 4-hydroxycyclophosphamide (mean combination index values ranged from 0.38 [P<.001] to 0.73 [P = .010]), docetaxel (mean combination index values ranged from 0.30 [P<.001] to 0.62 [P<.001]), and vinorelbine (mean combination index values ranged from 0.24 [P<.001] to 0.78 [P<.034]).  Additive interactions were obsd. in all four cell lines with trastuzumab plus doxorubicin, epirubicin, and paclitaxel.  Interactions between trastuzumab and gemcitabine were synergistic at low concns. of gemcitabine and antagonistic at high concns.  A synergistic interaction was obsd. with a three-drug combination of docetaxel plus carboplatin plus trastuzumab in SK-BR-3 cells (mean combination index value = 0.09; P<.001).  Consistent synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine across a wide range of clin. relevant concns. in HER2-overexpressing breast cancer cells indicate that these are rational combinations to test in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ5NdDhTJwpLVg90H21EOLACvtfcHk0lj4TLVGyIEmjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Sqsbo%253D&md5=1fb831bd3fbb62277de025c4a99f383d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjh131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjh131%26sid%3Dliteratum%253Aachs%26aulast%3DPegram%26aufirst%3DM.%2BD.%26aulast%3DKonecny%26aufirst%3DG.%2BE.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DC.%26aulast%3DBeryt%26aufirst%3DM.%26aulast%3DPietras%26aufirst%3DR.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DRational%2520combinations%2520of%2520trastuzumab%2520with%2520chemotherapeutic%2520drugs%2520used%2520in%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2004%26volume%3D96%26spage%3D739%26epage%3D749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Shepard, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarup, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendly, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maneval, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mordenti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figari, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotts, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palladino, M. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic</span> <span class="citation_source-journal">J. Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1007%2FBF00918679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=1679763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADyaK3MXmsFent7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1991&pages=117-127&author=H.+M.+Shepardauthor=G.+D.+Lewisauthor=J.+C.+Sarupauthor=B.+M.+Fendlyauthor=D.+Manevalauthor=J.+Mordentiauthor=I.+Figariauthor=C.+E.+Kottsauthor=M.+A.+Palladinoauthor=A.+Ullrich&title=Monoclonal+antibody+therapy+of+human+cancer%3A+taking+the+HER2+protooncogene+to+the+clinic"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Monoclonal antibody therapy of human cancer:  taking the HER2 protooncogene to the clinic</span></div><div class="casAuthors">Shepard, H. Michael; Lewis, Gail D.; Sarup, Jay C.; Fendly, Brian M.; Maneval, Daniel; Mordenti, Joyce; Figari, Irene; Kotts, Claire E.; Palladino, Michael A., Jr.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Immunology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">117-27</span>CODEN:
                <span class="NLM_cas:coden">JCIMDO</span>;
        ISSN:<span class="NLM_cas:issn">0271-9142</span>.
    </div><div class="casAbstract">A review, with 35 refs., on: the HER2 protoncogene and human cancer; derivation of muMAb 4D5; in vivo preclin. efficacy; and mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE9uMsOqiof7Vg90H21EOLACvtfcHk0lj4TLVGyIEmjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmsFent7w%253D&md5=8c323a0c6d081fc00a2b3328a8711f75</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2FBF00918679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00918679%26sid%3Dliteratum%253Aachs%26aulast%3DShepard%26aufirst%3DH.%2BM.%26aulast%3DLewis%26aufirst%3DG.%2BD.%26aulast%3DSarup%26aufirst%3DJ.%2BC.%26aulast%3DFendly%26aufirst%3DB.%2BM.%26aulast%3DManeval%26aufirst%3DD.%26aulast%3DMordenti%26aufirst%3DJ.%26aulast%3DFigari%26aufirst%3DI.%26aulast%3DKotts%26aufirst%3DC.%2BE.%26aulast%3DPalladino%26aufirst%3DM.%2BA.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DMonoclonal%2520antibody%2520therapy%2520of%2520human%2520cancer%253A%2520taking%2520the%2520HER2%2520protooncogene%2520to%2520the%2520clinic%26jtitle%3DJ.%2520Clin.%2520Immunol.%26date%3D1991%26volume%3D11%26spage%3D117%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Spector, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwell, K. L.</span><span> </span><span class="NLM_article-title">Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">5838</span><span class="NLM_x">–</span> <span class="NLM_lpage">5847</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1200%2FJCO.2009.22.1507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=19884552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVWitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=5838-5847&author=N.+L.+Spectorauthor=K.+L.+Blackwell&title=Understanding+the+mechanisms+behind+trastuzumab+therapy+for+human+epidermal+growth+factor+receptor+2-positive+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer</span></div><div class="casAuthors">Spector, Neil L.; Blackwell, Kimberly L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">5838-5847</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Purpose: Targeted therapy with the humanized monoclonal antibody trastuzumab has become a mainstay for human epidermal growth factor receptor 2 (HER2) -pos. breast cancer (BC).  The mechanisms of action of trastuzumab have not been fully elucidated, and data available to date are reviewed here.  The impact of the mechanisms of action on clin. benefit also is discussed.  Methods: An extensive literature review of trastuzumab and proposed mechanisms of action was performed.  Results: At least five potential extracellular and intracellular antitumor mechanisms of trastuzumab have been identified in the preclin. setting.  These include activation of antibody-dependent cellular cytotoxicity, inhibition of extracellular domain cleavage, abrogation of intracellular signaling, redn. of angiogenesis, and decreased DNA repair.  These effects lead to tumor cell stasis and/or death.  Clin. benefit from trastuzumab-based therapy in both early and advanced BC has been demonstrated.  The benefit of trastuzumab use beyond progression has also been shown, which indicates the need for continuous suppression of the HER2 pathway.  Targeting both HER2, with various approaches, and other pathways may enhance the clin. benefit obsd. with trastuzumab and overcome potential resistance.  Novel combinations include pertuzumab (a HER2 dimerization inhibitor), lapatinib (a HER1/HER2 tyrosine kinase inhibitor), bevacizumab (an antiangiogenic agent), tanespimycin (a heat shock protein inhibitor), antiestrogen therapies, and an antibody-drug conjugate (trastuzumab-DM1).  Conclusion: Trastuzumab is the foundation of care for patients with HER2-pos. BC.  Emerging data from studies of other targeted agents may provide alternative treatment combinations to maximize the clin. benefit from trastuzumab and prevent or delay resistance.  The continued development of trastuzumab highlights promising treatment approaches for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUKW7T01USzrVg90H21EOLACvtfcHk0lj4TLVGyIEmjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVWitro%253D&md5=d54f228c3b69c973238fb1279ee8572d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.22.1507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.22.1507%26sid%3Dliteratum%253Aachs%26aulast%3DSpector%26aufirst%3DN.%2BL.%26aulast%3DBlackwell%26aufirst%3DK.%2BL.%26atitle%3DUnderstanding%2520the%2520mechanisms%2520behind%2520trastuzumab%2520therapy%2520for%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202-positive%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D5838%26epage%3D5847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leyland-Jones, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paton, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajamonde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span> </span><span class="NLM_article-title">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">783</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1056%2FNEJM200103153441101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=11248153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVGktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=783-792&author=D.+J.+Slamonauthor=B.+Leyland-Jonesauthor=S.+Shakauthor=H.+Fuchsauthor=V.+Patonauthor=A.+Bajamondeauthor=T.+Flemingauthor=W.+Eiermannauthor=J.+Wolterauthor=M.+Pegramauthor=J.+Baselgaauthor=L.+Norton&title=Use+of+chemotherapy+plus+a+monoclonal+antibody+against+HER2+for+metastatic+breast+cancer+that+overexpresses+HER2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span></div><div class="casAuthors">Slamon, Dennis J.; Leyland-Jones, Brian; Shak, Steven; Fuchs, Hank; Paton, Virginia; Bajamonde, Alex; Fleming, Thomas; Eiermann, Wolfgang; Wolter, Janet; Pegram, Mark; Baselga, Jose; Norton, Larry</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">783-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 % of breast cancers, increasing the aggressiveness of the tumor.  We evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody against HER2, in women with metastatic breast cancer that overexpressed HER2.  We randomly assigned 234 patients to receive std. chemotherapy plus trastuzumab.  Patients who had not previously received adjuvant (postoperative) therapy with an anthracycline were treated with doxorubicin (or epirubicin in the case of 36 women) and cyclophosphamide with (143 women) or without trastuzumab (138 women).  Patients who had previously received adjuvant anthracycline were treated with paclitaxel alone (96 women) or paclitaxel with trastuzumab (92 women).  The addn. of trastuzumab to chemotherapy was assocd. with a longer time to disease progression (median, 7.4 vs. 4.6 mo; P<0.001), a higher rate of objective response (50 % vs. 32 %, P<0.001), a longer duration of response (median, 9.1 vs. 6.1 mo; P<0.001), a lower rate of death at 1 yr (22 % vs. 33 %, P=0.008), longer survival (median survival, 25.1 vs. 20.3 mo; P=0.046), and a 20 % redn. in the risk of death.  The most important adverse event was cardiac dysfunction, which occurred in 27 % of the group given an anthracycline, cyclophosphamide, and trastuzumab; 8 % of the group given an anthracycline and cyclophosphamide alone; 13 % of the group given paclitaxel and trastuzumab; and 1 % of the group given paclitaxel alone.  Although the cardiotoxicity was potentially severe and, in some cases, life-threatening, the symptoms generally improved with std. medical management.  Trastuzumab increases the clin. benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGK_4WWRZLKLVg90H21EOLACvtfcHk0lhj47clsgYEBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVGktrc%253D&md5=81112f11ffc66fc3a898b61e104322b6</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJM200103153441101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200103153441101%26sid%3Dliteratum%253Aachs%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DLeyland-Jones%26aufirst%3DB.%26aulast%3DShak%26aufirst%3DS.%26aulast%3DFuchs%26aufirst%3DH.%26aulast%3DPaton%26aufirst%3DV.%26aulast%3DBajamonde%26aufirst%3DA.%26aulast%3DFleming%26aufirst%3DT.%26aulast%3DEiermann%26aufirst%3DW.%26aulast%3DWolter%26aufirst%3DJ.%26aulast%3DPegram%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DNorton%26aufirst%3DL.%26atitle%3DUse%2520of%2520chemotherapy%2520plus%2520a%2520monoclonal%2520antibody%2520against%2520HER2%2520for%2520metastatic%2520breast%2520cancer%2520that%2520overexpresses%2520HER2%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D783%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Nahta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteva, F. J.</span><span> </span><span class="NLM_article-title">HER-2-targeted therapy: lessons learned and future directions</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">5078</span><span class="NLM_x">–</span> <span class="NLM_lpage">5084</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=14613984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVOgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=5078-5084&author=R.+Nahtaauthor=F.+J.+Esteva&title=HER-2-targeted+therapy%3A+lessons+learned+and+future+directions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">HER-2-Targeted Therapy: Lessons Learned and Future Directions</span></div><div class="casAuthors">Nahta, Rita; Esteva, Francisco J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5078-5084</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  HER-2 is overexpressed in 20-25% of invasive breast cancers and is assocd. with an aggressive tumor phenotype and reduced survival rates.  The HER-2 status of a tumor is the crit. determinant of response to the HER-2-targeted antibody trastuzumab.  Thus, accurate assessment of HER-2 expression levels is essential for identifying breast cancer patients who will benefit from HER-2-targeted therapy.  Trastuzumab combined with chemotherapy increases response rates, time to progression, and survival.  However, the majority of cancers that initially respond to trastuzumab begin to progress again within 1 yr.  This minireview describes HER-2 targeting strategies currently in use or in stages of development for the treatment of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaJ78rVpE6ybVg90H21EOLACvtfcHk0lhj47clsgYEBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVOgtb4%253D&md5=0c48944fbc257ee35c8197d04b31595f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNahta%26aufirst%3DR.%26aulast%3DEsteva%26aufirst%3DF.%2BJ.%26atitle%3DHER-2-targeted%2520therapy%253A%2520lessons%2520learned%2520and%2520future%2520directions%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D5078%26epage%3D5084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Metzger-Filho, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I.</span><span> </span><span class="NLM_article-title">Pertuzumab: optimizing HER2 blockade</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5552</span><span class="NLM_x">–</span> <span class="NLM_lpage">5556</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1158%2F1078-0432.CCR-13-0518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=23942091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ahurzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=5552-5556&author=O.+Metzger-Filhoauthor=E.+P.+Winerauthor=I.+Krop&title=Pertuzumab%3A+optimizing+HER2+blockade"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Pertuzumab: Optimizing HER2 Blockade</span></div><div class="casAuthors">Metzger-Filho, Otto; Winer, Eric P.; Krop, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5552-5556</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Pertuzumab has been approved by the U.S. Food and Drug Administration for use in combination with trastuzumab and docetaxel for the first-line treatment of patients with advanced HER2-pos. (HER2+) breast cancer.  Pertuzumab is a recombinant humanized monoclonal antibody that binds to the extracellular dimerization domain II of HER2 and inhibits heterodimerization of HER2 with other HER family members, including EGF receptor (EGFR), HER3, and HER4.  The HER2-HER3 heterodimer is a robust activator of phosphoinositide 3-kinase (PI3K) pathway signaling and functions as the most transforming and mitogenic of the receptor complexes formed by the HER family of proteins; thus, blockade of HER2-HER3 likely represents the most relevant action of pertuzumab.  In the seminal phase III study, patients with HER2+ metastatic breast cancer were randomized to receive trastuzumab and docetaxel, with or without pertuzumab: Addn. of pertuzumab significantly prolonged progression-free survival with an increase of 6.1 mo (12.4 vs. 18.5 mo, resp.).  In a subsequent anal. with 30 mo of median follow-up, pertuzumab conferred a 34% redn. in the risk of mortality.  Here, we review the mechanism of action of pertuzumab, the rationale for combining it with trastuzumab/pertuzumab, clin. data, and future directions for this work.  Clin Cancer Res; 19(20); 5552-6. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo90EvFOonkWrVg90H21EOLACvtfcHk0lhj47clsgYEBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ahurzK&md5=a72443fe22216b25ad4b438bd604f44e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0518%26sid%3Dliteratum%253Aachs%26aulast%3DMetzger-Filho%26aufirst%3DO.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DKrop%26aufirst%3DI.%26atitle%3DPertuzumab%253A%2520optimizing%2520HER2%2520blockade%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D5552%26epage%3D5556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W. C.</span><span> </span><span class="NLM_article-title">Antibody–drug conjugates: an emerging concept in cancer therapy</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3796</span><span class="NLM_x">–</span> <span class="NLM_lpage">3827</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=3796-3827&author=R.+V.+Chariauthor=M.+L.+Millerauthor=W.+C.+Widdison&title=Antibody%E2%80%93drug+conjugates%3A+an+emerging+concept+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26atitle%3DAntibody%25E2%2580%2593drug%2520conjugates%253A%2520an%2520emerging%2520concept%2520in%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D3796%26epage%3D3827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Blattler, W. A.; Chari, R. V. J.</span><span> </span><span class="NLM_article-title">Methods of treatment using anti-ERBB antibody–maytansinoid conjugates</span>. U.S. Patent 8,337,856,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=W.+A.+Blattler&author=R.+V.+J.+Chari&title=Methods+of+treatment+using+anti-ERBB+antibody%E2%80%93maytansinoid+conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26atitle%3DMethods%2520of%2520treatment%2520using%2520anti-ERBB%2520antibody%25E2%2580%2593maytansinoid%2520conjugates%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Sedlacek, H. H.</span> <span class="citation_source-book">Antibodies as Carriers of Cytotoxicity</span>; <span class="NLM_publisher-name">Karger</span>: <span class="NLM_publisher-loc">Basel, Switzerland</span>,<span class="NLM_x"> </span><span class="NLM_year">1992</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&pages=1-145&author=H.+H.+Sedlacek&title=Antibodies+as+Carriers+of+Cytotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSedlacek%26aufirst%3DH.%2BH.%26btitle%3DAntibodies%2520as%2520Carriers%2520of%2520Cytotoxicity%26pub%3DKarger%26date%3D1992%26spage%3D1%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Chari Ravi, V. J.</span><span> </span><span class="NLM_article-title">Targeted cancer therapy: conferring specificity to cytotoxic drugs</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=98-107&author=V.+J.+Chari+Ravi&title=Targeted+cancer+therapy%3A+conferring+specificity+to+cytotoxic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChari%2BRavi%26aufirst%3DV.%2BJ.%26atitle%3DTargeted%2520cancer%2520therapy%253A%2520conferring%2520specificity%2520to%2520cytotoxic%2520drugs%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D98%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Kupchan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komoda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branfman, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sneden, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Court, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hintz, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howie, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dailey, R. G.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerly, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumner, W. C.,  Jr.</span><span> </span><span class="NLM_article-title">The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">2349</span><span class="NLM_x">–</span> <span class="NLM_lpage">2357</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00434a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1977&pages=2349-2357&author=S.+M.+Kupchanauthor=Y.+Komodaauthor=A.+R.+Branfmanauthor=A.+T.+Snedenauthor=W.+A.+Courtauthor=G.+J.+Thomasauthor=H.+P.+Hintzauthor=R.+M.+Smithauthor=A.+Karimauthor=G.+A.+Howieauthor=A.+K.+Vermaauthor=Y.+Nagaoauthor=R.+G.+Daileyauthor=V.+A.+Zimmerlyauthor=W.+C.+Sumner&title=The+maytansinoids.+Isolation%2C+structural+elucidation%2C+and+chemical+interrelation+of+novel+ansa+macrolides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjo00434a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00434a001%26sid%3Dliteratum%253Aachs%26aulast%3DKupchan%26aufirst%3DS.%2BM.%26aulast%3DKomoda%26aufirst%3DY.%26aulast%3DBranfman%26aufirst%3DA.%2BR.%26aulast%3DSneden%26aufirst%3DA.%2BT.%26aulast%3DCourt%26aufirst%3DW.%2BA.%26aulast%3DThomas%26aufirst%3DG.%2BJ.%26aulast%3DHintz%26aufirst%3DH.%2BP.%26aulast%3DSmith%26aufirst%3DR.%2BM.%26aulast%3DKarim%26aufirst%3DA.%26aulast%3DHowie%26aufirst%3DG.%2BA.%26aulast%3DVerma%26aufirst%3DA.%2BK.%26aulast%3DNagao%26aufirst%3DY.%26aulast%3DDailey%26aufirst%3DR.%2BG.%26aulast%3DZimmerly%26aufirst%3DV.%2BA.%26aulast%3DSumner%26aufirst%3DW.%2BC.%26atitle%3DThe%2520maytansinoids.%2520Isolation%252C%2520structural%2520elucidation%252C%2520and%2520chemical%2520interrelation%2520of%2520novel%2520ansa%2520macrolides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1977%26volume%3D42%26spage%3D2349%26epage%3D2357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Widdison, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavanagh, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leece, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovtun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeves, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span> </span><span class="NLM_article-title">Semisynthetic maytansine analogues for the targeted treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4392</span><span class="NLM_x">–</span> <span class="NLM_lpage">4408</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060319f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFent7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4392-4408&author=W.+C.+Widdisonauthor=S.+D.+Wilhelmauthor=E.+E.+Cavanaghauthor=K.+R.+Whitemanauthor=B.+A.+Leeceauthor=Y.+Kovtunauthor=V.+S.+Goldmacherauthor=H.+Xieauthor=R.+M.+Steevesauthor=R.+J.+Lutzauthor=R.+Zhaoauthor=L.+Wangauthor=W.+A.+Blattlerauthor=R.+V.+Chari&title=Semisynthetic+maytansine+analogues+for+the+targeted+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Semisynthetic Maytansine Analogs for the Targeted Treatment of Cancer</span></div><div class="casAuthors">Widdison, Wayne C.; Wilhelm, Sharon D.; Cavanagh, Emily E.; Whiteman, Kathleen R.; Leece, Barbara A.; Kovtun, Yelena; Goldmacher, Victor S.; Xie, Hongsheng; Steeves, Rita M.; Lutz, Robert J.; Zhao, Robert; Wang, Lintao; Blaettler, Walter A.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4392-4408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clin. trials because of unacceptable systemic toxicity.  The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells.  A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized.  The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied.  Several of these maytansinoids were found to be even more potent in vitro than maytansine.  The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozfQO-pe0iJLVg90H21EOLACvtfcHk0lgpoRJa0sIpoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFent7o%253D&md5=a06c19d2d5166b0ca806babf9624c48b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm060319f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060319f%26sid%3Dliteratum%253Aachs%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DWilhelm%26aufirst%3DS.%2BD.%26aulast%3DCavanagh%26aufirst%3DE.%2BE.%26aulast%3DWhiteman%26aufirst%3DK.%2BR.%26aulast%3DLeece%26aufirst%3DB.%2BA.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DSteeves%26aufirst%3DR.%2BM.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DSemisynthetic%2520maytansine%2520analogues%2520for%2520the%2520targeted%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4392%26epage%3D4408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Issell, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crooke, S. T.</span><span> </span><span class="NLM_article-title">Maytansine</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1016%2FS0305-7372%2878%2980014-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=367597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A280%3ADyaE1M7gsFektw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1978&pages=199-207&author=B.+F.+Issellauthor=S.+T.+Crooke&title=Maytansine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Maytansine</span></div><div class="casAuthors">Issell B F; Crooke S T</div><div class="citationInfo"><span class="NLM_cas:title">Cancer treatment reviews</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">199-207</span>
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQuFvddg8VPVMve_zCu79I8fW6udTcc2eaUdEHwFcK5Brntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE1M7gsFektw%253D%253D&md5=73ec733c0581edc2085d87aa26291f26</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS0305-7372%2878%2980014-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0305-7372%252878%252980014-0%26sid%3Dliteratum%253Aachs%26aulast%3DIssell%26aufirst%3DB.%2BF.%26aulast%3DCrooke%26aufirst%3DS.%2BT.%26atitle%3DMaytansine%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D1978%26volume%3D5%26spage%3D199%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Kupchan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sneden, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branfman, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howie, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebhun, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIvor, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnaitman, T. C.</span><span> </span><span class="NLM_article-title">Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00199a006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1978&pages=31-37&author=S.+M.+Kupchanauthor=A.+T.+Snedenauthor=A.+R.+Branfmanauthor=G.+A.+Howieauthor=L.+I.+Rebhunauthor=W.+E.+McIvorauthor=R.+W.+Wangauthor=T.+C.+Schnaitman&title=Structural+requirements+for+antileukemic+activity+among+the+naturally+occurring+and+semisynthetic+maytansinoids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm00199a006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00199a006%26sid%3Dliteratum%253Aachs%26aulast%3DKupchan%26aufirst%3DS.%2BM.%26aulast%3DSneden%26aufirst%3DA.%2BT.%26aulast%3DBranfman%26aufirst%3DA.%2BR.%26aulast%3DHowie%26aufirst%3DG.%2BA.%26aulast%3DRebhun%26aufirst%3DL.%2BI.%26aulast%3DMcIvor%26aufirst%3DW.%2BE.%26aulast%3DWang%26aufirst%3DR.%2BW.%26aulast%3DSchnaitman%26aufirst%3DT.%2BC.%26atitle%3DStructural%2520requirements%2520for%2520antileukemic%2520activity%2520among%2520the%2520naturally%2520occurring%2520and%2520semisynthetic%2520maytansinoids%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1978%26volume%3D21%26spage%3D31%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martell, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenzie, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span> </span><span class="NLM_article-title">Immunoconjugates containing novel maytansinoids: promising anticancer drugs</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">131</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=1727373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADyaK38Xht1Snu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1992&pages=127-131&author=R.+V.+Chariauthor=B.+A.+Martellauthor=J.+L.+Grossauthor=S.+B.+Cookauthor=S.+A.+Shahauthor=W.+A.+Blattlerauthor=S.+J.+McKenzieauthor=V.+S.+Goldmacher&title=Immunoconjugates+containing+novel+maytansinoids%3A+promising+anticancer+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoconjugates containing novel maytansinoids:  promising anticancer drugs</span></div><div class="casAuthors">Chari, Ravi V. J.; Martell, Bridget A.; Gross, Jonathan L.; Cook, Sherrilyn B.; Shah, Sudhir A.; Blattler, Walter A.; McKenzie, Sara J.; Goldmacher, Victor S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-31</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">The potential of immunoconjugates of cytotoxic drugs for the treatment of cancer has not yet been realized owing to the difficulty of delivering therapeutic concns. of these drugs to the target cells.  In an effort to overcome this problem the authors have synthesized maytansinoids that have 100- to 1000-fold higher cytotoxic potency than clin. used anticancer drugs.  These maytansinoids are linked to antibodies via disulfide bonds, which ensures the release of fully active drug inside the cells.  The conjugates show high antigen-specific cytotoxicity for cultured human cancer cells (50% inhibiting concn., 10 to 40 pM), low systemic toxicity in mice, and good pharmacokinetic behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9PfQvlOYozLVg90H21EOLACvtfcHk0lhs8VhDa8sHAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xht1Snu7s%253D&md5=33e7613da2a71800fc13e0b2bc6e21f1</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DMartell%26aufirst%3DB.%2BA.%26aulast%3DGross%26aufirst%3DJ.%2BL.%26aulast%3DCook%26aufirst%3DS.%2BB.%26aulast%3DShah%26aufirst%3DS.%2BA.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DMcKenzie%26aufirst%3DS.%2BJ.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26atitle%3DImmunoconjugates%2520containing%2520novel%2520maytansinoids%253A%2520promising%2520anticancer%2520drugs%26jtitle%3DCancer%2520Res.%26date%3D1992%26volume%3D52%26spage%3D127%26epage%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Kellogg, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovtun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leece, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeves, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span> </span><span class="NLM_article-title">Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">717</span><span class="NLM_x">–</span> <span class="NLM_lpage">727</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc100480a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFKnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=717-727&author=B.+A.+Kelloggauthor=L.+Garrettauthor=Y.+Kovtunauthor=K.+C.+Laiauthor=B.+Leeceauthor=M.+Millerauthor=G.+Payneauthor=R.+Steevesauthor=K.+R.+Whitemanauthor=W.+Widdisonauthor=H.+Xieauthor=R.+Singhauthor=R.+V.+Chariauthor=J.+M.+Lambertauthor=R.+J.+Lutz&title=Disulfide-linked+antibody-maytansinoid+conjugates%3A+optimization+of+in+vivo+activity+by+varying+the+steric+hindrance+at+carbon+atoms+adjacent+to+the+disulfide+linkage"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage</span></div><div class="casAuthors">Kellogg, Brenda A.; Garrett, Lisa; Kovtun, Yelena; Lai, Katharine C.; Leece, Barbara; Miller, Michael; Payne, Gillian; Steeves, Rita; Whiteman, Kathleen R.; Widdison, Wayne; Xie, Hongsheng; Singh, Rajeeva; Chari, Ravi V. J.; Lambert, John M.; Lutz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">717-727</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this report, we describe the synthesis of a panel of disulfide-linked huC242 (anti-CanAg) antibody maytansinoid conjugates (AMCs), which have varying levels of steric hindrance around the disulfide bond, in order to investigate the relationship between stability to redn. of the disulfide linker and antitumor activity of the conjugate in vivo.  The conjugates were first tested for stability to redn. by dithiothreitol in vitro and for plasma stability in CD1 mice.  It was found that the conjugates having the more sterically hindered disulfide linkages were more stable to reductive cleavage of the maytansinoid in both settings.  When the panel of conjugates was tested for in vivo efficacy in two human colon cancer xenograft models in SCID mice, it was found that the conjugate with intermediate disulfide bond stability having two Me groups on the maytansinoid side of the disulfide bond and no Me groups on the linker side of the disulfide bond (huC242-SPDB-DM4) displayed the best efficacy.  The ranking of in vivo efficacies of the conjugates was not predicted by their in vitro potencies, since all conjugates were highly active in vitro, including a huC242-SMCC-DM1 conjugate with a noncleavable linkage which showed only marginal activity in vivo.  These data suggest that factors in addn. to intrinsic conjugate potency and conjugate half-life in plasma influence the magnitude of antitumor activity obsd. for an AMC in vivo.  We provide evidence that bystander killing of neighboring nontargeted tumor cells by diffusible cytotoxic metabolites produced from target cell processing of disulfide-linked antibody-maytansinoid conjugates may be one addnl. factor contributing to the activity of these conjugates in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGmGw-cH238bVg90H21EOLACvtfcHk0lhs8VhDa8sHAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFKnsro%253D&md5=ef2969ceaaea23e81da2edf06f62ea7e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fbc100480a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc100480a%26sid%3Dliteratum%253Aachs%26aulast%3DKellogg%26aufirst%3DB.%2BA.%26aulast%3DGarrett%26aufirst%3DL.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DK.%2BC.%26aulast%3DLeece%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DPayne%26aufirst%3DG.%26aulast%3DSteeves%26aufirst%3DR.%26aulast%3DWhiteman%26aufirst%3DK.%2BR.%26aulast%3DWiddison%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26atitle%3DDisulfide-linked%2520antibody-maytansinoid%2520conjugates%253A%2520optimization%2520of%2520in%2520vivo%2520activity%2520by%2520varying%2520the%2520steric%2520hindrance%2520at%2520carbon%2520atoms%2520adjacent%2520to%2520the%2520disulfide%2520linkage%26jtitle%3DBioconjugate%2520Chem.%26date%3D2011%26volume%3D22%26spage%3D717%26epage%3D727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Wakankar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gokarn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, F. S.</span><span> </span><span class="NLM_article-title">Analytical methods for physicochemical characterization of antibody drug conjugates</span> <span class="citation_source-journal">mAbs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=161-172&author=A.+Wakankarauthor=Y.+Chenauthor=Y.+Gokarnauthor=F.+S.+Jacobson&title=Analytical+methods+for+physicochemical+characterization+of+antibody+drug+conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakankar%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGokarn%26aufirst%3DY.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26atitle%3DAnalytical%2520methods%2520for%2520physicochemical%2520characterization%2520of%2520antibody%2520drug%2520conjugates%26jtitle%3DmAbs%26date%3D2011%26volume%3D3%26spage%3D161%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Wakankar, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. J.</span><span> </span><span class="NLM_article-title">Physicochemical stability of the antibody–drug conjugate trastuzumab-DM1: changes due to modification and conjugation processes</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1588</span><span class="NLM_x">–</span> <span class="NLM_lpage">1595</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc900434c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=1588-1595&author=A.+A.+Wakankarauthor=M.+B.+Feeneyauthor=J.+Riveraauthor=Y.+Chenauthor=M.+Kimauthor=V.+K.+Sharmaauthor=Y.+J.+Wang&title=Physicochemical+stability+of+the+antibody%E2%80%93drug+conjugate+trastuzumab-DM1%3A+changes+due+to+modification+and+conjugation+processes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical Stability of the Antibody-Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation Processes</span></div><div class="casAuthors">Wakankar, Aditya A.; Feeney, Maria B.; Rivera, Javier; Chen, Yan; Kim, Michael; Sharma, Vikas K.; Wang, Y. John</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1588-1595</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the manuf. of the antibody-drug conjugate Trastuzumab-DM1 (T-DM1), the lysine residues on the antibody trastuzumab (Tmab) are modified to form the intermediate Tmab-MCC (T-MCC) and then conjugated with the drug DM1.  Our goal is to understand the effects of modification and conjugation steps on the physicochem. stability of the antibody.  The structural stability of Tmab relative to its modified and conjugated forms was assessed, employing thermally induced stress conditions to formulations contg. Tmab, T-MCC, and T-DM1.  DSC, SEC, CE-SDS, and LC-MS were used to study the stability of Tmab, T-MCC, and T-DM1 to thermal stress.  The DSC thermograms show a decrease in melting temp. for the CH2 transition, in the order Tmab > T-MCC > T-DM1.  As per SEC anal., a significant increase in level of aggregation was detected in T-MCC (∼32%) and T-DM1 (∼5%) after 14 days at 40°.  Tmab did not show significant aggregate formation.  CE-SDS and LC-MS data demonstrate that the aggregation in the case of T-MCC is largely covalent and involves mechanisms other than formation of intermol. disulfide crosslinks.  The aggregation obsd. for T-MCC was significantly inhibited upon addn. of amino acids with nucleophilic side chains contg. thiol (Cys) and hydroxyl moieties (Ser, Tyr).  The covalent aggregation obsd. for T-MCC and the ability of nucleophilic amino acids, particularly Cys, to inhibit it indicate that the maleimide moiety in the MCC linker may react to form intermol. covalent crosslinks between T-MCC mols., possibly through a Michael addn. mechanism.  In addn., DSC results demonstrate that the conjugation of the drug moiety DM1 to Tmab results in destabilization of the CH2 domain of the antibody.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoTooyTYRrPLVg90H21EOLACvtfcHk0lj2cyAay2t5ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyltbk%253D&md5=6c67fb904a35f97adfeb62ec69b7d4be</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fbc900434c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc900434c%26sid%3Dliteratum%253Aachs%26aulast%3DWakankar%26aufirst%3DA.%2BA.%26aulast%3DFeeney%26aufirst%3DM.%2BB.%26aulast%3DRivera%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DSharma%26aufirst%3DV.%2BK.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26atitle%3DPhysicochemical%2520stability%2520of%2520the%2520antibody%25E2%2580%2593drug%2520conjugate%2520trastuzumab-DM1%253A%2520changes%2520due%2520to%2520modification%2520and%2520conjugation%2520processes%26jtitle%3DBioconjugate%2520Chem.%26date%3D2010%26volume%3D21%26spage%3D1588%26epage%3D1595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwall, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenkare-Mitra, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9280</span><span class="NLM_x">–</span> <span class="NLM_lpage">9290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1158%2F0008-5472.CAN-08-1776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=19010901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9280-9290&author=G.+D.+Lewis+Phillipsauthor=G.+Liauthor=D.+L.+Duggerauthor=L.+M.+Crockerauthor=K.+L.+Parsonsauthor=E.+Maiauthor=W.+A.+Blattlerauthor=J.+M.+Lambertauthor=R.+V.+Chariauthor=R.+J.+Lutzauthor=W.+L.+Wongauthor=F.+S.+Jacobsonauthor=H.+Koeppenauthor=R.+H.+Schwallauthor=S.+R.+Kenkare-Mitraauthor=S.+D.+Spencerauthor=M.+X.+Sliwkowski&title=Targeting+HER2-positive+breast+cancer+with+trastuzumab-DM1%2C+an+antibody-cytotoxic+drug+conjugate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate</span></div><div class="casAuthors">Lewis Phillips, Gail D.; Li, Guangmin; Dugger, Debra L.; Crocker, Lisa M.; Parsons, Kathryn L.; Mai, Elaine; Blaettler, Walter A.; Lambert, John M.; Chari, Ravi V. J.; Lutz, Robert J.; Wong, Wai Lee T.; Jacobson, Frederic S.; Koeppen, Hartmut; Schwall, Ralph H.; Kenkare-Mitra, Sara R.; Spencer, Susan D.; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9280-9290</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER2 is a validated target in breast cancer therapy.  Two drugs are currently approved for HER2-pos. breast cancer: trastuzumab (Herceptin), introduced in 1998, and lapatinib (Tykerb), in 2007.  Despite these advances, some patients progress through therapy and succumb to their disease.  A variation on antibody-targeted therapy is utilization of antibodies to deliver cytotoxic agents specifically to antigen-expressing tumors.  We detd. in vitro and in vivo efficacy, pharmacokinetics, and toxicity of trastuzumab-maytansinoid (microtubule-depolymg. agents) conjugates using disulfide and thioether linkers.  Antiproliferative effects of trastuzumab-maytansinoid conjugates were evaluated on cultured normal and tumor cells.  In vivo activity was detd. in mouse breast cancer models, and toxicity was assessed in rats as measured by body wt. loss.  Surprisingly, trastuzumab linked to DM1 through a nonreducible thioether linkage (SMCC), displayed superior activity compared with unconjugated trastuzumab or trastuzumab linked to other maytansinoids through disulfide linkers.  Serum concns. of trastuzumab-MCC-DM1 remained elevated compared with other conjugates, and toxicity in rats was negligible compared with free DM1 or trastuzumab linked to DM1 through a reducible linker.  Potent activity was obsd. on all HER2-overexpressing tumor cells, whereas nontransformed cells and tumor cell lines with normal HER2 expression were unaffected.  In addn., trastuzumab-DM1 was active on HER2-overexpressing, trastuzumab-refractory tumors.  In summary, trastuzumab-DM1 shows greater activity compared with nonconjugated trastuzumab while maintaining selectivity for HER2-overexpressing tumor cells.  Because trastuzumab linked to DM1 through a nonreducible linker offers improved efficacy and pharmacokinetics and reduced toxicity over the reducible disulfide linkers evaluated, trastuzumab-MCC-DM1 was selected for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpP5fkJnRorrVg90H21EOLACvtfcHk0lj2cyAay2t5ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK&md5=e86e8687d5f8884f8e28514299dcbbf1</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1776%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DSchwall%26aufirst%3DR.%2BH.%26aulast%3DKenkare-Mitra%26aufirst%3DS.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTargeting%2520HER2-positive%2520breast%2520cancer%2520with%2520trastuzumab-DM1%252C%2520an%2520antibody-cytotoxic%2520drug%2520conjugate%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9280%26epage%3D9290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Erickson, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leipold, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Provenzano, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audette, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span> </span><span class="NLM_article-title">The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1133</span><span class="NLM_x">–</span> <span class="NLM_lpage">1142</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1158%2F1535-7163.MCT-11-0727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=22408268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1yrtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1133-1142&author=H.+K.+Ericksonauthor=G.+D.+Lewis+Phillipsauthor=D.+D.+Leipoldauthor=C.+A.+Provenzanoauthor=E.+Maiauthor=H.+A.+Johnsonauthor=B.+Gunterauthor=C.+A.+Audetteauthor=M.+Guptaauthor=J.+Pinkasauthor=J.+Tibbitts&title=The+effect+of+different+linkers+on+target+cell+catabolism+and+pharmacokinetics%2Fpharmacodynamics+of+trastuzumab+maytansinoid+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates</span></div><div class="casAuthors">Erickson, Hans K.; Lewis Phillips, Gail D.; Leipold, Douglas D.; Provenzano, Carmela A.; Mai, Elaine; Johnson, Holly A.; Gunter, Bert; Audette, Charlene A.; Gupta, Manish; Pinkas, Jan; Tibbitts, Jay</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1133-1142</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate consisting of the anti-HER2 antibody trastuzumab linked via a nonreducible thioether linker to the maytansinoid antitubulin agent DM1.  T-DM1 has shown favorable safety and efficacy in patients with HER2-pos. metastatic breast cancer.  In previous animal studies, T-DM1 exhibited better pharmacokinetics (PK) and slightly more efficacy than several disulfide-linked versions.  The efficacy findings are unique, as other disulfide-linked antibody-drug conjugates (ADC) have shown greater efficacy than thioether-linked designs.  To explore this further, the in vitro and in vivo activity, PK, and target cell activation of T-DM1 and the disulfide-linked T-SPP-DM1 were examd.  Both ADCs showed high in vitro potency, with T-DM1 displaying greater potency in two of four breast cancer cell lines.  In vitro target cell processing of T-DM1 and T-SPP-DM1 produced lysine-N.vepsiln.-MCC-DM1, and lysine-N.vepsiln.-SPP-DM1 and DM1, resp.; in vivo studies confirmed these results.  The in vitro processing rates for the two conjugate to their resp. catabolites were similar.  In vivo, the potencies of the conjugates were similar, and T-SPP-DM1 had a faster plasma clearance than T-DM1.  Slower T-DM1 clearance translated to higher overall tumor concns. (conjugate plus catabolites), but unexpectedly, similar levels of tumor catabolite.  These results indicate that, although the ADC linker can have clear impact on the PK and the chem. nature of the catabolites formed, both linkers seem to offer the same payload delivery to the tumor.  Mol Cancer Ther; 11(5); 1133-42.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoynXKVoEvq_7Vg90H21EOLACvtfcHk0lj2cyAay2t5ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1yrtLs%253D&md5=e7485e8164a5bf3210f6c68f174df112</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0727%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DH.%2BK.%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DProvenzano%26aufirst%3DC.%2BA.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DJohnson%26aufirst%3DH.%2BA.%26aulast%3DGunter%26aufirst%3DB.%26aulast%3DAudette%26aufirst%3DC.%2BA.%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DPinkas%26aufirst%3DJ.%26aulast%3DTibbitts%26aufirst%3DJ.%26atitle%3DThe%2520effect%2520of%2520different%2520linkers%2520on%2520target%2520cell%2520catabolism%2520and%2520pharmacokinetics%252Fpharmacodynamics%2520of%2520trastuzumab%2520maytansinoid%2520conjugates%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1133%26epage%3D1142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Junttila, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1007%2Fs10549-010-1090-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=20730488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnslehsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2011&pages=347-356&author=T.+T.+Junttilaauthor=G.+Liauthor=K.+Parsonsauthor=G.+L.+Phillipsauthor=M.+X.+Sliwkowski&title=Trastuzumab-DM1+%28T-DM1%29+retains+all+the+mechanisms+of+action+of+trastuzumab+and+efficiently+inhibits+growth+of+lapatinib+insensitive+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer</span></div><div class="casAuthors">Junttila, Teemu T.; Li, Guangmin; Parsons, Kathryn; Phillips, Gail Lewis; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">347-356</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Trastuzumab (Herceptin) is currently used as a treatment for patients whose breast tumors overexpress HER2/ErbB2.  Trastuzumab-DM1 (T-DM1, trastuzumab emtansine) is designed to combine the clin. benefits of trastuzumab with a potent microtubule-disrupting drug, DM1 (a maytansine deriv.).  Currently T-DM1 is being tested in multiple clin. trials.  The mechanisms of action for trastuzumab include inhibition of PI3K/AKT signaling pathway, inhibition of HER-2 shedding and Fcγ receptor mediated engagement of immune cells, which may result in antibody-dependent cellular cytotoxicity (ADCC).  Here we report that T-DM1 retains the mechanisms of action of unconjugated trastuzumab and is active against lapatinib resistant cell lines and tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_OYfy685E27Vg90H21EOLACvtfcHk0lhpfwQM0V2abQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnslehsbo%253D&md5=f3b04d9b9bb099007f338c619dd65f00</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs10549-010-1090-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-010-1090-x%26sid%3Dliteratum%253Aachs%26aulast%3DJunttila%26aufirst%3DT.%2BT.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DParsons%26aufirst%3DK.%26aulast%3DPhillips%26aufirst%3DG.%2BL.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTrastuzumab-DM1%2520%2528T-DM1%2529%2520retains%2520all%2520the%2520mechanisms%2520of%2520action%2520of%2520trastuzumab%2520and%2520efficiently%2520inhibits%2520growth%2520of%2520lapatinib%2520insensitive%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2011%26volume%3D128%26spage%3D347%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Barok, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koninki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isola, J.</span><span> </span><span class="NLM_article-title">Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">306</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1016%2Fj.canlet.2011.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=21458915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsV2nt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2011&pages=171-179&author=M.+Barokauthor=M.+Tannerauthor=K.+Koninkiauthor=J.+Isola&title=Trastuzumab-DM1+is+highly+effective+in+preclinical+models+of+HER2-positive+gastric+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer</span></div><div class="casAuthors">Barok, Mark; Tanner, Minna; Koeninki, Katri; Isola, Jorma</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-179</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: A novel antibody-drug conjugate (trastuzumab-DM1, T-DM1) is currently in clin. trials for patients with trastuzumab resistant HER2-pos. breast cancer.  Since no clin. data is available from gastric cancer, we studied T-DM1 on HER2-pos. human gastric cancer cells and xenograft tumors.  Methods: Effects of T-DM1 were studied in four HER2-pos. gastric cancer cell lines (N-87, OE-19, SNU-216 and MKN-7) in vitro.  Xenograft tumors from N-87 and OE-19 were studied to det. the effect of T-DM1 in vivo.  Results: T-DM1 was found more effective than trastuzumab in N-87 and OE-19, and moderately effective in MKN-7 cells.  On SNU-216 cells both trastuzumab and T-DM1 showed limited efficacy.  In xenograft tumor expts., complete pathol. response was obsd. in all OE-19 xenografted mice and in half of the N-87 xenografted mice.  The results were equally good irresp. of the tumor burden at therapy initiation, or preceding trastuzumab treatment.  T-DM1 treatment showed direct effects (apoptotic cell death and aberrant mitosis) as well as it mediated antibody-dependent cellular cytotoxcity (ADCC).  Conclusions: T-DM1 showed a promising anti-tumor effect in HER2-pos. gastric cancer cell lines in vitro and in vivo, even in tumors which had developed resistance to trastuzumab.  T-DM1 therapy may warrant clin. trials for HER2-pos. gastric cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi4stzIURpSrVg90H21EOLACvtfcHk0lhpfwQM0V2abQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsV2nt7k%253D&md5=b3c549e901da81d69ccdf85af4808310</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2011.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2011.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DBarok%26aufirst%3DM.%26aulast%3DTanner%26aufirst%3DM.%26aulast%3DKoninki%26aufirst%3DK.%26aulast%3DIsola%26aufirst%3DJ.%26atitle%3DTrastuzumab-DM1%2520is%2520highly%2520effective%2520in%2520preclinical%2520models%2520of%2520HER2-positive%2520gastric%2520cancer%26jtitle%3DCancer%2520Lett.%26date%3D2011%26volume%3D306%26spage%3D171%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Kovtun, Y. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audette, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ab, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellogg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span> </span><span class="NLM_article-title">Antibody–maytansinoid conjugates designed to bypass multidrug resistance</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">2528</span><span class="NLM_x">–</span> <span class="NLM_lpage">2537</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=2528-2537&author=Y.+V.+Kovtunauthor=C.+A.+Audetteauthor=M.+F.+Mayoauthor=G.+E.+Jonesauthor=H.+Dohertyauthor=E.+K.+Maloneyauthor=H.+K.+Ericksonauthor=X.+Sunauthor=S.+Wilhelmauthor=O.+Abauthor=K.+C.+Laiauthor=W.+C.+Widdisonauthor=B.+Kelloggauthor=H.+Johnsonauthor=J.+Pinkasauthor=R.+J.+Lutzauthor=R.+Singhauthor=V.+S.+Goldmacherauthor=R.+V.+Chari&title=Antibody%E2%80%93maytansinoid+conjugates+designed+to+bypass+multidrug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKovtun%26aufirst%3DY.%2BV.%26aulast%3DAudette%26aufirst%3DC.%2BA.%26aulast%3DMayo%26aufirst%3DM.%2BF.%26aulast%3DJones%26aufirst%3DG.%2BE.%26aulast%3DDoherty%26aufirst%3DH.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DErickson%26aufirst%3DH.%2BK.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DAb%26aufirst%3DO.%26aulast%3DLai%26aufirst%3DK.%2BC.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DKellogg%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DH.%26aulast%3DPinkas%26aufirst%3DJ.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DAntibody%25E2%2580%2593maytansinoid%2520conjugates%2520designed%2520to%2520bypass%2520multidrug%2520resistance%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D2528%26epage%3D2537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span> </span><span class="NLM_article-title">Role of multidrug resistance transporters in the biological response to trastuzumab–cytotoxic drug conjugates</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">Abstract 618</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=Abstract+618&issue=Suppl.+1&author=J.+Guoauthor=G.+Liauthor=G.+D.+Lewis+Phillips&title=Role+of+multidrug+resistance+transporters+in+the+biological+response+to+trastuzumab%E2%80%93cytotoxic+drug+conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26atitle%3DRole%2520of%2520multidrug%2520resistance%2520transporters%2520in%2520the%2520biological%2520response%2520to%2520trastuzumab%25E2%2580%2593cytotoxic%2520drug%2520conjugates%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26issue%3DSuppl.%25201%26spage%3DAbstract%2520618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Jumbe, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leipold, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielder, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span> </span><span class="NLM_article-title">Modeling the efficacy of trastuzumab–DM1, an antibody drug conjugate, in mice</span> <span class="citation_source-journal">J. Pharmacokinet. Pharmacodyn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1007%2Fs10928-010-9156-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=20424896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnslyktLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=221-242&author=N.+L.+Jumbeauthor=Y.+Xinauthor=D.+D.+Leipoldauthor=L.+Crockerauthor=D.+Duggerauthor=E.+Maiauthor=M.+X.+Sliwkowskiauthor=P.+J.+Fielderauthor=J.+Tibbitts&title=Modeling+the+efficacy+of+trastuzumab%E2%80%93DM1%2C+an+antibody+drug+conjugate%2C+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice</span></div><div class="casAuthors">Jumbe, Nelson L.; Xin, Yan; Leipold, Douglas D.; Crocker, Lisa; Dugger, Debra; Mai, Elaine; Sliwkowski, Mark X.; Fielder, Paul J.; Tibbitts, Jay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacokinetics and Pharmacodynamics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-242</span>CODEN:
                <span class="NLM_cas:coden">JPPOAH</span>;
        ISSN:<span class="NLM_cas:issn">1567-567X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Trastuzumab-DM1 (T-DM1) is a novel antibody-drug conjugate under investigation for the treatment of human epidermal growth factor receptor 2 (HER2)-pos. metastatic breast cancer.  One challenge in oncol. drug development is detg. the optimal dose and treatment schedule.  A novel dose regimen-finding strategy was developed for T-DM1 using exptl. data and pharmacokinetic/pharmacodynamic modeling.  To characterize the disposition of T-DM1, pharmacokinetic studies were conducted in athymic nude and beige nude mice.  The pharmacokinetics of T-DM1 were described well by a two-compartment model.  Tumor response data were obtained from single-dose, multiple-dose and time-dose-fractionation studies of T-DM1 in animal models of HER2-pos. breast cancer, specifically engineered to be insensitive to trastuzumab.  A sequential population-based pharmacokinetic/pharmacodynamic modeling approach was developed to describe the anti-tumor activity of T-DM1.  A cell-cycle-phase nonspecific tumor cell kill model incorporating transit compartments captured well the features of tumor growth and the activity of T-DM1.  Key findings of the model were that tumor cell growth rate played a significant role in the sensitivity of tumors to T-DM1; anti-tumor activity was schedule independent; and tumor response was linked to the ratio of exposure to a concn. required for tumor stasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbvgyQzzXl_7Vg90H21EOLACvtfcHk0lipPvMMcym1UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnslyktLw%253D&md5=28bac6e680530a3aeba7b44607669c8c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs10928-010-9156-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10928-010-9156-2%26sid%3Dliteratum%253Aachs%26aulast%3DJumbe%26aufirst%3DN.%2BL.%26aulast%3DXin%26aufirst%3DY.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DCrocker%26aufirst%3DL.%26aulast%3DDugger%26aufirst%3DD.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DFielder%26aufirst%3DP.%2BJ.%26aulast%3DTibbitts%26aufirst%3DJ.%26atitle%3DModeling%2520the%2520efficacy%2520of%2520trastuzumab%25E2%2580%2593DM1%252C%2520an%2520antibody%2520drug%2520conjugate%252C%2520in%2520mice%26jtitle%3DJ.%2520Pharmacokinet.%2520Pharmacodyn.%26date%3D2010%26volume%3D37%26spage%3D221%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dere, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrasco-Triguero, M.</span><span> </span><span class="NLM_article-title">Bioanalytical assay strategies for the development of antibody–drug conjugate biotherapeutics</span> <span class="citation_source-journal">Bioanalysis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">226</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=201-226&author=S.+Kaurauthor=K.+Xuauthor=O.+M.+Saadauthor=R.+C.+Dereauthor=M.+Carrasco-Triguero&title=Bioanalytical+assay+strategies+for+the+development+of+antibody%E2%80%93drug+conjugate+biotherapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DSaad%26aufirst%3DO.%2BM.%26aulast%3DDere%26aufirst%3DR.%2BC.%26aulast%3DCarrasco-Triguero%26aufirst%3DM.%26atitle%3DBioanalytical%2520assay%2520strategies%2520for%2520the%2520development%2520of%2520antibody%25E2%2580%2593drug%2520conjugate%2520biotherapeutics%26jtitle%3DBioanalysis%26date%3D2013%26volume%3D5%26spage%3D201%26epage%3D226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Poon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dybdal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, T.</span><span> </span><span class="NLM_article-title">Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability</span> <span class="citation_source-journal">Toxicol. Appl. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1016%2Fj.taap.2013.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=24035823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslGlsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=2013&pages=298-313&author=K.+A.+Poonauthor=K.+Flagellaauthor=J.+Beyerauthor=J.+Tibbittsauthor=S.+Kaurauthor=O.+Saadauthor=J.+H.+Yiauthor=S.+Girishauthor=N.+Dybdalauthor=T.+Reynolds&title=Preclinical+safety+profile+of+trastuzumab+emtansine+%28T-DM1%29%3A+mechanism+of+action+of+its+cytotoxic+component+retained+with+improved+tolerability"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability</span></div><div class="casAuthors">Poon, Kirsten Achilles; Flagella, Kelly; Beyer, Joseph; Tibbitts, Jay; Kaur, Surinder; Saad, Ola; Yi, Joo-Hee; Girish, Sandhya; Dybdal, Noel; Reynolds, Theresa</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">298-313</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is the first antibody-drug conjugate (ADC) approved for patients with human epidermal growth factor receptor 2 (HER2)-pos. metastatic breast cancer.  The therapeutic premise of ADCs is based on the hypothesis that targeted delivery of potent cytotoxic drugs to tumors will provide better tolerability and efficacy compared with non-targeted delivery, where poor tolerability can limit efficacious doses.  Here, we present results from preclin. studies characterizing the toxicity profile of T-DM1, including limited assessment of unconjugated DM1.  T-DM1 binds primate ErbB2 and human HER2 but not the rodent homolog c-neu.  Therefore, antigen-dependent and non-antigen-dependent toxicity was evaluated in monkeys and rats, resp., in both single- and repeat-dose studies; toxicity of DM1 was assessed in rats only.  T-DM1 was well tolerated at doses up to 40 mg/kg (~ 4400 μg DM1/m2) and 30 mg/kg (~ 6000 μg DM1/m2) in rats and monkeys, resp.  In contrast, DM1 was only tolerated up to 0.2 mg/kg (1600 μg DM1/m2).  This suggests that at least two-fold higher doses of the cytotoxic agent are tolerated in T-DM1, supporting the premise of ADCs to improve the therapeutic index.  In addn., T-DM1 and DM1 safety profiles were similar and consistent with the mechanism of action of DM1 (i.e., microtubule disruption).  Findings included hepatic, bone marrow/hematol. (primarily platelet), lymphoid organ, and neuronal toxicities, and increased nos. of cells of epithelial and phagocytic origin in metaphase arrest.  These adverse effects did not worsen with chronic dosing in monkeys and are consistent with those reported in T-DM1-treated patients to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp36u8JDO92mbVg90H21EOLACvtfcHk0lipPvMMcym1UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslGlsbbO&md5=f2ae6f6fc865d8ad027752e1301be3cc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2013.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2013.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DPoon%26aufirst%3DK.%2BA.%26aulast%3DFlagella%26aufirst%3DK.%26aulast%3DBeyer%26aufirst%3DJ.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DSaad%26aufirst%3DO.%26aulast%3DYi%26aufirst%3DJ.%2BH.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DDybdal%26aufirst%3DN.%26aulast%3DReynolds%26aufirst%3DT.%26atitle%3DPreclinical%2520safety%2520profile%2520of%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529%253A%2520mechanism%2520of%2520action%2520of%2520its%2520cytotoxic%2520component%2520retained%2520with%2520improved%2520tolerability%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2013%26volume%3D273%26spage%3D298%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leece, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, H.</span><span> </span><span class="NLM_article-title">Design of antibody–maytansinoid conjugates allows for efficient detoxification via liver metabolism</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">728</span><span class="NLM_x">–</span> <span class="NLM_lpage">735</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc100498q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivFyitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=728-735&author=X.+Sunauthor=W.+Widdisonauthor=M.+Mayoauthor=S.+Wilhelmauthor=B.+Leeceauthor=R.+Chariauthor=R.+Singhauthor=H.+Erickson&title=Design+of+antibody%E2%80%93maytansinoid+conjugates+allows+for+efficient+detoxification+via+liver+metabolism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Antibody-Maytansinoid Conjugates Allows for Efficient Detoxification via Liver Metabolism</span></div><div class="casAuthors">Sun, Xiuxia; Widdison, Wayne; Mayo, Michele; Wilhelm, Sharon; Leece, Barbara; Chari, Ravi; Singh, Rajeeva; Erickson, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">728-735</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody-maytansinoid conjugates (AMCs) are targeted chemotherapeutic agents consisting of a potent microtubule-depolymg. maytansinoid (DM1 or DM4) attached to lysine residues of a monoclonal antibody (mAb) using an uncleavable thioether linker or a stable disulfide linker.  Most of the administered dose of an antibody-based therapeutic is slowly catabolized by the liver and other tissues of the reticuloendothelial system.  Maytansinoids released from an AMC during this catabolic process could potentially be a source of toxicity.  To investigate this, we isolated and identified liver metabolites in mice for three different [3H]AMCs with structures similar to those currently undergoing evaluation in the clinic.  We then synthesized each metabolite to confirm the identification and assessed their cytotoxic potencies when added extracellularly.  We found that the uncleavable mAb-SMCC-[3H]DM1 conjugate was degraded to a single major maytansinoid metabolite, lysine-SMCC-[3H]DM1, that was nearly 50-fold less cytotoxic than maytansine.  The two disulfide-linked conjugates, mAb-SPP-[3H]DM1 and mAb-SPDB-[3H]DM4, were also catabolized to the analogous lysine-linked maytansinoid metabolites.  However, subsequent redn., S-methylation, and NADPH-dependent oxidn. steps in the liver yielded the corresponding S-Me sulfoxide and S-Me sulfone derivs.  The cytotoxic potencies of the oxidized maytansinoids toward several human carcinoma cell lines were 5- to 50-fold less potent than maytansine.  Our results suggest that liver plays an important role in the detoxification of both cleavable and uncleavable AMCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT3zBTd4ysBbVg90H21EOLACvtfcHk0lh8WcQr2RCdEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivFyitL4%253D&md5=042dafa46e287f5a8a76af8714c124ce</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fbc100498q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc100498q%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DWiddison%26aufirst%3DW.%26aulast%3DMayo%26aufirst%3DM.%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DLeece%26aufirst%3DB.%26aulast%3DChari%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DErickson%26aufirst%3DH.%26atitle%3DDesign%2520of%2520antibody%25E2%2580%2593maytansinoid%2520conjugates%2520allows%2520for%2520efficient%2520detoxification%2520via%2520liver%2520metabolism%26jtitle%3DBioconjugate%2520Chem.%26date%3D2011%26volume%3D22%26spage%3D728%26epage%3D735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Fishkin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span> </span><span class="NLM_article-title">A novel pathway for maytansinoid release from thioether linked antibody–drug conjugates (ADCs) under oxidative conditions</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">10752</span><span class="NLM_x">–</span> <span class="NLM_lpage">10754</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=10752-10754&author=N.+Fishkinauthor=E.+K.+Maloneyauthor=R.+V.+Chariauthor=R.+Singh&title=A+novel+pathway+for+maytansinoid+release+from+thioether+linked+antibody%E2%80%93drug+conjugates+%28ADCs%29+under+oxidative+conditions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFishkin%26aufirst%3DN.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DSingh%26aufirst%3DR.%26atitle%3DA%2520novel%2520pathway%2520for%2520maytansinoid%2520release%2520from%2520thioether%2520linked%2520antibody%25E2%2580%2593drug%2520conjugates%2520%2528ADCs%2529%2520under%2520oxidative%2520conditions%26jtitle%3DChem.%2520Commun.%26date%3D2011%26volume%3D47%26spage%3D10752%26epage%3D10754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holden, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutzker, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.</span><span> </span><span class="NLM_article-title">Phase I study of trastuzumab–DM1, an HER2 antibody–drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">2698</span><span class="NLM_x">–</span> <span class="NLM_lpage">2704</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1200%2FJCO.2009.26.2071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=20421541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXoslykt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=2698-2704&author=I.+E.+Kropauthor=M.+Beeramauthor=S.+Modiauthor=S.+F.+Jonesauthor=S.+N.+Holdenauthor=W.+Yuauthor=S.+Girishauthor=J.+Tibbittsauthor=J.+H.+Yiauthor=M.+X.+Sliwkowskiauthor=F.+Jacobsonauthor=S.+G.+Lutzkerauthor=H.+A.+Burris&title=Phase+I+study+of+trastuzumab%E2%80%93DM1%2C+an+HER2+antibody%E2%80%93drug+conjugate%2C+given+every+3+weeks+to+patients+with+HER2-positive+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer</span></div><div class="casAuthors">Krop, Ian E.; Beeram, Muralidhar; Modi, Shanu; Jones, Suzanne F.; Holden, Scott N.; Yu, Wei; Girish, Sandhy; Tibbitts, Jay; Yi, Joo-Hee; Sliwkowski, Mark X.; Jacobson, Fred; Lutzker, Stuart G.; Burris, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2698-2704</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate that uses trastuzumab to specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-pos. cells.  This first-in-human study of T-DM1 evaluated safety, pharmacokinetics, and preliminary activity of T-DM1 in patients with advanced HER2-pos. breast cancer.  Patients and Methods: Successive cohorts of patients who had progressed on trastuzumab-based therapy received escalating doses of T-DM1.  Outcomes were assessed by std. solid-tumor phase I methods.  Results: Twenty-four patients who had received a median of four prior chemotherapeutic agents for metastatic disease received T-DM1 at 0.3 mg/kg to 4.8 mg/kg on an every-3-wk schedule.  Transient thrombocytopenia was dose-limiting at 4.8 mg/kg; the max.-tolerated dose (MTD) was 3.6 mg/kg.  The half-life of T-DM1 at the MTD was 3.5 days, with peak DM1 levels < 10 ng/mL.  Clearance at doses < 1.2 mg/kg was faster than at higher doses.  Common drug-related adverse events (AEs) included grade ≤ 2 thrombocytopenia, elevated transaminases, fatigue, nausea, and anemia.  No grade > 1 nausea, vomiting, alopecia, or neuropathy events and no cardiac effects requiring dose modification were reported.  The clin. benefit rate (objective response plus stable disease at 6 mo) among 15 patients treated at the MTD was 73%, including five objective responses.  The confirmed response rate in patients with measurable disease at the MTD (n = 9) was 44%.  Conclusion: At the MTD of 3.6 mg/kg every 3 wk, T-DM1 was assocd. with mild, reversible toxicity and substantial clin. activity in a heavily pretreated population.  Phase II and III trials in patients with advanced HER2-pos. breast cancer are under way.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo65WWeQ3_JV7Vg90H21EOLACvtfcHk0lh8WcQr2RCdEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXoslykt7c%253D&md5=98ba29a289f4ac0ea38c37a9b6bd0c5d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.26.2071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.26.2071%26sid%3Dliteratum%253Aachs%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DS.%2BF.%26aulast%3DHolden%26aufirst%3DS.%2BN.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DYi%26aufirst%3DJ.%2BH.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DJacobson%26aufirst%3DF.%26aulast%3DLutzker%26aufirst%3DS.%2BG.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26atitle%3DPhase%2520I%2520study%2520of%2520trastuzumab%25E2%2580%2593DM1%252C%2520an%2520HER2%2520antibody%25E2%2580%2593drug%2520conjugate%252C%2520given%2520every%25203%2520weeks%2520to%2520patients%2520with%2520HER2-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D2698%26epage%3D2704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Phase I and II clinical trials of trastuzumab</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S49</span><span class="NLM_x">–</span> <span class="NLM_lpage">S55</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=S49-S55&issue=Suppl.+1&author=J.+Baselga&title=Phase+I+and+II+clinical+trials+of+trastuzumab"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DPhase%2520I%2520and%2520II%2520clinical%2520trials%2520of%2520trastuzumab%26jtitle%3DAnn.%2520Oncol.%26date%3D2001%26volume%3D12%26issue%3DSuppl.%25201%26spage%3DS49%26epage%3DS55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holden, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span> </span><span class="NLM_article-title">A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">5733</span><span class="NLM_x">–</span> <span class="NLM_lpage">5740</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2012&pages=5733-5740&author=M.+Beeramauthor=I.+E.+Kropauthor=H.+A.+Burrisauthor=S.+R.+Girishauthor=W.+Yuauthor=M.+W.+Luauthor=S.+N.+Holdenauthor=S.+Modi&title=A+phase+1+study+of+weekly+dosing+of+trastuzumab+emtansine+%28T-DM1%29+in+patients+with+advanced+human+epidermal+growth+factor+2-positive+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DGirish%26aufirst%3DS.%2BR.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DHolden%26aufirst%3DS.%2BN.%26aulast%3DModi%26aufirst%3DS.%26atitle%3DA%2520phase%25201%2520study%2520of%2520weekly%2520dosing%2520of%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529%2520in%2520patients%2520with%2520advanced%2520human%2520epidermal%2520growth%2520factor%25202-positive%2520breast%2520cancer%26jtitle%3DCancer%26date%3D2012%26volume%3D118%26spage%3D5733%26epage%3D5740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Burris, H. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugo, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vukelja, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limentani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan-Chiu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klencke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shaughnessy, J. A.</span><span> </span><span class="NLM_article-title">Phase II study of the antibody drug conjugate trastuzumab–DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">398</span><span class="NLM_x">–</span> <span class="NLM_lpage">405</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1200%2FJCO.2010.29.5865" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=21172893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivFWmsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=398-405&author=H.+A.+Burrisauthor=H.+S.+Rugoauthor=S.+J.+Vukeljaauthor=C.+L.+Vogelauthor=R.+A.+Borsonauthor=S.+Limentaniauthor=E.+Tan-Chiuauthor=I.+E.+Kropauthor=R.+A.+Michaelsonauthor=S.+Girishauthor=L.+Amlerauthor=M.+Zhengauthor=Y.+W.+Chuauthor=B.+Klenckeauthor=J.+A.+O%E2%80%99Shaughnessy&title=Phase+II+study+of+the+antibody+drug+conjugate+trastuzumab%E2%80%93DM1+for+the+treatment+of+human+epidermal+growth+factor+receptor+2+%28HER2%29-positive+breast+cancer+after+prior+HER2-directed+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy</span></div><div class="casAuthors">Burris, Howard A., III; Rugo, Hope S.; Vukelja, Svetislava J.; Vogel, Charles L.; Borson, Rachel A.; Limentani, Steven; Tan-Chiu, Elizabeth; Krop, Ian E.; Michaelson, Richard A.; Girish, Sandhya; Amler, Lukas; Zheng, Maoxia; Chu, Yu-Waye; Klencke, Barbara; O'Shaughnessy, Joyce A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">398-405</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The antibody-drug conjugate trastuzumab-DM1 (T-DM1) combines the biol. activity of trastuzumab with targeted delivery of a potent antimicrotubule agent, DM1, to human epidermal growth factor receptor 2 (HER2) -overexpressing cancer cells.  Based on results from a phase I study that showed T-DM1 was well tolerated at the max.-tolerated dose of 3.6 mg/kg every 3 wk, with evidence of efficacy, in patients with HER2-pos. metastatic breast cancer (MBC) who were previously treated with trastuzumab, we conducted a phase II study to further define the safety and efficacy of T-DM1 in this patient population.  This report describes a single-arm phase II study (TDM4258g) that assessed efficacy and safety of i.v. T-DM1 (3.6 mg/kg every 3 wk) in patients with HER2-pos. MBC who had tumor progression after prior treatment with HER2-directed therapy and who had received prior chemotherapy.  With a follow-up of ≥ 12 mo among 112 treated patients, the objective response rate by independent assessment was 25.9% (95% CI, 18.4% to 34.4%).  Median duration of response was not reached as a result of insufficient events (lower limit of 95% CI, 6.2 mo), and median progression-free survival time was 4.6 mo (95% CI, 3.9 to 8.6 mo).  The response rates were higher among patients with confirmed HER2-pos. tumors (immunohistochem. 3+ or fluorescent in situ hybridization pos.) by retrospective central testing (n = 74).  Higher response rates were also obsd. in patients whose tumors expressed ≥ median HER2 levels by quant. reverse transcriptase polymerase chain reaction for HER2 expression, compared with patients who had less than median HER2 levels.  T-DM1 was well tolerated with no dose-limiting cardiotoxicity.  Most adverse events (AEs) were grade 1 or 2; the most frequent grade ≥ 3 AEs were hypokalemia (8.9%), thrombocytopenia (8.0%), and fatigue (4.5%).  T-DM1 has robust single-agent activity in patients with heavily pretreated, HER2-pos. MBC and is well tolerated at the recommended phase II dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhJbpnx142HbVg90H21EOLACvtfcHk0lhaTAY8K4VByg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivFWmsrc%253D&md5=94f0c939a12a7875590fc02f3f056d65</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.29.5865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.29.5865%26sid%3Dliteratum%253Aachs%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DVukelja%26aufirst%3DS.%2BJ.%26aulast%3DVogel%26aufirst%3DC.%2BL.%26aulast%3DBorson%26aufirst%3DR.%2BA.%26aulast%3DLimentani%26aufirst%3DS.%26aulast%3DTan-Chiu%26aufirst%3DE.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DMichaelson%26aufirst%3DR.%2BA.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DAmler%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DKlencke%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%2BA.%26atitle%3DPhase%2520II%2520study%2520of%2520the%2520antibody%2520drug%2520conjugate%2520trastuzumab%25E2%2580%2593DM1%2520for%2520the%2520treatment%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520%2528HER2%2529-positive%2520breast%2520cancer%2520after%2520prior%2520HER2-directed%2520therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D398%26epage%3D405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yardley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guardino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugo, H. S.</span><span> </span><span class="NLM_article-title">A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3234</span><span class="NLM_x">–</span> <span class="NLM_lpage">3241</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1200%2FJCO.2011.40.5902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=22649126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKrsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3234-3241&author=I.+E.+Kropauthor=P.+LoRussoauthor=K.+D.+Millerauthor=S.+Modiauthor=D.+Yardleyauthor=G.+Rodriguezauthor=E.+Guardinoauthor=M.+Luauthor=M.+Zhengauthor=S.+Girishauthor=L.+Amlerauthor=E.+P.+Winerauthor=H.+S.+Rugo&title=A+phase+II+study+of+trastuzumab+emtansine+in+patients+with+human+epidermal+growth+factor+receptor+2-positive+metastatic+breast+cancer+who+were+previously+treated+with+trastuzumab%2C+lapatinib%2C+an+anthracycline%2C+a+taxane%2C+and+capecitabine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine</span></div><div class="casAuthors">Krop, Ian E.; LoRusso, Patricia; Miller, Kathy D.; Modi, Shanu; Yardley, Denise; Rodriguez, Gladys; Guardino, Ellie; Lu, Michael; Zheng, Maoxia; Girish, Sandhya; Amler, Lukas; Winer, Eric P.; Rugo, Hope S.; Krop, Ian E.; Winer, Eric P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3234-3241</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose. To det. whether the antibody-drug conjugate trastuzumab emtansine (T-DM1), which combines human epidermal growth factor receptor 2 (HER2) -targeted delivery of the potent antimicrotubule agent DM1 with the antitumor activity of trastuzumab, is effective in patients with HER2-pos. metastatic breast cancer (MBC) who have previously received all std. HER2-directed therapies.  Patients and Methods. In this single-arm phase II study, T-DM1 3.6 mg/kg was administered i.v. every 3 wk to patients with HER2-pos. MBC who had prior treatment with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.  The primary objectives were overall response rate (ORR) by independent review and safety.  Results. Among 110 pretreated patients (median, seven prior agents for MBC; median follow-up, 17.4 mo), the ORR was 34.5% (95% CI, 26.1% to 43.9%), clin. benefit rate was 48.2% (95% CI, 38.8% to 57.9%), median progression-free survival (PFS) was 6.9 mo (95% CI, 4.2 to 8.4 mo), and median duration of response was 7.2 mo (95% CI, 4.6 mo to not estimable).  In patients with confirmed HER2-pos. tumors (n = 80 by retrospective central testing), the response rate was 41.3% (95% CI, 30.4% to 52.8%), and median PFS was 7.3 mo (95% CI, 4.6 to 12.3 mo).  Most adverse events were grades 1 to 2; the most frequent grade ≥ 3 events were thrombocytopenia (9.1%), fatigue (4.5%), and cellulitis (3.6%).  Conclusion. T-DM1 is well tolerated and has single-agent activity in patients with HER2-pos. MBC who have previously received both approved HER2-directed therapies and multiple chemotherapy agents.  T-DM1 may be an effective new treatment for this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQImjifp0YS7Vg90H21EOLACvtfcHk0lhaTAY8K4VByg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKrsL%252FJ&md5=e3c54c63b8a2c6a585818e35c0e4aab9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.40.5902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.40.5902%26sid%3Dliteratum%253Aachs%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DYardley%26aufirst%3DD.%26aulast%3DRodriguez%26aufirst%3DG.%26aulast%3DGuardino%26aufirst%3DE.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DAmler%26aufirst%3DL.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520trastuzumab%2520emtansine%2520in%2520patients%2520with%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202-positive%2520metastatic%2520breast%2520cancer%2520who%2520were%2520previously%2520treated%2520with%2520trastuzumab%252C%2520lapatinib%252C%2520an%2520anthracycline%252C%2520a%2520taxane%252C%2520and%2520capecitabine%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3234%26epage%3D3241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Hurvitz, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dirix, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocsis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinholes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guardino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, E. A.</span><span> </span><span class="NLM_article-title">Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1157</span><span class="NLM_x">–</span> <span class="NLM_lpage">1163</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1200%2FJCO.2012.44.9694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=23382472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVyhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1157-1163&author=S.+A.+Hurvitzauthor=L.+Dirixauthor=J.+Kocsisauthor=G.+V.+Bianchiauthor=J.+Luauthor=J.+Vinholesauthor=E.+Guardinoauthor=C.+Songauthor=B.+Tongauthor=V.+Ngauthor=Y.+W.+Chuauthor=E.+A.+Perez&title=Phase+II+randomized+study+of+trastuzumab+emtansine+versus+trastuzumab+plus+docetaxel+in+patients+with+human+epidermal+growth+factor+receptor+2-positive+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer</span></div><div class="casAuthors">Hurvitz, Sara A.; Dirix, Luc; Kocsis, Judit; Bianchi, Giulia V.; Lu, Janice; Vinholes, Jeferson; Guardino, Ellie; Song, Chunyan; Tong, Barbara; Ng, Vivian; Chu, Yu-Waye; Perez, Edith A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1157-1163</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Trastuzumab emtansine (T-DM1), an antibody-drug conjugate composed of the cytotoxic agent DM1 conjugated to trastuzumab via a stable thioether linker, has shown clin. activity in single-arm studies enrolling patients with human epidermal growth factor receptor 2 (HER2)-pos. metastatic breast cancer (MBC) whose disease had progressed on HER2-targeted therapy in the metastatic setting.  Patients and Methods: Patients (N = 137) with HER2-pos. MBC or recurrent locally advanced breast cancer were randomly assigned to trastuzumab plus docetaxel (HT; n = 70) or T-DM1 (n = 67) as first-line treatment until disease progression or unacceptable toxicity.  Primary end points were investigator-assessed progression-free survival (PFS) and safety.  Key secondary end points included overall survival (OS), objective response rate (ORR), duration of objective response, clin. benefit rate, and quality of life.  Results: Median PFS was 9.2 mo with HT and 14.2 mo with T-DM1 (hazard ratio, 0.59; 95% CI, 0.36 to 0.97); median follow-up was approx. 14 mo in both arms.  ORR was 58.0% (95% CI, 45.5% to 69.2%) with HT and 64.2% (95% CI, 51.8% to 74.8%) with T-DM1.  T-DM1 had a favorable safety profile vs. HT, with fewer grade ≥ 3 adverse events (AEs; 46.4% v 90.9%), AEs leading to treatment discontinuations (7.2% v 34.8%), and serious AEs (20.3% v 25.8%).  Preliminary OS results were similar between treatment arms; median follow-up was approx. 23 mo in both arms.  Conclusion: In this randomized phase II study, first-line treatment with T-DM1 for patients with HER2-pos. MBC provided a significant improvement in PFS, with a favorable safety profile, vs. HT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv8fMDYaxdIrVg90H21EOLACvtfcHk0lhaTAY8K4VByg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVyhtbs%253D&md5=95cd6eb05ce016e971b2af745d1b587f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.44.9694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.44.9694%26sid%3Dliteratum%253Aachs%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DDirix%26aufirst%3DL.%26aulast%3DKocsis%26aufirst%3DJ.%26aulast%3DBianchi%26aufirst%3DG.%2BV.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DVinholes%26aufirst%3DJ.%26aulast%3DGuardino%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DB.%26aulast%3DNg%26aufirst%3DV.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DPerez%26aufirst%3DE.%2BA.%26atitle%3DPhase%2520II%2520randomized%2520study%2520of%2520trastuzumab%2520emtansine%2520versus%2520trastuzumab%2520plus%2520docetaxel%2520in%2520patients%2520with%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D1157%26epage%3D1163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Suter, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Procter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Veldhuisen, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muscholl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlomagno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perren, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passalacqua, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bighin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klijn, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ageev, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groetz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knap, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gnant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muehlbauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelber, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piccart-Gebhart, M. J.</span><span> </span><span class="NLM_article-title">Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3859</span><span class="NLM_x">–</span> <span class="NLM_lpage">3865</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1200%2FJCO.2006.09.1611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=17646669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFanu7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=3859-3865&author=T.+M.+Suterauthor=M.+Procterauthor=D.+J.+van+Veldhuisenauthor=M.+Muschollauthor=J.+Berghauthor=C.+Carlomagnoauthor=T.+Perrenauthor=R.+Passalacquaauthor=C.+Bighinauthor=J.+G.+Klijnauthor=F.+T.+Ageevauthor=E.+Hitreauthor=J.+Groetzauthor=H.+Iwataauthor=M.+Knapauthor=M.+Gnantauthor=S.+Muehlbauerauthor=A.+Spenceauthor=R.+D.+Gelberauthor=M.+J.+Piccart-Gebhart&title=Trastuzumab-associated+cardiac+adverse+effects+in+the+herceptin+adjuvant+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial</span></div><div class="casAuthors">Suter, Thomas M.; Procter, Marion; van Veldhuisen, Dirk J.; Muscholl, Michael; Bergh, Jonas; Carlomagno, Chiara; Perren, Timothy; Passalacqua, Rodolfo; Bighin, Claudia; Klijn, Jan G. M.; Ageev, Fail T.; Hitre, Erika; Greetz, Juergen; Iwata, Hiroji; Knap, Malgorzata; Gnant, Michael; Muehlbauer, Susanne; Spence, Alison; Gelber, Richard D.; Piccart-Gebhart, Martine J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">3859-3865</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: The purpose of this anal. was to investigate trastuzumab-assocd. cardiac adverse effects in breast cancer patients after completion of (neo)adjuvant chemotherapy with or without radiotherapy.  Patients and Methods: The Herceptin Adjuvant (HERA) trial is a three-group, multicenter, open-label randomized trial that compared 1 or 2 years of trastuzumab given once every 3 wk with observation in patients with HER-2-pos. breast cancer.  Only patients who after completion of (neo)adjuvant chemotherapy with or without radiotherapy had normal left ventricular ejection fraction (LVEF ≥ 55%) were eligible.  A repeat LVEF assessment was performed in case of cardiac dysfunction.  Results: Data were available for 1,693 patients randomly assigned to 1 yr trastuzumab and 1,693 patients randomly assigned to observation.  The incidence of trastuzumab discontinuation due to cardiac disorders was low (4.3%).  The incidence of cardiac end points was higher in the trastuzumab group compared with observation (severe congestive heart failure [CHF], 0.60% v 0.00%; symptomatic CHF, 2.15% v 0.12%; confirmed significant LVEF drops, 3.04% v 0.53%).  Most patients with cardiac dysfunction recovered in fewer than 6 mo.  Patients with trastuzumab-assocd. cardiac dysfunction were treated with higher cumulative doses of doxorubicin (287 mg/m2 v 257 mg/m2) or epirubicin (480 mg/m2 v 422 mg/m2) and had a lower screening LVEF and a higher body mass index.  Conclusion: Given the clear benefit in disease-free survival, the low incidence of cardiac adverse events, and the suggestion that cardiac dysfunction might be reversible, adjuvant trastuzumab should be considered for treatment of breast cancer patients who fulfill the HERA trial eligibility criteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUJztSuVkZCbVg90H21EOLACvtfcHk0ljeAQjP-xqPdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFanu7zE&md5=9aa4ecb50b0566677b2552e7c645b2f2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.09.1611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.09.1611%26sid%3Dliteratum%253Aachs%26aulast%3DSuter%26aufirst%3DT.%2BM.%26aulast%3DProcter%26aufirst%3DM.%26aulast%3Dvan%2BVeldhuisen%26aufirst%3DD.%2BJ.%26aulast%3DMuscholl%26aufirst%3DM.%26aulast%3DBergh%26aufirst%3DJ.%26aulast%3DCarlomagno%26aufirst%3DC.%26aulast%3DPerren%26aufirst%3DT.%26aulast%3DPassalacqua%26aufirst%3DR.%26aulast%3DBighin%26aufirst%3DC.%26aulast%3DKlijn%26aufirst%3DJ.%2BG.%26aulast%3DAgeev%26aufirst%3DF.%2BT.%26aulast%3DHitre%26aufirst%3DE.%26aulast%3DGroetz%26aufirst%3DJ.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DKnap%26aufirst%3DM.%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DMuehlbauer%26aufirst%3DS.%26aulast%3DSpence%26aufirst%3DA.%26aulast%3DGelber%26aufirst%3DR.%2BD.%26aulast%3DPiccart-Gebhart%26aufirst%3DM.%2BJ.%26atitle%3DTrastuzumab-associated%2520cardiac%2520adverse%2520effects%2520in%2520the%2520herceptin%2520adjuvant%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26spage%3D3859%26epage%3D3865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Verma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welslau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dieras, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guardino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwell, K.</span><span> </span><span class="NLM_article-title">Trastuzumab emtansine for HER2-positive advanced breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">1783</span><span class="NLM_x">–</span> <span class="NLM_lpage">1791</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1056%2FNEJMoa1209124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=23020162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1783-1791&author=S.+Vermaauthor=D.+Milesauthor=L.+Gianniauthor=I.+E.+Kropauthor=M.+Welslauauthor=J.+Baselgaauthor=M.+Pegramauthor=D.+Y.+Ohauthor=V.+Dierasauthor=E.+Guardinoauthor=L.+Fangauthor=M.+W.+Luauthor=S.+Olsenauthor=K.+Blackwell&title=Trastuzumab+emtansine+for+HER2-positive+advanced+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab emtansine for HER2-positive advanced breast cancer</span></div><div class="casAuthors">Verma, Sunil; Miles, David; Gianni, Luca; Krop, Ian E.; Welslau, Manfred; Baselga, Jose; Pegram, Mark; Oh, Do-Youn; Dieras, Veronique; Guardino, Ellie; Fang, Liang; Lu, Michael W.; Olsen, Steven; Blackwell, Kim</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1783-1791</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.  The antibody and the cytotoxic agent are conjugated by means of a stable linker.  METHODS: We randomly assigned patients with HER2-pos. advanced breast cancer, who had previously been treated with trastuzumab and a taxane, to T-DM1 or lapatinib plus capecitabine.  The primary end points were progression-free survival (as assessed by independent review), overall survival, and safety.  Secondary end points included progression-free survival (investigator-assessed), the objective response rate, and the time to symptom progression.  Two interim analyses of overall survival were conducted.  RESULTS: Among 991 randomly assigned patients, median progression-free survival as assessed by independent review was 9.6 mo with T-DM1 vs. 6.4 mo with lapatinib plus capecitabine (hazard ratio for progression or death from any cause, 0.65; 95% confidence interval [CI], 0.55 to 0.77; P<0.001), and median overall survival at the second interim anal. crossed the stopping boundary for efficacy (30.9 mo vs. 25.1 mo; hazard ratio for death from any cause, 0.68; 95% CI, 0.55 to 0.85; P<0.001).  The objective response rate was higher with T-DM1 (43.6%, vs. 30.8% with lapatinib plus capecitabine; P<0.001); results for all addnl. secondary end points favored T-DM1.  Rates of grade 3 or above were higher with lapatinib plus capecitabine than with T-DM1 (57% vs. 41%).  The incidences of thrombocytopenia and increased serum aminotransferase levels were higher with T-DM1, whereas the incidences of diarrhea, nausea, vomiting, and palmar-plantar erythrodysesthesia were higher with lapatinib plus capecitabine.  CONCLUSIONS: T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-pos. advanced breast cancer previously treated with trastuzumab and a taxane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGRhxRQ7JSJrVg90H21EOLACvtfcHk0ljeAQjP-xqPdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73M&md5=3be5bac27a81b530442dc8a6b4a1f82e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1209124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1209124%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DS.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DGianni%26aufirst%3DL.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DWelslau%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DPegram%26aufirst%3DM.%26aulast%3DOh%26aufirst%3DD.%2BY.%26aulast%3DDieras%26aufirst%3DV.%26aulast%3DGuardino%26aufirst%3DE.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DS.%26aulast%3DBlackwell%26aufirst%3DK.%26atitle%3DTrastuzumab%2520emtansine%2520for%2520HER2-positive%2520advanced%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1783%26epage%3D1791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Martin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrero, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wildiers, H.</span><span> </span><span class="NLM_article-title">Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomized open-label phase 3 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">689</span><span class="NLM_x">–</span> <span class="NLM_lpage">699</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1016%2FS1470-2045%2814%2970178-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=24793816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntl2gs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=689-699&author=I.+E.+Kropauthor=S.+B.+Kimauthor=A.+Gonzalez-Martinauthor=P.+M.+LoRussoauthor=J.+M.+Ferreroauthor=M.+Smittauthor=R.+Yuauthor=A.+Leungauthor=H.+Wildiers&title=Trastuzumab+emtansine+versus+treatment+of+physician%E2%80%99s+choice+for+pretreated+HER2-positive+advanced+breast+cancer+%28TH3RESA%29%3A+a+randomized+open-label+phase+3+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial</span></div><div class="casAuthors">Krop, Ian E.; Kim, Sung-Bae; Gonzalez-Martin, Antonio; LoRusso, Patricia M.; Ferrero, Jean-Marc; Smitt, Melanie; Yu, Ron; Leung, Abraham C. F.; Wildiers, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">689-699</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic breast cancer have few effective therapeutic options.  We aimed to compare trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent DM1 linked to trastuzumab, with treatment of physician's choice in this population of patients.This randomised, open-label, phase 3 trial took place in medical centers in 22 countries across Europe, North America, South America, and Asia-Pacific.  Eligible patients (≥18 years, left ventricular ejection fraction ≥50%, Eastern Cooperative Oncol. Group performance status 0-2) with progressive HER2-pos. advanced breast cancer who had received two or more HER2-directed regimens in the advanced setting, including trastuzumab and lapatinib, and previous taxane therapy in any setting, were randomly assigned (in a 2:1 ratio) to trastuzumab emtansine (3·6 mg/kg i.v. every 21 days) or physician's choice using a permuted block randomization scheme by an interactive voice and web response system.  Patients were stratified according to world region (USA vs western Europe vs other), no. of previous regimens (excluding single-agent hormonal therapy) for the treatment of advanced disease (two to three vs more than three), and presence of visceral disease (any vs none).  Coprimary endpoints were investigator-assessed progression-free survival (PFS) and overall survival in the intention-to-treat population.  We report the final PFS anal. and the first interim overall survival anal.  This study is registered with ClinicalTrials.gov, no. NCT01419197.From Sept 14, 2011, to Nov 19, 2012, 602 patients were randomly assigned (404 to trastuzumab emtansine and 198 to physician's choice).  At data cutoff (Feb 11, 2013), 44 patients assigned to physician's choice had crossed over to trastuzumab emtansine.  After a median follow-up of 7·2 mo (IQR 5·0-10·1 mo) in the trastuzumab emtansine group and 6·5 mo (IQR 4·1-9·7) in the physician's choice group, 219 (54%) patients in the trastuzumab emtansine group and 129 (65%) of patients in the physician's choice group had PFS events.  PFS was significantly improved with trastuzumab emtansine compared with physician's choice (median 6·2 mo [95% CI 5·59-6·87] vs 3·3 mo [2·89-4·14]; stratified hazard ratio [HR] 0·528 [0·422-0·661]; p<0·0001).  Interim overall survival anal. showed a trend favoring trastuzumab emtansine (stratified HR 0·552 [95% CI 0·369-0·826]; p=0·0034), but the stopping boundary was not crossed.  A lower incidence of grade 3 or worse adverse events was reported with trastuzumab emtansine than with physician's choice (130 events [32%] in 403 patients vs 80 events [43%] in 184 patients).  Neutropenia (ten [2%] vs 29 [16%]), diarrhoea (three [<1%] vs eight [4%]), and febrile neutropenia (one [<1%] vs seven [4%]) were grade 3 or worse adverse events that were more common in the physician's choice group than in the trastuzumab emtansine group.  Thrombocytopenia (19 [5%] vs three [2%]) was the grade 3 or worse adverse event that was more common in the trastuzumab emtansine group. 74 (18%) patients in the trastuzumab emtansine group and 38 (21%) in the physician's choice group reported a serious adverse event.  Trastuzumab emtansine should be considered as a new std. for patients with HER2-pos. advanced breast cancer who have previously received trastuzumab and lapatinib.Genentech.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNXUpmCIdTY7Vg90H21EOLACvtfcHk0ljeAQjP-xqPdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntl2gs7o%253D&md5=975dd9e786d96360b163c2583aefc4b8</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970178-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970178-0%26sid%3Dliteratum%253Aachs%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DKim%26aufirst%3DS.%2BB.%26aulast%3DGonzalez-Martin%26aufirst%3DA.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DFerrero%26aufirst%3DJ.%2BM.%26aulast%3DSmitt%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DR.%26aulast%3DLeung%26aufirst%3DA.%26aulast%3DWildiers%26aufirst%3DH.%26atitle%3DTrastuzumab%2520emtansine%2520versus%2520treatment%2520of%2520physician%25E2%2580%2599s%2520choice%2520for%2520pretreated%2520HER2-positive%2520advanced%2520breast%2520cancer%2520%2528TH3RESA%2529%253A%2520a%2520randomized%2520open-label%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D689%26epage%3D699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedrini, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pienkowski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knott, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benyunes, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swain, S. M.</span><span> </span><span class="NLM_article-title">Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1056%2FNEJMoa1113216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=22149875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFSlt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=109-119&author=J.+Baselgaauthor=J.+Cortesauthor=S.+B.+Kimauthor=S.+A.+Imauthor=R.+Heggauthor=Y.+H.+Imauthor=L.+Romanauthor=J.+L.+Pedriniauthor=T.+Pienkowskiauthor=A.+Knottauthor=E.+Clarkauthor=M.+C.+Benyunesauthor=G.+Rossauthor=S.+M.+Swain&title=Pertuzumab+plus+trastuzumab+plus+docetaxel+for+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer</span></div><div class="casAuthors">Baselga, Jose; Cortes, Javier; Kim, Sung-Bae; Im, Seock-Ah; Hegg, Roberto; Im, Young-Hyuck; Roman, Laslo; Pedrini, Jose Luiz; Pienkowski, Tadeusz; Knott, Adam; Clark, Emma; Benyunes, Mark C.; Ross, Graham; Swain, Sandra M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-119</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The anti-human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-pos. metastatic breast cancer.  However, most cases of advanced disease eventually progress.  Pertuzumab, an anti-HER2 humanized monoclonal antibody that inhibits receptor dimerization, has a mechanism of action that is complementary to that of trastuzumab, and combination therapy with the two antibodies has shown promising activity and an acceptable safety profile in phase 2 studies involving patients with HER2-pos. breast cancer.  METHODS We randomly assigned 808 patients with HER2-pos. metastatic breast cancer to receive placebo plus trastuzumab plus docetaxel (control group) or pertuzumab plus trastuzumab plus docetaxel (pertuzumab group) as first-line treatment until the time of disease progression or the development of toxic effects that could not be effectively managed.  The primary end point was independently assessed progression-free survival.  Secondary end points included overall survival, progression-free survival as assessed by the investigator, the objective response rate, and safety.  RESULTS The median progression-free survival was 12.4 mo in the control group, as com pared with 18.5 mo in the pertuzumab group (hazard ratio for progression or death, 0.62; 95% confidence interval, 0.51 to 0.75; P < 0.001).  The interim anal. of overall survival showed a strong trend in favor of pertuzumab plus trastuzumab plus docetaxel.  The safety profile was generally similar in the two groups, with no increase in left ventricular systolic dysfunction; the rates of febrile neutropenia and diarrhea of grade 3 or above were higher in the pertuzumab group than in the control group.  CONCLUSIONS The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-pos. metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmwMDP53z_VLVg90H21EOLACvtfcHk0lhfPG_aTT-T0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFSlt7Y%253D&md5=8f8a05c82e4722049923dd069f1863b4</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1113216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1113216%26sid%3Dliteratum%253Aachs%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BB.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DHegg%26aufirst%3DR.%26aulast%3DIm%26aufirst%3DY.%2BH.%26aulast%3DRoman%26aufirst%3DL.%26aulast%3DPedrini%26aufirst%3DJ.%2BL.%26aulast%3DPienkowski%26aufirst%3DT.%26aulast%3DKnott%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DE.%26aulast%3DBenyunes%26aufirst%3DM.%2BC.%26aulast%3DRoss%26aufirst%3DG.%26aulast%3DSwain%26aufirst%3DS.%2BM.%26atitle%3DPertuzumab%2520plus%2520trastuzumab%2520plus%2520docetaxel%2520for%2520metastatic%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D109%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fields, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowbenko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albain, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbeck, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dieras, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crivellari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guardino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">456</span><span class="NLM_x">–</span> <span class="NLM_lpage">468</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1158%2F1078-0432.CCR-13-0358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=24097864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKrs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=456-468&author=G.+D.+Phillipsauthor=C.+T.+Fieldsauthor=G.+Liauthor=D.+Dowbenkoauthor=G.+Schaeferauthor=K.+Millerauthor=F.+Andreauthor=H.+A.+Burrisauthor=K.+S.+Albainauthor=N.+Harbeckauthor=V.+Dierasauthor=D.+Crivellariauthor=L.+Fangauthor=E.+Guardinoauthor=S.+R.+Olsenauthor=L.+M.+Crockerauthor=M.+X.+Sliwkowski&title=Dual+targeting+of+HER2-positive+cancer+with+trastuzumab+emtansine+and+pertuzumab%3A+critical+role+for+neuregulin+blockade+in+antitumor+response+to+combination+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy</span></div><div class="casAuthors">Phillips, Gail D. Lewis; Fields, Carter T.; Li, Guangmin; Dowbenko, Donald; Schaefer, Gabriele; Miller, Kathy; Andre, Fabrice; Burris, Howard A.; Albain, Kathy S.; Harbeck, Nadia; Dieras, Veronique; Crivellari, Diana; Fang, Liang; Guardino, Ellie; Olsen, Steven R.; Crocker, Lisa M.; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">456-468</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Targeting HER2 with multiple HER2-directed therapies represents a promising area of treatment for HER2-pos. cancers.  We investigated combining the HER2-directed antibody-drug conjugate trastuzumab emtansine (T-DM1) with the HER2 dimerization inhibitor pertuzumab (Perjeta).  Exptl. Design: Drug combination studies with T-DM1 and pertuzumab were performed on cultured tumor cells and in mouse xenograft models of HER2-amplified cancer.  In patients with HER2-pos. locally advanced or metastatic breast cancer (mBC), T-DM1 was dose-escalated with a fixed std. pertuzumab dose in a 3+3 phase Ib/II study design.  Results: Treatment of HER2-overexpressing tumor cells in vitro with T-DM1 plus pertuzumab resulted in synergistic inhibition of cell proliferation and induction of apoptotic cell death.  The presence of the HER3 ligand, heregulin (NRG-1β), reduced the cytotoxic activity of T-DM1 in a subset of breast cancer lines; this effect was reversed by the addn. of pertuzumab.  Results from mouse xenograft models showed enhanced antitumor efficacy with T-DM1 and pertuzumab resulting from the unique antitumor activities of each agent.  In patients with mBC previously treated with trastuzumab, lapatinib, and chemotherapy, T-DM1 could be dosed at the max. tolerated dose (MTD; 3.6 mg/kg every 3 wk) with std. dose pertuzumab.  Adverse events were mostly grade 1 and 2, with indications of clin. activity.  Conclusions: Dual targeting of HER2 with the combination of T-DM1 and pertuzumab in cell culture and mouse xenograft models resulted in enhanced antitumor activity.  In patients, this combination showed an encouraging safety and tolerability profile with preliminary evidence of efficacy.  Clin Cancer Res; 20(2); 456-68. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXtv33Olw_qrVg90H21EOLACvtfcHk0lhfPG_aTT-T0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKrs7c%253D&md5=71f2be1c5fccaee1d613d09c0eaf48b5</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0358%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DG.%2BD.%26aulast%3DFields%26aufirst%3DC.%2BT.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDowbenko%26aufirst%3DD.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DAlbain%26aufirst%3DK.%2BS.%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DDieras%26aufirst%3DV.%26aulast%3DCrivellari%26aufirst%3DD.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DGuardino%26aufirst%3DE.%26aulast%3DOlsen%26aufirst%3DS.%2BR.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DDual%2520targeting%2520of%2520HER2-positive%2520cancer%2520with%2520trastuzumab%2520emtansine%2520and%2520pertuzumab%253A%2520critical%2520role%2520for%2520neuregulin%2520blockade%2520in%2520antitumor%2520response%2520to%2520combination%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D456%26epage%3D468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dees, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span> </span><span class="NLM_article-title">Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">911</span><span class="NLM_x">–</span> <span class="NLM_lpage">922</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.2174%2F138920012802138688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=22475266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1OlurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=911-922&author=D.+Luauthor=H.+A.+Burrisauthor=B.+Wangauthor=E.+C.+Deesauthor=J.+Cortesauthor=A.+Joshiauthor=M.+Guptaauthor=J.+H.+Yiauthor=Y.+W.+Chuauthor=T.+Shihauthor=L.+Fangauthor=S.+Girish&title=Drug+interaction+potential+of+trastuzumab+emtansine+%28T-DM1%29+combined+with+pertuzumab+in+patients+with+HER2-positive+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer</span></div><div class="casAuthors">Lu, Dan; Burris, Howard A., III; Wang, Bei; Dees, E. Claire; Cortes, Javier; Joshi, Amita; Gupta, Manish; Yi, Joo-Hee; Chu, Yu-Waye; Shih, Ted; Fang, Liang; Girish, Sandhya</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">911-922</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate comprised of trastuzumab and the cytotoxic agent DM1 (deriv. of maytansine) linked by a stable linker N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC).  T-DM1 targets an epitope located at subdomain IV of human epidermal growth factor receptor 2 (HER2).  Pertuzumab is a monoclonal antibody that targets an epitope located at subdomain II of HER2, distinct from the epitope recognized by T-DM1.  The pharmacokinetics (PK), safety, and efficacy of T-DM1 combined with pertuzumab were studied in a phase 1b/2 trial in 67 patients with HER2-pos., locally advanced or metastatic breast cancer (MBC).  The therapeutic protein-drug interaction (TP-DI) potential of T-DM1 plus pertuzumab was evaluated.  The PK of T-DM1-related analytes and pertuzumab were compared with historical PK data.  The results show that the exposure of T-DM1 and DM1, as estd. by noncompartmental analyses, was comparable with that reported by historical single-agent studies in patients with HER2-pos. MBC.  T-DM1 clearance and vol. of distribution in the central compartment, as estd. by population PK anal., were also comparable between this study and historical single-agent studies in patients with HER2-pos. MBC.  Summary statistics of pertuzumab trough and maximal exposure (concns. at predose and 15-30 min after the end of infusion at cycle 1 and at steady state) were similar with those obsd. in a representative historical single-agent study with the same dosing regimen.  The visual predictive check plot by population simulation further confirmed that T-DM1 did not alter pertuzumab PK.  Based on these data and the PK and pharmacodynamic properties of T-DM1 and pertuzumab, the risk of TP-DI appears to be low when T-DM1 and pertuzumab are given together.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeUAf0n581h7Vg90H21EOLACvtfcHk0lihvy5ftqVqWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1OlurrO&md5=ee2756eb89baee7a08a95ff9d43eb736</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.2174%2F138920012802138688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012802138688%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DDees%26aufirst%3DE.%2BC.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DYi%26aufirst%3DJ.%2BH.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DShih%26aufirst%3DT.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DGirish%26aufirst%3DS.%26atitle%3DDrug%2520interaction%2520potential%2520of%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529%2520combined%2520with%2520pertuzumab%2520in%2520patients%2520with%2520HER2-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D911%26epage%3D922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Bartsch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berghoff, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preusser, M.</span><span> </span><span class="NLM_article-title">Breast cancer brain metastases responding to primary systemic therapy with T-DM1</span> <span class="citation_source-journal">J. Neuro-Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1007%2Fs11060-013-1257-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=24065570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252Fht1SlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2014&pages=205-206&author=R.+Bartschauthor=A.+S.+Berghoffauthor=M.+Preusser&title=Breast+cancer+brain+metastases+responding+to+primary+systemic+therapy+with+T-DM1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer brain metastases responding to primary systemic therapy with T-DM1</span></div><div class="casAuthors">Bartsch Rupert; Berghoff Anna S; Preusser Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">205-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRM0sDqGuOnpXtlzo9xastyfW6udTcc2eYVrumOxe1RdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252Fht1SlsA%253D%253D&md5=cb5391468373267301aadd8c16fc8e06</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs11060-013-1257-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-013-1257-5%26sid%3Dliteratum%253Aachs%26aulast%3DBartsch%26aufirst%3DR.%26aulast%3DBerghoff%26aufirst%3DA.%2BS.%26aulast%3DPreusser%26aufirst%3DM.%26atitle%3DBreast%2520cancer%2520brain%2520metastases%2520responding%2520to%2520primary%2520systemic%2520therapy%2520with%2520T-DM1%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2014%26volume%3D116%26spage%3D205%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holden, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, A.</span><span> </span><span class="NLM_article-title">Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1229</span><span class="NLM_x">–</span> <span class="NLM_lpage">1240</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1007%2Fs00280-011-1817-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=22271209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1Kru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=1229-1240&author=S.+Girishauthor=M.+Guptaauthor=B.+Wangauthor=D.+Luauthor=I.+E.+Kropauthor=C.+L.+Vogelauthor=H.+A.+Burrisauthor=P.+M.+LoRussoauthor=J.+H.+Yiauthor=O.+Saadauthor=B.+Tongauthor=Y.+W.+Chuauthor=S.+Holdenauthor=A.+Joshi&title=Clinical+pharmacology+of+trastuzumab+emtansine+%28T-DM1%29%3A+an+antibody%E2%80%93drug+conjugate+in+development+for+the+treatment+of+HER2-positive+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer</span></div><div class="casAuthors">Girish, Sandhya; Gupta, Manish; Wang, Bei; Lu, Dan; Krop, Ian E.; Vogel, Charles L.; Burris, Howard A., III; LoRusso, Patricia M.; Yi, Joo-Hee; Saad, Ola; Tong, Barbara; Chu, Yu-Waye; Holden, Scott; Joshi, Amita</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1229-1240</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate comprising trastuzumab and DM1, a microtubule polymn. inhibitor, covalently bound via a stable thioether linker.  To characterize the pharmacokinetics (PK) of T-DM1 in patients with human epidermal growth factor receptor 2 (HER2)-pos. metastatic breast cancer, data from four studies (TDM3569g, TDM4258g, TDM4374g, and TDM4688g) of single-agent T-DM1 administered at 3.6 mg/kg every 3 wk (q3w) were assessed in aggregate.  Methods: Multiple analytes-T-DM1, total trastuzumab (TT), DM1, and key metabolites-were quantified using enzyme-linked immunosorbent assays or liq. chromatog. tandem mass spectrometry.  PK parameters of T-DM1, TT, and DM1 exposure were calcd. using std. noncompartmental approaches and correlated to efficacy (objective response rate) and safety (platelet counts, hepatic transaminase concns.).  Immunogenicity was evaluated by measuring anti-therapeutic antibodies (ATA) to T-DM1 after repeated dosing using validated bridging antibody electrochemiluminescence or enzyme-linked immunosorbent assays.  Results: PK parameters for T-DM1, TT, and DM1 were consistent across studies at cycle 1 and steady state.  T-DM1 PK was not affected by residual trastuzumab from prior therapy or circulating extracellular domain of HER2.  No significant correlations were obsd. between T-DM1 exposure and efficacy, thrombocytopenia, or increased concns. of transaminases.  Across the studies, ATA formation was detected in 4.5% (13/286) of evaluable patients receiving T-DM1 q3w.  Conclusions The PK profile of single-agent T-DM1 (3.6 mg/kg q3w) is predictable, well characterized, and unaffected by circulating levels of HER2 extracellular domain or residual trastuzumab.  T-DM1 exposure does not correlate with clin. responses or key adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjA6MaBSuH37Vg90H21EOLACvtfcHk0lihvy5ftqVqWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1Kru70%253D&md5=f4b2a4ef4aaa79a96adbb1810a0c44d9</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1817-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1817-3%26sid%3Dliteratum%253Aachs%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DVogel%26aufirst%3DC.%2BL.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DYi%26aufirst%3DJ.%2BH.%26aulast%3DSaad%26aufirst%3DO.%26aulast%3DTong%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DHolden%26aufirst%3DS.%26aulast%3DJoshi%26aufirst%3DA.%26atitle%3DClinical%2520pharmacology%2520of%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529%253A%2520an%2520antibody%25E2%2580%2593drug%2520conjugate%2520in%2520development%2520for%2520the%2520treatment%2520of%2520HER2-positive%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D1229%26epage%3D1240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span> </span><span class="NLM_article-title">An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">672</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1007%2Fs40262-013-0060-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=23553425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVSnu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=657-672&author=D.+Luauthor=A.+Joshiauthor=B.+Wangauthor=S.+Olsenauthor=J.+H.+Yiauthor=I.+E.+Kropauthor=H.+A.+Burrisauthor=S.+Girish&title=An+integrated+multiple-analyte+pharmacokinetic+model+to+characterize+trastuzumab+emtansine+%28T-DM1%29+clearance+pathways+and+to+evaluate+reduced+pharmacokinetic+sampling+in+patients+with+HER2-positive+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer</span></div><div class="casAuthors">Lu, Dan; Joshi, Amita; Wang, Bei; Olsen, Steve; Yi, Joo-Hee; Krop, Ian E.; Burris, Howard A.; Girish, Sandhya</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">657-672</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background and Objective: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate recently approved by the US Food and Drug Administration for the treatment of human epidermal growth factor receptor 2 (HER2)-pos. metastatic breast cancer previously treated with trastuzumab and taxane chemotherapy.  It comprises the microtubule inhibitory cytotoxic agent DM1 conjugated to the HER2-targeted humanized monoclonal antibody trastuzumab via a stable linker.  To characterize the pharmacokinetics of T-DM1 in patients with metastatic breast cancer, concns. of multiple analytes were quantified, including serum concns. of T-DM1 conjugate and total trastuzumab (the sum of conjugated and unconjugated trastuzumab), as well as plasma concns. of DM1.  The clearance of T-DM1 conjugate is approx. 2 to 3 times faster than its parent antibody, trastuzumab.  However, the clearance pathways accounting for this faster clearance rate are unclear.  An integrated population pharmacokinetic model that simultaneously fits the pharmacokinetics of T-DM1 conjugate and total trastuzumab can help to elucidate the clearance pathways of T-DM1.  The model can also be used to predict total trastuzumab pharmacokinetic profiles based on T-DM1 conjugate pharmacokinetic data and sparse total trastuzumab pharmacokinetic data, thereby reducing the frequency of pharmacokinetic sampling.  Methods: T-DM1 conjugate and total trastuzumab serum concn. data, including baseline trastuzumab concns. prior to T-DM1 treatment, from phase I and II studies were used to develop this integrated population pharmacokinetic model.  Based on a hypothetical T-DM1 catabolism scheme, two-compartment models for T-DM1 conjugate and trastuzumab were integrated by assuming a one-step deconjugation clearance from T-DM1 conjugate to trastuzumab.  The ability of the model to predict the total trastuzumab pharmacokinetic profile based on T-DM1 conjugate pharmacokinetics and various sampling schemes of total trastuzumab pharmacokinetics was assessed to evaluate total trastuzumab sampling schemes.  Results: The final model reflects a simplified catabolism scheme of T-DM1, suggesting that T-DM1 clearance pathways include both deconjugation and proteolytic degrdn.  The model fits T-DM1 conjugate and total trastuzumab pharmacokinetic data simultaneously.  The deconjugation clearance of T-DM1 was estd. to be ∼0.4 L/day.  Proteolytic degrdn. clearances for T-DM1 and trastuzumab were similar (∼0.3 L/day).  This model accurately predicts total trastuzumab pharmacokinetic profiles based on T-DM1 conjugate pharmacokinetic data and sparse total trastuzumab pharmacokinetic data sampled at preinfusion and end of infusion in cycle 1, and in one addnl. steady state cycle.  Conclusions: This semi-mechanistic integrated model links T-DM1 conjugate and total trastuzumab pharmacokinetic data, and supports the inclusion of both proteolytic degrdn. and deconjugation as clearance pathways in the hypothetical T-DM1 catabolism scheme.  The model attributes a faster T-DM1 conjugate clearance vs. that of trastuzumab to the presence of a deconjugation process and suggests a similar proteolytic clearance of T-DM1 and trastuzumab.  Based on the model and T-DM1 conjugate pharmacokinetic data, a sparse pharmacokinetic sampling scheme for total trastuzumab provides an entire pharmacokinetic profile with similar predictive accuracy to that of a dense pharmacokinetic sampling scheme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeRfgJg8C3KrVg90H21EOLACvtfcHk0liaR_84aNapWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVSnu7jI&md5=b5b591684a66774da1b9161926217f32</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs40262-013-0060-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-013-0060-y%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DOlsen%26aufirst%3DS.%26aulast%3DYi%26aufirst%3DJ.%2BH.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DGirish%26aufirst%3DS.%26atitle%3DAn%2520integrated%2520multiple-analyte%2520pharmacokinetic%2520model%2520to%2520characterize%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529%2520clearance%2520pathways%2520and%2520to%2520evaluate%2520reduced%2520pharmacokinetic%2520sampling%2520in%2520patients%2520with%2520HER2-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2013%26volume%3D52%26spage%3D657%26epage%3D672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Chudasama, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaedeli Stark, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrold, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mager, D. E.</span><span> </span><span class="NLM_article-title">Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">520</span><span class="NLM_x">–</span> <span class="NLM_lpage">527</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1038%2Fclpt.2012.153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=22968044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2iurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=520-527&author=V.+L.+Chudasamaauthor=F.+Schaedeli+Starkauthor=J.+M.+Harroldauthor=J.+Tibbittsauthor=S.+R.+Girishauthor=M.+Guptaauthor=N.+Freyauthor=D.+E.+Mager&title=Semi-mechanistic+population+pharmacokinetic+model+of+multivalent+trastuzumab+emtansine+in+patients+with+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Semi-mechanistic Population Pharmacokinetic Model of Multivalent Trastuzumab Emtansine in Patients with Metastatic Breast Cancer</span></div><div class="casAuthors">Chudasama, V. L.; Schaedeli Stark, F.; Harrold, J. M.; Tibbitts, J.; Girish, S. R.; Gupta, M.; Frey, N.; Mager, D. E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">520-527</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) composed of multiple mols. of the antimicrotubule agent DM1 linked to trastuzumab, a humanized anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody.  Pharmacokinetics data from phase I (n = 52) and phase II (n = 111) studies in HER2-pos. metastatic breast cancer patients show a shorter terminal half-life for T-DM1 than for total trastuzumab (TTmAb).  In this work, we translated prior preclin. modeling in monkeys to develop a semi-mechanistic population pharmacokinetics model to characterize T-DM1 and TTmAb concn. profiles.  A series of transit compartments with the same disposition parameters was used to describe the deconjugation process from higher to lower drug-to-antibody ratios (DARs).  The structure could explain the shorter terminal half-life of T-DM1 relative to TTmab.  The final model integrates prior knowledge of T-DM1 DARs from preclin. studies and could provide a platform for understanding and characterizing the pharmacokinetics of other ADC systems.  Clin. Pharmacol. & Therapeutics (2012); 92 4, 520-527. doi:10.1038/clpt.2012.153.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsh_7mNP3TbrVg90H21EOLACvtfcHk0liaR_84aNapWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2iurfP&md5=1d04057bdead10453770c704e5ed28f4</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2012.153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2012.153%26sid%3Dliteratum%253Aachs%26aulast%3DChudasama%26aufirst%3DV.%2BL.%26aulast%3DSchaedeli%2BStark%26aufirst%3DF.%26aulast%3DHarrold%26aufirst%3DJ.%2BM.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DGirish%26aufirst%3DS.%2BR.%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DFrey%26aufirst%3DN.%26aulast%3DMager%26aufirst%3DD.%2BE.%26atitle%3DSemi-mechanistic%2520population%2520pharmacokinetic%2520model%2520of%2520multivalent%2520trastuzumab%2520emtansine%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D92%26spage%3D520%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Bender, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaedeli-Stark, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friberg, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, M.</span><span> </span><span class="NLM_article-title">A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">601</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1007%2Fs00280-012-1934-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=22886072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVentbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2012&pages=591-601&author=B.+C.+Benderauthor=F.+Schaedeli-Starkauthor=R.+Kochauthor=A.+Joshiauthor=Y.+W.+Chuauthor=H.+Rugoauthor=I.+E.+Kropauthor=S.+Girishauthor=L.+E.+Fribergauthor=M.+Gupta&title=A+population+pharmacokinetic%2Fpharmacodynamic+model+of+thrombocytopenia+characterizing+the+effect+of+trastuzumab+emtansine+%28T-DM1%29+on+platelet+counts+in+patients+with+HER2-positive+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer</span></div><div class="casAuthors">Bender, Brendan C.; Schaedeli-Stark, Franziska; Koch, Reinhold; Joshi, Amita; Chu, Yu-Waye; Rugo, Hope; Krop, Ian E.; Girish, Sandhya; Friberg, Lena E.; Gupta, Manish</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">591-601</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate in the development for the treatment of human epidermal growth factor receptor 2-pos. cancers.  Thrombocytopenia (TCP) is the dose-limiting toxicity of T-DM1.  A semimechanistic population pharmacokinetic/pharmacodynamic (PK/PD) model was developed to characterize the effect of T-DM1 on patient platelet counts.  Methods: A PK/PD model with transit compartments that mimic platelet development and circulation was fit to concn.-platelet-time course data from two T-DM1 single-agent studies (TDM3569g; N = 52 and TDM4258g; N = 112).  NONMEM 7 software was used for model development.  Data from a sep. phase II study (TDM4374g; N = 110) were used for model evaluation.  Patient baseline characteristics were evaluated as covariates of model PD parameters.  Results: The model described the platelet data well and predicted the incidence of grade ≥3 TCP.  The model predicted that with T-DM1 3.6 mg/kg given every 3 wk (q3w), the lowest platelet nadir would occur after the first dose.  Also predicted was a patient subgroup (46 %) having variable degrees of downward drifting platelet-time profiles, which were predicted to stabilize by the eighth treatment cycle to platelet counts above grade 3 TCP.  Baseline characteristics were not significant covariates of PD parameters in the model.  Conclusions: This semimechanistic PK/PD model accurately captures the cycle 1 platelet nadir, the downward drift noted in some patient platelet-time profiles, and the ∼8 % incidence of grade ≥3 TCP with T-DM1 3.6 mg/kg q3w.  This model supports T-DM1 3.6 mg/kg q3w as a well-tolerated dose with minimal dose delays or redns. for TCP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIqlu3H3iJv7Vg90H21EOLACvtfcHk0liaR_84aNapWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVentbjN&md5=52d01f2d24af314edf8c54d87304af23</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2Fs00280-012-1934-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-012-1934-7%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DB.%2BC.%26aulast%3DSchaedeli-Stark%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DR.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DRugo%26aufirst%3DH.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DFriberg%26aufirst%3DL.%2BE.%26aulast%3DGupta%26aufirst%3DM.%26atitle%3DA%2520population%2520pharmacokinetic%252Fpharmacodynamic%2520model%2520of%2520thrombocytopenia%2520characterizing%2520the%2520effect%2520of%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529%2520on%2520platelet%2520counts%2520in%2520patients%2520with%2520HER2-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D70%26spage%3D591%26epage%3D601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Shen, B. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bumbaca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastuskovas, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span> </span><span class="NLM_article-title">Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">901</span><span class="NLM_x">–</span> <span class="NLM_lpage">910</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.2174%2F138920012802138598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=22475269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1OlurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=901-910&author=B.+Q.+Shenauthor=D.+Bumbacaauthor=O.+Saadauthor=Q.+Yueauthor=C.+V.+Pastuskovasauthor=S.+C.+Khojastehauthor=J.+Tibbittsauthor=S.+Kaurauthor=B.+Wangauthor=Y.+W.+Chuauthor=P.+M.+LoRussoauthor=S.+Girish&title=Catabolic+fate+and+pharmacokinetic+characterization+of+trastuzumab+emtansine+%28T-DM1%29%3A+an+emphasis+on+preclinical+and+clinical+catabolism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism</span></div><div class="casAuthors">Shen, Ben-Quan; Bumbaca, Daniela; Saad, Ola; Yue, Qin; Pastuskovas, Cinthia V.; Khojasteh, S. Cyrus; Tibbitts, Jay; Kaur, Surinder; Wang, Bei; Chu, Yu-Waye; LoRusso, Patricia M.; Girish, Sandhya</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">901-910</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate in clin. development for the treatment of human epidermal growth factor receptor 2 (HER2)-pos. cancers.  Herein, we describe a series of studies to assess T-DM1 absorption, distribution, metab., and excretion (ADME) in rats as well as to assess human exposure to T-DM1 catabolites.  Following administration of unlabeled and radiolabeled T-DM1 in female Sprague Dawley rats as a single dose, plasma, urine, bile and feces were assessed for mass balance, profiling and identification of catabolites.  In rats, the major circulating species in plasma was T-DM1, while DM1 concns. were low (1.08 to 15.6 ng/mL).  The major catabolites found circulating in rat plasma were DM1, [N-maleimidomethyl] cyclohexane-1-carboxylate-DM1 (MCC-DM1), and Lysine-MCC-DM1.  These catabolites identified in rats were also detected in plasma samples from patients with HER2-pos. metastatic breast cancer who received single-agent T-DM1 (3.6 mg/kg every 3 wk) in a phase 2 clin. study.  There was no evidence of tissue accumulation in rats or catabolite accumulation in human plasma following multiple dosing.  In rats, T-DM1 was distributed nonspecifically to the organs without accumulation.  The major pathway of DM1-contg. catabolite elimination in rats was the fecal/biliary route, with up to 80% of radioactivity recovered in the feces and 50% in the bile.  The rat T-DM1 ADME profile is likely similar to the human profile, although there may be differences since trastuzumab does not bind the rat HER2- like receptor.  Further research is necessary to more fully understand the T-DM1 ADME profile in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDuHn1EbzEhLVg90H21EOLACvtfcHk0lhi9_iXbhyDaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1OlurrN&md5=faf70e5692e4d6a5a7789a0510705837</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.2174%2F138920012802138598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012802138598%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DB.%2BQ.%26aulast%3DBumbaca%26aufirst%3DD.%26aulast%3DSaad%26aufirst%3DO.%26aulast%3DYue%26aufirst%3DQ.%26aulast%3DPastuskovas%26aufirst%3DC.%2BV.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DGirish%26aufirst%3DS.%26atitle%3DCatabolic%2520fate%2520and%2520pharmacokinetic%2520characterization%2520of%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529%253A%2520an%2520emphasis%2520on%2520preclinical%2520and%2520clinical%2520catabolism%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D901%26epage%3D910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Thon, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begonja, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Italiano, J. E.,  Jr.</span><span> </span><span class="NLM_article-title">High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">1975</span><span class="NLM_x">–</span> <span class="NLM_lpage">1984</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=1975-1984&author=J.+N.+Thonauthor=M.+T.+Devineauthor=A.+J.+Begonjaauthor=J.+Tibbittsauthor=J.+E.+Italiano&title=High-content+live-cell+imaging+assay+used+to+establish+mechanism+of+trastuzumab+emtansine+%28T-DM1%29-mediated+inhibition+of+platelet+production"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThon%26aufirst%3DJ.%2BN.%26aulast%3DDevine%26aufirst%3DM.%2BT.%26aulast%3DBegonja%26aufirst%3DA.%2BJ.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DItaliano%26aufirst%3DJ.%2BE.%26atitle%3DHigh-content%2520live-cell%2520imaging%2520assay%2520used%2520to%2520establish%2520mechanism%2520of%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529-mediated%2520inhibition%2520of%2520platelet%2520production%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26spage%3D1975%26epage%3D1984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Sendur, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aksoy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altundag, K.</span><span> </span><span class="NLM_article-title">Cardiotoxicity of novel HER2-targeted therapies</span> <span class="citation_source-journal">Curr. Med. Res. Opin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1015</span><span class="NLM_x">–</span> <span class="NLM_lpage">1024</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm500766w&amp;key=10.1185%2F03007995.2013.807232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm500766w&amp;key=23692263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm500766w&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeqsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2013&pages=1015-1024&author=M.+A.+Sendurauthor=S.+Aksoyauthor=K.+Altundag&title=Cardiotoxicity+of+novel+HER2-targeted+therapies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiotoxicity of novel HER2-targeted therapies</span></div><div class="casAuthors">Sendur, Mehmet A. N.; Aksoy, Sercan; Altundag, Kadri</div><div class="citationInfo"><span class="NLM_cas:title">Current Medical Research and Opinion</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1015-1024</span>CODEN:
                <span class="NLM_cas:coden">CMROCX</span>;
        ISSN:<span class="NLM_cas:issn">0300-7995</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Trastuzumab, an anti-HER2 humanized monoclonal antibody, is the std. treatment for both early and metastatic HER2-pos. breast cancer.  In addn. to other chemotherapeutic agents, trastuzumab significantly improves response rate and survival in HER2-pos. early and metastatic breast cancer.  Although it is well known that trastuzumab therapy is closely assocd. with both symptomatic and asymptomatic cardiotoxicity, less is known about novel HER2-targeted therapies.  The aim of this review is to discuss the cardiac safety data from recent studies of novel anti-HER2 drugs other than trastuzumab.  Scope: Novel HER2-targeted therapies showed favorable results in HER2 pos. metastatic breast cancer patients.  Pubmed database, ASCO and San Antonio Breast Cancer Symposium Meeting abstrs. were searched until Jan. 2013 using the following search keywords; trastuzumab, trastuzumab cardiotoxicity, HER-2 targeted therapies, lapatinib, pertuzumab, trastuzumab emtansine, afatinib and neratinib; papers which were considered relevant for the aim of this review were selected by the authors.  Lapatinib, pertuzumab, T-DM1, neratinib and afatinib mols. are evaluated in the study.  Findings: In a comprehensive anal., 3689 lapatinib treated patients enrolled in 49 trials; asymptomatic cardiac events were reported in 53 patients (1.4%) and symptomatic grade III and IV systolic dysfunction was obsd. only in 7 patients (0.2%) treated with lapatinib.  In phase I-III trials of pertuzumab, cardiac dysfunction was seen in 4.5-14.5% of patients with pertuzumab treatment and cardiac dysfunction was usually grade I and II.  Cardiotoxicity of pertuzumab was usually reported with the trastuzumab combination and no additive cardiotoxicity was reported with addn. of pertuzumab to trastuzumab.  T-DM1 had a better safety profile compared to trastuzumab, no significant cardiotoxicity was obsd. with T-DM1 in heavily pre-treated patients.  In the EMILIA study, only in 1.7% of patients in the T-DM1 group experienced redn. of left ventricular ejection fraction (LVEF) and grade III LVEF redn. developed only in one patient (0.2%) in the T-DM1 group compared to the lapatinib plus capecitabine group.  In phase I-II trials with neratinib no cardiotoxicity was reported whereas cardiotoxicity was seen between 0-5.3% with afatinib treatment.  Conclusion: Although cardiac toxicity has been reported as an adverse event for novel HER2-targeted therapies, cardiac dysfunction rate of the novel HER2-targeted therapies is significantly lower than the trastuzumab and combination of these agents with trastuzumab did not significantly increase the cardiac adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3-0lVbOFDsbVg90H21EOLACvtfcHk0lhi9_iXbhyDaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeqsL%252FN&md5=a5a593ec4ce6bbbb95584eb1e1d38d05</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1185%2F03007995.2013.807232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1185%252F03007995.2013.807232%26sid%3Dliteratum%253Aachs%26aulast%3DSendur%26aufirst%3DM.%2BA.%26aulast%3DAksoy%26aufirst%3DS.%26aulast%3DAltundag%26aufirst%3DK.%26atitle%3DCardiotoxicity%2520of%2520novel%2520HER2-targeted%2520therapies%26jtitle%3DCurr.%2520Med.%2520Res.%2520Opin.%26date%3D2013%26volume%3D29%26spage%3D1015%26epage%3D1024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm500766w&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-16%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm500766w%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm500766w" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798fc5efeb63d00","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
